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ABSTRACT 
Brandon Swift 
Investigation of Probe Substrates to Assess Hepatic Transport Function 
(Under the direction of Kim L.R. Brouwer, Pharm.D., Ph.D.) 
The objective of this research project was to identify and characterize probe 
substrates for specific hepatic transport proteins.  Identification of specific probe 
substrates for basolateral and canalicular transport proteins is necessary to 
elucidate mechanisms of hepatobiliary drug transport, phenotype for 
interindividual differences in transport protein function, and identify potential 
drug-drug interactions at the hepatic transport level. Three probe substrates were 
selected for investigation: fexofenadine, 99mTechnetium mebrofenin (99mTc-MEB), 
and 99mTechnetium sestamibi (99mTc-MIBI). Although fexofenadine has been 
touted as a P-gp specific probe substrate, pharmacokinetic modeling/siumulation 
of clinical data, sandwich-cultured human hepatocyte experiments and perfused 
liver studies in rats and mice demonstrated that fexofenadine is not a suitable 
probe for a specific transport protein due to compensatory efflux pathways. The 
hepatic uptake and excretion of 99mTc-MEB and 99mTc-MIBI have not been 
investigated fully despite their use as non-invasive probes to assess transport 
function.  Therefore, suspended and sandwich-cultured rat and human 
hepatocytes were used to fully characterize the mechanisms of hepatic transport 
of 99mTc-MEB and 99mTc-MIBI.  Then to validate the use of 99mTc-MEB and/or 
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99mTc-MIBI as probe substrates to predict the hepatic clearance of the anticancer 
agent, sorafenib studies were conducted to confirm similar mechanisms of 
hepatic uptake.  Lastly, the pharmacokinetics and hepatic exposure of 99mTc-MIBI 
and 99mTc-MEB were compared in a patient with hepatocellular carcinoma and 
Child’s Pugh B cirrhosis vs. healthy human volunteers.  Pharmacokinetic models 
were constructed to describe the distribution and elimination of 99mTc-MEB and 
99mTc-MIBI, to compare alterations in key rate constants representing hepatic 
uptake and efflux mechanisms secondary to disease.  In conclusion, 99mTc-MEB 
and 99mTc-MIBI may be very useful phenotypic probes that are sensitive to 
changes in hepatic function associated with liver disease. The hepatic exposure 
to 99mTc-MIBI was decreased in the patient with hepatocellular carcinoma and 
cirrhosis compared to healthy volunteers, whereas the hepatic exposure of 99mTc-
MEB was similar but the hepatic exposure profile was notably different with a 
lower maximum but more prolonged exposure. Collectively, the results of this 
research negate the use of fexofenadine as a probe for hepatic transport, but 
support the use of 99mTc-MEB and 99mTc-MIBI as probe substrates, which add the 
unique ability to quantify liver concentrations.  
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Transport proteins are responsible for drug absorption, distribution and excretion.  
Transporters govern movement of endogenous compounds and xenobiotics across 
biological membranes to maintain cellular and physiologic solute concentrations and 
fluid balance, or to protect the body from dietary and environmental toxins.  Most 
transport proteins are expressed in tissues with barrier functions such as the liver, 
kidney, intestine, placenta and brain, where they often play a key role in determining 
bioavailability, therapeutic efficacy and pharmacokinetics of drugs.  Transport proteins 
are classified into two superfamilies, the adenosine triphosphate (ATP)-binding cassette 
(ABC) protein family and the solute carrier (SLC) protein family.  ABC transport proteins 
function unidirectionally and actively efflux substrates directly utilizing the energy of ATP 
hydrolysis.  The SLC family transporters are facilitated transporters, secondary or 
tertiaty active transporters, which function bidirectionally allowing drugs/molecules to 
move across cell membranes utilizing the electrochemical potential gradient or ion 
gradient, and thus do not directly consume any chemical energy.  Proteins in the SLC 
and ABC familes often work in concert as a vectorial process to remove compounds 
from the blood and excrete them into bile or urine. 
Transport proteins involved in drug disposition are referred to as drug 
transporters.  Drug transporters play important roles in drug targeting, drug-drug 
interactions and drug-induced toxicity (1-6).  Therefore, phenotyping drug transport 
function may be of importance in individualizing drug therapy. The first section of this 
chapter will provide an introduction to the transport proteins in both superfamilies; 
discussion will concentrate on the transport proteins that have the greatest potential 
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impact on clinical pharmacokinetics, efficacy and safety of drugs. Subsequently, 
probes that have been used to assess specific transport protein function will be 
discussed. 
 
ABC Transport Proteins 
Multidrug Resistance (MDR1) P-glycoprotein (P-gp) 
 P-gp was one of the first ABC proteins to be studied because of its role in 
the development of multidrug-resistance to chemotherapeutic agents.  Like many 
other ABC proteins, P-gp comprises two membrane-bound domains, each made 
up of six transmembrane helices (7, 8).  P-gp is encoded by the ABCB1 gene, 
and is expressed at low levels in most tissues, but is found in much higher 
amounts at the apical surface of epithelial cells lining the colon, small intestine, 
pancreatic ductules, bile ductules (hepatocytes), kidney proximal tubules and the 
adrenal gland (9).  Tissue localization suggests that P-gp plays a physiological 
role in the protection of susceptible organs such as the brain and testis from toxic 
xenobiotics, the secretion of metabolites and xenobiotics into bile, urine and the 
lumen of the gastrointestinal tract, and possibly the transport of hormones from 
the adrenal gland.  P-gp represents the most widely studied ABC transport 
protein, and is responsible for the transport of predominantly bulky hydrophobic 
and cationic substrates including many chemotherapeutic agents, cardiac 
glycosides, cyclosporine A, and HIV-1 protease inhibitors. 
 
Breast Cancer Resistance Protein (BCRP) 
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 BCRP is encoded by the ABCG2 gene.  ABCG2 is considered a half-
transporter that forms a homodimer in order to function, as opposed to other ABC 
half-transporters that engage in heterodimeric association to form a functional 
transporter such as ABCG5/ABCG8 (10).  Little is known about the molecular 
mechanism(s) controlling expression; recent studies suggest that expression 
may be regulated by sex hormones or hypoxia (11-13).  Localization of BCRP is 
very similar to P-gp; the highest expression of ABCG2 mRNA is in placental 
tissue, with lower levels in brain, prostate, small intestine, testis, ovary, colon and 
liver (14, 15).  BCRP was discovered based on its affinity to mitoxantrone and 
shares some substrate overlap with P-gp.  BCRP also transports a variety of 
anticancer drugs such as SN-38, topotecan and doxorubicin (16-18).  Other 
BCRP substrates include sulfate conjugates (19) the tyrosine kinase inhibitors 
(CI1033, gefitinib and imatinib (20-22)) and fluoroquinolone antibiotics 
(grepafloxacin, ulifloxacin, ciprofloxacin and ofloxacin (23)). 
Multidrug Resistance Proteins (MRP) 
 There are 12 members of the ABCC family including nine MRPs, the 
cystic fibrosis transmembrane conductance regulator (CFTR), and the two 
sulfonyl-urea receptors SUR1 and SUR2.  According to current topology 
prediction programs, ABCC proteins have two cytoplasmic nucleotide-binding 
domains and depending on the isoform, two or three membrane-spanning 
domains (24).  The binding of ATP at the nucleotide-binding domains and 
subsequent ATP hydrolysis is required for MRP-mediated transport of 
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substances across the plasma membrane (1).  MRP2 was first localized to the 
canalicular membrane of rat and human hepatocytes (25, 26).  Since then, MRP2 
also has been identified on the apical membrane of kidney proximal tubules, 
small intestine, colon, gallbladder, bronchi and placenta (27-29).  The exclusive 
apical localization in these polarized cells underscores MRP2’s role in the 
excretion and detoxification of endogenous and xenobiotic organic anions.  
MRP2 substrates include many endogenous compounds such as leukotriene C4, 
as well as other glutathione, glucuronide, and sulfate conjugates of substrates 
such as S-glutathionyl 2,4-dinitrobenzene, mono- and bisglucuronosyl bilirubin, 
17β-glucuronosyl estradiol and estrone 3-sulfate (30-33).  The function and 
substrate specificity of MRP2 has been studied extensively by taking advantage 
of the naturally occurring Mrp2 deficient rats: Eisai hyperbilirubinemic (EHBR) 
rats and the CY/TR- mutant rats (25, 26, 34).    Furthermore, these hereditary 
hyperbilirubinemic mutant rats helped to elucidate the upregulation of basolateral 
Mrp3, a compensatory mechanism that enables the excretion of Mrp2 substrates 
into the systemic circulation when Mrp2 function is compromised, thus avoiding 
excessive accumulation of organic anions in the hepatocytes (35, 36).  A similar 
hereditary disorder has been discovered in humans; the absence of a functional 
ABCC2 protein on the canalicular membrane leads to conjugated 
hyperbilirubinemia characteristic of Dubin-Johnson syndrome in humans (37-39).  
MRP3 is localized in the basolateral membrane of hepatocytes, cholangiocytes, 
and polarized cells from the gallbladder, colon, pancreas, spleen and adrenal 
cortex (35, 40-42).  Hepatic MRP3 expression is inducible but appears to be 
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constitutive in other organs (42).  Several hereditary and acquired liver disorders 
lead to increased ABCC3 protein levels including Dubin-Johnson syndrome (35), 
progressive familial intrahepatic cholestasis type 3 (42), icteric primary biliary 
cirrhosis (43), and obstructive cholestasis (44). 
 
SLC Transport Proteins 
Organic Anion-Transporting Polypeptides (OATPs) 
The OATPs are encoded by the SLCO genes that contain 12 
transmembrane helices and are expressed in various epithelial cells.  There are 
11 human isoforms of which OATP1A2, OATP2A1, OATP2B1, OATP3A1 and 
OATP4A1 are expressed widely among human tissues while others appear to 
have tissue specific expression, such as OATP1B1 and OATP1B3 in liver, 
OATP4C1 in kidney and OATP6A1 in testes (45, 46).  OATPs generally are 
considered to function in a bidirectional manner, as dictated by the solute 
gradient across the membrane.  The mechanism of transport consists of anionic 
uptake into cells that is energized by countertransport with either bicarbonate 
(47) or reduced glutathione (48, 49).  OATPs mediate the sodium-independent 
transport of a diverse range of amphiphilic organic compounds including bile 
acids, bilirubin, steroid conjugates, thyroid hormones, anionic peptides, and 
numerous drugs.  Generally, substrates are negatively charged, but there are 
several examples of neutral (digoxin) and cationic (N-methylquinine) substrates.  
Several drug classes are susceptible to transport by OATPs including 3-hydroxy-
3methylglutarylcoenzyme A (HMG-CoA) reductase inhibitors (statins), 
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angiotensin II receptor antagonists, angiotensin converting enzyme inhibitors and 
cardiac glycosides.  Although a large number of OATPs have been identified, 
clinical relevance and drug-drug interactions related to OATPs have been noted 
primarily for OATP1A2, mediating intestinal absorption, and the liver-specific 
OATP1B1 and OATP1B3 isoforms, mediating hepatic uptake of drugs (50, 51).  
Furthermore, OATP1B1 and OATP1B3 have important physiological roles in the 
hepatic uptake of unconjugated and conjugated bilirubin (52, 53) and bile acid 
homeostasis based on direct transcriptional regulation by FXR (54) and down-
regulation in expression levels during cholestatic disease (55).  Both OATP1B1 
and OATP1B3 have been shown to be affected by drugs such as rifampin (56, 
57). 
 
Organic Cation Transporters (OCTs) 
 Three OCT isoforms identified in humans are members of the SLC22A 
family of transporters.   Transport of organic cations by the OCTs occurs by 
facilitated diffusion and is driven by the inside-negative membrane potential (58-
60).  OCT activity is insensitive to changes in the Na+ gradient (61).  The OCTs 
share common features such as structure and function, but there are important 
differences in tissue distribution.  OCT1 is characterized as liver-specific, and is 
expressed predominantly in human liver with lower levels of expression in other 
tissues (62, 63).  In contrast, OCT2 is expressed almost exclusively in kidney(62, 
64).  OCT3, also referred to as the extraneuronal monoamine transporter, has a 
broad tissue distribution with moderate levels of mRNA found in skeletal muscle, 
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prostate, adrenal gland, salivary gland and many other tissues (65).  OCTs 
mediate the uptake of low molecular weight  relatively hydrophilic organic cations 
(type I) such as the prototypical cations tetraethylammonium (TEA), the 
neurotoxin N-metyl-4-phenylpyridine (MPP+) and the endogenous compound N-
methylnicotinamide (NMN) (58, 66, 67).  Drugs that are substrates of the OCTs 
include metformin, famotidine, and ranitidine (67-69).  Most of the drug-drug 
interactions involving OCT proteins have been shown to occur for drugs 
predominantly excreted in urine by active renal secretion (70-72). 
 
Organic Anion Transporters (OATs)   
 OATs are in the same SLC22A family as the organic cation transporters.  
Five human isoforms have been identified (OAT1, OAT2, OAT3, OAT4 and 
URAT1), which are located primarily in the kidneys (73).  The uptake of organic 
anions is driven by the concentration gradient of intracellular dicarboxylates, such 
as α-ketoglutarate.  The high concentration gradient of dicarboxylates is 
maintained by the sodium-dicarboxylate cotransporter, which in turn is driven by 
the inwardly directed sodium gradient across the basolateral membrane 
generated by Na+/K+-ATPase.  Due to the high expression of the OATs in the 
kidneys, the majority of available data has been generated in the field of renal 
drug transport.  However, OAT2 is expressed predominantly in the sinusoidal 
membrane of hepatocytes (74).  The prototypical substrates of OATs are p-
aminohippurate and estrone 3-sulfate, but OATs also transport a wide range of 
drugs including angiotensin converting enzyme inhibitors, loop and thiazide 
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diuretics, β-lactam antibiotics, methotrexate and nonsteroidal anti-inflammatory 
drugs (75). 
 
Importance of Transport Protein Probe Substrates 
 Systemic concentrations typically correlate with drug efficacy and toxicity, 
and therapeutic concentration ranges have been established for a large number 
of drugs.  However, significant interindividual variability in the concentration-
response and/or concentration-toxicity relationships may exist for some drugs.  
Genetic polymorphisms and deficiencies in transport proteins are a well 
recognized source of variability resulting in altered pharmacokinetics and 
subsequent pharmacologic and toxicological effects of certain drugs (3).  
Recently, a high impact paper was published documenting that a common 
variant in SLCO1B1, the gene encoding OATP1B1, was strongly associated with 
increased risk of statin-induced myopathy (76).  In addition to genetic 
polymorphisms, various disease states such as cholestasis and cirrhosis may 
modify transport protein expression and/or localization, thereby affecting the 
pharmacokinetics and/or pharmacodynamics of some drugs (77, 78).  Therefore, 
utilizing a probe substrate to phenotype the functional changes in specific 
transport proteins due to genetics and/or disease state modifications would be 
useful in predicting the potential impact of alterations due to interindividual 
differences on the pharmacokinetics of drugs whose disposition is influenced by 
these specific proteins.  
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 Probe substrates are also crucial for elucidating drug-drug interactions at 
the transport level, and would be useful for preventing potential adverse events in 
patient populations that require the use of many concomitantly administered 
drugs.  A clinically important factor that may alter the efficacy and/or toxicity of a 
drug or endogenous compound is transporter-based drug interactions, which 
may result in inhibition, induction, or a mixed effect on the uptake and/or efflux of 
transport proteins (79).  To date, many reviews have documented the 
considerable number of transporter-based clinically important drug interactions 
(6, 79-81).  In fact, the US Food and Drug Administration (FDA) has issued a 
guidance on performing drug-drug interaction studies to determine P-gp inhibition 
in vivo (82).  Probe substrates are an important tool that can be used to clarify 
the impact that a specific transport protein may have on a drug’s disposition, 
interaction, efficacy and safety; information generated using probe substrates 
may lead to drug label changes that provide important mechanistic information 
useful for drug therapy.  This same approach can be applied in the drug 
development or in vitro setting to facilitate evaluation of transport/interaction 
mechanisms for new drug candidates in which transport processes are relatively 
unknown.  Utilizing a specific probe substrate in a cell-based, intact organ or in 
vivo model in the presence and absence of an investigational drug could aid in 
elucidating whether the investigational drug is an inhibitor, which often suggests 
the investigational drug is a substrate for that protein as well. 
 The aim of this review is to present an overview of potential probe 
substrates for use in humans in vivo.  The use of imaging technologies to assess 
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tissue concentrations of probe substrates to elucidate transporter-based drug-
drug interactions that may not be reflected by systemic concentrations will be 
highlighted.  In addition, the challenges in identifying specific probe substrates 
and inhibitors will be discussed.   
 
What Makes a Good Probe Substrate? 
 First and foremost, a probe substrate must be specific for a transport 
protein, and the pharmacokinetics of the probe substrate must be sensitive to 
functional changes in the transport protein.  Ideally, a transporter probe substrate 
would display little or predictable metabolism.  Furthermore, the probe would 
need to be safe for healthy human volunteer studies.  Another important 
characteristic to consider is the disposition properties of the probe substrate.  For 
instance, the clinical use of nitrofurantoin as a BCRP probe to assess BCRP-
mediated biliary excretion is limited due to the fact that 30-60% of the parent 
compound undergoes renal elimination with extensive metabolism after oral 
administration (83).  Other ideal characteristics include a short half-life allowing 
for a shorter sampling period and less laborious clinical study.  Probes that are 
radiolabeled (gamma emitters or positron emitters) or fluorescent are useful for in 
vivo or in vitro studies due to the ease of bioanalytical quantitation.  In addition to 
the obvious advantages from a bioanalysis standpoint, these probes may be 
capable of providing additional data that could not otherwise be obtained.  For 
example, with the use of positron emission tomography (PET) and gamma 
scintigraphy, tissue concentrations of the probe can be obtained to assist in 
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elucidating the distribution of the radiolabeled probe and determining organ 
exposure. 
Identification of specific probe substrates of transport proteins has proved 
to be difficult.  There are many limitations including the broad and overlapping 
substrate specificity of the specific isoforms of each transport protein subfamily.  
Similarly, species differences in the transport proteins primarily involved in the 
disposition of some substrates require assessment of the function, or evaluation 
of drug interactions, in the appropriate species.  This is the case for fexofenadine 
in which Mrp2 is primarily responsible for biliary excretion in mice whereas P-gp 
appears to play a more important role in rats (84, 85).  Another difficulty is 
determining the exact mechanism of interaction in the vectorial transport of 
substrates in polarized cells when uptake and efflux processes are involved.  For 
example, digoxin has been touted as a good P-gp probe substrate(82). However, 
an OATP-mediated interaction that inhibits the active uptake of digoxin into the 
hepatocytes or renal tubular cells before gaining access to P-gp could confound 
interpretation of data generated in a P-gp drug interaction study (86).  There is 
also evidence for multiple binding sites for P-gp (87, 88) and MRP2/Mrp2 (89, 
90); the binding of one compound may affect the binding of a second compound, 
regardless of whether the modulating compound is a substrate of that specific 
transport protein.  A comparison can be made with cytochrome P450 (CYP) 3A4 
and the need to use two compounds, midazolam and testosterone, as probe 
substrates for different binding sites to assess drug-drug interactions (51). 
Furthermore, drug-drug interactions may result in changes in concentration of the 
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substrate in a particular tissue without affecting the blood or plasma 
concentration of the substrate.  For example, the P-gp inhibitor cyclosporine A 
significantly increased the distribution of verapamil, a P-gp probe substrate into 
the brain, without significantly affecting the plasma or blood concentration-time 
profile of verapamil (91).  It is important to consider whether the clearance of a 
probe substrate reflects the function of a transport protein.  For instance, a probe 
with a high hepatic extraction will have a hepatic clearance that is reflective of 
changes in blood flow; thus, it may not be an appropriate probe for a transport 
protein unless the probe is validated to confirm that it is sensitive to perturbation 
in function of the transport protein while accounting for differences in blood flow. 
 
In vivo Probe Substrates 
P-gp 
P-gp is the most well known and widely studied transport protein.  P-gp 
expression in organs of clearance such as the liver and kidneys, and barrier-
forming tissues such as the gut and blood-brain barrier, may result in a significant 
contribution to the distribution and elimination of many drugs.  Furthermore, 
similar to CYP3A, which metabolizes up to 50% of currently marketed drugs(92, 
93), P-gp is able to transport a wide range of compounds with different chemical 
structures(94, 95).  Despite the high expression at important epithelial and 
endothelial barrier-forming tissues, there are few clinically relevant drug-drug 
interactions attributed solely to P-gp.  This may be due to the fact that many 
known P-gp substrates also are metabolized by CYPs, especially CYP3A4 (92).  
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For instance, when P-gp is inhibited in rat the metabolism of the dual CYP3A/P-
gp substrates tacrolimus and digoxin were increased (96-98).  Therefore, 
inhibition of P-gp leads to increased metabolism reducing any potential 
accumulation of the P-gp substrate.   
Digoxin is the recommended probe in the US FDA draft guidance 
(http://www.fda.gov/cder/quidance/index/htm) for assessing P-gp inhibition.  
Digoxin is considered the gold standard P-gp probe because it is metabolically 
stable in humans (99, 100), and pharmacokinetic changes in absorption and 
clearance can be attributed primarily to modulation in P-gp function in the gut and 
kidney/liver, respectively(101, 102).  In addition, many studies have assessed P-
gp mediated drug-drug interactions using digoxin as the probe substrate(103).  
However, one limitation with digoxin is that close monitoring is required for 
untoward signs of digitalis-mediated toxicity due to the narrow therapeutic 
window of this drug; furthermore, concomitant administration of numerous drugs 
(e.g. quinidine, amiodarone, and verapamil) may lead to toxicity (104-106), and 
represents an important exclusion criteria.  Another difficulty with digoxin is in 
separating interactions involving inhibition of P-gp function in the gut (105, 107) 
from those in the kidney and liver(108, 109).  However, digoxin can be 
administered both intravenously and orally, allowing the impact of P-gp on 
digoxin bioavailability to be dissected from its impact on systemic or renal 
clearance.  Lastly, digoxin is a good substrate of the basolateral uptake transport 
proteins OATP1B3 and OATP4C1 in the liver and kidney, respectively(110, 111).  
Thus, inhibition of digoxin transport might involve inhibition of uptake into the liver 
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and kidney, which has been shown with the specific P-gp/Bcrp inhibitor 
GF120918 in vitro(86), in addition to interactions at the level of P-gp mediated 
efflux. 
One limitation with most probe drugs is that concentrations can only be 
measured in the systemic circulation in vivo.  However, potential drug-drug 
interactions may result in tissue accumulation with minimal impact on systemic 
exposure.  This has been demonstrated with the use of pharmacokinetic 
modeling of pravastatin(112) and fexofenadine(85) in humans.  To overcome this 
problem, tissue concentrations should be determined in addition to blood 
concentrations with the use of imaging technologies such as single-photon 
computed tomography (SPECT), PET and magnetic resonance imaging (MRI).   
One such example is 99mTechnetium (99mTc)-labeled sestamibi, a 
monovalent cation complex that is used commonly in nuclear medicine to assess 
myocardial perfusion; 99mTc-sestamibi distributes into the heart in proportion to 
blood flow and myocardial viability(113-115).  99mTc-sestamibi undergoes minimal 
metabolism in guinea pigs (116) and humans (Cardiolite package insert), and 
has been shown to be a substrate of P-gp both in vitro (117, 118) and in vivo 
(119).  Accumulation of 99mTc-sestamibi in cells is a function of free diffusion 
based on electrical potentials across the plasma and mitochondrial membranes, 
with localization in the mitochondria by electrostatic forces (120).  Therefore, a 
drug-drug interaction with 99mTc-sestamibi would occur on the apical membrane 
as a result of P-gp modulation.  A few studies have been published using 99mTc-
sestamibi as a phenotypic probe demonstrating increased retention in the liver 
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and kidney in the presence of the specific P-gp inhibitors PSC833 and 
XR9576(121-123).  In fact, 66 patients genotyped for the G2677T/A and C3435T 
single nucleotide polymorphisms (SNPs) in ABCB1 exons 21 and 26, 
respectively, exhibited a significant reduction in the hepatic elimination rate 
constant of 99mTc-sestamibi(124).  This suggests that 99mTc-sestamibi hepatic 
scintigraphy may provide a useful indicator of P-gp-mediated drug clearance.  
However, there is limited evidence in vitro and in vivo in rats that 99mTc-sestamibi 
is a substrate of Mrp1 and Mrp2(117, 125) but the overall significance in humans 
is unknown. 
Another imaging agent utilized as a P-gp probe that has an advantage 
over 99mTc-sestamibi is the PET agent 11C-verapamil, which has been used for 
quantitative dynamic imaging studies.  Abundant data from in vitro and preclinical 
species studies have indicated that verapamil is a P-gp substrate(126-130); 
verapamil is also lipophilic so that it diffuses readily across the blood-brain 
barrier.  Therefore, any possible interaction is most likely due to P-gp inhibition, 
and not by other uptake mechanisms.  Working with a short-lived isotope such as 
11C has it advantages and disadvatages.  One advantage is that only a tracer 
amount of drug is required, thus avoiding verapamil’s pharmacologic effect and 
toxicity.  The 20-min half-life represents an experimental challenge, but also 
allows for an ideal crossover study design, such as a protocol with a before and 
after transport protein modulator effect to assess a potential drug-drug interaction 
in which the subject serves as his/her own control.  Verapamil is not an ideal 
probe due to extensive CYP3A-mediated metabolism in humans (131, 132) 
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generating the predominant metabolites norverapamil, D-620, and D-617 .  
However, norverapamil and D-620 would result in the loss of the 11C label while 
D-617 and several other minor metabolites would retain the label contributing to 
the imaging (133).  The majority of these unconjugated metabolites of verapamil 
have been shown to be substrates of P-gp and should mimic the disposition of 
11C-verapamil (91, 134).  Sasongko et al., successfully demonstrated a modest 
inhibition of P-gp in humans at the blood brain barrier utilizing 11C-verapamil PET 
imaging to quantify the AUCbrain to AUCblood ratio in the absence and presence of 
cyclosporine without affecting metabolism or protein binding (91).   
Other studies in vitro and in preclinical species have investigated the 
clinical use of the following PET tracers as P-gp probes: 11C-colchicine (135), 
11C-daunorubicin (126), 18F-fluorpaclitaxel (136), 11C-carazolol (137), 18F-
fluorocarazolol (137), 11C-carvedilol (138), 18F-MPFF (137), 11C-WAY100635 
(137), 11C-GR218231 (139), 11C-TMSX (140), 11C-MPDX (140), 11C-flumazenil 
(140), 11C-donepezil (140), 11C-loperamide (141), and 11C-carfentanyl (141).   
Some lipophilic drugs that traverse the basolateral membrane by passive 
diffusion are good P-gp substrates as mentioned with 99mTc-sestamibi and 11C-
verapamil.  Therefore, identifying such compounds would be ideal probe 
substrates for P-gp function, because they do not require uptake proteins to 
access the cell for subsequent efflux by P-gp.  This typically is not the case with 
other efflux proteins discussed below.  Although digoxin is the recommended and 
most widely used P-gp probe substrate, due to its safety profile and reliance on 
basolateral uptake transport proteins (OATPs), other substrates may be more 
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ideal P-gp probes.  At one point, fexofenadine was considered an optimal 
replacement(142), but has since been shown to be a substrate of multiple 
transport proteins(84, 85, 143).  Use of radiolabeled P-gp probes such as 99mTc-
sestamibi and 11C-verapamil allow for quantitation of tissue concentrations that 
are inaccessible with typical sampling, but are instrumental in demonstrating 
drug-drug interactions involving P-gp function at the canalicular membrane of 
hepatocytes in the liver, or the endothelial cells making up the blood brain barrier.  
More work is necessary to validate these and other radiolabeled probes. 
BCRP 
 Bcrp expression and substrates are similar to P-gp, suggesting that this 
protein plays a similar role in drug absorption and disposition.  However, this 
ABC half transporter is a relatively novel transporter, and its clinical relevance in 
drug absorption and elimination has not been characterized completely.  The 
ideal BCRP-selective clinical probe substrate remains to be identified; many 
BCRP substrates lack a safety profile acceptable for use in healthy volunteer 
studies(6).  There are several nonsynonymous SNPs in the human ABCG2 gene 
that are associated with decreased BCRP function including C421A, C376T, 
G34A, T1291C and T623C; these may contribute to the intersubject variability 
observed for drugs that are BCRP substrates(144-148).  The most widely studied 
SNP is C421A, which has been used to screen potential BCRP probe substrates. 
 Nitrofurantoin is a suitable Bcrp/BCRP substrate based on in vitro 
transport studies; nitrofurantoin is a substrate of mouse Bcrp and human BCRP 
in MDCKII cells (149), but not P-gp, MRP1 or MRP2 (149, 150).  In addition, in 
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vivo pharmacokinetic studies have shown that Bcrp affects the absorption and 
biliary excretion of nitrofurantoin utilizing Bcrp-knockout mice, which exhibited a 
4-fold higher plasma AUC after oral administration.  After intravenous 
administration, the nitrofurantoin AUC was 2-fold higher, and biliary excretion 
decreased 48-fold in Bcrp-knockout compared to wild-type mice (149).  
BCRP/Bcrp is the primary transport protein responsible for the active secretion of 
nitrofurantoin into milk in mice and humans, and Bcrp limits the fetal distribution 
of substrates in pregnant mice (149, 151, 152).  Nitrofurantoin is almost 
completely absorbed in humans, suggesting that BCRP efflux does not 
substantially influence intestinal absorption of this permeable compound(83).  
Nitrofurantoin elimination occurs primarily by renal (~30-60% unchanged) and 
biliary excretion, with some reductive metabolism by enzymes in human tissue 
and intestinal bacterial flora(83, 153).  Nitrofurantoin exhibits a short half life in 
humans of ~46 – 58 min(83, 154).  Recently, nitrofurantoin was assessed as a 
potential BCRP probe in healthy Chinese male subjects with the ABCG2 
polymorphism C421A, which is associated with reduced transport activity(154).  
Surprisingly, no significant differences in nitrofurantoin pharmacokinetics among 
the genotypic cohorts were observed.  One explanation for this finding may be 
that the C421A polymorphism affects the pharmacokinetics of specific 
substrates, as is the case for topotecan and diflomotecan in which the plasma 
exposure increased only 1.4-fold for oral topotecan vs. 4-fold for intravenous 
diflomotecan(155, 156).  Another explanation may be due to a smaller 
contribution of BCRP to the overall elimination of nitrofurantoin in humans in vivo 
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compared to in vitro experiments in human BCRP-transfected cell lines and in 
vivo rodent studies.  These data suggested that nitrofurantoin is not a suitable 
clinical probe substrate for assessing BCRP activity. 
Sulfasalazine is another probe that has been used clinically to phenotype 
BCRP function.  The bioavailability of sulfasalazine is relatively low, with only 
one-quarter to one-third of the drug absorbed; extensive metabolism by intestinal 
bacteria results in the release of sulfapyridine and 5-aminosalicylate(157, 158).  
Less than 10% of the absorbed sulfasalzine dose is excreted unchanged in urine, 
with the remainder excreted unchanged in bile(157, 158).  Therefore, 
sulfasalazine may be useful for assessing BCRP function in most tissues 
including the intestine.  Importantly, the plasma AUC of sulfasalazine increased 
111-fold in Bcrp-knockout compared to wild-type mice and was not significantly 
different in Mdr1a knockout mice, suggesting that sulfasalazine was sensitive 
and selective for Bcrp (159).  Urquhart et al., demonstrated that sulfasalazine 
was a substrate of human BCRP in the Caco-2 system, and evaluated 
sulfasalazine as an in vivo probe in 17 healthy individuals with either the ABCG2 
genotypes 34GG/421CC (wild-type) or 34GG/421CA (variant SNP)(160).  
Remarkably, subjects with the 34GG/421CA genotype exhibited a 2.4-fold 
greater sulfasalazine AUC compared to subjects with the wild-type 34GG/421CC 
genotype after administration of a 1000 mg oral suspension(160). 
Interestingly, rosuvastatin also has been used as a BCRP probe in 
subjects with the frequent ABCG2 SNP C421A (161).  Although rosuvastatin 
undergoes minimal metabolism via CYP2C9 (<10% of dose) (162, 163), it is a 
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substrate of multiple transport proteins including the OATPs, NTCP, P-gp and 
MRP2 (164, 165).  Therefore, rosuvastatin relies on multiple mechanisms for 
clearance, suggesting that it would not be sensitive to modulation of a specific 
clearance pathway.  Rosuvastatin, an HMG-CoA reductase inhibitor whose target 
site is the liver, is excreted extensively into bile with ~90% of the dose recovered 
in feces (76.8% unchanged); these characteristics suggest that rosuvastatin 
would be a good probe to assess hepatic transport protein function(162).  After 
intravenous administration of rosuvastatin, renal and nonrenal (hepatic) 
clearance accounted for 28 and 72% of total systemic clearance, respectively 
(166).  Zhang et al., evaluated the pharmacokinetics of rosuvastatin in individuals 
with the ABCG2 C421A SNP, excluding those with the SLCO1B1 521T>C variant 
and CYP2C9*1/*3, which would be expected to cause decreased hepatic uptake 
and metabolism, respectively.  Their findings demonstrated that rosuvastatin 
disposition was significantly altered by the ABCG2 C421A SNP (AUC was 
increased 80%; Cmax was increased 90%; oral clearance was decreased 43%) 
after exclusion of individuals with the SLCO1B1 T521C and CYP2C9*3 SNPs to 
get a clear understanding of the impact of the BCRP (421C>A) genetic 
polymorphism on rosuvastatin disposition(161).  This suggests rosuvastatin 
disposition is affected by BCRP function, but required the assessment of genetic 
polymorphisms in the OATP1B1 and CYP2C9 genes to be accounted for.  
Therefore, a drug-drug interaction study in vivo utilizing rosuvastatin as the 
phenotyping probe may be difficult to interpret because multiple mechanisms 
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may be involved in an interaction, including inhibition of uptake, metabolism 
and/or efflux.   
One of the most widely studied BCRP substrates is the anticancer drug 
topotecan; a 2.2-fold increase in plasma AUC was reported in cancer patients 
when coadministered with the dual BCRP/P-gp inhibitor GF120918(167, 168).  
However, this interaction was not due solely to BCRP because topotecan is also 
a P-gp substrate(169, 170).  Furthermore, topotecan cannot be administered to 
healthy humans due to its cytotoxic effects. 
 To date there are few candidate BCRP probe substrates identified, but 
sulfasalazine appears to be the most promising.  Other than the extensive 
metabolism in the gut, sulfasalazine is amenable to assessing BCRP function in 
the kidneys and liver.  Furthermore, a clinical study in 17 subjects demonstrated 
increased systemic exposure in patients expressing the variant SNP 421CA 
(160).  The difficulty in identifying specific probes for efflux proteins is the 
substrate overlap with uptake transport proteins.  This is one of the reasons that 
rosuvastatin is not an ideal BCRP probe.  More work is necessary to identify and 
validate probes that are sensitive to changes in BCRP function. 
MRP2 
 MRP2 mediates the efflux of many endogenous and xenobiotic organic 
anions including glutathione, glucuronide and sulfate conjugates.  The 
localization in intestinal and renal epithelia, hepatocytes and in blood-tissue 
barriers signifies the importance of this efflux protein in drug absorption, 
distribution and elimination.  The difficulty in identifying potential probes for 
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MRP2 function is that most substrates are likely substrates for the uptake 
proteins residing on the basolateral membrane (i.e. OATs and OATPs) of 
polarized cells in which MRP2 is localized on the apical membrane (i.e. renal 
tubular cells and hepatocytes).  Furthermore, considerable substrate overlap 
between MRP2 and MRP3 exists.  MRP3 is upregulated as a compensatory 
mechanism when MRP2 function is reduced in hepatocytes.  Therefore, the 
combination of uptake and efflux in both directions makes it difficult to ascertain 
which protein the probe is assessing.  For example, an increase in systemic 
exposure could be the result of either uptake inhibition, or MRP2 inhibition with 
increased MRP3 basolateral efflux.  This complex scenario could be resolved 
with the use of a radiolabeled probe that enabled external quantitative imaging 
and direct measurement of increased tissue exposure due to decreased MRP2 
efflux.   
99mTc-Mebrofenin is a candidate for phentoyping MRP2 function in vivo. 
99mTc-Mebrofenin is a substrate of OATP1B1, OATP1B3, MRP2 and MRP3 in 
transfected Xenopus oocytes and HEK293 cells (171).  In fact, case reports have 
documented a failure to visualize the hepatobiliary tree after 99mTc-disofenin 
(DISIDA), the diisopropyl analog of acetanilidoiminodiacetic acid, when 
administered to patients with Dubin-Johnson syndrome (MRP2-deficient) (172, 
173).   99mTc-HIDA, another analog of acetanilidoiminodiacetic acid, exhibited 
delayed biliary secretion in TR- rats (Mrp2-deficient) compared to wild-type rats, 
demonstrating the importance of Mrp2 in canalicular transport (125).  A 
distinguishing feature of 99mTc-mebrofenin is that hepatic uptake is up to 2-fold 
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greater than its analogs when serum bilirubin levels are as high as 20 mg/dL, 
suggesting that hepatic uptake of 99mTc-mebrofenin would not be inhibited by 
other OATP substrates (174).  99mTc-mebrofenin is a high hepatic extraction 
drug, with more than 98% of an intravenous dose taken up by the liver; the 
hepatic excretion half-life is rapid (16 min) and only ~1.5% of the dose is 
recovered in urine after 24 hours in humans (174).  Assuming well stirred 
conditions hepatic clearance would be limited by blood flow not uptake transport 
proteins (175) and the rapid excretion into bile (174) demonstrates the 
importance of  MRP2-mediated biliary excretion compared to MRP3-mediated 
basolateral efflux.  Therefore, 99mTc-mebrofenin is a potential hepatic probe of 
MRP2 and perhaps MRP3 in specific hereditary and acquired liver disorders 
including progressive familial intrahepatic cholestasis, cirrhosis and cholestasis 
(42-44). 
Angiotensin II receptor antagonists such as olmesartan and valsartan are 
substrates of MRP2 (176-178).   Olmesartan is not metabolized and hepatic 
clearance accounts for 60% of total clearance (179, 180).  Olmesartan is taken 
up in hepatocytes equally by OATP1B1 and OATP1B3 as determined by the 
relative activity factor method; olmesartan is a substrate for MRP2, but not P-gp 
or BCRP (176, 177).  In the kidney, olmesartan is a substrate of OAT1, OAT3, 
MRP2 and MRP4; however, the urinary excretion of olmesartan was unchanged 
in Mrp4-knockout compared to wild-type mice (176).  Determining the rate-
limiting step in hepatic and renal clearance of olmesartan would be important in 
establishing this drug as an MRP2 probe substrate.  Valsartan undergoes a 
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minor degree of metabolism with 89% of the unchanged form circulating in 
plasma and 85% excreted into feces as the unchanged form after oral 
administration (181, 182).  Similar to olmesartan, hepatic clearance of valsartan 
accounts for 70% of total clearance; valsartan is a substrate of OATP1B1, 
OATP1B3 and MRP2, but not P-gp or BCRP in transfected HEK293 and MDCKII 
cells (178).  CYP2C9 is the only isoform involved in the 4-hydroxylation of 
valsartan; many prototypical inhibitors (i.e. furafylline, S(+)-mephenytoin, 
quinidine and troleandomycin) did not affect CYP2C9-mediated 4-hyroxylation of 
valsartan, thus plasma concentrations and systemic clearance would not be 
effectively altered with concomitant administration of CYP2C9 inhibitors(183).  
Both drugs, however, have not been established as clinical probes, or 
investigated in patients with genetic variants in the ABCC2 gene which encodes 
for MRP2.  
Another approach to phenotyping MRP2 function has been to take 
advantage of the role of MRP2 in the biliary clearance of phase II conjugates.  
For example, mycophenolate mofetil, an ester prodrug, is rapidly and extensively 
(95%) hydrolyzed by esterases to the active metabolite mycophenolic acid (184).  
Mycophenolic acid is conjugated by glucuronidation primarily in the liver by 
UGT1A9 and UGT2B7, but also by UGT1A8 in the gastrointestinal tract (185, 
186).  The glucuronide conjugates of mycophenolic acid are excreted into bile by 
MRP2 (187, 188), where they undergo bacterial deconjugation and extensive 
enterohepatic circulation, which accounts for 10 to 61% of the AUC of 
mycophenolic acid AUC (189); the phenolic glucuronide is preferentially excreted 
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in urine (190).  Many studies have investigated the effect of ABCC2 
polymorphisms (C24T and G1249A) on the pharmacokinetics and 
pharmacodynamics of mycophenolic acid; however, the contribution of variants in 
the SLCO1B3 and UGT1A9 genes confound data interpretation (191-194).  
Overall, many mechanisms are involved in the clearance of mycophenolic acid, 
suggesting that the phenolic glucuronide may not be the best probe to assess 
MRP2 function. 
 Due to MRP2 localization on the apical membrane (i.e. renal tubular cells 
and hepatocytes), and the substrate overlap with many uptake proteins (i.e. 
OATs and OATPs), identifying specific probe substrates in which systemic 
concentrations are altered will be difficult.  Currently there are no identified 
probes for this protein, and some that have promise (i.e. valsartan and 
olmesartan) always will be limited by the potential for multiple sites of interaction 
altering the probe substrate pharmacokinetics.  For this reason 99mTc-mebrofenin 
is the most promising probe to assess hepatic MRP2 function due to its high 
hepatic extraction and the ability to directly assess systemic and tissue 
concentrations of this probe. 
OATPs 
Interest in the OATPs has increased in recent years due to the important 
role this subfamily of proteins plays in determining intestinal drug absorption, 
hepatic and renal clearance, and tissue distribution.  Many OATPs share 
common substrates, but there are a few examples of clear differences in 
substrate specificity (e.g., CCK-8 is a specific OATP1B3 subsrate(195)).  
27 
 
Isoform-specific substrates would be useful tools to define the contribution of 
specific OATP isoforms to drug disposition in vitro and in vivo. 
Mechanisms of hepatic transport have been studied extensively for the 
statins, a class of compounds where the target organ is the liver.  Except for 
pravastatin, most statins undergo negligible urinary excretion(196), and with the 
exception of pravastatin(197) and rosuvastatin(163, 198), most statins are 
metabolized by CYPs.  Thus, many statins are  susceptible to metabolism-
mediated drug-drug interactions(196).  Administration of potent CYP3A4, 
CYP2C9 and CYP2C19 inhibitors had no significant effects on the 
pharmacokinetics of pravastatin in healthy volunteers(199, 200).  Transport 
pathways are particularly important for pravastatin clearance.  However, 
pravastatin is a substrate of multiple transport proteins including BCRP, MRP2, 
BSEP, OATP1A2, OATP1B1, OATP2B1, and OAT3 (201-205).  Despite multiple 
mechanisms of transport, pravastatin uptake is the rate-limiting step in the overall 
hepatic clearance of this statin in the rat (206, 207).  Furthermore, pravastatin 
disposition has been studied in various ethnic groups and in patients exhibiting 
multiple genotypes.  Ho et al. investigated the effects of polymorphisms in the 
hepatic drug uptake transport protein OATP1B1 (SLCO1B1), and the efflux 
proteins MRP2 (ABCC2), BSEP (ABCB11) and BCRP (ABCG2), following a 
single 40 mg oral dose of pravastatin in healthy European-Americans and 
African-Americans (208).  The AUC and Cmax were significantly higher in the 
subjects with the SLCO1B1 T521C polymorphism while neither ABCC2, ABCB11 
or ABCG2 genotypes were associated with differences in pravastatin 
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pharmacokinetics.   Other studies using pravastatin as an in vivo probe for 
SLCO1B1 activity have demonstrated altered pharmacokinetics in Japanese and 
European Caucasian individuals who possess variant SLCO1B1 alleles *1b 
(A388G), *5 (T521C) and *15 (combination of *1b and *5) (209-211).   
Rosuvastatin, another potential probe, is metabolically stable, but is a 
substrate for many hepatic uptake and efflux transport proteins including 
OATP1B1, OATP1B3, OATP1A2, OATP2B1, NTCP, P-gp and MRP2 (164, 165).  
As discussed above, rosuvastatin undergoes minimal metabolism.  However, 
rosuvastatin relies on multiple transport proteins for clearance, suggesting that it 
would not be a good phenotypic probe specific for a given transport protein.  
Pharmacokinetic differences in rosuvastatin systemic exposure have been 
investigated in subjects with polymorphisms in the SLCO1B1 gene.  Following a 
10 mg oral dose of rosuvastatin administered to 30 healthy Koreans, the AUC 
and Cmax were significantly higher in the variant group SLCO1B1*15 compared to 
the control SLCO1B1*1a group (212).  Similarly, 32 young healthy white 
volunteers of European descent genotyped for the SLCO1B1 521T>C exhibited 
an increase of 65 and 79% in AUC and Cmax, respectively, compared to those 
with the CC genotype (213) following a 10 mg oral dose of rosuvastatin. 
Therefore, rosuvastatin disposition is sensitive to changes in OATP1B1 and 
BCRP function as a result of genetic polymorphism, but this drug is not the best 
probe due to the involvement of multiple transport mechanisms.   
Pitavastatin is also taken up efficiently from the systemic circulation into 
hepatocytes by OATP1B1 and OATP1B3 (214); BCRP is involved in the biliary 
29 
 
excretion of pitavastatin(215).  Unlike pravastatin and rosuvastatin, pitavastatin 
undergoes more extensive metabolism by CYP2C9 (216, 217), and 
glucuronidation by UGTs, that results in spontaneous lactonization by the 
elimination of the glucuronide moiety (218).  The lactone form can be converted 
back to the parent drug by a reversible reaction(218).  Two studies demonstrated 
that the  SLCO1B1*15 allele resulted in a significant increase in AUC and Cmax of 
pitavastatin in Korean and Japanese healthy volunteers (219, 220).  
Furthermore, the nonsynonymous ABCG2 variant C421A was not associated 
with altered pharmacokinetics of pitavastatin (220).  Therefore, OATP1B1 is a 
determinant of pravastatin, pitavastatin and rosuvastatin hepatic uptake affecting 
their pharmacokinetic profiles in humans.   
Fexofenadine is also a substrate of the OATPs, specifically OATP1B1, 
OATP1B3 and OATP1A2 in humans (221-224).  However, much like other OATP 
substrates, fexofenadine is also a substrate of many efflux proteins such as P-gp, 
MRP2, MRP3, BSEP, and MATE1 (143, 222, 223, 225).   Fexofenadine 
undergoes minimal metabolism (<10%) in humans (226‐228) ; 12% of an oral dose 
is excreted into urine while the remainder of the bioavailable dose is excreted 
into bile (228).  Therefore, fexofenadine relies on active transport as the major 
determinant for systemic clearance.  Fexofenadine has been recommended as 
an in vivo probe substrate for P-gp interactions in the intestine (142), and many 
drug-drug and food-drug interaction studies in humans have been performed 
utilizing fexofenadine as a probe with various co-administered drugs, herbal 
supplements and food components (221, 226, 227, 229-233).  However, the 
30 
 
mechanism(s) resulting in modulation of fexofenadine pharmacokinetics may not 
be straightforward.  In fact, when fexofenadine is administered with known P-gp 
modulators such as diltiazem (233) or verapamil (234), or in individuals with P-gp 
polymorphisms (C3435T and G2677T) (230, 235, 236), no significant change in 
fexofenadine pharmacokinetics has been observed.  However, significant 
changes in fexofenadine AUC have been reported in drug-drug interaction 
studies with known OATP modulators such as fruit juices (237), and in individuals 
with polymorphisms in the SLCO1B1 gene (238), suggesting that fexofenadine 
may be more suitable for assessing OATP function.  None the less fexofenadine 
is not an optimal probe due to the involvement of multiple transport proteins in 
uptake and excretion. 
Most of the aforementioned compounds are primarily substrates of 
OATP1B1.  The other liver-specific OATP isoform, OATP1B3, is involved 
predominantly in the hepatic uptake of telmisartan in humans.  Ishiguro et al., did 
not observe significant uptake of telmisartan in OATP1B1 expressing HEK293 
cells, but telmisartan displayed a high affinity for OATP1B3 with a Km of 0.81 µM 
(239).  Furthermore, 30 µM estrone-3-sulfate inhibited, the OATP substrate, 
estradiol 17β-D-glucuronide uptake, but did not inhibit the uptake of telmisartan in 
cyropreserved human hepatocytes(239).  Telmisartan is a fairly lipophilic 
compound (log P 3.2) that is metabolized to an inactive acyl glucuronide by 
UGTs in the intestine and liver.  The acyl glucuronide is excreted rapidly into bile 
and accounts for 10% of the circulating drug-related material 1 h after oral 
administration in humans.  After intravenously and orally administered 14C-
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labeled mass balance studies, 98% of the telmisartan was recovered in feces, 
and less than 1% was recovered in urine (240, 241).  One challenge in 
establishing an OATP1B3 probe is the lack of identified specific inhibitors in vitro, 
or especially in vivo, and the rare prevalence of functional polymorphisms in the 
SLCO1B3 gene. 
 The difficulties in identifying OATP probe substrates are the overlapping 
specificity of the different isoforms and the involvement of efflux proteins.  As 
mentioned above, statins distribute into the liver and may be useful for assessing 
OATP1B1 and OATP1B3 function.  Although it appears that pravastatin is uptake 
rate-limited, as with all of the probe drugs discussed, many efflux proteins also 
are involved in pravastatin hepatobiliary disposition.  Thus, assuming that 
alterations in the pharmacokinetics of the probe drug are due to decreased 
function of one specific transport protein may not be correct.  Therefore, better 
probes need to be identified although currently, fexofenadine has been used 
extensively and may be suitable for assessing transport protein-mediated 
interactions in the intestine.  With the improvement and increased availability of 
in vitro systems to study hepatic uptake, the differential involvement of OATP1B1 
vs. OATP1B3 will continue to be elucidated and better probes will be identified. 
OATs 
 The OAT family also facilitates the transport of anionic drugs.  There are 
five functional human OAT transport proteins that have been identified.  OAT1, 
OAT3, and OAT4 play a primary role in renal transport, whereas OAT2 is 
expressed significantly in the liver (242, 243).  Studies on the OATs focus on 
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their involvement in the kidney because they are thought to play a minor role in 
the hepatic uptake of drugs.  The potential for drug-drug interactions exists for 
drugs that are secreted actively by the OATs and whose renal clearance is a 
significant component of total clearance.  For example, the decrease in renal 
excretion caused by probenecid co-administration with penicillins, cephalosporins 
and antivirals can be attributed, at least in part, to active tubular secretion via 
OATs (244-246).  In general, the clinical significance of an OAT-mediated drug-
drug interaction resulting in marked inhibition of active renal clearance has a very 
minimal impact on systemic exposure or AUC (247).  An exception to this 
depends on the therapeutic margin of the OAT substrate of which the only 
clinically significant example is methotrexate when coadministered with other 
OAT inhibitors, probenecid and nonsteroidal anti-inflammatory drugs (248, 249).  
This may be due to the fact that renal elimination (a combination of glomerular 
filtration, active secretion, and in some cases reabsorption) typically accounts for 
50% or less of total clearance, and therefore, other routes of clearance can 
compensate for reduced OAT function due to a genetic polymorphism or 
competitive inhibition (5, 79).   
 Tenofovir disoproxil fumarate is an oral prodrug which is converted rapidly 
to tenofovir monoester by esterases or chemical hydrolysis, and then to tenofovir 
by phosphodiesterases (250).  Tenofovir is excreted primarily unchanged in 
urine, while biliary excretion of tenofovir is relatively low; tenofovir is not a 
substrate of CYP enzymes (251-253).  Tenofovir undergoes renal elimination 
through a combination of glomerular filtration and active tubular secretion based 
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on the observation that renal clearance exceeds that of creatinine clearance in 
patients (254).  Tenofovir is taken up with higher affinity for OAT1 than OAT3, 
and is not a substrate of OCT1 or OCT2 (255).  On the apical membrane, 
tenofovir is excreted by MRP4, but not by P-gp or MRP2, as determined in 
multiple transfected systems (256).  Data generated in TR- (Mrp2-deficient) rats 
demonstrated that Mrp2 has a significant influence on tenofovir biliary excretion, 
but not on intestinal excretion in in situ efflux experiments (257).  Two other 
nucleotide reverse transcriptase inhibitors, adefovir and cidofovir, also have been 
shown to be substrates of OAT1 and OAT3, but not OCT2 (255).  Both drugs are 
actively secreted by the kidney (258, 259).  Adefovir is a substrate of MRP2, 
MRP4 and MRP5 (260-262), but no interaction was reported with P-gp or MRP1 
(263), and the absence of Mrp2 in TR- rats did not affect renal clearance, 
suggesting that Mrp2 does not play a critical role in adefovir secretion (264).    
Overall, it appears that OAT1 and probably MRP4 play a significant role in the 
renal elimination of adeofovir, tenofovir and cidofovir, and OAT1 protein plays a 
critical role in mediating nephrotoxicity as a result of exposure of the renal tubular 
cells to clinical doses of adefovir and cidofovir  (265).  Of the twenty OAT1 SNPs 
identified in genomic DNA from African, Asian and Caucasian individuals, the 
R50H-OAT1 variant expressed in xenopus oocytes resulted in decreased 
adeofovir, tenofovir and cidofovir uptake (266).  A separate study identified 12 
coding region variants of OAT1; two of six non-synonymous variants were 
present at ≥ 1%.  Only the OAT1-R454Q was non-functional to the prototypical 
substrates p-aminohippurate, ochratoxin A and methotrexate in xenopus oocytes.  
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However, in a small family-based clinical study, no significant decrease in the 
renal secretory clearance of adefovir was observed in family members 
heterozygous for OAT1-R454Q in comparison to the reference OAT1-454R, 
suggesting that coding region variants of OAT1 may not contribute substantially 
to interindividual differences in renal clearance of adefovir (267). 
 Ro 64-0802 is the active metabolite of oseltamivir, which is converted by 
carboxylesterase 1A1 in the liver and/or intestines (268).  About 60-70% of an 
oral dose is excreted in urine as Ro 64-0802, and less than 5% as the prodrug 
(269).  Less than 20% of an oral dose appears in feces as equal parts of Ro 64-
0802 and oseltamivir (269).   The renal clearance of Ro 64-0802 exceeds the 
glomerular filtration rate, and Ro- 64-0802 has been identified as a substrate of 
OAT1, OAT3 and MRP4 (270, 271).  To investigate a potential transporter 
mediated drug-drug interaction in the renal secretion of Ro 64-0802, healthy 
volunteers were given 500 mg q.i.d. of probenecid starting 1 day before a single 
150 mg oral dose of oseltamivir, which resulted in a 50% decrease in renal 
clearance and a 2.5-fold increase in the plasma AUC (270, 271).  Probenecid is a 
general organic anion inhibitor, but also has been shown to inhibit P-gp, most of 
the MRPs and the OATs (272-276).  Therefore, it is difficult to discern whether 
the decrease in renal clearance of Ro 64-0802 is due to inhibition of OAT-
mediated uptake on the basolateral membrane, MRP-mediated excretion on the 
apical membrane, or a combination of both.  The 2.5-fold increase in exposure 
(plasma AUC) is not clinically relevant due to the large safety margin (269, 277) 
of olsetamavir.  Thus, olsetamavir is a relatively safe drug and may be used in 
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healthy volunteer studies as a probe in subjects expressing genetic variants 
resulting in increased or decreased OAT function.   
More work is necessary to identify and validate probes of OAT function.  
Full characterization of the antiretrovirals tenofovir, adefovir and cidofovir, and 
the active metabolite of the antiviral oseltamivir, as probe substrates are 
necessary to understand the rate-limiting steps in renal clearance.   However, Ro 
64-0802 is the better choice at this point for further investigation due to its safer 
profile when compared to adefovir and cidofovir based on their dose-limiting 
toxicity of nephrotoxicity  (278, 279). 
OCTs 
 The OCTs are a family of transport proteins responsible for the uptake of 
organic cations in a variety of tissues.  Thus far, thee human OCT isoforms have 
been extensively characterized (OCT1-3).  Based on substrates and tissue 
distributions, OCT1, OCT2, and OCT3 are thought to play important roles in the 
biliary and renal excretion of organic cationic drugs and the distribution of these 
compounds in the liver, kidney, heart and brain (66). 
 Metformin, a very hydrophilic organic cation, is metabolically stable.  
Greater than 98% of the absorbed dose of metformin is excreted by the kidneys 
(280-282); approximately 20 to 30% of the dose is recovered in feces unchanged 
(283, 284).  The renal clearance of metformin is much greater than the 
glomerular filtration rate, suggesting a significant contribution of tubular secretion 
(282).  Metformin is a known substrate of OCT1, OCT2, OCT3, MATE1, and 
MATE2-K (69, 285-287) and the newly identified proton-coupled transporter, 
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plasma membrane monoamine transporter (PMAT) (288).  Metformin is positively 
charged at physiologic pH and may be a good probe drug of organic cation 
transporters.  Many studies have investigated the effects of genetic variation in 
OCTs on the pharmacokinetics of metformin.  Shu et al., demonstrated that 
individuals carrying a reduced function OCT1 allele (R61C, G401S, 420del, or 
G465R) had a higher plasma AUC, higher Cmax and lower V/F compared to those 
carrying the OCT1-reference alleles after two oral doses of 850 and 1000 mg 
metformin (289).  Human OCT1 is expressed primarily in the liver (62, 63); in 
Oct1-/- mice, the hepatic uptake of metformin is decreased compared to wild-
type Oct1-/- mice (290).  Therefore, the effects of OCT1 genotype on metformin 
pharmacokinetics, as evidenced by the increased AUC, increased Cmax and 
decreased volume of distribution, in the individuals carrying the reduced function 
alleles of OCT1 may be explained by decreased hepatic uptake.  The same 
group assessed changes in the renal clearance of metformin in Caucasian and 
African-American individuals with genetic variation in OCT2 (amino acid change 
A270S).  The renal clearance and secretory clearance were significantly greater 
in individuals heterozygous for the variant allele (808G/T) of OCT2 than those 
homozygous for the reference allele (808G/G) (291).  A separate study also 
examined genetic variants 596C>T, 620C>T, and 808G>T in the OCT2 gene, 
SLC22A2, which resulted in increased plasma concentrations and decreased 
renal clearance of metformin compared to the reference genotype (292).  The 
discrepancy between the two studies with the 808G>T variant allele may be due 
to the small sample size of the second study and the fact that the reference 
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subjects did not have diabetes.  The importance of OCT1 in the disposition of 
metformin is supported further by a study in 103 healthy male Caucasians; 
metformin renal clearance was significantly dependent on polymorphisms in 
OCT1, but not in OCT2, OCT3, OCTN1 and MATE1 (293).  Cimetidine has been 
reported to significantly increase metformin plasma concentrations and reduce 
metformin renal clearance (72).  The proposed mechanism of this interaction is 
inhibition of the organic cation transporters in the kidney; cimetidine is a 
substrate and inhibitor of OCT1 and OCT2 (64, 294).  Recently, clinically relevant 
concentrations of cimetidine (1 µM) were shown to inhibit MATE1 on the apical 
membrane resulting in increased intracellular accumulation of metformin without 
affecting OCT2-mediated basolateral uptake in double transfected MDCKII cells 
(295).  A clinical study investigated metformin renal clearance in 14 Chinese 
males with the 808G>T polymorphism of OCT2 in a crossover design in the 
presence and absence of cimetidine.  The polymorphism significantly decreased 
metformin renal clearance by 26%.  Inhibition by cimetidine was dependent on 
the genetic variant, resulting in a 42% decrease in metformin renal clearance in 
the reference allele subjects with a subsequent increase in plasma AUC.  In 
contrast, cimetidine treatment significantly decreased renal and total clearance 
but did not significantly change metformin maximum concentration or plasma 
AUC in participants who were heterozygous for the OCT2 808G>T mutation 
(296).  This may be due to increased metformin accumulation in renal epithelial 
cells, which may not be reflected by changes in the plasma concentration.  This 
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hypothesis would support the notion that MATE plays an important role in the 
cimetidine-metformin interaction in vivo.  
Therefore, metformin may not be an ideal probe for a specific organic 
cation transport protein due to changes in its pharmacokinetics associated with 
modulation of OCT1, OCT2 and MATE function, as demonstrated in the various 
clinical studies utilizing individuals with transport protein polymorphisms, and the 
possible cimetidine interaction with MATE on the apical membrane.  What 
distinguishes metformin from other OCT substrates is that it is not a substrate for 
P-gp (297, 298).  Based on its safety profile, high bioavailability, lack of 
metabolism, and extensive use in clinical studies, metformin may continue to be 
used as a general probe for OCT1 and OCT3 function in the liver, and OCT2 
function in the kidney. 
Conclusion 
 To date, there are not many probes suitable for clinical studies that are 
specific for a particular transport protein.  The common difficulty is specificity, and 
the involvement of multiple transport proteins, oftentimes both uptake and efflux 
transporters, in polarized cells.  This highlights the need to investigate transport 
mechanisms and potential drug-drug interactions in an isolated polarized in vitro 
system to help elucidate the in vivo handling of the probe.  Radiolabeled probes 
are optimal due to their ability to provide direct, quantitative measures of 
exposure in multiple compartments, including those that are not routinely 
accessible.  Additionally, radiolabeled probes may be useful for elucidating the 
precise protein affected if the probe is a substrate for an uptake and efflux 
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protein.  Further investigations are necessary to identify and validate specific 
probes, which are needed to advance scientific knowledge in the field of drug 
transport. 
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Project Rational and Specific Aims 
A review of the current literature clearly emphasizes the need for more thorough 
evaluation of three existing probes: fexofenadine, 99mTc-mebrofenin (99mTc-MEB) 
and 99mTc-sestamibi (99mTc-MIBI).  Fexofenadine has been touted as a specific 
P-gp probe substrate (299).  However, current literature suggests that other 
proteins are involved in the hepatic disposition of this compound.  To date, many 
clinical studies have utilized fexofenadine as a probe substrate to assess P-gp 
activity and the inhibitory effects of various xenobiotics, herbal supplements, and 
food components on P-gp function (230, 232-234, 300).  99mTc-MEB and 99mTc-
MIBI have been used as non-invasive probes to assess hepatic uptake and 
excretory function in humans and rodents (124, 301-303).  However, the 
mechanisms of hepatic transport of 99mTc-MEB and 99mTc-MIBI have not been 
elucidated completely in intact hepatocytes and in vivo, especially in disease 
states such as cirrhosis and hepatocellular carcinoma, where hepatic transport 
protein function is altered.  The anticancer agent sorafenib, a recently developed 
oral multikinase inhibitor, relies heavily on the liver for elimination in humans.  
The liver is the target site in the treatment of unresectable hepatocellular 
carcinoma.  Many patients with cirrhosis and hepatocellular carcinoma have 
impaired hepatic function, which results in highly variable clearance of drugs 
including sorafenib.  99mTc-MEB and/or 99mTc-MIBI may be useful probe 
substrates to predict the hepatobiliary disposition of drugs that share similar 
mechanisms of hepatic transport to individualize dosing and explain the 
pharmacokinetic variability. Therefore, elucidating the mechanisms of hepatic 
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uptake and the extent of biliary excretion of sorafenib in humans is an important 
step in validating 99mTc-MEB and/or 99mTc-MIBI as probe substrates to predict the 
hepatic clearance of sorafenib.   
 
Hypotheses: 
The hypothesis of Aim #1 is that fexofenadine is a substrate for multiple 
proteins on both the basolateral and canalicular membrane of hepatocytes in 
humans, rats and mice.  Suggesting, fexofendine is not an optimal probe 
substrate for a specific hepatic transport protein due to compensatory transport 
processes that may be involved in the hepatic clearance of this drug.  The 
hypothesis of Aim #2 is that 99mTc-MEB is primarily a marker for OATP-
mediated hepatic uptake and MRP2-mediated biliary excretion; 99mTc-MIBI is a 
marker for P-gp-mediated biliary excretion. Therefore, these diagnostic imaging 
agents may be used as specific probe substrate to phenotype these hepatic 
transport proteins clinically.  The hypothesis of Aim #3 is that the mechanisms 
of sorafenib hepatic disposition are similar to 99mTc-MEB and 99mTc-MIBI, making 
them ideal probe substrates to predict interindividual differences in hepatic 
clearance of sorafenib in patients with hepatocellular carcinoma and Child’s B 
cirrhosis to explain the variability in the pharmacokinetics and clearance of 
sorafenib.  Furthermore, 99mTc-MEB and 99mTc-MIBI can serve as tools to predict 
the locus and extent of modulation in hepatic transport due to disease states, 
genetics and/or drug interactions. 
This dissertation addresses the following specific aims: 
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Aim #1. Determine whether fexofenadine is an optimal probe substrate for a 
specific transport protein by elucidating the transport proteins and species 
differences in transport proteins responsible for the hepatic excretion of 
fexofenadine (Chapters 2-3). 
 
1.a.  Develop a pharmacokinetic model to describe the disposition of 
fexofenadine in healthy human subjects, and conduct simulations to 
determine if fexofenadine systemic and/or hepatic concentrations are 
sensitive to the inhibition or induction of hepatic transport pathways. 
1.b. Elucidate the involvement of P-gp in the biliary excretion of fexofenadine in 
humans using sandwich-cultured human hepatocytes and the P-gp inhibitor 
GF120918. Validate the results of the simulation studies in Aim #1.a by 
confirming changes in the systemic and hepatic compartment as a result of 
inhibition of fexofenadine biliary excretion. 
1.c.  Determine the canalicular transport protein(s) involved in the biliary 
excretion of fexofenadine using isolated perfused livers from Mrp2-deficient 
TR- rats in combination with “specific” transport protein inhibitors (GF120918 
and bosentan). 
1.d. Define the role of basolateral and canalicular transport proteins in the overall 
hepatic disposition of fexofenadine using isolated perfused livers from 
transport protein-deficient mice. 
 
Aim #2.  Examine the mechanisms of hepatic uptake and excretion of 
99mTechnetium mebrofenin (99mTc-MEB) and 99mTechnetium sestamibi 
(99mTc-MIBI) in intact hepatocytes, and the influence of altered hepatic 
transport protein function, on the hepatobiliary disposition of 99mTc-MEB 
and 99mTc-MIBI (Chapter 4).   
 
2.a. Characterize 99mTc-MEB and 99mTc-MIBI uptake in suspended rat and 
human hepatocytes in the absence and presence of “specific” inhibitors of 
basolateral transport proteins.  
2.b. Characterize 99mTc-MEB and 99mTc-MIBI hepatobiliary disposition in 
sandwich-cultured rat hepatocytes from wild-type (WT) wistar rats, TR- rats, 
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and in the presence of “specific” transport protein inhibitors (e.g., 
GF120918). 
2.c. Characterize 99mTc-MEB and 99mTc-MIBI hepatobiliary disposition in 
sandwich-cultured human hepatocytes in the absence and presence of 
“specific” transport protein inhibitors (e.g., GF120918 and MK-571).  
 
Aim #3.  Identify mechanisms of hepatic disposition of sorafenib in human 
hepatocytes, and evaluate 99mTc-MEB and 99mTc-MIBI as transport protein 
probe substrates to determine if their disposition is sensitive to changes in 
hepatic transport protein function as a result of hepatocellular carcinoma 
and cirrhosis (Chapters 5-6).   
 
3.a.  Investigate the hepatobiliary disposition of sorafenib in human 
hepatocytes. 
3.b. Compare the pharmacokinetics and hepatic exposure of 99mTc-MEB and 
99mTc-MIBI in a patient with hepatocellular carcinoma and Child’s Pugh B 
cirrhosis vs. healthy human volunteers. 
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TABLE 1: Clinical Transport Protein Probes 
Protein Probe Established 
No (n=1) 
Moderately (n=3-5 
studies) 
Yes (n=>5 studies)
Advantages Limitations 
P-gp Digoxin Yes (FDA 
recommended) 
Well established 
Oral and I.V. doses 
No metabolism 
OATP substrate, 
Narrow therapeutic window 
99mTc-Sestamibi Moderately Radiolabeled 
No metabolism 
No uptake protein interaction 
Contribution of MRPs unknown 
11C-Verapamil No Radiolabeled 
Assess P-gp at the BBB 
No uptake protein interaction 
CYP3A-mediated metabolism 
BCRP Sulfasalazine No  Low F due to extensive 
metabolism in the gut 
MRP2 99mTc-
Mebrofenin 
No Radiolabeled 
No metabolism 
 
Hepatic MRP2 only 
Substrate of OATPs but high 
hepatic E 
OATP1B1 Pravastatin Yes Minimal metabolism 
Uptake rate-limited 
Substrate of other OATPs and 
efflux proteins 
Higher degree of urinary 
excretion compared to other 
statins 
 
Rosuvastatin No Minimal metabolism Substrate of many other 
transport proteins including 
OATPs 
Possible BCRP probe 
Pitavastatin No  Substrate of many other 
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transport proteins 
Extensive metabolism 
Fexofenadine Yes Safe 
Minimal Metabolism 
Often used as a P-gp probe 
Substrate of many other 
transport proteins 
OATP1B3 Telmisartan No OATP1B3 specific Metabolized by UGTs to an 
acyl glucuronide 
OAT Tenofovir No  Substrate of Efflux Proteins  
Prodrug requires metabolism 
Ro 64-0802, 
active metabolite 
of Oseltamivir 
No Safe 
 
Substrate of Efflux Proteins 
Prodrug requires metabolism 
Needs further transport 
characterization 
OCT Metformin Yes Safe 
Minimal Metabolism 
Not a P-gp substrate 
Substrate of efflux proteins 
Not isoform specific 
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CHAPTER 2 
 
 
 
 
 
 
Integration of Preclinical and Clinical Data with Pharmacokinetic Modeling and 
Simulation to Evaluate Fexofenadine as a Probe for Hepatobiliary Transport 
Function 
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permission of Springer Science and Business Media. 
 Abstract 
The suitability of fexofenadine as a probe substrate to assess hepatobiliary transport 
function in humans was evaluated by pharmacokinetic modeling/simulation and in 
vitro/in situ studies using chemical modulators.  Simulations based on a pharmacokinetic 
model developed to describe fexofenadine disposition in humans were conducted to 
examine the impact of altered hepatobiliary transport on fexofenadine disposition.  The 
effect of GF120918 on fexofenadine disposition was evaluated in human sandwich-
cultured hepatocytes (SCH).   Additionally, the effect of GF120918, bosentan, and 
taurocholate on fexofenadine disposition in perfused livers from TR- Wistar rats was 
examined.  Based on modeling/simulation, fexofenadine systemic exposure was most 
sensitive to changes in the hepatic uptake rate constant, and did not reflect changes in 
hepatic exposure due to altered hepatic efflux.  GF120918 did not impair fexofenadine 
biliary excretion in human SCH.  GF120918 coadministration significantly decreased 
Cl’biliary to 27.5% of control in perfused rat livers.  Simulations were in agreement with 
perfused liver data which predicted changes in fexofenadine systemic exposure primarily 
due to altered hepatic uptake. Fexofenadine is not a suitable probe to assess hepatic 
efflux function based on systemic concentrations.  GF120918-sensitive protein(s) 
mediate fexofenadine biliary excretion in rat liver, whereas in human hepatocytes 
multiple efflux proteins are involved in fexofenadine hepatobiliary disposition. 
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 Introduction 
Fexofenadine is an orally administered nonsedating H1-receptor antagonist 
commonly used in the treatment of allergic rhinitis and chronic urticaria.  Fexofenadine 
has a low passive membrane permeability with reported Papp values in the absorptive 
direction of 0.17 x 106 to 0.27 x 106 cm/s determined in the Caco-2 model (1).  
Furthermore, the effective jejunal permeability in healthy human volunteers also was 
very low when fexofenadine was administered alone and with verapamil using jejunal 
single-pass perfusion (0.06 x 10-4 ± 0.07 x 10-4 and 0.04 x 10-4 ± 0.07 x 10-4 cm/s, 
respectively)(2, 3).  The primary elimination pathway of fexofenadine in humans is biliary 
excretion of the unchanged drug (4).  Tahara et al. demonstrated that biliary clearance 
accounts for ~56-72% and 40% of total body clearance in mice and rats, respectively (5).  
Therefore, fexofenadine relies on active hepatic transport as one of the determinants for 
systemic clearance. 
Identifying the degree and importance of drug-drug interactions in the human 
liver is very challenging because the bile and liver compartments are not readily 
accessible due to the anatomy of the human hepatobiliary tract.  The absolute oral 
bioavailability of fexofenadine was reported to be 33% (product information, Hoechst 
Marion, Roussel, Laval, Quebec, Canada), with 12% of the total administered dose 
recovered in urine (4).  Therefore, two-thirds of the bioavailable dose of fexofenadine is 
presumed to be excreted in bile, underscoring the importance of this excretory route to 
overall systemic clearance.  Fexofenadine has been used extensively as an in vivo 
probe substrate to assess P-glycoprotein/multidrug resistance protein 1 (P-gp/MDR1) 
activity; altered systemic concentrations and overall exposure have been reported due to 
perturbations in P-gp efflux in the intestine (6-9).  The contribution of P-gp to 
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 fexofenadine hepatobiliary transport, or the degree of interaction with hepatic P-gp, are 
poorly understood in humans. 
The organic anion transporting polypeptides (OATPs), specifically OATP1B1, 
OATP1B3 and OATP1A2 in humans, and Oatp1a1, Oatp1a4, and Oatp1b2 in rats, have 
been implicated in the cellular uptake of fexofenadine (8, 10-12).  In vitro studies 
demonstrated that P-gp mediated the cellular efflux of fexofenadine (10). Thus, 
fexofenadine has been recommended as an in vivo probe substrate for P-gp interactions 
in the intestine (13).  In fact many drug-drug and food-drug interaction studies in humans 
utilizing fexofenadine as a probe substrate for P-gp activity have been performed with 
various co-administered drugs, herbal supplements and food components (6-9, 14-17).  
Although P-gp plays a role in limiting intestinal absorption and blood-brain barrier 
penetration of fexofenadine (5, 10), multiple transport mechanisms are involved in the 
biliary excretion of fexofenadine (18, 19).   
In mice fexofenadine is excreted into bile predominantly by multidrug resistance-
associated protein 2 (Mrp2), and to a minor extent by P-gp and other yet unidentified 
mechanisms (18).  The mechanisms of biliary excretion of fexofenadine in vivo in rats 
and humans have not been elucidated.  However, the biliary excretion rate and intrinsic 
biliary clearance of fexofenadine in naturally occurring Mrp2-deficient TR- rats and Eisai 
hyperbilirubinemic rats (EHBR) were unchanged compared to wild-type rats (5, 18).  In 
the present studies, the role of other canalicular transport proteins including the bile salt 
export pump (Bsep) and P-gp in fexofenadine biliary clearance was investigated in rat 
perfused livers.   
Bsep is primarily involved in the biliary excretion of bile acids (20), but also is 
capable of transporting some xenobiotics including vinblastine, pravastatin and 
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 fexofenadine in transfected expression systems (19, 21, 22).  P-gp serves an important 
barrier function and is responsible for biliary excretion of bulky hydrophobic and cationic 
substrates, including many chemotherapeutic agents, cardiac glycosides, cyclosporin A, 
HIV protease inhibitors, and fexofenadine, as mentioned above (23).  Breast cancer 
resistance protein (Bcrp) transports sulfated steroids and many anticancer agents in 
addition to some organic anions and cations (24-26).  Fexofenadine does not appear to 
be a BCRP/Bcrp substrate based on the results of studies utilizing Bcrp knockout mice 
and MDCKII cells transfected with human BCRP (5, 19).   
The objective of the present study was to examine the suitability of fexofenadine 
as a probe substrate for altered hepatobiliary transport in humans.  A pharmacokinetic 
model was developed to describe the disposition of fexofenadine in healthy human 
subjects, and simulations were conducted to examine the effect of inhibition or induction 
of hepatic transport processes on fexofenadine disposition.   The findings from 
compartmental modeling and simulation were tested using chemical modulators of 
hepatic transport proteins.  The effect of GF120918, a human P-gp and BCRP inhibitor, 
was assessed in human sandwich-cultured hepatocytes (SCH).  In addition, livers from 
Mrp2-deficient TR- rats were perfused in situ in a single-pass manner in the presence 
and absence of the Bsep inhibitor bosentan (27), and GF120918 to examine the impact 
of modulation of uptake and efflux proteins on fexofendadine hepatobiliary disposition.  
Furthermore, the taurocholate infusion in perfused livers was withheld to perturb 
trafficking of ATP-binding cassette (ABC) transport proteins to the canalicular membrane 
(28, 29) in order to assess the contribution of impaired biliary excretion to fexofenadine 
disposition.   
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 Material and Methods 
Materials. Dulbecco’s modified Eagle’s medium (DMEM), insulin, MEM non-essential 
amino acids solution (100x), L-glutamine, insulin and penicillin G-streptomycin solution 
were purchased from Invitrogen (Carlsbad, CA). Collagenase (type 4), fetal bovine 
serum (FBS), fexofenadine, cetirizine, sodium taurocholate, digoxin, Triton X-100, 
dexamethasone, methanol, Krebs-Henseleit buffer packs (K-3753) and Hanks’ balanced 
salt solution (HBSS) modified with (H-1387) or without (H-4891) calcium chloride were 
obtained from Sigma-Aldrich (St. Louis, MO). BioCoat™ collagen I plates, Matrigel™ 
basement membrane matrix, and ITS+™ (insulin/transferrin/selenium) culture 
supplement were purchased from BD Biosciences Discovery Labware (Bedford, MA). 
[3H]-taurocholate (5 Ci/mmol, >97% purity) and [3H]-digoxin (40 Ci/mmol, >97% purity) 
were obtained from PerkinElmer Life and Analytical Sciences (Boston, MA). Bio-Safe II™ 
liquid scintillation cocktail was obtained from Research Products International (Mt. 
Prospect, IL). Centrifree® micropartition devices were obtained from Millipore (Billerica, 
MA). Bicinchoninic acid (BCA) protein assay reagents and BSA for the protein assay 
standard were purchased from Pierce Chemical Co. (Rockford, IL). N-(4-[2-(1,2,3,4-
tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-
acridine carboxamide (GF120918) was a gift from GlaxoSmithKline (Research Triangle 
Park, NC).  All other chemicals and reagents were of analytical grade and available from 
commercial sources. 
Pharmacokinetic Modeling 
Mean fexofenadine plasma concentrations and urinary excretion rate data were 
estimated from previously published data in healthy human subjects after a single oral 
dose of 120 mg (9).  Cumulative mass in bile after 48 hours was estimated based on the 
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 assumption that bioavailability of oral fexofenadine was 33% (product information, 
Hoechst Marion, Roussel, Laval, Quebec, Canada), of which approximately one-third of 
the 120 mg dose was excreted into urine (30), and two-thirds was excreted into bile.  To 
achieve model parsimony, the bioavailability of fexofendine was fixed at the 
aforementioned literature value (33%). The adoption of fixed bioavailability accounted for 
the first-pass extraction of fexofenadine; the remaining fixed fraction of the dose was 
assumed to be absorbed directly into the systemic compartment.  This assumption was 
supported by the fact that fexofenadine exhibited a low hepatic uptake clearance.     A 
number of different compartmental models were developed (including a peripheral 
compartment in addition to the liver compartment, with elimination from the peripheral, 
central and/or liver compartments) using the concentration- and mass-time profiles.  
Differential equations describing the disposition of fexofenadine in the compartments 
were fit simultaneously to plasma, urine and bile profiles using nonlinear least-squares 
regression (WinNonlin v. 4.1 Pharsight Corporation, Mountain View, CA).  The final 
parameter estimates were selected after fitting the model to the data using different sets 
of initial values combined with a broad range of lower and upper bounds to avoid 
convergence at a local minimum. The goodness of fit was based on Akaike’s Information 
Criterion, the residual sum of squares, coefficients of variation on the parameter 
estimates, the condition number, and visual inspection of the residual plots and of model 
fitting to the concentration- and mass-time profiles.  Due to the disparity in the number of 
data points for the mass in bile and the urinary excretion rate data compared with the 
plasma concentration data, a weighting scheme was used to account for the relative 
contribution of each data set to the overall number of data points.  Each data point was 
assigned a weight of )1(1 n
y
−× , where n is the fraction of the total number of data 
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 points that support a particular sample matrix.  The optimal model that best described 
the data is shown in Figure 2.1.  This model included a compartment depicting the 
systemic circulation described by the plasma concentration-time profile after absorption, 
represented by a first-order rate constant Kabsorb, from the gut compartment.  A first-order 
rate constant, K12, governed fexofenadine uptake from the central compartment into a 
peripheral compartment, representing the liver. K21 represented a first-order rate 
constant for hepatic basolateral efflux; Kbile and  Kurine represented biliary and urinary 
excretion rate constants, respectively.  The following differential equations described 
fexofenadine disposition in healthy human subjects: 
gutabsorb
gut XK
dt
dX ×−=                                           0.33XX dose oral0gut ×=
curine
c
liver21c12
c
gutabsorb
C CK
V
1XKCK
V
1XK
dt
dC ×−××+×−××=                       0C0C =
liverbileliver21CC12
liver XKXKVCK
dt
dX ×−×−××=     0X0liver =
liverbile
bile XK
dt
dX ×=                      0X0bile =
ccurine
urine VCK
dt
dX ××=                                                                                0X0urine =
Pharmacokinetic Simulations 
The contribution of each parameter in this compartment model to the overall disposition 
of fexofenadine was assessed through a series of simulation experiments.  Each 
parameter was varied sequentially from the baseline value by either increasing (i.e. 
induction) or decreasing (i.e. inhibition) the parameter estimate by 50%, 100% or 300%.  
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 The concentration-, mass- and excretion rate-time profiles were simulated using 
WinNonlin v.4.1, and the area under the curve (AUC) for the plasma concentration-time 
and hepatic mass-time profiles were calculated utilizing a standard noncompartmental 
approach. 
Isolation and In Vitro Culture of Primary Human Hepatocytes 
Human liver tissue was obtained by qualified medical staff from the University of North 
Carolina, School of Medicine, as waste from surgical resection.  Written informed 
consent was obtained from patients before undergoing hepatic surgery.  IRB approval 
was obtained for the collection of human liver tissue.  Hepatocytes were isolated by a 
modification of the two-step collagenase perfusion, as described previously (31). Cell 
viability, determined by trypan blue exclusion, was >88%. Hepatocytes were seeded 
(~1.5 x 106 cells/well) in 6-well BioCoat™ plates in DMEM without phenol red 
supplemented with 2 mM L-glutamine, 1% (v/v) MEM non-essential amino acids, 100 
units penicillin G sodium, 100 µg streptomycin sulfate, 1 µM dexamethasone,  5% (v/v) 
FBS, and 10 µM insulin (day 0 of culture), and allowed to attach for 2-6 h in a humidified 
incubator (95% O2, 5% CO2) at 37oC. After cell attachment, culture plates were swirled 
gently and the culture medium was replaced with the same medium.  Cells were overlaid 
16-24 h (day 1 of culture) after seeding with ice-cold  Matrigel™ basement membrane 
matrix (0.25 mg/mL) in 2 mL/well cold serum-free DMEM containing 2 mM  L-glutamine, 
1% (v/v) MEM non-essential amino acids, 100 units penicillin G sodium, 100 µg 
streptomycin sulfate, 0.1 µM dexamethasone, and 1% (v/v) ITS+™. The culture medium 
was changed every 24 h until experiments were performed on day 9-10 of culture. 
Accumulation Experiments 
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 The method to determine substrate accumulation in SCH has been described previously 
(32). Briefly, hepatocytes were rinsed twice with 2 mL warm HBSS containing Ca2+ 
(standard buffer) or Ca2+-free HBSS and incubated with 2 mL of the same buffer for 10 
min at 37oC (to maintain tight junction integrity and bile canalicular networks, or disrupt 
tight junctions and open bile canalicular networks, respectively). The buffer was 
removed, and the cells were incubated for 10 min at 37oC with 1.5 mL of [3H]-
taurocholate (1 µM), [3H]-digoxin (1 µM) in the presence and absence of 2 µM 
GF120918, or for 30 min with fexofenadine (5 µM) in the presence and absence of 2 µM 
GF120918 in standard buffer. Hepatocytes were rinsed vigorously three times with 2 mL 
ice-cold standard buffer following the incubation. Taurocholate- and digoxin-treated 
hepatocytes were lysed with 1 mL 0.5% (v/v) Triton X-100 in phosphate-buffered saline 
by placing plates on an orbital shaker for a minimum of 20 min at room temperature. 
Substrate uptake was corrected for nonspecific binding by subtracting uptake on blank 
six-well BiocoatTM plates overlaid with MatrigelTM.  Data were normalized to protein 
concentration in each well, determined in duplicate aliquots using BCA protein assay 
reagent kit (Pierce) as instructed by the manufacturer.  BSA, as supplied by the 
manufacturer, was used as a standard (0.2 – 1 mg/mL).  Due to incompatability of the 
protein assay with methanol, the average protein concentration for standard HBSS or 
Ca2+-free HBSS incubations in the same liver preparation was used to normalize 
fexofenadine content.  The [3H]-taurocholate and [3H]-digoxin samples were analyzed by 
liquid scintillation spectroscopy in a Packard Tri-Carb scintillation counter (PerkinElmer 
Life and Analytical Sciences). Fexofenadine-treated hepatocytes were lysed with 1 mL 
70% (v/v) ice-cold methanol/water and stored at -80ºC until analysis. The cells were 
scraped off the plates and centrifuged at 10,000 g for 5 min before analysis by 
LC/MS/MS. 
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 Animals 
Male Mrp2-deficient TR- rats bred at the University of North Carolina (212–341 g; breeding 
stock obtained from Dr. Mary Vore, University of Kentucky, Lexington, KY) were used for 
perfused liver studies.  Rats had free access to water and food prior to surgery.  All animal 
procedures complied with the guidelines of the Institutional Animal Care and Use 
Committee (University of North Carolina, Chapel Hill, NC).  
In Situ Liver Perfusion 
All experimental procedures were performed under full anesthesia induced with 
ketamine/xylazine (140/8 mg/kg i.p.). The liver perfusion procedure was modified slightly 
from the previous report of Tian et al (2008). Briefly, the common bile duct was 
cannulated with polyethylene PE-10 tubing (Becton Dickinson, Parsippany, NJ). The 
portal vein was cannulated with a 16-gauge catheter (B. Braun Medical Inc., Bethlehem, 
PA), the abdominal vena cava below the liver was severed immediately by incision, and 
the inferior vena cava above the liver was cannulated with a 14-gauge catheter. 
Subsequently, the inferior vena cava was ligated between the liver and kidney to direct 
all perfusate outflow through the cannulated inferior vena cava above the liver. The liver 
was perfused in a single-pass manner (30 ml/min with fexofenadine-free, continually 
oxygenated, Krebs-Henseleit buffer in the presence of 5 µM taurocholate, unless 
otherwise indicated) for an equilibration period of ~15 min.  Following the pre-perfusion 
period to allow for equilibration of temperature (37ºC) and bile flow, the liver was 
perfused for 60 min with buffer containing 5 µM taurocholate, unless otherwise indicated, 
and 0.5 µM fexofenadine alone, or with 2 µM GF120918 or 5 µM bosentan.  Bile and 
outflow perfusate were collected in 10-min intervals in toto, and livers were isolated at 
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 the end of perfusion and stored at -80ºC until analysis. Perfusion pressure and bile flow 
were used to assess liver viability (33).  
Determination of Protein Binding 
Livers were thawed and homogenenized in three volumes (v/w) of 0.1 M phosphate 
buffer (pH 7.4).  Liver homogenate samples (500 µL) were placed in Centrifree® 
micropartition devices and centrifuged at 1000 g at 4oC for 10 min to pass ~10% of the 
original volume through the filter. The absence-of-protein condition was used to assess 
non-specific binding. Samples were obtained from above (total concentration in the 
presence of protein) and below (unbound concentration) the filter, and analyzed by liquid 
chromatography with detection by tandem mass spectrometry (LC/MS/MS). 
Analytical Methods 
Bile, outflow perfusate, liver homogenate, ultracentrifugation filtrate and human SCH 
lysates were analyzed by LC/MS/MS (Applied Biosystems API 4000 triple quadrupole 
with TurboIonSpray interface, MDS Sciex, Concord, ON, Canada).  Fexofenadine and 
cetirizine (internal standard) were eluted from an Aquasil C18 column (5μm, 50mm x 
2.1mm, Thermo-Electron, Waltham, MA) using a mobile phase gradient at a flow rate of 
0.75 mL/min (A: 0.1% formic acid in water, B: 0.1% formic acid in methanol); 0-0.8 min 
hold at 10% B, 0.8-3.5 min linear increase to 85% B, 3.5-4.0 min hold at 85% B, 4.0-4.5 
min return to 10% B, 4.5-5 min hold at 10% B (Shimazdu solvent delivery system, 
Columbia, MD). Fexofenadine and the internal standard, cetirizine, were detected in 
positive ion mode using multiple reaction monitoring: fexofenadine, 502.3 → 466.4 m/z; 
cetirizine, 389.0 → 201.0 m/z.  Fexofenadine was quantified with seven point standard 
curves prepared in the appropriate matrix, and coefficients of variation were  <14%. 
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 Data Analysis 
For SCH studies, the biliary excretion index (BEI, %) and in vitro biliary clearance 
(Clbiliary, mL/min/kg) were calculated using B-CLEAR® technology [Qualyst, Inc., Raleigh, 
NC; (32)]:  
 
100
onAccumulati
onAccumulationAccumulati
BEI
BileCells
CellsBileCells ×−=
+
+                                (1) 
 
where substrate accumulation in the cells + bile compartments was determined in 
hepatocytes preincubated in standard buffer; cellular accumulation of substrate was 
determined in hepatocytes preincubated with Ca2+-free HBSS.  
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CellsBileCells
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Clvitroin
−
+ −=                      (2) 
 
where AUC0-T represents the product of the incubation time (T) and the initial 
concentration in the medium.  In vitro Clbiliary values were scaled per kilogram body 
weight using 1 mg protein/1.5 x 106 cells (the typical value obtained in all preparations), 
107 x 106 hepatocytes/g of human liver tissue (34),  and 25.7 g of liver tissue per kg of 
body weight (35).   
89 
 
 90 
 
Steady-state fexofenadine concentrations were defined as the average perfusate 
concentration during the 50- to 60-min interval based on experiments performed by Tian 
et al. (18) in which outflow fexofenadine concentrations reached a plateau after 50 min 
of infusion in in situ single-pass perfused rat liver studies.  The hepatic extraction ratio 
was calculated as the ratio of the difference between steady-state inflow and outflow 
fexofenadine concentrations and the steady-state inflow concentration.  Unbound 
intrinsic biliary clearance (Cl’biliary) was calculated as the ratio of the fexofenadine biliary 
excretion rate and the unbound liver concentration (Cliver,unbound). 
All data were reported as mean ± SD (n = 3-4 per group). Statistical significance 
was assessed by one-way analysis of variance (ANOVA) with Dunnett’s post-hoc test. In 
all cases, p < 0.05 was considered to be statistically significant.  
 Results 
Pharmacokinetic Modeling and Simulation of Data from Healthy Human Subjects 
 The model scheme depicted in Fig. 2.1 best described the fexofenadine plasma 
concentration vs. time and urinary excretion rate vs. time data obtained from a 
previously published study (9), as shown in Fig. 2.2.  Parameter estimates for 
fexofenadine disposition based on the human data are reported in Table 2.1.  The ratio 
of the biliary (Kbile) and basolateral (K21) efflux  rate constants was 5.6, suggesting that 
once in the liver, the predominant process that determines fexofenadine disposition is 
excretion into bile.   
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 To assess the influence of alterations in hepatic uptake (K12) or excretion  (K21, 
Kbile) on fexofenadine systemic and hepatic exposure, simulations were performed using 
the parameter estimates in Table 2.1.  Based on these simulations, a 50%, 100% and 
300% change in the hepatic uptake rate constant (K12) resulted in a 18% or greater 
difference in the systemic exposure of fexofenadine, determined as the AUC of the 
plasma concentration-time profile (Fig. 2.3.A).  Similar changes in the basolateral efflux 
rate constant (K21), and biliary excretion rate constant (Kbile),  resulted in less than a 7% 
change in the systemic AUC, except for the 300% increase in basolateral efflux, which 
increased the systemic AUC ~14%.  Importantly, hepatic exposure, determined as the 
AUC of the hepatic mass-time profile, was sensitive to changes in the hepatic uptake 
rate constant (K12) as well as the biliary excretion rate constant (Kbile).  A 50%, 100% 
and 300% change in K12 resulted in a 12–16%, 26–30% and 39–46% change, 
respectively in hepatic exposure.  In contrast to systemic exposure, perturbations in Kbi
produced at least a 18% difference in hepatic exposure for all simulations.  Altera
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the basolateral efflux rate constant (K21) resulted in negligible changes in hepatic 
exposure of fexof
Biliary Excretion of Fexofenadine in Human Sandwich-Cultured Hepatocytes 
 The in vitro biliary excretion of [3H]taurocholate, [3H]digoxin and fexofenadine 
was measured in human SCH from two unrelated donors.  Cellular accumulation of the 
model bile acid [3H]taurocholate (73.8 and 57.8 pmol/mg protein) and BEI [58.1 and 52.4 
%, (Table 2.2)] were consistent with previous data generated in this model system.  As a 
positive control, the P-gp substrate [3H]digoxin was evaluated in the presence and 
absence of GF120918.  Cellular accumulation of [3H]digoxin was increased slightly by 
GF120918 for one liver (21.0 vs. 29.9 pmol/mg protein); the BEI and in vitro biliary 
clearance of [3H]digoxin were abolished completely  by GF120918 in both livers (Table 
2.2).  Fexofenadine cellular accumulation increased slightly in the presence of 
GF120918 in both livers (66.2 vs. 93.2 and 62.5 vs. 65.1 pmol/mg protein), but 
fexofenadine BEI and in vitro biliary clearance were not decreased by GF120918 in 
human SCH.  Both,  BEI and in vitro biliary clearance values were decreased in 
hepatocytes from the second liver donor compared to the first for all three compounds, 
suggesting decreased development of the bile canalicular networks and/or canalicular 
protein function in this liver donor.   
Fexofenadine Recovery in Perfused Livers from TR- Rats 
Bile flow rates (mean ± SD) in TR- rat livers perfused with 5 µM taurocholate and 
0.5 µM fexofenadine (control) or in combination with either 2 µM GF120918 or 5 µM 
bosentan, were 0.54 ± 0.04, 0.52 ± 0.02 and 0.60 ± 0.05 µL/min/g liver, respectively.  
Compared to control values, bile flow rates in livers from TR- rats perfused without 5 µM 
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taurocholate were decreased ~50% to 0.28 ± 0.03 µL/min/g liver.  Bile flow in each 
group was stable during the 60-min perfusion period (Fig. 2.4.A).  The total recovery of 
fexofenadine at the end of the perfusion period, as a percentage of the total infused 
dose, was 86 ± 16% in control, 77 ± 9% without taurocholate, 75 ± 4% with GF120918, 
and 81 ± 9% with bosentan. 
Fexofenadine concentrations in outflow perfusate are presented in Fig. 2.4.B 
(mean ± SD).  Outflow perfusate concentrations at the end of the infusion were 
significantly increased in the presence of GF120918 (171.5 ± 58.8 pmol/mL) and 
bosentan (209.0 ± 19.4 pmol/mL), compared to control (92.3 ± 29.4 pmol/mL); 
GF120918 and bosentan significantly decreased the extraction ratio of fexofenadine 
(Fig. 2.4.B; Table 2.3)].  The biliary excretion rate of fexofenadine was decreased ~38% 
when taurocholate was withheld from the inflow perfusate; coadministration of 
GF120918 and bosentan decreased the fexofenadine biliary excretion rate ~75% and 
~35%, respectively (Fig. 2.4.C; Table 2.3).  Unbound fexofenadine concentrations in 
livers were not significantly different among the treatment groups, although unbound 
liver concentrations tended to be higher in the presence of GF120918. Bosentan 
significantly decreased the ratio of fexofenadine unbound liver concentrations to outflow 
perfusate concentrations, consistent with inhibition of fexofenadine partitioning from 
perfusate to liver.  Fexofenadine Cl’biliary was only significantly decreased in the presence 
of GF120918.   
 Discussion 
To evaluate the utility of fexofenadine as a probe substrate for hepatobiliary 
transport function, pharmacokinetic modeling and simulation studies based on previously 
published data were utilized to examine the impact of hepatic transport modulation on 
the systemic and hepatic exposure of fexofenadine in humans.  Furthermore, modeling 
and simulation of fexofenadine data in humans was supported by in vitro studies in 
human SCH and perfused rat livers using various chemical modulators of hepatic 
transport proteins.   
The pharmacokinetic model adequately described the mean fexofenadine 
plasma concentrations, urinary excretion rate and estimated cumulative mass in bile 
data after a 120 mg oral dose (Fig. 2.2); low variability was associated with the 
parameter estimates (Table 2.1).  Although the predominant process determining the 
systemic clearance of fexofenadine in humans appears to be hepatic uptake based on 
the parameter estimates governing fexofenadine disposition (Table 2.1), the hepatic 
uptake clearance of fexofenadine is low [K12 x Vc = 6.92 L/h] relative to hepatic blood 
flow in humans ~87 L/h (35) . 
To examine the sensitivity of systemic and hepatic exposure to changes in 
hepatic uptake and efflux processes in humans, a simulation approach was utilized, and 
the rate constants representing the active transport processes governing hepatic uptake 
and efflux were modulated in a systematic manner.  The results indicated that the central 
compartment, representing the systemic circulation, is most sensitive to changes in the 
hepatic uptake rate constant, rather than the basolateral efflux rate constant, or the 
biliary excretion rate constant (Fig. 2.3).  This finding is supported by the absence of 
drug-drug interactions (defined as a significant change in fexofenadine 
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 pharmacokinetics) when fexofenadine is administered with known P-gp modulators such 
as diltiazem (9) or verapamil (3), or in individuals with P-gp polymorphisms (C3435T and 
G2677T) (14, 36, 37).  Furthermore, simulations are consistent with drug-drug 
interaction studies with known OATP modulators such as fruit juices (30), and in 
individuals with polymorphisms of the SLCO1B1 gene (38), where significant changes in 
fexofenadine AUC have been reported.  In contrast, simulations revealed that hepatic 
fexofenadine exposure in humans was sensitive to alterations in either the hepatic 
uptake rate constant or the biliary excretion rate constant.  Most importantly, the marked 
increase in fexofenadine hepatic exposure due to modulation of Kbile was not reflected 
by changes in the systemic concentration-time profile in humans (Fig. 2.3).  This 
demonstrates the difficulty in assessing hepatic exposure by only measuring systemic 
concentrations of a substrate like fexofenadine.  In humans, multiple transport proteins 
appear to be involved in fexofenadine biliary excretion, thus, the suitability of this 
substrate as a probe to assess altered hepatic excretion in humans is limited.  However, 
based on perfused rat liver data, the GF120918-sensitive component of biliary excretion 
plays a predominant role in canalicular transport in rats; inhibition of fexofenadine biliary 
excretion resulted in increased perfusate concentrations. These data underscore the 
importance of species differences in hepatobiliary drug transport, and the important role 
that compensatory transport proteins may play in determining the systemic and/or 
hepatic exposure of a substrate when hepatic transport processes are modulated. 
Furthermore, as depicted in Figure 2.3, significant interactions in hepatic excretion of a 
drug that displays hepatobiliary disposition characteristics similar to fexofenadine may 
not be reflected by changes in the plasma concentration-time profile. 
To investigate the changes in systemic and hepatic exposure after inhibition of 
fexofenadine biliary excretion, and examine the involvement of P-gp in the biliary 
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 excretion of fexofenadine in humans, studies were performed in human SCH using the 
inhibitor GF120918.  The possible involvement of BCRP was ruled out based on 
previously published data generated in MDCKII cells transfected with human BCRP 
demonstrating that BCRP does not transport fexofenadine (19).  OATP and P-gp 
function were assessed by the probe substrate [3H]digoxin as a positive control.  
Intracellular accumulation and BEI values of  [3H]digoxin were comparable to previously 
reported data (39, 40).  GF120918 (2 µM), used previously to inhibit P-gp in rat SCH 
(39), completely abolished the BEI and in vitro Clbiliary of [3H]digoxin in human SCH 
(Table 2.2).  Fexofenadine exhibited a low BEI and in vitro Clbiliary which was marginally 
affected by GF120918.  The trend towards increased hepatocellular accumulation of 
fexofenadine in the presence of GF120918 (Table 2.2) is in agreement with the 
pharmacokinetic simulations which predicted that hepatic accumulation would increase 
when the biliary excretion rate constant was decreased (Fig. 2.3.B).  However the 
possibility that GF120918-mediated inhibition of basolateral efflux results in increased 
hepatocellular accumulation of fexofenadine cannot be ruled out.  These data suggest 
that GF120918-sensitive protein(s) (presumably P-gp) play a minor role in fexofenadine 
biliary excretion in human hepatocytes.  Quite possibly, other canalicular transport 
proteins fully compensate when GF120918-sensitive protein(s) is/are inhibited.  
Fexofenadine is a known substrate for human MRP2 and BSEP based on previously 
published studies using MDCKII and HEK293 transfected cells (11, 19).  These data 
imply that fexofenadine would not be a suitable probe substrate in humans to assess 
altered biliary excretion associated with a specific canalicular transport process.   
Due to the limited availability of human hepatocytes, the lack of specific MRP2 
inhibitors that would not affect OATP-mediated fexofenadine uptake, and the multiplicity 
of efflux transport proteins involved in fexofenadine hepatobiliary disposition in humans 
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 (19, 41), further investigations were conducted in rat perfused livers.  Previous studies 
demonstrated that the biliary excretion and intrinsic biliary clearance of fexofenadine 
were not significantly different in wild-type and Mrp2-deficient rats (5, 18).  Therefore, 
TR- rats were employed in the present studies to rule out any compensatory role of Mrp2 
in the biliary excretion of fexofenadine.  Co-infusion of fexofenadine and GF120918 
resulted in a significant decrease in both the biliary excretion rate and the intrinsic biliary 
clearance of fexofenadine (Fig. 2.4.C; Table 2.3).  Fexofenadine is a substrate of the 
basolateral efflux protein Mrp3 (19, 41), which is upregulated 7-fold  in TR- rats (42) and 
may explain the significant increase in outflow perfusate concentrations of fexofenadine 
in the presence of GF120918.  This observation is supported by simulations examining 
the impact of induction of the basolateral efflux rate constant (K21) on fexofenadine 
disposition, which resulted in noticeable changes in the plasma AUC (Fig 2.3.A).  
Although fexofenadine liver concentrations tended to be higher when biliary excretion 
was inhibited by GF120918 in perfused TR- rat livers, as predicted in humans based on 
the pharmacokinetic simulations, differences failed to reach statistical significance.  This 
apparent discrepancy could be due to species differences in the role of basolateral efflux 
proteins in fexofenadine hepatobiliary disposition.  In humans, perturbations in biliary 
excretion only affected hepatic exposure; basolateral efflux was such a minor pathway 
that systemic exposure was not influenced by changes in biliary excretion.  Basolateral 
efflux may play a more important role in systemic exposure of fexofenadine in the rat 
based on the present data, and also in the mouse as reported previously using Mrp2 
knock-out mice (19, 41). 
Fexofenadine is not a substrate of human or mouse BCRP/Bcrp based on 
previously published data generated in MDCKII cells transfected with human BCRP, or 
in Bcrp knockout mice (5, 19).  Therefore, the predominant pathway for excretion of 
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 fexofenadine into rat bile is likely P-gp, in contrast to the mouse in which Mrp2 plays the 
greatest role (18).  This is supported by Milne et al., who demonstrated that the P-gp 
inhibitor erythromycin decreased cumulative recovery of fexofenadine in bile, and slightly 
increased hepatic accumulation and the perfusate AUC of fexofenadine in rat isolated 
perfused livers (43).  Interestingly, mass balance data reported by these investigators 
indicated that 50% of the fexofenadine dose remained in the liver at the end of perfusion.  
Our studies revealed that ~40% of the fexofenadine dose was retained within the rat 
liver at the end of perfusion.  As previously suggested, the liver may act as a reversible 
binding or sequestration site as well as an elimination organ for fexofenadine (3). 
Withholding taurocholate from the perfusion buffer resulted in a significant 
decrease in the biliary excretion rate of fexofenadine (Fig. 2.4.C; Table 2.3).  Hepatic 
fexofenadine concentrations were similar to control livers perfused with fexofenadine 
and taurocholate.  The significant decrease in the biliary excretion of fexofenadine may 
be due to reduced canalicular localization of Bsep and other ABC transport proteins that 
mediate fexofenadine biliary excretion, causing a modest shift in the route of 
fexofenadine excretion to perfusate.  Treatment of rats in vivo with taurocholate has 
been shown to modestly increase canalicular ABC transport protein expression on the 
hepatocyte canalicular membrane within minutes (28, 29). 
Fexofenadine has been shown to be a substrate of human and rat BSEP/Bsep 
using in vitro transfected systems (19).  Therefore, bosentan, a known inhibitor of Bsep 
(27), was concurrently infused into the perfusate.  Although bosentan was expected to 
decrease fexofenadine biliary excretion, only a 35% decrease in the biliary excretion rate 
was noted (Table 2.3). Interestingly, bosentan significantly decreased the extraction ratio 
and partitioning of fexofenadine from perfusate to liver (Table 2.3).  These results may 
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 be due to bosentan-mediated inhibition of fexofenadine hepatic uptake, and/or to 
increased basolateral efflux as a result of inhibition of fexofenadine biliary excretion; 
either scenario would result in significantly increased fexofenadine perfusate 
concentrations  (Fig. 2.4.B; Table 2.3).  Bosentan is a substrate of all three Oatp 
isoforms in the rat liver [Oatp1a1, 1a4 and 1b2; (44)] which are responsible for 
fexofenadine hepatic uptake (8).  Furthermore, bosentan (100 µM) competitively 
inhibited (by ~40%) the transport of model probes of the human OATP1B1, 1B3 and 2B1 
isoforms in transfected CHO cell lines (45).  Interestingly, the simulations of impaired 
hepatic uptake of fexofenadine in humans agreed with the results from perfused rat liver 
studies: perfusate (a surrogate for plasma) concentrations significantly increased in the 
presence of bosentan (Fig. 2.4.B). 
Conclusion  
In summary, pharmacokinetic modeling and simulation studies revealed that 
fexofenadine in humans is not an optimal probe for any specific hepatic efflux transport 
protein due to compensatory hepatic transport mechanisms.  Systemic fexofenadine 
concentrations are most sensitive to changes in fexofenadine hepatic uptake.  Increased 
or decreased hepatocyte concentrations as a result of impaired or induced biliary or 
hepatic basolateral efflux, respectively, associated with drug-drug interactions or genetic 
mutations, has minimal impact on systemic exposure.  Furthermore, pharmacokinetic 
modeling and simulation studies were in good agreement with preclinical data that 
predicted changes in systemic and liver exposure due to inhibition of hepatic uptake.  
Studies in perfused livers from TR- rats demonstrated that fexofenadine biliary excretion 
is mediated primarily by a GF120918-sensitive (presumably P-gp) mechanism.  In 
contrast, either P-gp plays a minor role in fexofenadine biliary excretion in human 
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 hepatocytes, or other canalicular transport proteins fully compensate when P-gp is 
inhibited.   
 
List of Nonstandard Abbreviations: 
SCH, sandwich-cultured hepatocytes, OATP, organic anion transporting polypeptide; 
MDR1, multidrug resistance protein 1; P-gp, P-glycoprotein; Mrp, multidrug resistance-
associated protein; TR-, Mrp2-deficient Wistar rat; EHBR, Eisai hyperbilirubinemic rats; 
Bsep, bile salt export pump; Bcrp, breast cancer resistance protein; WT, wild-type Wistar 
rat; GF120918, N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-phenyl)-
9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide; ABC, ATP-binding cassette; 
DMEM, Dulbecco’s modified Eagle’s medium; FBS, Fetal bovine serum; HBSS, Hanks’ 
balanced salt solution; BCA, Bicinchoninic acid; LC/MS/MS, liquid chromatography with 
detection by tandem mass spectrometry; AUC, area under the curve; ABC, ATP binding 
cassette 
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 Legend to Figures 
Figure 2.1.   Model scheme depicting fexofenadine disposition in healthy humans.  Xgut 
represents the amount of fexofenadine in the gut after an oral dose; Kabsorb represents 
the first–order absorption rate constant; CC represents the concentration of fexofenadine 
in the central compartment (systemic circulation) with volume VC; K12 represents the 
first–order rate constant for hepatic uptake; K21 represents the first-order rate constant 
for hepatic basolateral efflux; Xliver represents the amount of fexofenadine in the liver; 
Kbile represents the first–order rate constant for biliary excretion; Xbile represents the 
amount of fexofenadine in bile; Kurine represents the first–order rate constant for urinary 
excretion; Xurine represents the amount of fexofenadine in urine. 
 
Figure 2.2.  Mean fexofenadine disposition in healthy humans.  The curves represent 
the best fit of the pharmacokinetic model based on the scheme depicted in Fig. I to the 
data obtained from Shimizu et al. (9).  The plasma concentration-time profile (♦; solid 
line) and urinary excretion rate-time profile (▲; dashed line) are plotted on log-linear 
scale.  Symbols represent actual data points while lines represent the best fit of the 
model to the data. 
 
Figure 2.3.  Simulated percentage change from baseline in the AUC of the (A) plasma 
concentration-time profile, predictive of systemic exposure, and (B) hepatic mass-time 
profile, predictive of hepatic exposure, associated with perturbations in the hepatic 
uptake rate constant (K12; solid bars), basolateral efflux rate constant (K21; hatched bars) 
and biliary excretion rate constant (Kbile; open bars). 
 
Figure 2.4. Data generated in perfused livers from Mrp2-deficient TR- rats.  (A) Bile flow 
rates, (B) Fexofenadine concentrations in outflow perfusate, and (C) Biliary excretion 
rates of fexofenadine in livers perfused with 0.5 µM fexofenadine (●), 0.5 µM 
fexofenadine without 5 µM taurocholate (□), 0.5 µM fexofenadine + GF120918 (Δ), and 
0.5 µM fexofenadine + bosentan (◊).  Perfusate buffer contained 5 µM  taurocholate, 
unless otherwise noted.  Data represent mean ± SD (n-3-4 per group). 
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 Table 2.1 Pharmacokinetic parameters governing fexofenadine disposition in healthy 
humans estimated using nonlinear regression analysis based on the compartmental 
model scheme depicted in Fig. 3.1.  Parameter estimates and coefficients of variation 
were generated based on mean data (n=8 healthy subjects) from a previously published 
report (6). 
 
Parameters Estimate CV (%) 
Kabsorb (h-1) 1.67 23.0 
Vc (L) 55.8 7.71 
K12 (h-1) 0.124 11.0 
K21 (h-1) 0.00788 49.7 
Kbile (h-1) 0.0438 11.1 
Kurine (h-1) 0.0689 10.1 
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 Table 2.2. Accumulation, BEI and in vitro Clbiliary of  [3H]Taurocholate, [3H]Digoxin and 
Fexofenadine in human SCH.  SCH were incubated with 1 µM [3H]taurocholate (10 min), 
1 µM [3H]digoxin (10 min) or 5 µM fexofenadine (30 min) in the presence and absence of 
2 µM GF120918.  Results are presented as representative data from triplicate 
experiments from two livers.  The incubation time (t) is indicated in parentheses. 
 
 Accumulation Accumulation  in vitro Clbiliary 
Substrate Cells + Bile (pmol/mg) Cells (pmol/mg) BEI % (mL/min/kg) 
[3H]Taurocholate 
(t=10 min) 
176 ± 5 
121 ± 11 
73.8 ± 2.3 
57.8 ± 5.5 
58.1 
52.4 
18.7 
11.6 
[3H]Digoxin          
(t=10 min) 
28.1 ± 1.6 
26.9 ± 1.5 
21.0 ± 1.3 
25.1 ± 2.4 
25.0 
6.76 
1.29 
0.33 
[3H]Digoxin + 2 µM 
GF120918            
(t=10 min) 
26.2 ± 0.9 
23.4 ± 2.3 
29.9 ± 1.6 
25.2 ± 1.6 
0 
0 
0 
0 
Fexofenadine       
(t=30 min) 
78.8 ± 8.2 
66.3 ± 19.1 
66.2 ± 3.7 
62.5 ± 4.3 
16.0 
5.79 
0.15 
0.05 
Fexofenadine + 2 µM 
GF120918           
(t=30 min) 
112 ± 6 
73.2 ± 3.8 
93.2 ± 9.7 
65.1 ± 2.3 
16.8 
11.0 
0.23 
0.10 
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 Table 2.3 Fexofenadine disposition in single-pass perfused TR- rat livers.  Mean ± SD (n 
= 3-4 per group). * p< 0.05 fexofenadine ± modulator vs. fexofenadine alone. # Total 
concentration determined based on 50–60-min collection interval. Perfusate buffer 
contained 5 µM taurocholate, unless otherwise noted. 
 
 
 
 0.5 µM Fexofenadine  
0.5 µM 
Fexofenadine 
without TC 
0.5 µM Fexofenadine 
+  
2 µM GF120918 
0.5 µM Fexofenadine 
+ 
5 µM Bosentan 
Css,out (pmol/mL) # 92.3 ± 29.4 135 ± 21 172 ± 59* 209 ± 19* 
Cliver (pmol/mL) 7295 ± 786 7156 ± 1529 8159 ± 720 5561 ± 873 
Cliver, unbound (pmol/mL) 1389 ± 196 1282 ± 142 1631 ± 620 1235 ± 369 
Cliver, unbound / Css,out 16.2 ± 5.4 9.53± 0.46 10.8 ± 6.0 6.05 ± 2.34* 
Extraction Ratio 0.82 ± 0.06 0.73 ± 0.04 0.66 ± 0.12* 0.58± 0.04* 
Biliary Excretion Rate 
(pmol/min/g liver) 
218 ± 66 136 ± 34* 55.6 ± 6.4* 142 ± 29 
Cl’biliary (mL/h/g liver) 8.57 ± 2.00 6.56 ± 2.27 2.36 ± 1.12* 7.52 ± 2.78 
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 Figure 2.1 
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 Figure 2.3 
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Figure 2.4 
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CHAPTER 3 
 
 
 
 
 
 
Impact of Basolateral Mrp3 (Abcc3) and Mrp4 (Abcc4) on the Hepatobiliary 
Disposition of Fexofenadine in Perfused Mouse Livers 
 
 
 
 
 
 
This chapter is published in Drug Metabolism and Disposition 2008 May; 
36(5):911-5, Copyright 2008 by The American Society for Pharmacology and 
Experimental Therapeutics, and is presented in the style of that journal. 
Reprinted with permission of the American Society for Pharmacology and 
Experimental Therapeutics.  All rights reserved. 
 Abstract 
The disposition of fexofenadine, a commonly-used antihistamine drug, is governed 
primarily by active transport. Biliary excretion of the parent compound is the major route 
of systemic clearance. Previous studies demonstrated that fexofenadine hepatic uptake 
is mediated by organic anion transporting polypeptides. Recently, we showed that in 
mice fexofenadine is excreted into bile primarily by Mrp2 (Abcc2). In the present study, 
the role of Mrp3 (Abcc3) and Mrp4 (Abcc4) in the hepatobiliary disposition of 
fexofenadine was examined in knockout mice using in situ liver perfusion. Compared to 
wild-type mice, basolateral excretion of fexofenadine was impaired resulting in a ~50% 
decrease in perfusate recovery in Abcc3(-/-) mice; in contrast, fexofenadine hepatobiliary 
disposition was unaltered in Abcc4(-/-) mice. As expected, in  Abcc2(-/-) mice, 
fexofenadine was redirected from the canalicular to the basolateral membrane for 
excretion. In Abcc2(-/-)/Abcc3(-/-) double knock-out mice, fexofenadine biliary excretion 
was impaired, but perfusate recovery was similar to wild-type mice, and more than 2-fold 
higher than in Abcc3(-/-) mice, presumably due to compensatory basolateral transport 
mechanism(s). These results demonstrate that multiple transport proteins are involved in 
the hepatobiliary disposition of fexofenadine.  In addition to Mrp2 and Mrp3, other 
transport proteins play an important role in the biliary and hepatic basolateral excretion 
of this zwitterionic drug. 
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 Introduction 
Fexofenadine is an H1 receptor antagonist commonly used in the treatment of 
seasonal allergies and chronic urticaria. The intestinal absorption of fexofenadine is 
mediated by organic anion transporting polypeptides (Oatps), a process that is 
counteracted by P-glycoprotein-mediated efflux (Cvetkovic et al., 1999).  Metabolism 
accounts for less than 5% of total fexofenadine clearance in humans, and the oral and 
intravenous exposure of fexofenadine in rats is not altered by the pan-cytochrome P450 
mechanism-based inactivator, aminobenzotriazole (Strelevitz et al., 2005). However, 
specific information regarding fexofenadine metabolism in mice is not available. Biliary 
excretion of unchanged fexofenadine is the primary route of systemic clearance (Tahara 
et al., 2005).  Although fexofenadine intestinal absorption and blood-brain barrier 
penetration are limited by P-glycoprotein (Cvetkovic et al., 1999; Tahara et al., 2005), 
the biliary excretion of fexofenadine is mediated by multiple transport mechanisms (Tian 
et al., 2008).  The unusual dispositional properties of fexofenadine, i.e. low metabolism 
and extensive transport, have led to its use as a probe for the analysis of both Oatp and 
P-glycoprotein modulation by various co-administered drugs and herbal products 
(Banfield et al., 2002; Zhou et al., 2004; Shon et al., 2005; Lemma et al., 2006).   
Following uptake from sinusoidal blood into the hepatocyte, drugs and derived 
metabolites, may undergo excretion across the canalicular membrane into bile or across 
the basolateral membrane into blood. For example, carboxydichlorofluorescein is taken 
up into hepatocytes via basolateral Oatps, and is subsequently  excreted unchanged into 
bile by multidrug resistance-associated protein (Mrp) 2 and also undergoes basolateral 
export into blood by Mrp3 (Zamek-Gliszczynski et al., 2003; Nezasa et al., 2006).  
Similarly, glucuronide conjugates of acetaminophen and morphine also are subject to 
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 bidirectional excretion into bile and blood by Mrp2 and Mrp3, respectively (Xiong 2000, 
2002, van de Wetering 2007, Zelcer 2005). Basolateral Mrp3 is similar to canalicular 
Mrp2 in terms of amino acid sequence, membrane topology, and substrate specificity 
(Konig et al., 1999; Ogawa et al., 2000). Mrp3 is highly upregulated in obstructive 
cholestasis (e.g. bile duct ligation) and hereditary conjugated hyperbilirubinemia in rats 
and humans (e.g. Mrp2-deficient animals, Dubin-Johnson patients), acting as an 
overflow pump for hepatic excretion of Mrp2 substrates and conjugated bile acids when 
biliary excretion is impaired (Hirohashi et al., 1998; Konig 1999). Although expression 
levels of Mrp3 protein are relatively high in mice, a 2-fold up-regulation of Mrp3 protein is 
still observed in Mrp2-knockout mice (Nezasa et al., 2005). Based upon recent findings 
that the biliary excretion of fexofenadine is mediated in part by Mrp2 in mice (Tian et al., 
2008), we hypothesized that fexofenadine may also undergo hepatic basolateral 
excretion via Mrp3. In addition to Mrp3, Mrp4 functions as an excretory mechanism on 
the hepatic basolateral membrane (Rius et al., 2003). Limited evidence of functional 
overlap between Mrp3 and Mrp4 exists. For example, both Mrp3 and Mrp4 are 
upregulated in response to obstructive cholestasis (Hirohashi et al., 1998; Denk et al., 
2004). Furthermore, both Mrp3 and Mrp4 mediate the hepatic basolateral excretion of 
the sulfate metabolites of acetaminophen, 4-methylumbelliferone, and harmol in mice 
(Zamek-Gliszczynski et al., 2006). While these features suggest that Mrp3 and Mrp4 
may be involved in the hepatic basolateral excretion of fexofenadine, the extent to which 
these pumps function in this capacity has not been investigated. 
Studies outlined in this manuscript tested the hypothesis that fexofenadine 
undergoes basolateral excretion from the liver via Mrp3 and Mrp4. Perfused livers from 
relevant transporter-gene knockout mice were utilized to examine the role of Mrp2, Mrp3 
and Mrp4 in the hepatobiliary disposition of fexofenadine. Furthermore, the combined 
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 role of Mrp2 and Mrp3 in the overall hepatic excretion of this zwitterion was studied in 
livers from Abcc2(-/-)/Abcc3(-/-) double-knockout mice. The data presented herein 
demonstrate the importance of Mrp2 and Mrp3 in the biliary and hepatic basolateral 
excretion, respectively, of fexofenadine in mice. 
 
118 
 
 Material and Methods 
Chemicals. Fexofenadine, cetirizine, taurocholate, and Krebs-Henseleit buffer packets 
were purchased from Sigma Chemical Co. (St. Louis, MO). All other chemicals were of 
reagent grade and were readily available from commercial sources.   
Animals. Male C57BL/6 wild-type (WT) (age-matched heterozygotes), Abcc2(-/-), 
Abcc3(-/-), Abcc2(-/-)/Abcc3(-/-), and Abcc4(-/-) mice (23-31g) were generated as 
described previously (Belinsky et al., 2005; Belinsky et al., 2007). Abcc2(-/-) mice have 
been generated recently by gene-targeting methods in the laboratory of Dr. Gary Kruh 
(unpublished).  Abcc2(-/-), Abcc3(-/-) and Abcc4(-/-) mice employed in this study were 
derived from mixed 129/C57BL/6 animals and were backcrossed to C57BL/6 for eight 
generations.  Abcc2(-/-) and Abcc3(-/-) mice on the C57BL/6 background were used to 
breed the Abcc2(-/-)/Abcc3(-/-) mice. Mice were maintained on a 12-h light/dark cycle 
with free access to water and rodent chow. Experiments were performed at Fox Chase 
Cancer Center and approved by their Institutional Animal Care and Use Committee. 
In Situ Liver Perfusion. All experimental procedures were performed under full 
anesthesia induced with ketamine/xylazine (140/8 mg/kg i.p.). The liver perfusion 
procedure was modified slightly from the previous report of Tian et al (2007). Briefly, the 
common bile duct was ligated above the duodenum to prevent bile from entering the 
intestine, and the gallbladder was cannulated with PE-10 tubing (Becton Dickinson, 
Parsippany, NJ). The portal vein was cannulated with a 20-gauge catheter (B. Braun 
Medical Inc., Bethlehem, PA), the abdominal vena cava below the liver was severed 
immediately by incision, and the inferior vena cava above the liver was cannulated with a 
20-gauge catheter. The liver was perfused (5 ml/min with fexofenadine-free continually 
oxygenated Krebs-Henseleit buffer containing 5 µM taurocholate) for an equilibration 
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 period of approximately 15 min.  Subsequently, the inferior vena cava was ligated 
between the liver and kidney to direct all perfusate outflow through the cannulated 
inferior vena cava above the liver. Following the pre-perfusion period to allow for 
equilibration of temperature and bile flow, the liver was perfused for 30 min with buffer 
containing 0.5 µM fexofenadine, followed by a washout with fexofenadine-free buffer for 
45 min. Bile was collected in 7-min intervals; outflow perfusate was collected at 
designated time points in toto. Perfusion pressure and bile flow were monitored to 
assess liver viability (Chandra et al., 2005). 
Analytical Methods. Bile and outflow perfusate samples were analyzed by liquid 
chromatography with detection by tandem mass spectrometry (Applied Biosystems API 
4000 triple quadrupole with TurboIonSpray interface, MDS Sciex, Concord, ON, 
Canada).  Fexofenadine and cetirizine (internal standard) were eluted from an Aquasil 
C18 column (5μm, 50mm x 2.1mm, Thermo-Electron, Waltham, MA) using a mobile 
phase gradient (A: 0.1% formic acid in water, B: 0.1% formic acid in methanol); 0-0.8 
min hold at 10% B, 0.8-3.5 min linear increase to 85% B, 3.5-4.0 min hold at 85% B, 4.0-
4.5 min return to 10% B, 4.5-5 min hold at 10% B; flow rate was 0.75 mL/min (Shimazdu 
solvent delivery system, Columbia, MD). Fexofenadine and the internal standard, 
cetirizine, were detected in positive ion mode using multiple reaction monitoring: 
fexofenadine: 502.3 → 466.4 m/z, cetirizine: 389.0 → 201.0 m/z.  Fexofenadine was 
quantified with standard curves prepared in the appropriate matrix.   
Data Analysis.  All data were reported as mean ± SD (n = 3-4, per group). Statistical 
significance was assessed by one-way analysis of variance (ANOVA) with Tukey's post-
hoc test. In cases where the normality test failed, data were log-transformed prior to 
statistical analysis.  In all cases, p < 0.05 was considered to be statistically significant. 
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 Results 
Body weight, liver weight, and bile flow. Body weight was comparable between WT 
and knockout mice (Table 3.1). Liver weight (normalized for body weight) was 
significantly increased (~30%) in Abcc2(-/-) and (~46%) in Abcc2(-/-)/Abcc3(-/-) relative 
to WT mice.  Abcc3(-/-) and Abcc4(-/-) mouse liver weights were comparable to WT 
controls (Table 3.1). The bile flow rate was decreased ~30% in Abcc2(-/-) and Abcc2(-/-
)/Abcc3(-/-) mouse livers relative to WT, but was normal in livers from Abcc3(-/-) and 
Abcc4(-/-) mice (Table 3.1).  
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Recovery of fexofenadine in outflow perfusate.  Fexofenadine concentrations in 
outflow perfusate from WT and knockout mouse livers are presented in Figure 3.1. For 
clarity, only mean data are plotted; standard deviations were within ~50% of the mean 
data. The total recovery of fexofenadine at the end of the washout period as a 
percentage of the infused dose was 73 ± 10% in WT, 62 ± 30% in Abcc3(-/-),  68 ± 9% in 
Abcc4(-/-), 77 ± 12% in Abcc2(-/-), and 71 ± 15% in Abcc2(-/-)/Abcc3(-/-) mouse livers. 
In order to quantify the impact of Mrp3 and Mrp4 genetic ablation on the basolateral 
efflux of fexofenadine from the liver, fexofenadine recovery in perfusate during the 
washout phase was expressed as a percentage of liver fexofenadine content at the end 
of the infusion (determined as the difference between infused dose and the cumulative 
mass of fexofenadine excreted in outflow perfusate and bile through 30 min; Table 3.2). 
The fraction of fexofenadine excreted into outflow perfusate was significantly decreased 
(~50%) in livers from Abcc3(-/-) mice; in contrast, significantly increased perfusate 
recovery (~60%) was noted in Abcc2(-/-) relative to WT mouse livers. Interestingly, 
perfusate recovery of fexofenadine in livers from Abcc2(-/-)/Abcc3(-/-) mice was similar 
to WT control livers. In contrast to livers from Abcc3(-/-) mice, perfusate recovery of 
fexofenadine in livers from Abcc4(-/-) mice was unchanged.   
 
 Recovery of fexofenadine in bile.  Fexofenadine biliary excretion rates and cumulative 
biliary excretion in livers from WT and knockout mice are presented in Figures 3.2A and 
B, respectively; standard deviations were within ~50% of the mean data and are not 
included in the figures for clarity. The biliary recovery of fexofenadine was not 
significantly different in Abcc3(-/-) and Abcc4(-/-) mouse livers relative to WT controls 
(Figure 3.2B; Table 3.2). Fexofenadine biliary excretion rates and cumulative biliary 
excretion were significantly decreased in livers from Abcc2(-/-) and Abcc2(-/-)/Abcc3(-/-) 
mice (Figure 3.2). The biliary recovery of fexofenadine during the washout phase, 
normalized for liver content of fexofenadine at the end of the infusion, was ~61% and 
~53% lower in Abcc2(-/-) and Abcc2(-/-)/Abcc3(-/-) relative to WT mouse livers, 
respectively (Table 3.2). Interestingly, liver fexofenadine concentrations at the end of the 
washout period were not altered in Abcc3(-/-), Abcc4(-/-) and Abcc2(-/-)/Abcc3(-/-) mice 
(Table 3.2). However, consistent with our previous report (Tian et al., 2008), liver 
fexofenadine concentrations decreased ~2-fold in Abcc2(-/-) mice after the washout 
phase (Table 3.2). 
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 Discussion 
Previous studies utilizing transporter gene knockout mice identified Mrp2 as the 
predominant protein responsible for fexofenadine biliary excretion (Tian et al., 2008). In 
contrast, fexofenadine biliary excretion was not impaired in mice lacking the breast 
cancer resistance protein or P-glycoprotein (Tahara et al., 2005). In agreement with 
previous work, Mrp2 was responsible for ~60% of fexofenadine biliary excretion in the 
current study. However, the present data also establish the importance of Mrp3 in the 
hepatic basolateral excretion of fexofenadine. Approximately 50% of fexofenadine 
basolateral excretion may be attributed to Mrp3-mediated transport when outflow 
perfusate concentrations are in the range of 300 ng/ml based on the 2-fold decrease in 
perfusate recovery of fexofenadine in livers from Abcc3(-/-) mice. These data highlight 
the functional interplay between Mrp2 and Mrp3 in fexofenadine hepatobiliary 
disposition. However, the basolateral excretion of fexofenadine in Abcc2(-/-)/Abcc3(-/-) 
mice was not impaired. Fexofenadine concentrations in Abcc3(-/-) and Abcc2(-/-
)/Abcc3(-/-) mouse livers were similar to those in WT mouse livers. Mechanism(s) 
responsible for the Mrp2- and Mrp3-independent component of fexofenadine 
hepatobiliary clearance remain to be elucidated. 
Mrp2 plays a critical role as an organic anion excretory system in liver 
detoxification. Unlike human MRP3, MRP2 protein is highly expressed in humans under 
normal conditions (Stöckel et al., 2000). Protein expression of Mrp3, the“Mrp2 backup 
system”, is increased markedly in rats and humans that are deficient in Mrp2 (Hirohashi 
et al., 1998; Konig et al., 1999; Xiong et al., 2002). Mrp3 constitutive expression levels in 
mice are already high, but in Mrp2-knockout mice, Mrp3 is further upregulated (Nezasa 
et al., 2006). In contrast, this functional compensation is not reciprocal in mouse liver; 
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 the absence of Mrp3 does not result in a notable upregulation of Mrp2 protein or function 
in mouse liver, as demonstrated by this and other studies (Belinsky et al., 2005; Zamek-
Gliszczynski et al., 2006). This suggests that hepatic protection mechanisms other than 
Mrp2-mediated biliary excretion exist in mice when Mrp3 function is ablated. Mrp4 is 
another efflux transport protein located on the hepatic basolateral membrane (Rius et al., 
2003). Limited evidence of functional overlap between Mrp3 and Mrp4 (Hirohashi et al 
1999; Denk et al., 2004; Zamek-Gliszczynski et al., 2006) prompted the exploration of 
fexofenadine disposition in livers from Abcc4(-/-) mice.  Interestingly, fexofenadine 
basolateral excretion was not affected by the absence of Mrp4. The impact of genetic 
ablation of Mrp4 has been associated with impaired Sulfotransferase 2a1 expression 
and function (Assem et al., 2004), but an appreciable effect on the function or 
expression of other hepatic transport proteins has not been observed (Assem et al., 
2004; Mennone et al., 2006; Zamek-Gliszczynski et al., 2006). Whether Mrp4 serves as 
the backup system for Mrp3-mediated fexofenadine basolateral excretion requires 
further investigation. 
The existence of multiple transport and backup transport systems on both the 
basolateral and canalicular membranes complicates the extrapolation of transport 
studies from single-knockout to double-knockout animals (van de Wetering et al., 2007). 
The biliary and basolateral excretion of the Mrp2 and Mrp3 substrate, morphine-3-
glucuronide in Abcc2(-/-)/Abcc3(-/-) mice following morphine administration was severely 
impaired, resulting in considerable hepatic accumulation of the glucuronide metabolite.  
However, residual plasma concentrations of morphine-3-glucuronide in Abcc2(-/-
)/Abcc3(-/-) mice were substantial, and the concentrations of morphine-3-glucuronide 
were similar between Abcc2(-/-)/Abcc3(-/-) and WT mice 24 hrs post morphine 
administration, which resulted in near-normal urinary excretion of morphine-3-
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 glucuronide, suggesting that a low-capacity backup transport system was present for the 
basolateral excretion of  morphine-3-glucuronide into plasma in Abcc2(-/-)/Abcc3(-/-) 
mice (van de Wetering et al., 2007). In the present study, fexofenadine biliary excretion 
in livers from Abcc2(-/-)/Abcc3(-/-) mice was impaired to the same extent as in mice only 
lacking Mrp2; fexofenadine basolateral excretion in livers from these double-knockout 
mice was similar to WT mice, and was more than two-fold higher than in Mrp3 single-
knockout mice. The unchanged liver concentrations of fexofenadine in Abcc3(-/-) mice, 
and considerable basolateral excretion of fexofenadine in the livers of Abcc2(-/-)/Abcc3(-
/-) mice, are consistent with the hypothesis that additional clearance mechanisms 
compensate for the loss of Mrp3 function. Basolateral Mrps (other than Mrp3), the 
bidirectional organic anion transport proteins, or other basolateral export proteins may 
contribute to increased basolateral clearance of fexofenadine in Abcc2(-/-)/Abcc3(-/-) 
mouse livers. The possibility of altered fexofenadine metabolism in Abcc3(-/-) and 
Abcc2(-/-)/Abcc3(-/-) mouse livers cannot be ruled out because no detailed information 
on fexofenadine metabolism in mouse livers has been published. 
In summary, fexofenadine is taken up into the hepatocyte and undergoes biliary 
as well as basolateral excretion. Using perfused livers from relevant transporter gene 
knockout mice, Mrp2 and Mrp3 were identified as important transport proteins mediating 
fexofenadine biliary and hepatic basolateral excretion, respectively. Mrp4 did not appear 
to contribute to hepatic basolateral excretion of this zwitterionic drug in the intact mouse 
liver in the presence of Mrp3 and/or Mrp2 proteins. Mechanism(s) responsible for the 
residual, Mrp2- and Mrp3-independent, biliary and basolateral excretion of fexofenadine 
remain to be elucidated. Once again, this study exemplified the importance of using 
physiologically relevant systems such as the intact liver to evaluate the contributions of 
hepatic transport proteins in drug pharmacokinetic studies. 
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 Figure Legends 
Figure 3.1.  Fexofenadine concentrations in outflow perfusate from wild-type C57BL/6 
(●), Abcc3-/- (Δ), Abcc4-/- ( ∇ ), Abcc2-/- (□), and Abcc2-/-/Abcc3-/- (◊) mouse livers (mean 
data are plotted; n = 3-4 per group).  Livers were perfused (5 ml/min) with fexofenadine 
(0.5 μM) for 30 min followed by a 45-min washout phase. 
 
Figure 3.2.  Biliary excretion rate (A) and cumulative biliary excretion (B) of fexofenadine 
in perfused livers from wild-type C57BL/6 (●), Abcc3-/- (Δ), Abcc4-/- ( ∇ ), Abcc2-/- (□), and 
Abcc2-/-/Abcc3-/- (◊) mice (mean data are plotted; n = 3-4 per group).  Livers were 
perfused (5 ml/min) with fexofenadine (0.5 μM) for 30 min followed by a 45-min washout 
phase. 
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 Table 3.1. Body weight, liver weight normalized for body weight, and bile flow rate in 
wild-type and transporter gene knockout mice.  Mean ± SD (n = 3-4 per group). * p< 0.05 
knockout vs. wild type. 
 
Mice Body Weight (g) 
Liver Weight / 
Body Weight 
Bile Flow Rate 
(µL/min/g liver) 
Wild-Type 27.5 ± 1.4 0.041 ± 0.006 1.3 ± 0.3 
Abcc3(-/-) 27.9 ± 3.1 0.043 ± 0.001 1.3 ± 0.2 
Abcc4(-/-) 26.1 ± 2.4 0.041 ± 0.005 1.3 ± 0.4 
Abcc2(-/-) 29.4 ± 1.9 0.053 ± 0.001 * 0.87 ± 0.02 * 
Abcc2(-/-)/Abcc3(-/-) 27.7 ± 1.5 0.060 ± 0.002 * 0.85 ± 0.15 * 
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 Table 3.2.  Recovery of fexofenadine in perfusate and bile during the washout phase of 
mouse liver perfusions, and liver concentrations after the washout phase. Values are 
expressed as percentage of fexofenadine liver content after the 30-min infusion.  Mean ± 
SD (n = 3-4 per group). * p< 0.05 knockout vs. wild type. 
 
Mice 
Biliary Recovery  Recovery in Perfusate   Liver Concentration  
(% liver content at 30 min) (% liver content at 30 min) (ng/g liver) 
Wild-Type 15.3 ± 3.8 25.8 ± 4.1 1500 ± 330 
Abcc3(-/-) 13.5 ± 6.1 12.7 ± 6.1* 1500 ± 500 
Abcc4(-/-) 12.3 ± 3.3 26.2 ± 7.6 1300 ± 420 
Abcc2(-/-) 5.9 ± 3.4* 42.0 ± 2.7 * 850 ± 400 
Abcc2(-/-)/ 
Abcc3(-/-) 
7.1 ± 2.9 * 28.6 ± 12.3 1600 ± 420 
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CHAPTER 4 
 
 
 
 
 
 
Evaluation of 99mTechnetium-Mebrofenin and 99mTechnetium-Sestamibi as 
Specific Probes for Hepatic Transport Protein Function in Rat and Human 
Hepatocytes 
 
 
 
 
 
 
 
 
 
 
This chapter will be submitted to Journal of Nuclear Medicine and is formatted in 
the style of the journal.
 Abstract  
The present study characterized the transport proteins involved in uptake and 
excretion of 99mTc-MEB and 99mTc-MIBI, and the preferential route of efflux 
(canalicular vs. basolateral), in rat and human hepatocytes. Initial 99mTc-MEB 
uptake was reduced to 20.7 and 35.4% of control in the presence of the general 
Oatp/OATP inhibitor rifamycin SV in rat and human suspended hepatocytes, 
respectively.  Initial 99mTc-MIBI uptake in suspended rat hepatocytes was not 
influenced by inhibitors or replacement of sodium with choline.  99mTc-MEB 
canalicular efflux was decreased 6.6-fold and 30% in the presence of MK571 
(100µM) in rat and human SCH, and completely ablated in Mrp2-deficient TR- 
SCH, suggesting that 99mTc-MEB hepatic uptake is predominantly Oatp-mediated 
with biliary excretion by Mrp2.  99mTc-MEB efflux in human SCH was 
predominantly canalicular (45.8±8.6%), and ~3-fold greater than in rat SCH. 
99mTc-MEB basolateral efflux in human (16.7±0.6%) and rat (25.0±6.7%) SCH 
was similar.  99mTc-99mTc-MIBI canalicular efflux was similar in human and rat 
SCH, but basolateral efflux was 37% greater in human compared to rat SCH.  
99mTc-MIBI cellular accumulation, biliary excretion index (BEI) and in vitro biliary 
clearance (Clbiliary) in rat SCH were unaffected by Bcrp knockdown (siBcrp).  
99mTc-MIBI BEI and in vitro Clbiliary were ablated by GF120918 (2µM) in siBcrp 
SCH.  99mTc-MIBI hepatic uptake appears to occur by passive diffusion with 
biliary excretion mediated by P-gp. The SCH model is a useful system to 
investigate the influence of factors (e.g., species differences, drug interactions) 
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that may alter the route and/or extent of basolateral and canalicular efflux of 
substrates from hepatocytes.  
 Introduction 
Probe substrates are used to obtain an in vivo phenotypic measure of 
specific biotransformation or transport pathways in preclinical or clinical species.  
Ideally, a transport probe substrate would be specific for a single transport 
protein, relatively safe for healthy human volunteer studies and metabolically 
stable.  There are currently very few identified transport probe substrates suitable 
for clinical use.  Digoxin has been recommended as a multidrug resistance P-
glycoprotein (P-gp) probe in the FDA guidance 
(http://www.fda.gov/Cder/drug/drugInteractions/default.htm), however, digoxin 
also is transported by organic anion transporting polypeptide 1B3, 4C1 
(OATP1B3 and OATP4C1) and recent publications have investigated other 
potential probe substrates for breast cancer resistance protein (BCRP) including 
sulfasalazine (Urquhart et al., 2008), nitrofurantoin (Adkison et al., 2008) and 
rosuvastatin (Zhang et al., 2006).  99mTechnetium-mebrofenin (99mTc-MEB) and 
99mTechnetium-sestamibi (99mTc-MIBI) are candidate probe substrates for 
multidrug resistance associated protein 2 (MRP2) and P-gp, respectively. 
99mTc-MEB is the 99mTc-labeled trimethylbromo analogue of 
acetanilidoiminodiacetic acid (BRIDA) derivative commonly used in nuclear 
medicine for hepatobiliary scintigraphy.  This compound belongs to a class of 
agents that couples a lidocaine-like structure, resulting in high liver extraction, 
with 99mtechnetium, which is ideal for gamma scintigraphy (Krishnamurthy and 
Turner, 1990).  99mTc-MEB commonly is used to evaluate the presence of 
gallbladder dysfunction (Doo et al., 1991), although several investigators have 
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 proposed other uses, including preoperative assessment of liver function 
(Erdogan et al., 2004), evaluation of hepatocyte viability in vivo (Gencoglu et al., 
2002; Koruk et al., 2003), and detection of genetic diseases that could affect 
biliary excretion (Bujanover et al., 1983; Pinos et al., 1990).  Several analogs of 
99mTc-MEB have been developed, all of which are anions at physiologic pH and 
bind to albumin to varying degrees, depending on their lipophilicity (Nunn et al., 
1983).  Several hepatic transport proteins involved in the hepatobiliary disposition 
of 99mTc-MEB were characterized recently by Ghibellini et al., who demonstrated 
that 99mTc-MEB is a substrate of OATP1B1, OATP1B3, MRP2 and MRP3 in 
expressed systems (Ghibellini et al., 2008).  99mTc-MEB exhibited increased and 
prolonged hepatic exposure measured by gamma scintigraphy in Mrp2-deficient 
TR- rats compared to wild-type rats, suggesting that Mrp2 is involved in 
canalicular transport (Bhargava et al., 2009).  Furthermore, case reports have 
documented a failure to visualize the hepatobiliary tree after administration of 
99mTc-disofenin (DISIDA), the diisopropyl analogue of acetanilidoiminodiacetic 
acid, when administered to patients with Dubin-Johnson syndrome (MRP2-
deficiency) (Pinos et al., 1990).  More than 98% of a 99mTc-MEB dose is taken up 
by the liver; the hepatic excretion half-life of 99mTc-MEB is rapid (16 min) and 
~1.5% of the dose was recovered in urine after 24 hours in humans 
(Krishnamurthy and Turner, 1990).  
99mTc-MIBI a monovalent cation complex of 99mTc (99mTc-2-
methoxyisobutylisonitrile), is used clinically to assess myocardial perfusion; 
99mTc-MIBI distributes into the heart in proportion to blood flow and myocardial 
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 viability (Beller and Sinusas, 1990; Mobasseri and Hendel, 2002; Ravizzini et al., 
2002).  Accumulation of 99mTc-MIBI in cells is a function of free diffusion based 
on electrical potentials across the plasma and mitochondrial membranes, with 
localization in the mitochondria by electrostatic forces (Chiu et al., 1990).  
Decreased uptake of 99mTc-MIBI in resistant cells also has been attributed to a 
lower membrane potential and reduced mitochondrial density (Piwnica-Worms et 
al., 1993).  Several groups have used 99mTc-MIBI as a functional P-gp probe 
substrate in rodents and humans (Chen et al., 1997; Luker et al., 1997; Slapak et 
al., 2001; Wong et al., 2005).  Further investigations using cancer cells in culture 
revealed that 99mTc-MIBI is a MRP1 substrate (Hendrikse et al., 1998; Chen et 
al., 2000; Perek et al., 2000).  In TR- rats, 99mTc-MIBI cumulative recovery in bile 
and liver activity profiles based on in vivo imaging were similar compared to wild-
type rats, suggesting that Mrp2 is not involved, or other mechanisms compensate 
for impaired hepatic excretion (Hendrikse et al., 2004).   99mTc-MIBI clearance in 
humans is similarly distributed between renal elimination and feces mediated by 
biliary excretion and possible contribution by intestinal secretion [Cardiolite® 
package insert (Ghibellini et al., 2008)].   
99mTc-MIBI and analogs of 99mTc-MEB have been used as probe 
substrates to assess interindividual variation in hepatic drug handling and 
function (Wong et al., 2005; Michael et al., 2006; Wong et al., 2006).  99mTc-MIBI 
has been used to phenotype P-gp function with the P-gp inhibitors PSC833 and 
LY335979 resulting in prolonged hepatic exposure (Chen et al., 1997; Luker et 
al., 1997; Slapak et al., 2001).  Alterations in 99mTc-MIBI pharmacokinetics were 
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assessed in a cohort of cancer patients with common single nucleotide 
polymorphisms (SNPs) in ABCB1 exons 12 (C1236T) and 26 (C3435T) resulting 
in a significantly decreased elimination rate constant (Wong et al., 2005).  
However, the mechanisms of hepatic transport have not been fully investigated, 
including potential compensatory proteins involved in hepatobiliary disposition.  
The purpose of the current study was to characterize the mechanisms of uptake 
and excretion of 99mTc-MEB and 99mTc-MIBI in rat and human hepatocytes.  The 
processes involved in hepatic uptake, basolateral efflux and canalicular excretion 
are too complicated to be completely elucidated in vivo.  Therefore, suspended 
hepatocytes were used to investigate uptake mechanisms because of the loss of 
cell polarity after isolation (Groothuis et al., 1981; Oude Elferink et al., 1995).  
While sandwich-cultured hepatocytes (SCH) were used to elucidate the 
hepatobiliary disposition of 99mTc-MEB and 99mTc-MIBI (Liu et al., 1999a; Liu et 
al., 1999b).  TR- rats serve as a useful tool to examine altered hepatobiliary 
disposition in response to impaired Mrp2 function, and facilitate the identification 
of compensatory basolateral and apical efflux mechanisms involved in 99mTc-
MEB hepatobiliary disposition. 
 Material and Methods 
Materials. Dulbecco’s modified Eagle’s medium (DMEM), insulin, MEM non-
essential amino acids solution (100x), L-glutamine, insulin and penicillin G-
streptomycin solution were purchased from Invitrogen (Carlsbad, CA). Estradiol-
17-β-D-glucuronide (E217G),  para-aminohippuric acid sodium salt (PAH), 
tetraethylammonium (TEA), rifamycin SV, glycyrrhizic acid, clonidine, 
desipramine, ketoprofen, fetal bovine serum (FBS), Triton X-100, 
dexamethasone, and Hanks’ balanced salt solution (HBSS) modified with (H-
1387) or without (H-4891) calcium chloride were obtained from Sigma-Aldrich 
(St. Louis, MO). Collagenase (type 1) was obtained from Worthington 
Biochemical Corporation (Freehold, NJ).  BioCoat™ collagen I plates, Matrigel™ 
basement membrane matrix, and ITS+™ (insulin/transferrin/selenium) culture 
supplement were purchased from BD Biosciences Discovery Labware (Bedford, 
MA). Bicinchoninic acid (BCA) protein assay reagents and BSA for the protein 
assay standard were purchased from Pierce Chemical Co. (Rockford, IL). 99mTc-
MEB and 99mTc-MIBI were purchased as sterile doses on the day of the 
experiment from Cardinal Health Nuclear Pharmacy (Research Triangle Park, 
NC).  Ultima GoldTM XR scintillation cocktail, 3H-PAH (3.28 Ci/mmol) and 3H-
E217G (45.8 Ci/mmol) were purchased from Perkin Elmer Life Sciences (Boston, 
MA).  14C-TEA (55mCi/mmol) was purchased from American Radiolabeled 
Chemicals.  MK-571 sodium salt was purchased from Cayman Chemical Co 
(Ann Arbor, MI).  N-(4-[2-(1,2,3,4-tetrahydro-6,7-dimethoxy-2-isoquinolinyl)ethyl]-
phenyl)-9,10-dihydro-5-methoxy-9-oxo-4-acridine carboxamide (GF120918) was 
142 
 
 a gift from GlaxoSmithKline (Research Triangle Park, NC).  All other chemicals 
and reagents were of analytical grade and available from commercial sources.   
Animals. Male Wistar wild-type (WT) rats (201-312 g) from Charles River 
Laboratories, Inc. and Mrp2-deficient TR- rats bred at the University of North 
Carolina (228–306 g; breeding stock obtained from Dr. Mary Vore, University of 
Kentucky, Lexington, KY) were used for sandwich-cultured hepatocyte studies.  
All animals acclimated for one week before experiments.  Rats were housed in 
an alternating 12-h light and dark cycle with free access to water and food prior 
to surgery.  All animal procedures complied with the guidelines of the Institutional 
Animal Care and Use Committee (University of North Carolina, Chapel Hill, NC). 
Suspended Hepatocyte Isolation/Uptake Studies. 
Rat hepatocytes were isolated by a two-step collagenase perfusion method as 
described previously (LeCluyse et al., 1996).  Viability, as determined by trypan 
blue exclusion, was 90 to 95% (mean = 92%).  CellzDirect, Life Technologies 
(RTP, NC) kindly provided freshly isolated human hepatocytes in suspension.  
Hepatocyte donors included a 60 yr old female Caucasian, and 63 and 69 yr old 
male Caucasians, with no recent history of smoking or alcohol use. Hepatocyte 
viability, as determined by trypan blue exclusion, was 90, 86 and 89%, 
respectively.  Cells were suspended in cold modified Hank’s buffer with 10 mM 
Tris/5 mM glucose (pH = 7.4) or Na+-free choline buffer (10 mM Tris, 5 mM 
glucose, 5.4 mM KCl, 1.8 mM CaCl2, 0.9 mM MgSO4, 10 mM HEPES and 137 
mM choline; pH = 7.4) and stored on ice prior to conducting uptake studies 
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 (Leslie et al., 2007).  Isolated hepatocytes were suspended at 1 x 106 cells/ml in 
the same buffer, placed on ice, and used immediately in experiments.  
Hepatocyte suspensions (4 ml; n = 3 – 6 livers, in duplicate or triplicate) were 
preincubated in bottom inverted Erlenmeyer flasks at 37˚C for 5 min; 0.1% 
DMSO or chemical inhibitor was added 1 min before, followed by 99mTc-MEB (0.5 
µCi/ml), 99mTc-MIBI (0.5 µCi/ml), 3H-E217G (1 µM, 60 nCi/mL), 14C-TEA (20 µM, 
60 nCi/mL) or 3H-PAH (0.2, 1 or 20 µM, 60 nCi/mL).  The following 
concentrations of inhibitors were selected based upon reported affinities for the 
given active transport processes: 20 µM rifamycin SV (Oatp1a1, Oatp1a4, 
OATP1B1, OATP1B3, and OATP2B1 inhibitor), 20 µM glycyrrhizic acid 
(Oatp1a1, 1a4 and 1b2 inhibitor), 200 µM clonidine [organic cation transporter 
(Oct1) inhibitor], 10 µM desipramine (Oct1 and 3 inhibitor), 5 µM decynium 22 
(OCT inhibitor), 10 µM ketoprofen [organic anion transporter 2 (Oat2) inhibitor].  
Aliquots (100 µL) of the suspension were removed at timed intervals (up to 5 
min), placed in 0.4-ml polyethylene tubes and centrifuged immediately through a 
top layer of silicone oil:mineral oil (82:18, v/v; 100 µL) and a bottom layer of 3M 
KOH (50 µL).  99mTc-MEB and 99mTc-MIBI in the cell pellet and supernatant were 
analyzed using a sodium iodide well counter and corrected for decay (99mTc 
t1/2=6.01 hr).  3H-E217G, 14C-TEA or 3H-PAH were analyzed by liquid scintillation 
counting.  Adherent fluid volume was estimated with 14C-inulin as previously 
described (Baur et al., 1975).  Protein concentrations for individual hepatocyte 
suspensions were determined with the BCA protein assay reagent kit (Pierce) as 
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 instructed by the manufacturer.  BSA, as supplied by the manufacturer, was used 
as a standard (0.2 – 1 mg/mL). 
Sandwich-Cultured Hepatocyte Studies. 
CellzDirect, Life Technologies (RTP, NC) provided human hepatocytes plated on 
six-well BiocoatTM plates and overlaid with MatrigelTM.  Hepatocyte donors were a 
56 and 64 yr old female Caucasian with no history of smoking or alcohol use.  
Rat hepatocytes (>88% viability) were seeded [~1.5 x 106 cells/well (TR-) or 1.75 
x 106 cells/well (WT)] in 6-well BioCoat™ plates in DMEM without phenol red 
supplemented with 2 mM L-glutamine, 1% (v/v) MEM non-essential amino acids, 
100 units penicillin G sodium, 100 µg streptomycin sulfate, 1 µM 
dexamethasone,  5% (v/v) FBS, and 10 µM insulin (day 0 of culture), and allowed 
to attach for 2-6 h in a humidified incubator (95% O2, 5% CO2) at 37ºC. After cell 
attachment, culture plates were swirled gently and the culture medium was 
replaced with the same medium.  Cells were overlaid 16-24 h (day 1 of culture) 
after seeding with ice-cold  Matrigel™ basement membrane matrix (0.25 mg/mL) 
in 2 mL/well cold serum-free DMEM containing 2 mM  L-glutamine, 1% (v/v) 
MEM non-essential amino acids, 100 units penicillin G sodium, 100 µg 
streptomycin sulfate, 0.1 µM dexamethasone, and 1% (v/v) ITS+™. The culture 
medium was changed every 24 h until experiments were performed on day 4 of 
culture.   
Efflux Studies. 
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 On day 4, efflux experiments were performed as previously described (Liu et al., 
1999a) with modifications. Briefly, hepatocytes were rinsed with 2 mL warm 
standard buffer and incubated with 1.5 mL of 99mTc-MEB or 99mTc-MIBI (5 µCi/ml) 
in standard HBSS for 20 min in a humidified incubator (95% O2, 5% CO2) at 
37ºC.  Subsequently, hepatocytes were rinsed vigorously twice with 2 mL warm 
standard HBSS or Ca2+-free HBSS (to maintain or disrupt tight junctions, 
respectively), and incubated with 1.5 mL of the same buffer supplemented with 
chemical inhibitors (100 µM MK571 or 20 µM GF120918) or vehicle control (0.6% 
dimethyl sulfoxide) for 20 min at 37ºC. The amount of 99mTc-MEB or 99mTc-MIBI in 
the efflux buffer was sampled at 20 min and medium was aspirated.  
Hepatocytes were lysed as detailed above.  Data were normalized to protein 
concentration in each well, determined in duplicate aliquots using the BCA 
protein assay reagent kit with BSA as a standard, as described previously.    
Samples were analyzed using a gamma counter and corrected for decay. 
The amount of substrate was measured in the medium at 20 min and in 
the lysed SCH at the end of the efflux phase.  The extent of basolateral and 
canalicular efflux was determined based on the following equations and 
normalized to the total substrate mass preloaded in the hepatocytes, which was 
determined as the sum of the substrate mass in the efflux medium and in the 
hepatocyte lysate at the end of the efflux phase: 
 
HBSSStandard
MediumEffluxinMassTotalEffluxlBasolatera =  
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Accumulation Studies. 
The method to determine substrate accumulation in the bile canalicular networks 
of SCH has been described previously (Liu et al., 1999a; Wolf et al., 2008). Cells 
were incubated for 10 min at 37ºC with 1.5 mL of 99mTc-MIBI (0.5 µCi/ml) with or 
without RNAi knockdown of Bcrp, and in the presence and absence of 2µM 
GF120918 in standard buffer. Substrate uptake was corrected for nonspecific 
binding by subtracting uptake on blank six-well BiocoatTM plates overlaid with 
MatrigelTM.  Hepatocytes were lysed as detailed above and data were normalized 
to protein concentration in each well, as described above.   
The biliary excretion index (BEI, %) was calculated using B-CLEAR® 
technology [Qualyst, Inc., Raleigh, NC; (Liu et al., 1999a)]:  
 
010
onAccumulati
onAccumulationAccumulati
BEI
BileCells
CellsBileCells ×−=
+
+                                 
 
where substrate accumulation in the cells+bile compartments was determined in 
hepatocytes preincubated in standard buffer; cellular accumulation of substrate 
was determined in hepatocytes preincubated with Ca2+-free HBSS. 
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where AUC0-T represents the product of the incubation time (T) and the initial 
concentration in the medium.  In vitro Clbiliary values were scaled per kilogram 
body weight assuming the following: 200 mg protein/g rat liver tissue and 40 g rat 
liver tissue/kg body weight (Seglen, 1976). 
RNAi knockdown of Bcrp. 
The methods for packaging of recombinant siRNA-expressing adenoviral vectors 
and infection of sandwich-cultured hepatoctyes have been described previously 
(Yue et al., 2009).  Briefly, after seeding hepatocytes on BiocoatTM plates and 
changing seeding medium, cells were infected overnight with a non-target siRNA 
(siNT), or siRNA sequences targeting the rat Bcrp gene at positions 288-306 
(siBcrp) at a multiplicity of infection of 20.  Approximately 24 h after-seeding, cells 
were overlaid and cultured as described above. Knockdown of Bcrp was 
confirmed by western blot analysis and determination of the biliary clearance of 
nitrofurantoin using LC/MS/MS analysis, as detailed previously (Yue et al., 2009). 
Immunoblots. 
Cells were washed once with HBSS, and resuspended in lysis buffer consisting 
of 1% SDS, 1 mM EDTA and Complete protease inhibitor cocktail tablets (Roche 
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Diagnostics, Mannheim, Germany).  Protein concentrations were determined by 
the BCA assay.  Whole-cell lysates (30-40 µg) were resolved on NuPAGE 4 to 
20% Bis-Tris gel (Invitrogen Corp, Carlsbad, CA) and the proteins were 
transferred to polyvinylidene difluoride (PVDF) membranes.  After blocking in 5% 
milk-Tris-buffered saline with Tween 20 (TBST) for 30 min, blots were incubated 
overnight at 4°C with the following antibodies: Bcrp (BXP-53, Alexis 
Biochemicals, San Diego, CA) and β-actin (C4, Chemicon, San Francisco, CA).  
After incubation with HRP-conjugated secondary antibody, signals were detected 
by chemiluminescent substrate Supersignal West Dura (Pierce, Rockford, IL) 
with a Bio-Rad VersaDoc imaging system; densitometry analysis was performed 
using Quantity One v4.1 software (Bio-Rad Laboratories, Hercules, CA). 
 Results. 
Uptake of 99mTc-MEB, 99mTc-MIBI, 3H-E217G, and 14C-TEA in Suspended Rat 
and Human Hepatocytes.  Preliminary experiments in suspended rat 
hepatocytes sampling over 60 min indicated that the linear range of uptake was 
2.5, 1.5, 2.5, and 5 min for 99mTc-MIBI, 99mTc-MEB, 3H-E217G, and 14C-TEA, 
respectively.  Therefore, subsequent experiments were conducted up to the 
respective times to evaluate the initial uptake rate of each substrate. The 
Oct/OCT inhibitors clonidine, desipramine and decynium 22, and the Oat/OAT 
inhibitor ketoprofen, and the absence of sodium (substitution with choline-based 
buffer to rule out the involvement of Ntcp/NTCP) had marginal effects on the 
initial uptake of 99mTc-MEB in WT rat and human hepatocytes compared to 
control (Fig. 4.1A and 4.2A).  Initial 99mTc-MEB uptake was reduced to 20.7 and 
35.4% of control in the presence of the Oatp/OATP inhibitor rifamycin SV in WT 
rat and human hepatocytes, respectively (Fig. 4.1A and 4.2A).  In WT rat 
hepatocytes, the Oatp inhibitor glycyrrhizic acid reduced 99mTc-MEB initial uptake 
to 39.5% of control (Fig. 4.1A).  Initial 99mTc-MIBI uptake in suspended WT rat 
hepatocytes was not influenced by inhibitors or replacement of sodium with 
choline in the uptake buffer; all values were within 10% of control (Fig. 4.1B).     
In order to confirm the specificity of the selected inhibitors, transport of 
probe substrates was assessed in the presence of each inhibitor.  3H-E217G, 
14C-TEA, and 3H-PAH were selected based on their selective affinities for the 
Oatps/OATPs, Octs/OCTs and Oats/OATs, respectively.  As expected, initial 
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 hepatocyte uptake of the Oatp probe substrate 3H-E217G was inhibited to 15.5 
and 23.8% of control in the presence of rifamycin SV and glycyrrhizic acid, 
respectively, in suspended WT rat hepatoyctes (Fig. 4.1C), and 51.5% of control 
in the presence of rifamycin SV in suspended human hepatocytes (Fig. 4.2B).  All 
other inhibitors had marginal effects on 3H-E217G uptake in both WT rat and 
human suspended hepatocytes (Fig. 4.1C and 4.2B).  Initial uptake of the Oct 
probe substrate 14C-TEA was inhibited to 23.7% and 25.6% of control in the 
presence of clonidine and desipramine, respectively, in suspended rat 
hepatocytes (Fig. 4.1D), and 54.2% of control in the presence of decynium 22 
(Fig. 4.2C) in suspended human hepatocytes.  Interestingly, the Oatp1a1, 
Oatp1a4 and Oatp1b2 inhibitor glycyrrhizic acid reduced 14C-TEA uptake by 
62.1% compared to control in suspended rat hepatocytes (Fig. 4.1D).  The 
uptake of 20 µM 3H-PAH over 60 min was marginally greater than background, 
which was attributed primarily to nonspecific binding to the hepatocytes.  3H-PAH 
uptake was not significantly influenced by the presence of 50 µM MK571 in the 
incubation medium (a known Mrp inhibitor added to inhibit potential basolateral 
efflux; data not shown).  
Hepatobiliary Disposition of 99mTc-MEB in Rat and Human Sandwich-
Cultured Hepatocytes 
99mTc-MEB canalicular efflux was slightly lower than basolateral efflux over 20 
min in SCH from WT rats (15.3 ± 5.7% vs. 25.0 ± 6.7 of total preloaded mass).  
In contrast, in human SCH 99mTc-MEB canalicular efflux was greater than 
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 basolateral efflux (45.8 ± 8.6% vs. 16.7 ± 0.6% of total preloaded mass).  99mTc-
MEB canalicular efflux was ~3-fold greater in human compared to rat SCH, while 
basolateral efflux in human SCH was slightly lower than in rat SCH (Fig. 4.3A).  
99mTc-MEB basolateral efflux tended to be higher in TR- SCH (31.8 ± 6.2 % of 
total preloaded mass) relative to WT values, while canalicular efflux of 99mTc-
MEB in TR- SCH was negligible (Fig. 4.3A).  MK571 (100 µM) decreased 99mTc-
MEB canalicular efflux 665% in rat SCH and 30% in human SCH (Fig. 4.3A), but 
increased 99mTc-MEB basolateral efflux 136% in rat SCH and 240% in human 
SCH (Fig. 4.3A).  99mTc-MEB hepatocellular content (cell only) at the end of the 
20-min efflux phase was slightly greater in rat SCH (58.7 ± 7.2%) compared to 
human SCH (37.6 ± 8.0%) (Fig. 4.3B), consistent with the species differences 
observed in the total efflux of 99mTc-MEB in rat (40.3 ± 5.4%) and human (62.4 ± 
8.0%) SCH.  
Hepatobiliary Disposition of 99mTc-MIBI in Rat and Human Sandwich-
Cultured Hepatocytes. 
99mTc-MIBI basolateral efflux was greater than canalicular efflux over 20 min in 
SCH from WT rats (40.5 ± 7.6 vs. 23.6 ± 3.4% of total preloaded mass), TR- rats 
(39.4 ± 7.1 vs. 30.9 ± 2.1% of total preloaded mass), and humans (64.0 ± 4.2 vs. 
25.4 ± 6.0% of total preloaded mass) (Fig. 4.4A).  99mTc-MIBI canalicular efflux 
was similar between human and WT rat SCH, but basolateral efflux was 37% 
greater in human compared to WT rat SCH (Fig. 4.4A).  99mTc-MIBI basolateral 
efflux was similar in SCH from TR- and WT rats; likewise, canalicular efflux of 
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 99mTc-MIBI was not altered in SCH from TR- compared to WT rats (Fig. 4.4A).  
GW918 (20 µM) decreased 99mTc-MIBI canalicular efflux 1.5-fold in rat SCH and 
2.1-fold in human SCH. Interestingly, GW918 also decreased 99mTc-MIBI 
basolateral efflux in rat and human SCH (~2.3- and ~2.9-fold, respectively) (Fig. 
4.4A). Hepatocellular content of 99mTc-MIBI at the end of the 20-min efflux phase 
was greater in rat SCH compared to human SCH (34.0 ± 4.3 vs. 10.6 ± 1.8 % of 
total preloaded mass; Fig. 4.4B), consistent with greater total efflux of 99mTc-MIBI 
in human (89.4 ± 1.8%) compared to rat (64.0 ± 8.2%) SCH using the 20-min 
efflux study design. 
Using the 10-min accumulation study design, 99mTc-MIBI accumulation in 
cells+bile and cells was determined in rat SCH; BEI and in vitro Clbiliary values 
were 18.8% and 4.07 mL/min/kg, respectively.  To examine whether Bcrp and/or 
P-gp were responsible for the biliary excretion of 99mTc-MIBI in rat SCH, 10-min 
accumulation studies were conducted.  99mTc-MIBI BEI (26.6 and 36.0%) and in 
vitro Clbiliary (8.08 and 9.73 mL/min/kg) in day 4 WT rat SCH were marginally 
increased by infection with adenoviral vectors expressing a non-target control 
(siNT) or short hairpin RNA targeting rat Bcrp (siBcrp), respectively (Fig. 4.5A).  
99mTc-MIBI BEI and in vitro Clbiliary were ablated in the presence of 2µM GW918 
in siNT- and siBcrp-infected SCH, which resulted in a ~2-fold increase in 
hepatocellular accumulation (cells only) of 99mTc-MIBI (Fig. 4.5A).  As shown in 
Figure 4.5B, in day 4 rat SCH, protein levels of Bcrp (normalized by β-actin) in 
siBcrp-infected cells were ~20% of those in control (siNT-infected) cells.  No 
significant differences in nitrofurantoin cellular accumulation, BEI, or in vitro 
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Clbiliary in noninfected or control siNT-infected rat SCH were noted (Fig. 4.5C).  As 
expected, the cellular accumulation of nitrofurantoin, a Bcrp substrate, was 
increased due to the ~6-fold decrease in BEI in siBcrp-infected cells compared to 
control (siNT-infected) cells.   
 Discussion. 
The utility of 99mTc-MEB and 99mTc-MIBI as probe substrates for 
phenotyping the function of specific hepatic transport proteins was confirmed 
using well established in vitro methods.  Suspended hepatocytes and SCH were 
utilized from rats and humans to characterize hepatic uptake and efflux 
mechanisms in combination with the use of “specific” chemical inhibitors to 
examine the impact of hepatic transport modulation on the disposition of 99mTc-
MEB and 99mTc-MIBI.     
 Two inhibitors were selected to encompass all Oatp/OATP isoforms 
reported to be expressed in rat and human liver.  Rifamycin SV inhibits Oatp1a1 
and 1a4  (Fattinger et al., 2000) and all of the relevant human isoforms 
expressed in the liver (OATP1A2, OATP1B1, OATP1B3 and OATP2B1) 
(Vavricka et al., 2002); glycyrrhzic acid inhibits Oatp1b2, OATP1B1 and 
OATP1B3 (Ismair et al., 2003).  Octs were inhibited by clonidine (Martel et al., 
1996), desipramine (Grundemann et al., 1994) and decynium 22 (Hayer-Zillgen 
et al., 2002), and Oat function was inhibited with ketoprofen (Morita et al., 2001; 
Ohtsuki et al., 2002).  To assess sodium-dependent transport by the sodium 
taurocholate co-transporting polypeptide (Ntcp), choline-based buffer was 
substituted for sodium-based buffer in suspended hepatocytes.   
 Probe substrates were evaluated in the presence and absence of the 
panel of inhibitors to confirm the specificity of the selected inhibitors.  The use of 
3H-E217G as a model Oatp/OATP probe substrate is well established (Brock and 
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 Vore, 1984; Shitara et al., 2003).  3H-E217G initial uptake was decreased 
significantly only by the Oatp/OATP inhibitors rifamycin SV and glycyrrhzic acid 
(Fig. 4.1C and 4.2B), which supports the use of these compounds as broad (not 
specific for any given isoform) Oatp/OATP inhibitors, and confirms that the other 
inhibitors used in this study did not interfere with the uptake of this model 
substrate.  Oct/OCT function in the presence of the panel of inhibitors was 
assessed with the probe substrate 14C-TEA, which has reported Km values for 
Oct1 ranging from 35 to 251 µM (Grundemann et al., 1994; Busch et al., 1996; 
Chen and Nelson, 2000).  As expected, the Oct/OCT inhibitors (clonidine, 
desipramine, and decynium 22) significantly reduced the initial uptake of 14C-TEA 
(Fig. 4.1D and 4.2C).  Unexpectedly, the Oatp/OATP inhibitor glyzyrrhizic acid 
significantly decreased 14C-TEA initial uptake to 37.9% of control, suggesting that 
this inhibitor is not specific for Oatp isoforms because TEA is not a substrate of 
the Oatps expressed in the rat liver (Cattori et al., 2001).  Rifamycin SV and 
ketoprofen had no effect on 14C-TEA, supporting the hypothesis that these 
inhibitors may be specific for Oatps/OATPs and Oat2/OAT2, respectively.  Lastly, 
the function of Oat2/OAT2 (Simonson et al., 1994; Hilgendorf et al., 2007), was 
assessed with the model Oat/OAT substrate 3H-PAH (Sekine et al., 1998; 
Kobayashi et al., 2005).  3H-PAH is not a substrate for Oatp1a1, Oatp1a4 or 
Oatp1b2 individually expressed in Xenopus laevis oocytes (Cattori et al., 2001).  
However, incubation of freshly isolated rat and human hepatocytes with 0.2, 1 or 
20 µM 3H-PAH over 60 min in the absence and presence of 50 µM MK571, co-
administered to inhibit potential basolateral efflux, resulted in no measurable 
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 increase in activity above background.  Carrier-mediated retrieval of human 
OAT1 expressed in Xenopus oocytes and HEK293 cells from the cell membrane 
results in decreased function (Wolff et al., 2003).  These findings suggest that 
Oat2/OAT2 may not be properly localized to assess transport function in freshly 
isolated rat and human hepatocytes. 
 Based on the specificity of the chosen inhibitors, 99mTc-MEB and 99mTc-
MIBI hepatic uptake were examined.  99mTc-MEB initial uptake was sodium-
independent, and was only affected by the Oatp/OATP inhibitors, rifamycin SV 
and glycyrrhizic acid (Fig. 4.1A and 4.2A).  These data support the hypothesis 
that MEB uptake is predominantly mediated by Oatps/OATPs in rat and human 
hepatocytes, and is in agreement with data demonstrating 99mTc-MEB is a 
substrate of OATP1B1 and OATP1B3 in HEK293 overexpressing cells (Ghibellini 
et al., 2008).  Bilirubin (20 µM), an Oatp substrate, inhibited 99mTc-MEB initial 
uptake in plated rat hepatocytes by ~30% (Lan et al., 1988).   
 99mTc-MIBI initial uptake was not influenced by inhibitors or the absence of 
sodium in the uptake buffer (Fig. 4.1B), suggesting that an active transport 
process is not involved in 99mTc-MIBI hepatic uptake at these low concentrations.  
Concentrations of 99mTc-MIBI were increased (5 - 200 µCi/mL) to saturate a 
possible active transport process but partitioning of 99mTc-MIBI into hepatocytes 
was linear at designated time points collected for 60 min.  These findings are 
consistent with previous reports that MIBI uptake is a function of free diffusion 
based on electrical potentials across the plasma and mitochondrial membranes, 
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 with localization in the mitochondria by electrostatic forces (Chiu et al., 1990; 
Delmon-Moingeon et al., 1990).  Therefore, 99mTc-MIBI uptake experiments were 
not conducted in human hepatocytes to conserve this limited resource.   
Further studies were undertaken to examine the efflux processes involved 
in 99mTc-MEB hepatic disposition.  Remarkably, the canalicular efflux of 99mTc-
MEB was ~3-fold greater in human compared to WT rat SCH, whereas the 
basolateral efflux was comparable (Fig. 4.3A).  This cannot be attributed to 
differences in the absolute amount of Mrp2/MRP2 protein primarily responsible 
for biliary excretion of 99mTc-MEB, but could be explained by affinity differences.  
Based on work by Li et al., total Mrp2/MRP2 protein was not significantly different 
in day 4 rat and day 7 human SCH (~4 fmol/µg protein) utilizing a quantitative 
LC-MS/MS analysis (Li et al., 2009).  99mTc-MEB total efflux also was greater in 
human compared to rat SCH due to this increased canalicular efflux (Fig. 4.3A).  
99mTc-MEB canalicular efflux was completely ablated in TR- rat SCH.  The Mrp2 
inhibitor MK571 decreased 99mTc-MEB canalicular efflux ~6.7-fold in rat SCH, but 
only 30% in human SCH (Fig. 4.3A).  This apparent discrepancy could be due to 
limitations in the experimental design of the efflux experiments.  For example, 
during the preloading phase, 99mTc-MEB accumulates in the canalicular networks 
and may not be completely washed away before initiating the efflux phase or 
rapid canalicular excretion of 99mTc-MEB may occur before MK571 had time to 
access the hepatocyte and reach the site of MRP2 inhibition, especially in human 
SCH.  Overall,  MK571 inhibition and the absence of 99mTc-MEB in the bile 
canalicular networks of TR- rat SCH support the hypothesis that 99mTc-MEB is a 
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 specific Mrp2 probe substrate, consistent with other reports documenting 
increased hepatic exposure of 99mTc-MEB in TR- rats (Bhargava et al., 2009), 
and decreased biliary excretion in patients with Dubin-Johnson syndrome 
(MRP2-deficiency) administered 99mTc-MEB analogs (Pinos et al., 1990).  99mTc-
MEB basolateral efflux was increased in TR- sandwich-cultured rat hepatocytes 
compared to WT, and in the presence of MK571 (Fig. 4.3A), while intracellular 
accumulation of 99mTc-MEB was unchanged (Fig. 4.3B).  These important 
findings suggest that this probe can be redirected from biliary excretion to 
basolateral efflux.  This increase in basolateral efflux also could be due, in part, 
to inhibition of 99mTc-MEB hepatic re-uptake, because MK571 has been shown to 
inhibit OATP1B3 with a reported Ki of 0.6 µM (Letschert et al., 2005).    
Further studies were conducted to investigate the efflux processes 
involved in 99mTc-MIBI hepatic disposition.  The absence of Mrp2 based on efflux 
studies in sandwich-cultured TR- rat hepatocytes did not alter basolateral or 
canalicular efflux, suggesting that either Mrp2 is not involved, or other proteins 
(e.g. P-gp) are able to fully compensate (Fig.4.4A).   In TR- rats, 99mTc-MIBI 
hepatic scintigraphy and biliary excretion were unchanged compared to WT 
control rats (Hendrikse et al., 2004).  99mTc-MIBI efflux was assessed in the 
presence of 20 µM GW918, a concentration 10-fold greater than previously used 
to inhibit P-gp in rat SCH (Annaert et al., 2001).  This concentration was selected 
based on studies in cancer cell lines expressing multidrug resistance transport 
proteins (P-gp and Bcrp) demonstrating GW918 is a more potent inhibitor of P-gp 
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 than Bcrp by an order of magnitude or more (de Bruin et al., 1999), and the use 
of 10 µM GW918 in isolated perfused rat livers to impair Bcrp-mediated biliary 
excretion of 4-methylumbelliferyl sulfate generated in the hepatocyte (Zamek-
Gliszczynski et al., 2006).  As expected, 99mTc-MIBI canalicular efflux was 
GW918 sensitive, consistent with a role for P-gp and/or Bcrp in 99mTc-MIBI biliary 
excretion. Surprisingly, 99mTc-MIBI basolateral efflux was GW918 sensitive, 
suggesting involvement of an active transport process.  Recently, GW918 was 
demonstrated to inhibit MRP4 in inside-out membrane vesicles prepared from 
transiently transfected HEK293 cells (Lee, 2009).  Hepatocellular accumulation of 
99mTc-MIBI increased in the presence of GW918 (Fig. 4.4B) due to decreased 
basolateral and canalicular efflux of MIBI (Fig. 4.4A).  
In order to further investigate the transport processes involved in 99mTc-
MIBI biliary excretion, accumulation studies were conducted in rat SCH.  The 
involvement of Bcrp in the biliary excretion of 99mTc-MIBI was assessed with the 
use of RNAi knockdown of Bcrp, as confirmed by immunoblot (Fig. 4.5B) and 
significantly impaired biliary excretion of the rat Bcrp probe susbstrate 
nitrofurantoin (Fig. 4.5C).  This approach using adenoviral vectors expressing a 
non-target control (siNT) and short hairpin RNA targeting Bcrp (siBcrp) has been 
shown to efficiently and specifically knock down Bcrp in sandwich-cultured rat 
hepatocytes (Yue et al., 2009).  Bcrp knockdown did not affect 99mTc-MIBI 
cellular accumulation, biliary excretion or in vitro biliary clearance (Fig. 4.5A).  
This finding was consistent with data generated in the cancer cell lines SIM1 and 
MCF-7, and their BCRP overexpressing derivative cells (Chen et al., 2000).  
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 99mTc-MIBI biliary excretion was inhibited completely by 2µM GW918 (Fig. 4.5A), 
used previously to inhibit P-gp in rat SCH (Annaert et al., 2001).  Cellular 
accumulation also increased in the presence of GW918 (Fig. 4.5A), suggesting 
that P-gp is the primary protein responsible for the biliary excretion of 99mTc-MIBI.  
These findings are in agreement with reduced 99mTc-MIBI biliary elimination 
and/or increased retention of 99mTc-MIBI in the liver determined by hepatic 
scintigraphy in humans with single nucleotide polymorphisms in the ABCB1 gene 
resulting in decreased P-gp function (Wong et al., 2005), and in cancer patients 
administered MIBI and the P-gp inhibitor PSC833 (Chen et al., 1997) (Luker et 
al., 1997).  
Remarkable species differences existed in the fraction of canalicular vs. 
basolateral efflux of 99mTc-MEB in rats (38.0% and 62.0%, respectively) and 
humans (73.3% and 26.7%, respectively; Fig. 4.3A), suggesting that biliary 
excretion would be the preferential route of hepatic elimination of this probe in 
humans. This finding is consistent with in vivo data from healthy human subjects 
indicating that ~84% of a 2.3 µCi dose of intravenously administered 99mTc-MEB 
was recovered in bile (Ghibellini et al., 2004).  In contrast, the fraction of 
canalicular vs. basolateral efflux of 99mTc-MIBI in rats (36.8% and 63.2%, 
respectively) and humans (28.3% and 71.7%, respectively; Fig. 4.4A), 
basolateral excretion of 99mTc-MIBI appears to be the preferential route of hepatic 
elimination of this probe in both rats and humans.  This finding is consistent with 
biliary recovery of ~22% of a 3.1 µCi dose of intraveneously administered 99mTc-
MIBI in healthy human subjects (Ghibellini et al., 2007). Overall the efflux method 
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 is useful for examining the preferential route of hepatic efflux (canalicular vs. 
basolateral) and elucidating species differences in hepatic efflux. 
In summary, the hepatic uptake of 99mTc-MIBI appears to occur by passive 
diffusion; 99mTc-MIBI biliary excretion is mediated by P-gp.  99mTc-MEB hepatic 
uptake is predominantly Oatp-mediated with biliary excretion by Mrp2.  
Remarkable species differences exist between rat and human in the total efflux 
and route of efflux for 99mTc-MEB.  Preloading SCH and measurement of efflux 
over 20 min in SCH is a useful approach to investigate the route of hepatic 
excretion (basolateral vs. canalicular), species differences in basolateral and 
canalicular efflux, and compensatory changes in canalicular and basolateral 
efflux due to impaired transport function associated with drug interactions, 
disease state alterations or genetic variation.   
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 Legend to Figures 
Figure 4.1 Initial uptake rate of (A) MEB (5 µCi/mL), (B) MIBI (5 µCi/mL), (C) 3H-
E217G (1 µM), and (D) 14C-TEA (20 µM) in suspended WT rat hepatocytes in the 
absence and presence of transport protein inhibitors (mean percentage ± SEM; 
n=3 livers per group, in duplicate or triplicate; Glcy Acid =glycyrrhizic acid); *, 
p<0.05 versus control. 
 
Figure 4.2 Initial uptake rate of (A) MEB (5 µCi/mL), (B) 3H-E217G (1 µM), and 
(C) 14C-TEA (20 µM) in suspended human hepatocytes in the absence and 
presence of transport protein inhibitors (mean percentage ± SEM; n=2-3 livers 
per group, in duplicate or triplicate; Glcy Acid =glycyrrhizic acid); *, p<0.05 versus 
control. 
 
Figure 4.3 MEB (A) basolateral (dark grey bars) and canalicular (white bars) 
efflux over 20 min (5 µCi/mL, 20-min preload) and (B) hepatocellular content 
(cross hatched bars) in cell lysate at the end of the 20-min efflux experiments in 
day 4 rat (WT and TR-) and day 7 human (hatched) sandwich-cultured 
hepatocytes.  Data were obtained after a 20-min efflux phase in incubation 
medium containing standard (basolateral) or Ca+-free (basolateral + canalicular) 
HBSS (Mean ± SEM or Range; n=4 WT rat livers, n=3 TR- rat livers and n=2 
human livers in triplicate). 
 
Figure 4.4 MIBI (A) basolateral (dark grey bars) and canalicular (white bars) 
efflux over 20 min (5 µCi/mL, 20-min preload) and (B) hepatocellular content 
(cross hatched bars) in cell lysate at the end of the 20-min efflux experiments in 
day 4 rat (WT and TR-) and day 7 human (hatched) sandwich-cultured 
hepatocytes.  Data were obtained after a 20-min efflux phase in incubation 
medium containing standard (basolateral) or Ca+-free (basoleral + canalicular) 
HBSS (Mean ± SEM or Range; n=4 WT rat livers, n=3 TR- rat livers and n=2 
human livers in triplicate). 
 
Figure 4.5 MIBI (A) accumulation in cells+bile (black bars) and cells (white bars),  
biliary excretion index (BEI) and in vitro Clbiliary determined after a 10-min 
incubation with 0.5 µCi/mL MIBI in day 4 WT sandwich-cultured rat hepatocytes 
non-infected or infected with adenoviral vectors expressing short hairpin RNA 
targeting rat Bcrp (siBcrp) or a non-target control (siNT) (representative data; 
mean ± SD; n=3 livers).  Bcrp (B) expression in day 4 non-infected (None) or 
sandwich-cultured rat hepatocytes infected with adenoviral vectors siNT and 
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 siBcrp.  Representative results are shown with β-actin as the loading control.  
Nitrofurantoin (C) accumulation in cells+bile (black bars) and cells (white bars), 
BEI and in vitro Clbiliary determined after a 10-min incubation with 5 µM 
nitrofurantoin in day 4 WT sandwich-cultured rat hepatocytes non-infected or 
infected with siBcrp or siNT (representative data; mean ± SD). 
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 Figure 4.2 
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 Figure 4.4 
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Figure 4.5 
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This chapter will be submitted to Drug Metabolism and Disposition and is 
presented in the style of that journal. 
 Abstract  
Sorafenib is an orally active tyrosine kinase inhibitor used in the treatment of 
renal and hepatocellular carcinoma. Emerging data suggest that transport 
proteins play an important role in sorafenib disposition in humans.  This study 
was designed to identify the transport proteins responsible for the hepatic uptake 
of sorafenib, and to determine the extent of biliary excretion of sorafenib in 
human hepatocytes.  Initial uptake was assessed in freshly isolated, suspended 
human hepatocytes in the presence of inhibitors and modulators.  [14C]Sorafenib 
(1 µM) uptake at 4°C was ~40 to 50% of the uptake at 37°C, suggesting a high 
degree of passive diffusion.  Hepatocyte uptake of [14C]sorafenib did not exhibit 
sodium dependence, and was not influenced by the organic anion transport 
(OAT) inhibitor ketoprofen.  However, initial [14C]sorafenib hepatocyte uptake 
was reduced to 54 and 70% of control values in the presence of the organic 
anion transporting polypeptide (OATP) inhibitor rifamycin SV, and the organic 
cation transporter (OCT) inhibitor decynium 22, respectively.  Transport of 
[14C]sorafenib also was studied in OCT1 stably transfected Chinese hamster 
ovary (CHO) cells.  [14C]sorafenib uptake in OCT1 transfected CHO cells was 
temperature dependent, similar to mock cells in the linear range up to 5 min, and 
increased ~2-fold compared to mock cells at >5 min.  The OCT inhibitor, 
decynium 22, decreased [14C]sorafenib uptake in OCT1 transfected CHO cells by 
30% at all time points.  Sandwich-cultured human hepatocytes were utilized to 
determine the extent of biliary excretion of sorafenib.  The biliary excretion index 
(BEI) and the in vitro biliary clearance of sorafenib (1 µM) were low (1% and 1.0 
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ml/min/kg, respectively).  These results suggest that sorafenib uptake in human 
hepatocytes occurs via passive diffusion and active transport mediated by OCT1 
and OATPs.    
 Introduction 
Sorafenib, an orally active multikinase inhibitor, blocks tumor cell 
proliferation by targeting Raf/MEK/ERK, and exerts an antiangiogenic effect by 
targeting vascular endothelial growth factor receptor-1/-2/-3 (VEGFR-1/-2/-3), 
and platelet derived growth factor receptor beta (PDGFR-β) tyrosine kinases 
(Wilhelm et al., 2004; Carlomagno et al., 2006).  Sorafenib is approved for the 
treatment of renal and hepatocellular carcinomas, and has demonstrated activity 
toward other malignancies (Ratain et al., 2006; Llovet et al., 2008; Miller et al., 
2009).   
Following oral administration of [14C]sorafenib to healthy volunteers, 
approximately 77% of a 100 mg oral dose was excreted in feces ( 51% as 
parent), and 19% of the dose was excreted in urine as glucuronidated 
metabolites (Lathia et al., 2006).  Sorafenib is subject to two parallel pathways in 
man yielding the N-oxide mediated by cytochrome P450 3A4 (CYP3A4) and 
sorafenib glucuronide catalyzed by uridine disphosphate-glucuronsyl-transferase 
(UGT1A9) as primary metabolites (Lathia et al., 2006)(Radtke et al, 2005).;  
Approximately 17% of circulating radioactivity in plasma was in the form of 
sorafenib N-oxide (Lathia et al., 2006).  Peak plasma concentrations of sorafenib 
occur within 2 to 3 hours (Strumberg et al., 2005) after a single, oral dose; 
secondary peaks in the plasma concentration-time profile have been attributed to 
enterohepatic recirculation of sorafenib following cleavage of the glucuronide 
conjugate or reduction of the N-oxide in the gut (Lathia et al., 2006).  High 
interpatient variability in the Cmax and AUC in human plasma of sorafenib and the 
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 primary metabolite, sorafenib N-oxide, have been reported following multiple oral 
doses of sorafenib (Strumberg et al., 2007; Miller et al., 2009).   
Sorafenib administration to patients with hepatic dysfunction who exhibited 
increased serum levels of total bilirubin, AST and albumin resulted in dose-
limiting elevations in total bilirubin concentrations (Miller et al., 2009).  Possible 
explanations for the sorafenib-mediated increases in serum bilirubin include 
UGT1A1 inhibition of bilirubin glucuronidation as has been demonstrated in vitro 
(Kalyanaraman et al., 2006), or possibly due to inhibition of the transport proteins 
responsible for the hepatobiliary disposition of bilirubin or its conjugates.  
Understanding the mechanisms of hepatic uptake and the extent of biliary 
excretion of sorafenib is particularly important in patients with unresectable 
hepatocellular carcinoma, where the target site of sorafenib is the liver. 
 Transport proteins play an important role in the clearance of drugs from 
hepatic sinusoidal blood, and the excretion of parent drug and/or metabolite(s) 
across the apical membrane into the bile canaliculus.  The basolateral proteins 
that mediate uptake of endogenous and exogenous compounds into hepatocytes 
include members of the solute carrier (SLC) superfamily: Na+-taurocholate co-
transporting polypeptide (NTCP), organic anion transporters (OATs), organic 
cation transporters (OCTs), and organic anion transporting polypeptides 
(OATPs).  NTCP is expressed exclusively in the liver, is sodium-dependent, and 
predominately accounts for uptake of bile acids (Ho et al., 2004).  Recently, other 
drugs like rosuvastatin have been identified as NTCP substrates  (Ho et al., 
2006).  The OATPs are characterized by having broad and overlapping substrate 
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specificity, and display an affinity for organic anions as well as some bulky 
cations and neutral steroids (Mikkaichi et al., 2004).  In contrast to NTCP, the 
OATPs operate in a sodium-independent manner, and have been shown to 
function as bidirectional carriers (Li et al., 2000; Briz et al., 2006; Mahagita et al., 
2007).  There are three human isoforms, OATP1B1, 1B3 and 2B1, that play a 
substantial role in hepatic uptake of many endogenous and exogenous 
compounds including bilirubin (Konig et al., 2000; Cui et al., 2001), fexofenadine 
(Cvetkovic et al., 1999) and many statins (Shitara and Sugiyama, 2006).  OCTs 
are electrogenic uniporters that primarily mediate transport of small cations, 
although transport of anions and uncharged compounds has been reported 
(Koepsell et al., 2003).  The OATs constitute a family of proteins that mediate 
transport of negatively charged endogenous and exogenous compounds in 
exchange for dicarboxylate ions.  OATs are predominantly expressed in the 
kidney, although OAT2 has higher expression on the sinusoidal membrane of 
hepatocytes compared to the basolateral membrane of proximal kidney tubules 
(Sun et al., 2001).   
The objective of the present study was to identify the transport proteins 
responsible for the hepatic uptake of sorafenib, and to determine the extent of 
biliary excretion of sorafenib in human hepatocytes.  Initial uptake was assessed 
in freshly isolated human hepatocytes and in OCT1 transfected CHO cells.  
Sandwich-cultured human hepatocytes were utilized to determine the extent of 
biliary excretion of sorafenib. 
 Material and Methods 
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Materials. Dulbecco’s modified Eagle’s medium (DMEM), F-12 Nutrient Mixture, 
MEM non-essential amino acids solution (100x), L-glutamine, penicillin G-
streptomycin solution (100x), geneticin, and penicillin G-streptomycin-
amphotericin B solution (100x) were purchased from Invitrogen (Carlsbad, CA).  
Rifamycin SV, ketoprofen, dexamethasone, tetraethylammonium (TEA), 1,1-
dimethyl-biguanide hydrochloride (metformin), fetal bovine serum (FBS), Triton 
X-100, HEPES, D-glucose, dexamethasone, trypsin-EDTA solution (1x), and 
Hanks’ balanced salt solution (HBSS) modified with (H-1387) or without (H-4891) 
calcium chloride were obtained from Sigma-Aldrich (St. Louis, MO). Sorafenib 
(purity 99.7%), [14C]sorafenib (3.09 MBq/mg, radiochemical purity 99.2%), the 
internal standard [2H3, 15N] sorafenib tosylate, and decynium 22 were provided 
by Bayer HealthCare AG (Wuppertal, Germany).  [14C]TEA (55 mCi/mmol) wa
purchased from American Radiolabeled Chemicals (St. Louis, MO).  
[14C]biguanide (metformin, 110 mi/mmol) was purchased from Moraveck 
Biochemcials (Brea, CA).  ITS+™ (insulin/transferrin/selenium) culture 
supplement was purchased from BD Biosciences Discovery Labware (Bedford, 
MA). Bicinchoninic acid (BCA) protein assay reagents and BSA for the protein 
assay standard were purchased from Pierce Chemical Co. (Rockford, IL). Ultima 
GoldTM XR scintillation cocktail, was purchased from Perkin Elmer Life Sciences 
(Boston, MA).  All other chemicals and reagents were of analytical grade and 
available from commercial sources.   
 
 
 Suspended Hepatocyte Isolation and Uptake Studies. 
CellzDirect, Life Technologies (RTP, NC) kindly provided freshly isolated human 
hepatocytes in suspension.  Hepatocyte donors were a 60 yr old female 
Caucasian and a 63 yr old male Caucasian with no recent history of smoking or 
alcohol use. Hepatocyte viability, as determined by trypan blue exclusion, was 89 
and 90%.  Cells were suspended in cold modified Hank’s buffer with 10 mM 
Tris/5 mM glucose (pH = 7.4) or Na+-free choline buffer (10mM Tris, 5 mM 
glucose, 5.4 mM KCl, 1.8mM CaCl2, 0.9 mM MgSO4, 10 mM HEPES and 137 
mM choline; pH = 7.4) and stored on ice prior to conducting uptake studies 
(Leslie et al., 2007).  Isolated hepatocytes were suspended in the same buffer (1 
x 106 cells/ml), placed on ice, and used immediately in experiments.  Hepatocyte 
suspensions (1 ml; n = 2 livers, in triplicate) were preincubated in 16 x 100 mm 
glass test tubes at 37˚C for 3 min; 0.1% DMSO or chemical inhibitor was added 1 
min before 14C-sorafenib (0.09 µM; 3.86 nCi; 0.9% Methanol).  The following 
concentrations of inhibitors were selected based upon reported affinities for the 
given active transport processes: 20 µM rifamycin SV (OATP1B1, 1B3 and 2B1 
inhibitor), 5 µM decynium 22 (OCT inhibitor) and 10 µM ketoprofen (OAT2 
inhibitor).  Aliquots (100 µL) of the suspension were removed at timed intervals 
(up to 2.5 min), placed in 0.4-ml polyethylene tubes and centrifuged immediately 
through a top layer of silicone oil:mineral oil (82:18, v/v; 100 µL) into a bottom 
layer of 3M KOH (50 µL).  14C-Sorafenib in the cell pellet and supernatant were 
analyzed by liquid scintillation counting.  Adherent fluid volume was estimated 
with [14C]inulin as previously described (Baur et al., 1975).  Protein 
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 concentrations for individual hepatocyte suspensions were determined with the 
BCA protein assay reagent kit (Pierce) as instructed by the manufacturer.  BSA, 
as supplied by the manufacturer, was used as a standard (0.2 – 1 mg/mL). 
Transport Studies in hOCT1-Expressing CHO cells. 
Transfected CHO cells with empty vector (mock cells) and clone number 18 of 
hOCT1 were kindly provided by Dr. Dhiren Thakker (Ming et al., 2009).  
Transport studies were carried out five days post-seeding, as previously 
described (Ming et al., 2009).  Briefly, stably transfected CHO cells were grown 
as monolayers in 24-well plates. Medium was changed every other day.  Cells 
were preincubated for 30 min at 37°C in transport buffer (HBSS with calcium 
chloride, 25 mM D-glucose and 10 mM HEPES, pH 7.4).  Experiments were 
initiated by replacement of the transport buffer with 0.4 mL of radiolabeled dose 
solutions in transport buffer.  After incubation, dose solutions were aspirated and 
cells were washed four times with 4°C transport buffer.  Cells were lysed with 
500 µL of 0.1 N NaOH/0.1% sodium dodecyl sulfate (SDS) for 4 h on an orbital 
shaker, and samples were analyzed by liquid scintillation counting.  Data were 
normalized to protein concentration in each well, determined in duplicate aliquots 
using BCA protein assay reagent kit (Pierce), as detailed above.   
Sandwich-Cultured Human Hepatocyte Studies. 
A B-CLEAR®-Human Kit was purchased from Qualyst, Inc. (RTP, NC). Human 
hepatocytes isolated from a 44 yr old Caucasian female were seeded ~1.75 x 106 
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 cells/well on 6-well BioCoat™ plates in DMEM without phenol red supplemented 
with 2 mM L-glutamine, 1% (v/v) MEM non-essential amino acids, 100 units 
penicillin G sodium, 100 µg streptomycin sulfate, 1 µM dexamethasone,  5% (v/v) 
FBS, and 10 µM insulin (day 0 of culture), and allowed to attach for 2-6 h in a 
humidified incubator (95% O2, 5% CO2) at 37ºC. After cell attachment, culture 
plates were swirled gently and the culture medium was replaced with the same 
medium.  Cells were overlaid 16-24 h (day 1 of culture) after seeding with ice-
cold  Matrigel™ basement membrane matrix (0.25 mg/mL) in 2 mL/well cold 
serum-free DMEM containing 2 mM  L-glutamine, 1% (v/v) MEM non-essential 
amino acids, 100 units penicillin G sodium, 100 µg streptomycin sulfate, 0.1 µM 
dexamethasone, and 1% (v/v) ITS+™. The culture medium was changed every 
24 h until experiments were performed on day 7 of culture.   
Accumulation Studies. 
The method to determine substrate accumulation in sandwich-cultured 
hepatocytes has been described previously (Leslie et al., 2007; Wolf et al., 
2008). Cells were incubated for 10 min at 37ºC with 1.5 mL of sorafenib solution 
(1 and 10 µM). Medium samples were collected immediately, and hepatocytes 
were rinsed vigorously three times with 2 mL ice-cold standard buffer following 
the incubation. Substrate uptake was corrected for nonspecific binding by 
subtracting uptake on blank six-well BiocoatTM plates overlaid with MatrigelTM.  
Data were normalized to protein concentration in each well, determined in 
duplicate with the BCA protein assay reagent kit (Pierce), as instructed by the 
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 manufacturer.  Due to incompatability of the protein assay with organic solvent, 
the average protein concentration for standard HBSS or Ca2+-free HBSS 
incubations in the same liver preparation was used to normalize sorafenib 
content.  Sorafenib-treated hepatocytes were stored immediately at -80ºC until 
analysis. The cells were lysed with 1mL of mobile phase containing internal 
standard, scraped off the plates and centrifuged at 10,000 g for 5 min before 
analysis by LC/MS/MS. 
Sample Analysis. 
Sorafenib and sorafenib N-oxide concentrations were determined by a LC-
MS/MS assay using a LTQ Orbitrap XL(Thermo Scientific, Bremen, Germany) 
coupled to an Agilent 1200 system (Waldbronn, Germany). Sorafenib and its 
metabolites were eluted from a Synergi Hydro RP 2.5 µm (20  x 2 mm i.d., 
Phenomenex, Torrance, CA, USA) using a mobile phase gradient at a flow rate 
of 0.3 mL/min (A: 0.05% formic acid in water, B: 0.05% formic acid in 
acetonitrile); 0 min 30% B, 5 min 60% B, 5.3 min 30% B.  The column effluent 
was monitored using a LTQ Orbitrap XL (Thermo Scientific, Bremen, Germany) 
by quantification of the exact mass of sorafenib, internal standard, sorafenib N-
oxide and sorafenib glucuronide. 
 Data Analysis. 
For accumulation studies in sandwich-cultured hepatocytes, the biliary excretion 
index (BEI, %) was calculated using B-CLEAR® technology [Qualyst, Inc., 
Raleigh, NC; (Liu et al., 1999)]:  
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where substrate accumulation in the cells+bile compartments was determined in 
hepatocytes preincubated in standard buffer; cellular accumulation of substrate 
was determined in hepatocytes preincubated with Ca2+-free HBSS. 
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where AUC0-T  was calculated using the log trapezoidal method.  In vitro Clbiliary 
values were scaled per kilogram body weight using 0.948 mg protein/1.75 x 106 
cells (the typical value obtained in all preparations), 107 x 106 hepatocytes/g of 
human liver tissue (Wilson et al., 2003),  and 25.7 g of liver tissue per kg of body 
weight (Davies and Morris, 1993). 
 Results. 
Uptake of Sorafenib in Suspended Human Hepatocytes.   
Initial uptake of [14C]sorafenib into suspended human hepatocytes was linear up 
to ~ 2 min (Fig. 5.2.A).    Uptake at 4°C was ~ 40 to 50% of the uptake at 37°C 
(Fig. 5.2.A - C).  Sorafenib uptake at 1.5 min (Fig. 5.2.C) did not exhibit sodium 
dependence ([14C]sorafenib uptake was within 4% of control values when sodium 
was replaced with choline in the uptake buffer), and was not influenced by 
ketoprofen (uptake was within 13% of control uptake).  Initial [14C]sorafenib 
uptake was reduced to 54 and 70% of control values in the presence of the 
OATP inhibitor rifamycin SV and the OCT inhibitor decynium 22, respectively 
(Fig. 5.2.C).   
Transport of Sorafenib in hOCT1 Transfected CHO cells. 
As expected, uptake of 10 µM [14C]metformin (data not shown) and 5 µM 
[14C]TEA in hOCT1 transfected CHO cells was increased ~7-fold compared to 
mock cells, confirming OCT1 function in these cells (Fig. 5.3.A).  The uptake of 
10 µM [14C]TEA was completely abated in the presence of 10 µM decynium 22 
(Fig. 5.3.A).  
 [14C]sorafenib uptake was extensive and linear up to ~5 min in mock CHO 
cells incubated at 37°C.  Uptake in mock CHO cells at 4°C was ~32 – 57% of the 
uptake at 37°C up to 30 min (data not shown).  Interestingly, uptake of 
[14C]sorafenib in hOCT1 transfected CHO cells was similar to mock cells in the 
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 linear range, and increased ~2-fold compared to mock cells at 5 min and beyond.  
The OCT inhibitor, decynium 22, decreased [14C]sorafenib uptake in OCT1 
transfected CHO cells by 30% at all time points (Fig. 5.3.B). 
Hepatobiliary Dispostion of Sorafenib in Human Sandwich-Cultured 
Hepatocytes.   
The hepatobiliary disposition of [3H]taurocholate and sorafenib was 
measured in human sandwich-cultured hepatocytes.  Following a 10-min 
incubation with (1µM) 3H-taurocholate, cellular accumulation of the model bile 
acid taurocholate (41.5 pmol/mg protein) and the BEI (64.8%) and in vitro biliary 
clearance (59.9 mL/min/kg) were consistent with previous data generated in this 
model system [data not shown; (Ghibellini et al., 2007; Swift et al., 2009)].  The 
percentage of the sorafenib dose that was recovered in day 7 sandwich-cultured 
human hepatocyte lysate after a 10-min incubation with either 2 or 10 µM 
sorafenib was greater than 94% (Table 5.1).  The cellular accumulation of 
sorafenib and sorafenib N-oxide, the major metabolite in humans, was dose-
proportionate (Table 5.1; Fig. 5.4).  The cellular accumulation of sorafenib was 
approximately two orders of magnitude greater than the primary metabolite 
sorafenib N-oxide after a 10-min incubation at both the 2 and 10 µM doses (Fig. 
5.4).  Sorafenib BEI (6%) and in vitro biliary clearance (1 ml/min/kg) were 
relatively low compared to taurocholate (Fig. 5.4.A).  Sorafenib glucuronide 
cellular accumulation was two-fold greater after a 10-min incubation with 2 µM 
sorafenib compared to the 10 µM dose (Fig. 5.4.C).  Sorafenib N-oxide and 
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sorafenib glucuronide BEI were negligible following a 10-min incubation with 2 
µM sorafenib, but increased to 22 and 20%, respectively, when sandwich-
cultured human hepatocytes were incubated with 10 µM sorafenib for 10 min 
(Fig. 5.4.B and C).  Sorafenib N-oxide concentrations were below the detection 
limit (<1 ng/mL) in medium following a 10-min incubation with either the 2 or 10 
µM sorafenib, whereas the medium peak area ratio of sorafenib glucuronide was 
higher at 10-min following incubation with 10 compared to 2 µM sorafenib (Fig. 
5.4.C).  
 Discussion. 
Hepatic transport proteins are recognized increasingly as important 
determinants of the pharmacokinetics of many drugs, as well as key sites of 
drug-drug interactions (Soars et al., 2009). Genetic polymorphisms of uptake 
transport proteins have also been implicated in interindividual differences in the 
pharmacokinetics and pharmacodynamics of clinically relevant drugs such as the 
statins (Ieiri et al., 2009).  In the present study, the transport proteins involved in 
the hepatic uptake of sorafenib were investigated, and the hepatobiliary 
disposition of sorafenib was assessed.   
 Sorafenib is a very lipophilic compound (log D7 5.16; predicted properties 
SciFinder Scholar version 2007).  The initial uptake of sorafenib in human 
hepatocytes was examined at 37°C vs. 4°C to assess the contribution of passive 
diffusion to overall uptake.  Approximately 50 and 40% of [14C]sorafenib initial 
uptake at 0.5 and 1 min, respectively, was due to passive diffusion (Fig. 5.2.A - 
C).  There was also a high degree of passive diffusion in CHO cells (Fig. 5.3.B) 
that partially masked the contribution of OCT1 to the uptake of sorafenib.  
Furthermore, >94% of the sorafenib dose partitioned into human sandwich-
cultured hepatocytes after a 10-min incubation with either 2 or 10 µM sorafenib 
(Table 5.1). 
The active uptake of [14C]sorafenib (1 µM) was investigated with transport 
protein modulators.  Rifamycin SV (20 µM) was selected as an inhibitor of all the 
relevant human isoforms of OATP expressed in the liver: OATP1A2, OATP1B1, 
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 OATP1B3 and OATP2B1 (Vavricka et al., 2002).  Decynium 22 (5 µM) was used 
as an OCT inhibitor  (Zhang et al., 1997; Hayer-Zillgen et al., 2002), and OAT2 
function was inhibited with ketoprofen (10 µM) (Morita et al., 2001; Ohtsuki et al., 
2002).  To assess sodium-dependent transport by Ntcp, choline-based buffer 
was substituted for sodium-based buffer in suspended hepatocytes.  The 
sensitivity of the transport proteins and specificity to the inhibitors rifamycin SV 
and decynium 22 were confirmed in the presence and absence of the model 
probe substrates [3H]estradiol-17-β-D-glucuronide (OATP substrate) and 
[14C]TEA (OCT substrate), as published previously (Chapter 4, Fig. 4.2).  
Sorafenib uptake at 1.5 min was sensitive to rifamycin SV and decynium 22, 
suggesting that the OATPs and OCTs are involved in the hepatic uptake of this 
tyrosine kinase inhbitor (Fig. 5.2.C).    The involvement of OCT1 in sorafenib 
uptake was investigated further using a hOCT1-expressing CHO cell line.  
Imatinib, another tyrosine kinase inhibitor is an OCT1 substrate in the human T-
lymphoblastoid cell line CCRF-CEM (Thomas et al., 2004).  Some substrate 
overlap exists between OCTs and OATPs, which have affinity for some type II 
(bulky) cations such as N-methylquinine (van Montfoort et al., 1999).     
Interestingly, the uptake of sorafenib over time was greater in OCT1 
transfected CHO cells compared to mock transfected only after 5 min (Fig. 
5.3.B).  The high degree of passive diffusion masked the involvement of OCT1-
mediated uptake in these CHO cells at early time points.  Solubility limitations of 
sorafenib, coupled with high passive diffusion, make it challenging to accurately 
195 
 
 characterize the Km and Vmax for sorafenib uptake in transfected CHO cells and 
suspended human hepatocytes. The OCT1-dependent uptake of sorafenib 
(determined as the difference in sorafenib uptake in OCT1-CHO cells compared 
to mock-CHO cells) was sensitive to 10 µM decynium 22, a potent inhibitor of 
organic cation transporters (Hayer-Zillgen et al., 2002), as demonstrated by 
complete inhibition of the positive control, TEA (Fig. 5.3.A).  These data 
confirmed that sorafenib is an OCT1substrate.   
 To investigate the hepatobiliary disposition of sorafenib, studies were 
performed in human sandwich-cultured hepatocytes.  Sorafenib exhibited a low 
BEI and in vitro Clbiliary which is not surprising due to the extent of CYP3A4- and 
UGT1A9-mediated metabolism seen in vivo (Lathia et al., 2006).   Sorafenib 
plasma concentration-time profiles have been reported to increase less than 
proportional to increasing dose (Clark et al., 2005; Strumberg et al., 2005; 
Strumberg et al., 2007).  The dosing solutions (2 and 10 µM) used in these 
studies which resulted in linear hepatocellular accumulation (Fig. 5.4) were in the 
range of the reported Cmax in plasma (5 to 21 µM) after multiple oral doses of 
sorafenib (100 to 600 mg twice daily) (Strumberg et al., 2005).  Furthermore, 
there was good agreement in the uptake rate in human sandwich-cultured 
hepatocytes (85 and 94 pmol/mg/min) compared to that in suspended 
hepatocytes (73 and 97 pmol/mg/min), suggesting linear pharmacokinetics in this 
in vitro system after a single dose.   
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 Biotransformation of sorafenib to the N-oxide is mediated primarly by 
CYP3A4 (Lathia et al., 2006).  The low formation of sorafenib N-oxide in day 7 
human sandwich-cultured hepatocytes may be due to lower cytochrome P450 
enzyme activity after isolation and culture (Hoen et al., 2000; Boess et al., 2003).  
Dexamethasone is a prototypical CYP inducer that is added to cell culture 
medium.  In the present studies dexamethasone concentrations in the culture 
medium were only 0.1 µM, which is much lower than the 10 µM or higher 
concentrations utilized in human and rat sandwich-cultured hepatocyte studies to 
induce CYP3A4 and Cyp3A1/2 protein expression (Hoen et al., 2000; McCune et 
al., 2000; Lindley et al., 2002), and increased activity of CYP3A4 and Cyp3A1/2 
as measured by testosterone 6β-hydroxylation formation (LeCluyse et al., 1996; 
McCune et al., 2000; Lindley et al., 2002).  Sorafenib N-oxide is the primary 
circulating metabolite in human plasma (Lathia et al., 2006), however 
concentrations in medium, a surrogate for blood, were below the limit of 
quantitation, probably due to the short incubation time (10 min).  In contrast, 
medium concentrations of sorafenib glucuronide were more extensive and thus 
basolateral efflux may represent the primary route of hepatic clearance..  
Incubation with 10 µM sorafenib for 10 min resulted in 2-fold greater excretion 
into medium compared to the 2 µM treatment, in which cellular accumulation of 
sorafenib glucuronide was 2-fold greater (Fig. 5.4.C).   
In conclusion sorafenib uptake in suspended human hepatocytes, CHO 
cells and sandwich-cultured human hepatocytes was extensive.  Uptake into 
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 human hepatocytes and CHO cells was temperature dependent and decreased 
only ~50% at 4°C, suggesting a high degree of passive diffusion.  The active 
portion of hepatic uptake was sensitive to rifamycin SV and decynium 22, 
suggesting OATP- and OCT-mediated uptake in human hepatocytes.  OCT1-
mediated uptake of sorafenib was confirmed in OCT1 overexpressing CHO cells.  
Biliary excretion of sorafenib in human sandwich-cultured hepatocytes is low.  
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 Legend to Figures 
Figure 5.1 Chemical structure of sorafenib. 
 
Figure 5.2 Uptake of (A and B) [14C]sorafenib (0.9 µM) in suspended human 
hepatocytes over 2.5 min.  Hepatocytes were incubated at 37°C (●) 
or 4°C (○) (mean ± SEM from a representative liver; n=2 livers in 
triplicate). Initial uptake of (C) [14C]sorafenib (0.9 µM) at 1.5 min in 
suspended human hepatocytes incubated at 37°C unless otherwise 
specified in the absence and presence of transport protein 
modulators (n=2 livers; Mean Percentage ± Range).   
 
Figure 5.3 Uptake of the positive control (A) [14C]TEA (5 µM) in the absence and 
presence of 10 µM decynium 22 (hatched bar) was assessed in 
CHO-hOCT1 (white bars) and mock cells (black bars).  Uptake of (B) 
[14C]sorafenib (1 µM) in CHO-hOCT1 cells. CHO-hOCT1 cells were 
incubated in the absence (▲) and presence of 10 µM decynium 22 
(Δ), and mock cells in the absence (●) and presence of 10 µM 
decynium 22 (○) for the designated times over 30 min. Data 
represent mean ± SD of experiments in triplicate.  
 
Figure 5.4 Hepatobiliary disposition of (A) sorafenib, (B) sorafenib N-oxide and 
(C) sorafenib glucuronide in sandwich-cultured human hepatocytes. 
Accumulation in cells+bile (black bars) and cells (white bars) and the 
biliary excretion index (BEI) were determined after a 10-min 
incubation with 2 and 10 µM sorafenib in day 7 sandwich-cultured 
human hepatocytes; in vitro Clbiliary also was calculated for sorafenib. 
Data represent mean ± SD (n=1) in triplicate. 
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 Table 5.1 Mass balance of sorafenib in incubation medium and hepatocyte cell 
lysates after a 10-min incubation in day 7 sandwich-cultured human 
hepatocytes (Mean ± SD in triplicate). 
 
  Medium 
% of Total 
Dose Cell Lysate
% of Total 
Dose 
Total 
Dose 
Treatment (nM) in Medium (nM) in Cell Lysate (nM) 
Sorafenib 2 µM 41.8 ± 3.7 1.9 2191 ± 43 98.1 2233 
Sorafenib 10 µM 588 ± 143 5.6 9974 ± 690 94.4 10562 
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CHAPTER 6 
 
 
 
 
 
 
Pharmacokinetics and Hepatic Exposure of 99mTechnetium-Sestamibi and 
99mTechnetium-Mebrofenin In A Patient with Hepatocellular Carcinoma and 
Child's Pugh B Cirrhosis versus Healthy Human Volunteers: An 
Exploratory Analysis 
 
 
 
 
 
 
 
 
 
 
 Abstract 
Hepatocellular carcinoma and cirrhosis of the liver result in adaptive changes in 
transport protein expression and function, potentially altering the disposition of 
many drugs.  In the present study two phenotypic probes, 99mTechnetium-
sestamibi (99mTc-MIBI) and 99mTechnetium-mebrofenin (99mTc-MEB), were used 
to predict the locus and extent of modulation in hepatic transport due to cirrhosis 
and hepatocellular carcinoma.  Pharmacokinetic models were constructed to 
describe the distribution and elimination of 99mTc-MIBI and 99mTc-MEB in a 
patient with hepatocellular carcinoma and in healthy individuals.  Rate constants 
representing hepatic uptake and renal excretion of 99mTc-MIBI were reduced 
~58% and ~80%, respectively, while rate constants representing basolateral and 
biliary efflux were increased 5.4 and 4.0-fold, respectively, in a patient with 
hepatocellular carcinoma and Child’s Pugh B cirrhosis compared to healthy 
subjects.  The area under the hepatic mass-time profile was decreased 76% in 
the patient.  The parameter for 99mTc-MEB intrinsic hepatic uptake clearance 
exceeded liver blood flow by 2.6-fold and at least ~4-fold in the patient and in 
healthy subjects,, respectively, suggesting hepatic blood flow is the rate-limiting 
step in 99mTc-MEB disposition.  Intrinsic biliary clearance was reduced 3.6-fold in 
the patient compared to healthy volunteers, while the area under the hepatic 
mass-time profile was similar.  Alterations in key rate constants representing 
hepatic uptake and efflux mechanisms secondary to disease may prove useful in 
predicting changes in drug disposition, and potentially drug action, for therapeutic 
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 compounds that are handled by mechanisms similar to those governing hepatic 
exposure of 99mTc-MEB and 99mTc-MIBI. 
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 Introduction 
 Cirrhosis is an advanced stage of liver fibrosis that is accompanied by 
distortion of the hepatic vasculature (1),  which leads to shunting of the arterial 
and portal blood supply, and compromised sinusoidal blood flow. Ultimately, the 
perfusion changes that occur secondary to cirrhosis impair the access of blood-
borne solutes to hepatocytes, the cells responsible for most liver functions (1).  
Cirrhosis, therefore, leads to impaired liver function and increased intrahepatic 
resistance (portal hypertension), potentially progressing to the development of 
hepatocellular carcinoma. 
 Hepatic uptake and biliary excretion of many drugs are mediated by 
transport proteins localized on the basolateral and apical membranes of 
hepatocytes (2-4).  It is well recognized that adaptive changes in transport 
protein expression, aimed at protecting the hepatocyte from the intracellular 
accumulation of toxic compounds such as bile acids, are induced in  patients with 
liver disease (5-7).  For example, patients with primary biliary cirrhosis evidenced 
down-regulation of basolateral uptake proteins, while expression of canalicular 
and basolateral efflux proteins was maintained or even up-regulated (8-10).  
These modifications in clearance mechanisms (uptake from blood into liver, 
representing a form of systemic clearance; removal from the liver across either 
the basolateral or canalicular membrane, representing two routes of organ 
clearance) contribute to altered drug disposition, and ultimately drug action, in 
subjects with cirrhosis and hepatocellular carcinoma.  Therefore, the ability to 
assess the functional consequences of disease-related modulation of hepatic 
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 uptake or biliary excretion may facilitate the optimization of administration 
regimens for drugs with a narrow therapeutic window.  
 In vivo probes have been used to assess the function of drug-metabolizing 
enzymes and transport proteins in human subjects (11-14).  Furthermore, the 
use of radiolabeled probes such as analogs of 99mTechnetium-sestamibi (99mTc-
MIBI) and 99mTechnetium-mebrofenin [99mTc-MEB,  (12, 14, 15)] coupled with 
imaging technology provides a noninvasive method to quantify tissue exposure in 
vivo. The concentration-time profile of the substrate in a relevant target tissue 
allows a more sophisticated elucidation of the functional consequences of 
changes in vectorial transport than is possible through examination of the 
systemic concentration-time profile alone (15-18). 
 99mTc-MIBI, a monovalent cation complex, is taken up into liver by passive 
diffusion [(19); Chapter 4]. The primary pathway for 99mTc-MIBI clearance in 
humans is into bile; 33% of an intravenously-injected dose appears in the feces, 
with 27% in urine, by 48 hr post-dose (Cardiolite® package insert).  Biliary 
excretion of 99mTc-MIBI is mediated by multidrug resistance protein 1 [MDR1, P-
glycoprotein, P-gp; (15-17, 20); Chapter 4].  99mTc-MEB, an iminodiacetic acid 
derivative, is taken up extensively (98% of the dose) by the liver; the hepatic 
excretion half-life is short (16 min) and ~1.5% of the dose is recovered in urine 
after 24 hr in humans (21).  The high hepatic extraction of 99mTc-MEB is 
governed by organic anion-transporting polypeptides 1B1- and 1B3- (OATP1B1, 
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 OATP1B3) that mediate hepatic uptake, followed by rapid canalicular excretion 
into bile by multidrug resistance protein 2 [MRP2; (22); Chapter 4].   
The present study was conducted to test the hypothesis that adaptive 
changes in transport protein expression secondary to hepatic disease result in 
functional changes and altered disposition of 99mTc-MIBI and 99mTc-MEB.  
Therefore, these probes can serve as tools to predict the locus and extent of 
modulation in hepatic transport due to cirrhosis and hepatocellular carcinoma.  
To address this hypothesis, pharmacokinetic models were constructed to 
describe the distribution and elimination of 99mTc-MIBI and 99mTc-MEB. These 
models in a patient with Child’s Pugh B cirrhosis and hepatocellular carcinoma 
were supported by quantitative hepatic scintigraphy, blood concentrations, and 
cumulative mass excreted in urine for both probes. In healthy subjects, 
analogous models were supported by hepatic scintigraphy (99mTc-MEB only), 
blood concentrations, and cumulative mass excreted in bile and urine.  
Parameter values, especially those associated with the processes of hepatic 
uptake and efflux, were generated by fitting each pharmacokinetic model to the 
relevant data, and were compared between the patient and the healthy subjects.  
Hepatic exposure generated from quantitative hepatic scintigraphy of 99mTc-MIBI 
and 99mTc-MEB also was compared to assess the potential influence of the 
disease state on this important metric. 
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 Materials and Methods 
Clinical Protocol, Subject History and Demographics 
Patient demographics and history are noted for three separate clinical 
studies.  All procedures were approved by the Committee on the Protection of 
the Rights of Human Subjects (institutional review board), Clinical Research 
Advisory Committee, and Oncology Protocol Review Committee (where 
applicable) at the University of North Carolina. 
Patient with hepatocellular carcinoma and Child’s Pugh B cirrhosis 
 A 71 year-old female with end-stage liver disease of unknown etiology, 
multifocal (2 masses found by MRI), inoperable hepatocellular carcinoma 
confirmed after biopsy and Child’s Pugh B cirrhosis participated in this study.  
This patient’s history of present disease was positive for encephalopathy, portal 
hypertension, ascites, grade IV esophageal varices and type I gastric varices 
(over 1 yr ago), anemia, and osteomyelitis.  Concomitant medications included 
lactulose, lisinopril, propranolol, spironolactone, furosemide, prilosec, calcium, 
fosamax, iron, vitamin K 5, and actigall.  This patient’s basic metabolic panel, 
liver function tests and CBC were all within normal limits except: urea nitrogen 34 
mg/dL, creatinine 1.03 mg/dL, phosphorus 4.6, mg/dL, albumin 3.1 g/dL, AST 45 
U/L, ALT 60 U/L, alkaline phosphatase 132 U/L, RBC 3.66 x1012/L, platelets 92 x 
109/L, and absolute lymphocytes 1.0 x 109/L.  The patient was positive for 
hepatitis A total antibody and B surface antibody, and negative for hepatitis B 
surface antigen, hepatitis B core total and hepatitis C antibody.  
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 Healthy Volunteers 
99mTc-MIBI  
The study design and disposition of 99mTc-MIBI in seven nonsmoking male 
volunteers (21-41 years of age) within 20% of their ideal body weight who 
received a 2.5 mCi dose of 99mTc-MIBI has been reported in detail previously 
(23).  Unfortunately, quantitative hepatic scintigraphy data were not obtained in 
this patient population.  However, bile samples were collected through the use of 
a custom-made oroenteric tube positioned in the duodenum for determination of 
the hepatic clearance of 99mTc-MIBI.  This protocol was not feasible in the patient 
with hepatocellular carcinoma and cirrhosis.    
99mTc-MEB  
A study of 99mTc-MEB disposition in healthy volunteers (21 and 29 year old 
Caucasian male and a 21 year old Caucasian female) was conducted, as 
described previously  (24), with modifications to the hepatic nuclear imaging as 
detailed below.  All subjects were in good health as documented by medical 
history, physical examination, electrocardiogram, and routine laboratory tests.  All 
subjects were asked to abstain from any medication for 2 weeks before the 
study, and to abstain from caffeine and alcohol during the study.  A custom-made 
oroenteric catheter passed through the mouth and positioned in the duodenum 
was utilized to collect bile samples from the healthy volunteers, but was too 
invasive for the elderly patient with hepatocellular carcinoma. 
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 Hepatic Nuclear Imaging 
 The patient fasted overnight and received a 5-mCi IV bolus dose of 
99mTc-MEB (Choletec® Bracco Diagnostics, Princeton, NJ) followed 48 hr later by 
a 5-mCi IV bolus dose of 99mTc-MIBI (Cardiolite® Bristol-Myers Squibb, New 
York, NY). Both probe compounds were purchased from Cardinal Health 
(Research Triangle Park, NC).  
 Before injection of labeled compound, a transmission acquisition was 
performed using a 57Cobalt-flood source (Isotope Products Laboratories, 
Burbank, CA) positioned posterior, and gamma rays were detected in the cobalt 
window (122 KeV ± 20%) for 10 min on the anterior detector in the absence and 
presence of the subject to correct for attenuation of the photons in the subject.  
The patient was positioned under a scintillation camera (E.Cam Dual Head 180º 
fixed angle SPECT and whole body system, Siemens) in the supine position and 
received an IV bolus of 99mTc-MEB or 99mTc-MIBI via an indwelling catheter 
placed in a forearm vein. The patient remained still while 99mTc was monitored 
(140 KeV ± 20%) for 180 min, as established in previous studies (23, 24).  
Continuous scan acquisition of the anterior and posterior abdomen on a dual-
headed gamma camera occurred every minute for 3 hr for a total of 180 data 
points.  Blood samples (~2 mL) were collected at 2.5, 5, 7.5, 10, 20, 40, 60, 80, 
100, 120, 140, 165 and 180 min post-dose from the contralateral arm through an 
indwelling catheter.  Urine was collected in toto at ~180 min.  Blood and urine 
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 samples were analyzed with a sodium iodide well counter, and corrected for 
decay (99mTc t1/2=6.01 hr).   
 The geometric mean of the anterior and posterior gamma images was 
multiplied by a patient-specific attenuation correction factor. This correction factor 
was obtained by dividing the transmission acquisition of the 57Cobalt-flood source 
without the patient (Io) by the transmission acquisition of the 57Cobalt-flood 
source with the patient (I), as described previously (25, 26).  Time-activity curves 
were generated for each organ or tissue of interest, which included the heart, 
liver (excluding gall bladder), spleen, and kidney using Syngo MI applications 
version 6.5.9.19 (Siemens, New York, NY).  The generated time-activity curves 
were converted to 99mTc concentrations based on standards and pilot 
experiments with an anthropomorphic torso phantomTM (Data Spectrum 
Corporation, Hillsborough, NC).  Deconvolution analysis was performed as 
described previously (12, 27-29) with Matlab version 7.6.0.324 (R2008a; The 
MathWorks Inc., Natick, MA) to subtract the vascular component from the hepatic 
time-activity curve.  This enabled separation of the “true” 99mTc concentration-
time profile in liver tissue from the sum of the activity in tissue and blood resident 
in the organ. 
 Three healthy human volunteers fasted overnight and received a 2.5-
mCi IV bolus dose of 99mTc-MEB. In these subjects, biliary secretions were 
collected utilizing a novel oroenteric catheter positioned in the duodenum, as 
described previously (24).  Imaging and data analysis were performed as 
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 described above.  The study with 99mTc-MIBI in healthy human volunteers did not 
include quantitative hepatic scintigraphy, and therefore substrate mass in the 
liver was not available for modeling  (23). 
Determination of Protein Binding 
Human liver tissue was obtained from the University of North Carolina 
Hospital by qualified medical personnel from surgical resection.  Written informed 
consent was obtained from the subject prior to surgery.  The tissue was flash 
frozen and stored at -80°C. To determine protein binding in liver, thawed tissue 
was homogenenized in two volumes (v/w) of 0.1 M phosphate buffer (pH 7.4).  
The liver homogenate was incubated with three concentrations of 99mTc-MEB (2, 
20, and 225 µCi/mL which is 155 pM, 15.5 nM, and 1.55 nM, respectively) in 
triplicate for 30 min in a shaking 37°C water bath.  Liver homogenate samples (1 
mL) were placed in Centrifree® micropartition devices and centrifuged at 1380 x g 
at room temperature for 5 min to pass < 10% of the original volume through the 
filter. Preliminary experiments were conducted in the absence of protein to 
assess non-specific binding to the device. Samples of liver homogenate (total 
concentration in the presence of protein) and ultrafiltrate (unbound concentration) 
were collected post-centrifugation, analyzed with a sodium iodide well counter, 
and corrected for decay.  The unbound fraction determined from the diluted liver 
tissue homogenate (fu2) was calculated as the ratio of unbound concentration to 
total concentration, and was corrected to yield an estimate of the true unbound 
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 fraction in undiluted tissue (fu) acccording to a previously published approach 
(30): 
1/D1))((1/fu
1/Dfu
2 +−
=  
where D represents the dilution factor (tissue-to-buffer ratio; w/v) . 
Pharmacokinetic Modeling 
During the first few minutes post-dose, concentrations obtained from the arm 
contralateral to the injection site increased with time. These data points, obtained 
prior to substrate equilibration throughout the venous blood pool, were not used 
to support development of compartmental models. Such models are based on an 
assumption of well-stirred distributional units, which clearly was not the case at 
early time points in this study (31).  Differential equations describing the 
disposition of 99mTc-MIBI and 99mTC-MEB in each of the compartments, as well 
as excretory sites (urine, bile) were fit simultaneously to blood, hepatic, urine and 
bile profiles using nonlinear least-squares regression (WinNonlin v. 5.2.1 
Pharsight Corporation, Mountain View, CA).  All processes were assumed to be 
approximately linear under the present experimental conditions [only trace 
amounts (2.5 mCi = ~194 nmol of 99mTC-MEB and 99mTc-MIBI) were 
administered] and therefore, were modeled with first-order rate constants.  
Goodness of fit assessment was based on Akaike’s Information Criterion, the 
residual sum of squares, coefficients of variation on the parameter estimates, the 
condition number, and visual inspection of the residual plots.  Due to differences 
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 in the number of data points supporting each pharmacokinetic function, each 
data point was assigned a weight of )1(1 n
y
−× , where n is the fraction of the total 
number of data points that support a particular sample matrix.  The final 
parameter estimates were selected after fitting the model to the data using 
different sets of initial values combined with a broad range of lower and upper 
bounds to avoid convergence at a local minimum. 
 
99mTc-MIBI Pharmacokinetic Modeling 
 Six different compartmental models were developed (including multiple 
peripheral compartments in addition to the liver compartment, with elimination 
from the peripheral, central, and/or liver compartments) to describe the 
concentration- and mass-time profiles.  The optimal model that best described 
the data is shown schematically in Figure 6.1.  In the patient, the blood 
concentration at 80 min resulted in a second peak during the elimination phase 
and was given a weight of zero to aid the model fit to the entire profile.  This 
model included a compartment depicting the systemic circulation described by 
the blood concentration-time profile after an intravenous bolus dose (Xiv).  A first-
order rate constant, Kuptake, governed MIBI uptake from the central compartment 
into a peripheral compartment, representing the liver.  Kbasolateral represented a 
first-order rate constant for hepatic basolateral efflux; Kbile and Kurine represented 
biliary and urinary excretion rate constants, respectively.  A second peripheral 
compartment with a first-order distributional rate constant (K13) governing MIBI 
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 uptake from the central compartment into a peripheral compartment represented 
MIBI distribution into the heart and spleen, which is extensive based on the 
distributional properties reported previously (32); K31 governs efflux back into the 
central compartment.  The following differential equations described MIBI 
disposition in healthy human and diseased subjects (initial conditions were 
denoted with a superscript zero): 
curine
c
peripheral31c13
c
liverlbasolateracuptake
C CK
V
1XKCK
V
1XKCK
dt
dC ×−××+×−××+×−=
   
c
iv0
C V
X
C =  
liverbileliverlbasolateraccuptake
liver XKXKVCK
dt
dX ×−×−××=    0X0liver =
peripheral31cc13
peripheral XKVCK
dt
dX ×−××=      
     0X0peripheral =
liverbile
bile XK
dt
dX ×=         0X0bile =
ccurine
urine VCK
dt
dX ××=         
  
0X0urine =
    
99mTc-MEB Pharmacokinetic Modeling 
A semi-physiologic pharmacokinetic model was developed to describe the 
distribution and elimination of 99mTc-MEB. The trans-hepatic extraction of this 
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 drug is high; consequently, the hepatic clearance of 99mTc-MEB is expected to be 
dependent on hepatic blood flow, which is altered in patients with Child’s Pugh B 
cirrhosis.  Three different models were developed using the concentration- and 
mass-time profiles in healthy and diseased subjects.  Four physiologic 
parameters were fixed based on literature values and scaled to body weight for 
each subject.  Liver volume was fixed at 24.1 mL/kg for all subjects; liver blood 
flow was fixed at 20.7 mL/min/kg (33) for healthy subjects, and at 9.86 mL/min/kg 
for the patient with Child’s Pugh B cirrhosis, as previously reported based on 
magnetic resonance imaging (34).  The unbound fraction of 99mTc-MEB in plasma 
(fu,p) was determined  by ultrafiltration as described below.  The 40- and 60-min 
blood samples were chosen so that the ultrafiltrate would exceed the minimum 
sensitivity of the detector and to allow for protein binding equilibration.  The blood 
samples were centrifuged at 600 x g for 10 min at room temperature.  The 
plasma was placed in Centrifree® micropartition devices and centrifuged in a 
fixed angle rotor at 1380 x g at room temperature for 5 min to pass < 10% of the 
original volume through the filter. Samples of plasma (total concentration in the 
presence of protein) and ultrafiltrate (unbound concentration) were collected 
post-centrifugation and analyzed with a sodium iodide well counter.  The 
unbound concentration in blood (fu,B) was determined by the product of fu,p and 
total concentration in the plasma divided by the total concentration in the blood.  
The unbound fraction of 99mTc-MEB in liver (fu,H) was determined as detailed 
above and fixed at 0.078 (see Results section).  
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 A stepwise modeling approach was used to analyze the disposition of 
99mTc-MEB. In the first step of the analysis, the blood concentration-time profile 
for each subject was fit individually with an integrated biexponential function. The 
final estimates for the macro-rate constants (alpha and beta) and the 
concentration intercepts (A and B) were fixed, and the resulting subject-specific 
biexponential equation was used to represent 99mTc-MEB concentrations in 
blood.  In the second modeling step, differential equations describing the 
disposition of 99mTc-MEB in each of the distributional and excretory 
compartments were fit simultaneously to urine, liver, and bile (healthy volunteers 
only) concentration or mass versus time data with nonlinear least-squares 
regression.     
The optimal model that best described the disposition of 99mTc-MEB is 
shown schematically in Figure 6.2.  This model consisted of a central 
compartment describing the blood concentration-time profile after an intravenous 
bolus dose (Xiv), where Vc represents the apparent volume of distribution; a 
hepatic sinusoidal compartment where QH represents hepatic blood flow, with 
Cl’i,uptake and Cl’i,basolateral representing uptake into and basolateral efflux from the 
liver compartment; and VH represents the liver volume.  Urinary (Clrenal) and 
biliary (Cl’i,biliary) elimination were described as unidirectional flux from the central 
compartment and liver compartment, respectively.  The amount of 99m Tc-MEB in 
the liver, bile, and urine compartments was expressed as Xliver, Xbile, and Xurine, 
respectively.  In the three healthy volunteers, no mass in urine was detected, the 
elimination of 99mTc-MEB was more rapid, and the error associated with Clrenal 
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 and Cl’i,basolateral estimates was very high.  Therefore, Clrenal and Cl’i,basolateral were 
not required to describe the disposition of 99m Tc-MEB in healthy volunteers only.   
The following differential equations described 99m Tc-MEB disposition in healthy 
and diseased subjects (initial conditions were denoted with a superscript zero): 
crenalCHsinusoidH
C CClCQCQ
dt
dC ×−×−×=                  
c
iv0
C V
X
C =  
H
liver
Hu,lbasolaterai,sinsusoidBu,uptakei,sinsusoidHCH
sinusoid
V
X
fCl'CfCl'CQCQ
dt
dX ××+××−×−×=
                                
 0X0sinusoid =
H
liver
Hu,biliaryi,
H
liver
Hu,lbasolaterai,sinsusoidBu,uptakei,
liver
V
XfCl'
V
XfCl'CfCl'
dt
dX ××−××−××=     
 0X0liver =
H
liver
Hu,biliaryi,
bile
V
X
fCl'
dt
dX ××=                    
 0X0bile =
crenal
urine CCl
dt
dX ×=                    
 0X0urine =
Where fu,B and fu,H equal the unbound fraction of 99mTc-MEB in blood and the 
liver, respectively.  
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In addition, the AUC of the hepatic mass-time profile was calculated by 
standard noncompartmental analysis using the trapezoidal rule for the time 
imaged (AUC0→180 ) and extrapolation to infinity for AUC0→∞ .  
 Results 
 
99mTc-MIBI Disposition 
 
The model depicted in Figure 6.1 was suitable for describing 99m Tc-MIBI 
disposition in all subjects.  The fit of this model to the data obtained from the 
patient, together with that for a representative healthy subject, is shown in Figure 
6.3.  The estimates and associated coefficients of variation for relevant 
pharmacokinetic parameters derived from the patient data are compared to those 
for healthy subjects, utilizing data obtained from a previously-published study 
(23), in Table 6.1.  The apparent volume of the central compartment (Vc) was 
4.52 L in the patient and a mean of 8.10 L in healthy subjects, respectively, 
suggesting that distribution within this compartment was restricted primarily to the 
blood pool [~5.2 L of blood for a 70 kg person; (33)].   
The rate constants representing hepatic uptake (Kuptake) and renal 
excretion (Krenal) of 99mTc-MIBI were reduced ~58% and ~80%, respectively, in 
the patient compared to healthy subjects.  Basolateral (Kbasolateral) and biliary 
(Kbiliary) efflux rate constants were increased 5.4 and 4.0-fold, respectively, in the 
patient as compared to healthy subjects; 99mTc-MIBI partitioning into the non-liver 
peripheral compartment also was increased in the patient. 
The hepatic mass-time profiles in healthy individuals were simulated using 
the final parameter estimates listed in Table 6.1.  AUC0→180 of the hepatic mass-
time profile was decreased 76% in the patient (26.3 normalized µCi*min) 
compared to the average AUC0→180 of the simulated hepatic exposure in healthy 
individuals (110 ± 13 normalized µCi*min; Figure 6.4). 
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 99mTc-MEB Disposition 
The model scheme depicted in Figure 6.2 best described the 99mTc-MEB 
blood concentration-time profile, hepatic mass-time profile and the cumulative 
mass in urine and bile. Information regarding biliary excretion, obtained with a 
novel oroenteric tube protocol in healthy volunteers, was not available in the 
patient.  The estimates and associated coefficients of variation for the relevant 
pharmacokinetic parameters are reported in Table 6.2.   
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was 
In healthy subjects the predominant process that determined 99mTc-MEB 
fate was excretion into bile; the data from healthy subjects indicated that 
Cl’i,basolateral and Clrenal did not have an impact on the disposition of 99mTc-MEB.  In 
the patient, the modeling suggested that 99mTc-MEB was excreted from the liver 
back into sinusoidal blood for eventual reuptake by the liver or excretion into 
urine.  99mTc-MEB intrinsic hepatic uptake clearance (Cli,uptake) exceeded liver 
blood flow by ~2.6-fold and at least ~4-fold in diseased and healthy subjects, 
respectively (Table 6.2) suggesting that hepatic blood flow is the rate-limiting 
step in 99mTc-MEB hepatic clearance. There was a marginal difference in the 
volume of distribution (Vc) between the patient and healthy subjects.  The shape 
of the hepatic mass-time profile obtained via scintigraphy was notably different 
between the patient and the healthy subjects (Figure 6.6).  However, the 
AUC0→180 and AUC0→∞ were comparable between healthy volunteers (28.1 ± 
10.2 and 29.2 ± 9.9 normalized µCi*min, respectively) and the patient (28.1 and 
29.4 normalized µCi*min, respectively).  Intrinsic biliary clearance (Cl’i,biliary) 
 
 reduced 3.6-fold in the patient compared to the average Cl’i,biliary in healthy 
volunteers despite the similar hepatic exposure.   
Discussion. 
The purpose of the present study was to evaluate the utility of 99mTc-MIBI 
and 99mTc-MEB as phenotypic probes, and in particular to assess their sensitivity 
to changes in hepatic function due to hepatocellular carcinoma and cirrhosis.  
The potential use of quantitative hepatic scintigraphy, coupled with blood 
concentration monitoring, to support a robust pharmacokinetic model describing 
the disposition of the two probes was of particular interest. Perturbations in 
discrete mechanisms of hepatobiliary drug disposition, secondary to disease, 
drug interactions, or other reasons, logically would be easiest to evaluate with 
liver tissue concentration-time data of the compound of interest. Of course, this is 
not achievable with standard approaches. The technique evaluated in this study 
represents an attractive option, assuming that relevant labeled probe compounds 
are available.    
Due to the fact that only one patient was available for this study, the 
present results are intended only to represent “proof-of-concept” of the principle 
(i.e., that scintigraphy coupled with comprehensive sampling and sophisticated 
mathematical modeling has the potential to provide insight into subtle changes in 
drug disposition in the liver secondary to disease).  The underlying concept is 
that hepatic scintigraphy provides a more accurate indication of hepatic handling 
of these two probes than blood sampling alone. The blood concentration-time 
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 profile, while an important indicator of the time course and extent of systemic 
exposure, is not always predictive, or even necessarily reflective, of substrate 
exposure in relevant organs or tissue spaces (18, 35, 36). The present data 
demonstrate that scintigraphy has the potential to fill that information void, 
assuming that appropriate-labeled probe substrates are available.  
The compartmental model depicted in Figure 6.1 adequately described 
99mTc-MIBI blood concentrations, hepatic mass of 99mTc-MIBI in the patient, 
cumulative excretion of 99mTc-MIBI in the bile of healthy subjects, and cumulative 
excretion of 99mTc-MIBI in the urine (Figure 6.3). The parameters associated with 
the pharmacokinetic model were estimated with reasonably low variability (Table 
6.1).  The parameter representing hepatic uptake (kuptake) was reduced, and the 
basolateral efflux parameter (kbasolateral) was increased, in the patient compared to 
healthy human volunteers, consistent with the known decreased liver function, 
decreased total hepatic blood flow, altered liver perfusion, and up-regulated 
basolateral efflux proteins in this disease state (1, 8, 9, 37).  99mTc-MIBI biliary 
excretion is mediated by P-gp (15-17) and the rate constant governing biliary 
excretion (Kbiliary) was increased ~4-fold in the patient (Table 6.1), consistent with 
previous observations that P-gp mRNA and protein are upregulated in patients 
with primary biliary cirrhosis  (9, 37).  The urinary excretion rate constant (Krenal) 
was reduced 80% in the patient compared to the healthy volunteers.  This could 
be explained by a decrease in the glomerular filtration rate (GFR) as a result of 
age and disease state.  Based on laboratory values, the estimated GFR in this 
patient was ~52.8 mL/min/1.73m2 a 50% decrease compared to the average 
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 value obtained in healthy volunteers (101 ± 17 mL/min/1.73m2) with a mean age 
of 41 ± 11 yrs using the modification of diet in renal disease (MDRD) study 
method, and would be decreased further if comparing to the GFR for the younger 
healthy volunteer population used in this study (age distribution 21-41 yrs) (38, 
39). 
Based on pharmacokinetic modeling the, net decrease in hepatic 
exposure of 99mTc-MIBI, secondary to disease state, was attributed to a decrease 
in the rate constant for hepatic uptake and an increase in the rate constants 
representing hepatic efflux across the basolateral and canalicular membranes.  
Unfortunately, hepatic scintigraphy data were not obtained for 99mTc-MIBI in 
healthy subjects in the previous study (22). To address this deficiency, the time 
course of substrate mass in liver was simulated in each healthy subject utilizing 
the parameter estimates (Table 6.1) obtained from modeling the available data in 
these subjects (Figure 6.1). 99mTc-MIBI hepatic exposure for the time domain 
over which imaging was performed was ~76% lower in the patient compared to 
the mean simulated hepatic exposure of 99mTc-MIBI in healthy individuals (Figure 
6.4).  The terminal phase of the 99mTc-MIBI hepatic mass-time profile was not 
captured completely in this study. Therefore, future studies would need to 
incorporate a longer imaging time.   
99mTc-MEB has a high trans-hepatic extraction (21, 22); such compounds 
would be expected to evidence a hepatic clearance that is limited by hepatic 
blood flow (40).  Given this situation, a semi-physiologic pharmacokinetic model 
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 incorporating hepatic blood flow was developed to predict changes in biliary 
clearance secondary to alterations in liver perfusion.  Initially, fitting in toto the 
model depicted in Figure 6.2 to the data resulted in a poor fit of the blood 
concentration-time profile. The inability of this model to describe the blood 
concentration data adequately may have been due to the disparity in the amount 
of blood concentration data (n=13) relative to the amount of hepatic mass data 
(n=178). Differential weighting of these two functions did not rectify the problem. 
Therefore, a stepwise nonlinear least-squares regression approach was taken to 
analyze these data, with a simple biexponential function, representing a two 
compartment model, fit to the blood concentration-time data in each subject as 
the first step. The macro-constants recovered from this step of the analysis (A, α, 
B, and β) were used to define the blood concentration-time profile, while the 
parameters associated with the semi-physiologic model (governing hepatic 
uptake) were determined in the second step of the analysis.  Using this 
approach, the model depicted in Figure 6.2 described the data form the patient 
as well as the healthy subjects (Figure 6.5).   
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The robustness of the semi-physiologic model was supported further by 
the agreement between the estimates for hepatic intrinsic uptake clearance the 
major route of elimination of 99mTc-MEB, and total systemic clearance (Cltotal) 
using model independent methods calculated as the administered dose divided 
by the blood AUC0→∞ determined by the trapezoidal rule.  Using the well-stirred 
model to calculate hepatic clearance (ClH), which is equal to the product of the 
hepatic blood flow and intrinsic clearance divided by the sum of the hepatic blood 
 
 flow and intrinsic clearance (40) ClH is ~1.23 and ~0.120 L/min in healthy 
subjects and the patient, respectively.  This is in excellent agreement with the 
value obtained for Cltotal (1.38 and 0.148 L/min in healthy subjects and the 
patient, respectively) and is very similar to the hepatic blood flow, which was 
fixed for the model based on literature reported values (1.45 L/min and 0.492 
L/min in healthy subjects and the patient, respectively) demonstrating that 99mTc-
MEB has a high hepatic clearance (Table 6.2). 
In healthy subjects, hepatic blood flow was the rate-limiting step in 99mTc-
MEB hepatic clearance; the estimates for Cl’i,uptake were ~4-fold or greater than 
liver blood flow (Table 6.2).  The model structure in healthy individuals did not 
require a process for either basolateral efflux of 99mTc-MEB back into sinusoidal 
blood or renal clearance, 99mTc-MEB was not detected in urine upon completion 
of imaging.   These results differ from those reported by Ghibellini et al. (2008) in 
which a rate constant associated with basolateral efflux was incorporated into a 
compartmental model.  This difference in model structure may be due to recovery 
of 99mTc-MEB in the urine in the former study. Because hepatic uptake of 99mTc-
MEB is so efficient, it is likely that measurable renal excretion of the probe would 
occur only if it can escape the liver and re-enter the systemic circulation, a 
process that would proceed with kinetics defined by a rate constant representing 
basolateral efflux.   
In order to fit the 99mTc-MEB data obtained from the patient, the model 
required inclusion of both basolateral efflux and renal clearance. This difference 
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 between the patient and healthy subjects is understandable. If the disease state 
resulted in impaired hepatic uptake of 99mTc-MEB, more of the probe compound 
would be available for renal excretion; if the disease state resulted in impaired 
biliary excretion of 99mTc-MEB, more of the probe compound would be available 
for basolateral efflux (and also subsequently for renal excretion). The presence of 
basolateral efflux would prolong the residence time of 99mTc-MEB in blood, which 
also would explain the longer terminal half-life of the compound in the patient as 
compared to healthy subjects.   
99mTc-MEB is a known substrate of MRP3 (22), which is located on the 
basolateral membrane of hepatocytes and is up-regulated in subjects with 
primary biliary cirrhosis (8, 9).  Furthermore, MRP2 is primarily responsible for 
99mTc-MEB biliary excretion (22, 41).  MRP3 acts as a compensatory mechanism 
when MRP2 is impaired, decreasing hepatocellular accumulation of potentially 
toxic drugs (42, 43).  The parameter estimates for 99mTc-MEB hepatobiliary 
disposition obtained in the present study [higher basolateral clearance (0.214 
L/min) than intrinsic biliary clearance (0.0997 L/min) and a 3.6-fold decreased 
biliary clearance] in the patient compared to healthy subjects (Table 6.2) are 
consistent with a disease-dependent decrease in MRP2 and compensatory 
increase in MRP3.  Therefore, the recovery of 99mTc-MEB in urine in the 
presence of liver disease may be the result of increased basolateral efflux and a 
redirection of MEB from excretion into bile.   
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 Surprisingly, the dose-normalized hepatic exposure AUC0→180 and 
AUC0→∞  to 99mTc-MEB was similar in the patient with hepatocellular carcinoma 
and cirrhosis compared to healthy individuals (Figure 6.6).  Both the intrinsic 
uptake clearance and biliary clearance decreased ~5-fold in the patient 
compared to healthy subjects (Table 6.2).  However, a basolateral clearance 
process also was present in the diseased subject, which would be expected to 
decrease the hepatic exposure of 99mTc-MEB in the patient more significantly 
compared to healthy individuals.  The presence of a compensatory basolateral 
efflux process was only evident in the hepatic mass-time profile in which the 
maximum mass in the patient was ~3-fold lower compared to the average profile 
in healthy subjects.  However, prolonged exposure at a higher hepatic mass for 
more than two-thirds of the profile was noted (Higher mass starting at ~50 min in 
the patient compared to healthy volunteers, Figure 6.6). 
In conclusion, the results of the present study suggest that 99mTc-MIBI and 
99mTc-MEB may be very useful phenotypic probes that are sensitive to changes 
in hepatic function associated with liver disease. The hepatic exposure to 99mTc-
MIBI was decreased in the patient with hepatocellular carcinoma and cirrhosis 
compared to healthy volunteers, whereas the hepatic exposure of 99mTc-MEB 
was similar but the hepatic exposure profile was notably different with a lower 
maximum but more prolonged exposure.  Alterations in key rate constants 
representing hepatic uptake and efflux mechanisms secondary to disease may 
prove useful in predicting changes in drug disposition, and potentially drug 
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action, for therapeutic compounds that are handled by mechanisms similar to 
those governing hepatic exposure to 99mTc-MIBI and 99mTc-MEB. 
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 Legend to Figures 
Figure 6.1  Model scheme for 99mTc-MIBI disposition in a patient with 
hepatocellular carcinoma and Child’s Pugh B cirrhosis and healthy subjects.  CC 
represents the concentration of 99mTc-MIBI in the central compartment (systemic 
circulation) with an apparent volume VC; Kuptake represents the first–order rate 
constant for hepatic uptake; Kbasolateral represents the first-order rate constant for 
hepatic basolateral efflux; Xliver represents the amount of 99mTc-MIBI in the liver; 
Kbile represents the first–order rate constant for biliary excretion; Kurine represents 
the first–order rate constant for urinary excretion; K13 represents the first–order 
rate constant for uptake into the peripheral compartment; K31 represents the first-
order rate constant for egress from the peripheral compartment to the central 
compartment; Xperipheral represents the amount of 99mTc-MIBI in the peripheral 
compartment. 
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on. 
Figure 6.2  Semi-physiologic model scheme for 99mTc-MEB disposition in a 
patient with hepatocellular carcinoma and Child’s Pugh B cirrhosis and in healthy 
subjects.  CC represents the concentration of 99mTc-MEB in the central 
compartment (systemic circulation) with apparent volume VC; QH represents 
hepatic blood flow through the sinusoids of the liver; exchange of 99mTc-MEB 
between liver sinusoidal space and hepatocytes is characterized by Cl’i,uptake and 
Cl’I,basolateral; Xliver represents the amount of 99mTc-MEB in the liver with volume 
VH; Cl’I,biliary represents biliary excretion; Clrenal represents urinary excreti
Figure 6.3  Representative 99mTc-MIBI disposition in a patient with hepatocellular 
carcinoma and Child’s Pugh B cirrhosis (A) and a representative healthy subject 
(23) (B).  Symbols represent observed data; lines represent the best fit of the 
pharmacokinetic model (scheme depicted in Fig. 6.1) to the data.  Blood 
concentrations (●; solid line) are plotted on a log scale, while substrate mass in 
the liver (x; dashed line) and cumulative mass in urine (◊; dashed line) and bile 
(□; dashed line) are plotted on a linear scale.   
 
Figure 6.4  Dose-normalized hepatic mass-time profile of 99mTc-MIBI in a patient 
with hepatocellular carcinoma and Child’s Pugh B cirrhosis (x; n=1), and 
simulated hepatic mass-time profile, using final parameter estimates listed in 
Table 6.1, in healthy human volunteers (line; Mean ± SD, n=7). 
 
Figure 6.5 Representative 99mTc-MEB disposition in a patient with hepatocellular 
carcinoma and Child’s Pugh B cirrhosis (A) and a representative healthy subject 
(B).  Symbols represent observed data; lines represent the best fit of the semi-
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physiologic pharmacokinetic model (scheme depicted in Fig. 6.2) to the data.  
Blood concentrations (●; solid line) are plotted on a log scale while substrate 
mass in the liver (x; dashed line), and cumulative mass in urine (◊; dashed line) 
and bile (□; dashed line) are plotted on a linear scale.   
 
Figure 6.6  Dose normalized hepatic mass-time profile of 99mTc-MEB in a patient 
with hepatocellular carcinoma and Child’s Pugh B cirrhosis (x; n=1) and healthy 
human volunteers (○; Mean ± SD, n=3) 
 
 
Tables 
Table 6.1 Parameter estimates and associated variability (coefficient of variation) for 99mTc-MIBI disposition in the patient 
with hepatocellular carcinoma and Child’s Pugh B cirrhosis and in healthy subjects. Modeling was based on the 
compartmental model scheme depicted in Fig.  6.1.  Parameter estimates for healthy humans were generated from 
previously published data (23).   
 
  Healthy Volunteersb 
 Patienta Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 Subject 6 Subject 7 Mean SD 
Dose (µCi) 3860 2503 3384 3166 3182 3037 3563 3100 3134 331 
VC (L) 4.52 (30.5) 5.34 (5.8) 16.0 (4.3) 10.5 (9.7) 5.99 (5.7) 5.58 (9.9) 4.51 (20.4) 8.78 (5.0) 8.10 4.09 
Kuptake (min-1) 0.135 (8.24) 0.394 (9.7) 0.182 (35.8) 0.248 (21.8) 0.485 (8.0) 0.291 (20.1) 0.430 (25.4) 0.193 (32.4) 0.318 0.119 
Kbasolateral (min-
1) 0.0221 (23.4) 0.00563 (13.7) 0.00412 (62.5) 0.00387 (34.7) 0.00666 (11.5) 0.00232 (45.8) 0.00378 (32.9) 0.00214 (96.5) 0.00407 0.00163 
K  (min-1biliary ) 0.00817 (29.7) 0.00204 (2.5) 0.00222 (20.7) 0.00194 (10.4) 0.00215 (1.5) 0.00158 (10.0) 0.00156 (10.5) 0.00254 (18.9) 0.00200 0.0003 
K (min-1renal ) 0.00975 (27.8) 0.0747 (6.1) 0.0107 (4.9) 0.00327 (8.2) 0.0603 (6.1) 0.0656 (7.6) 0.0623 (15.4) 0.0491 (5.7) 0.0466 0.0281 
K  (min-113 ) 0.429 (10.7) 0.272 (12.1) 0.223 (26.5) 0.134 (32.5) 0.133 (18.5) 0.210 (22.6) 0.298 (25.5) 0.258 (22.4) 0.218 0.065 
K (min-131 ) 0.0178 (31.0) 0.0952 (19.3) 0.0347 (31.8) 0.0362 (42.1) 0.149 (34.2) 0.029 (26.5) 0.0345 (26.2) 0.0321 (29.0) 0.0587 0.0461 
 
(a) Model fit to blood, cumulative mass in urine and hepatic scintigraphy data. 
(b) Model fit to blood and cumulative mass in urine and bile data.  
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Table 6.2 Summary of 99mTc-MEB dose, recovery, gallbladder ejection fraction and pharmacokinetic parameters and 
associated variability (coefficient of variation) in a patient with hepatocellular carcinoma and Child’s Pugh B cirrhosis and 
healthy humans. Modeling was conducted according to the pharmacokinetic model scheme depicted in Fig.  6.2.  
   Healthy Volunteersb (n=3) 
  Patienta Subject 1 Subject 2 Subject 3 Mean SD 
Dose (µCi) 4818 2272 2407 2719 2466 229 
Weight (kg) 49.9 69.2 58.3 81.9 69.8 11.8 
Urinary Recovery (% of Dose)a 0.33 0 0 0 0 0 
Biliary Recovery corrected for 
EF (% of dose)c N/A 63.8 23.4 49.1 45.4 20 
Ejection Fraction (EF) N/A 0.96 0.68 0.54 0.727 0 
Fixed Parameters             
Liver Blood Flow (L/min) 0.492 1.43 1.21 1.70 1.45 0.25 
Liver Volume (L) 1.20 1.42 1.20 1.68 1.68 0.28 
Unbound Fraction in Blood 
(Fu,B) 0.123 0.0825d 0.0825d 0.0825   
Unbound Fraction in Liver (Fu,H)e 0.078 0.078 0.078 0.078   
Alphaf 0.00711 0.00508 0.00601 0.00878 0.00662 0.00192 
Af 240 5.97 3.33 4.53 4.61 1.32 
Betaf 0.0998 0.18 0.141 0.196 0.172 0.028 
Bf 642 377 95.5 325 266 150 
Parameter estimates (CV%)             
Clrenal (L/min) 0.00604 (28.9)         
Cl’i,uptake (L/min) 1.29 (4.6) 5.49 (7.94) 15.7 (26.4) 8.29 (15.78) 9.83 5.28 
Cl’basolateral (L/min)  0.214 (13.1)         
Cl’i,biliary (L/min) 0.0997 (4.9) 0.364 (1.63) 0.271 (2.45) 0.439 (2.63) 0.358 0.084 
Vc (L) 2.70 (3.1) 1.44 (1.66) 3.52 (2.49) 1.71 (2.72) 2.22 1.13 
248 
 
 
 (a) Model fit to blood, cumulative mass in urine and hepatic scintigraphy data. 
(b) Model fit to blood, cumulative mass in urine and bile and hepatic scintigraphy 
data. 
(c) Urinary and biliary (healthy only) recovery of 99mTc-MEB was measured after IV 
administration to one patient with hepatocellular carcinoma and Child’s Pugh B 
cirrhosis and three healthy human volunteers.  The biliary recovery was 
corrected for the degree of gallbladder contraction in response to 
pharmacological stimulation, thereby correcting the amount of 99mTc-MEB 
recovered in bile for the residual amount remaining in the gallbladder.   
(d) Blood (fu,B) unbound fraction was not determined and fixed based on subject #3 
data. 
(e) Liver (fu,H) unbound fraction was estimated in vitro by ultrafiltration as described 
in the methods section. 
(f) The macroconstants (A, α, B, β) were obtained by fitting the blood concentration-
time curve using nonlinear regression analysis with the algebraic function: 
concentration = Ae-αt+Be-βt.   
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Figure 6.4 
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 Figure 6.5 
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Figure 6.6 
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CHAPTER 7 
 
 
 
 
 
 
Conclusions and Future Directions 
 
 
 
 
 
 
 
 
 
 The objective of this research project was to identify and characterize 
substrates as probes for specific hepatic transport proteins for the purpose of 
elucidating the role of these transport proteins in hepatobiliary disposition of 
drugs in humans.  Identification of specific probe substrates for basolateral and 
canalicular transport proteins is necessary to elucidate mechanisms of 
hepatobiliary drug transport, phenotype for interindividual differences in transport 
protein function, and identify potential drug-drug interactions at the hepatic 
transport level. Three probe substrates were selected for investigation: 
fexofenadine, 99mTechnetium mebrofenin (99mTc-MEB), and 99mTechnetium 
sestamibi (99mTc-MIBI).  An important advantage of 99mTc-MEB and 99mTc-MIBI is 
that the gamma emitting properties of the 99mTc label allow non-invasive 
scintigraphic imaging for the quantitative assessment of hepatic exposure, which 
may be significantly different than systemic exposure based on readily obtained 
blood concentrations.    
 
Integration of Preclinical and Clinical Data with Pharmacokinetic Modeling 
and Simulation to Evaluate Fexofenadine as a Probe for Hepatobiliary 
Transport Function (Chapter 2) 
Fexofenadine has been labeled as a P-gp specific probe substrate (1), 
although current literature suggests that other proteins are involved in the hepatic 
disposition of this compound (2, 3).  Therefore, studies were designed to 
examine the suitablity of fexofenadine as a probe substrate for altered 
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 hepatobiliary transport in humans.  A pharmacokinetic model was developed to 
describe the disposition of fexofenadine in healthy human subjects, and 
simulations were conducted to examine the effect of inhibition or induction of 
hepatic transport processes on fexofenadine disposition.  To assess the 
influence of alterations in hepatic uptake or excretion on fexofenadine systemic 
and hepatic exposure, a simulation approach was utilized, and the rate constants 
representing the active transport processes governing hepatic uptake and efflux 
were modulated in a systematic manner.  Based on these simulations, systemic 
fexofenadine concentrations were most sensitive to changes in fexofenadine 
hepatic uptake.  Increased or decreased hepatocyte concentrations, as a result 
of impaired or induced biliary or hepatic basolateral efflux, associated with drug-
drug interactions or genetic mutations, had minimal impact on fexofenadine 
systemic exposure. 
Studies were performed in human sandwich-cultured hepatocytes (SCH) 
using the inhibitor GF120918 [P-gp and BCRP inhibitor] in order to investigate 
the changes in systemic and hepatic exposure after inhibition of fexofenadine 
biliary excretion, and to examine the involvement of P-gp in the biliary excretion 
of fexofenadine in humans. The possible involvement of BCRP was ruled out 
based on previously published data demonstrating that BCRP does not transport 
fexofenadine generated in MDCKII cells transfected with human BCRP (2).  
Results suggested that a GF120918-sensitive protein(s) (presumably P-gp) 
played a minor role in fexofenadine biliary excretion in human hepatocytes.  
Quite possibly, other canalicular transport proteins fully compensate when 
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 GF120918-sensitive protein(s) is/are inhibited.  These data imply that 
fexofenadine would not be a suitable probe substrate in humans to assess 
altered biliary excretion associated with a specific canalicular transport process. 
Due to the limited availability of human hepatocytes, the lack of specific 
MRP2 inhibitors that would not affect OATP-mediated fexofenadine uptake, and 
the multiplicity of efflux transport proteins involved in fexofenadine hepatobiliary 
disposition in humans (3, 4), further investigations were conducted in rat 
perfused livers to avoid the use of a chemical inhibitor and take advantage of the 
naturally occurring Mrp2-deficient (TR-) rats.  Previous studies demonstrated that 
the biliary excretion and intrinsic biliary clearance of fexofenadine were not 
significantly different in wild-type and TR- rats (3, 5).  Therefore, TR- rats were 
employed to rule out any compensatory role of Mrp2 in the biliary excretion of 
fexofenadine.  TR- rat livers were perfused in situ in a single-pass manner in the 
presence and absence of the Bsep inhibitor bosentan (6), and GF120918 to 
examine the impact of modulation of uptake and efflux proteins on fexofendadine 
hepatobiliary disposition.  Furthermore, the taurocholate infusion in perfused 
livers was withheld to perturb trafficking of ATP-binding cassette (ABC) transport 
proteins to the canalicular membrane (7, 8) in order to assess the contribution of 
impaired biliary excretion to fexofenadine disposition.  Fexofenadine intrinsic 
biliary clearance was only significantly decreased in the presence of GF120918.  
Studies in perfused livers from TR- rats demonstrated that fexofenadine biliary 
excretion is mediated primarily by a GF120918-sensitive (presumably P-gp) 
mechanism. 
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Impact of Basolateral Mrp3 and Mrp4 on the Hepatobiliary Disposition of 
Fexofenadine in Perfused Mouse Livers (Chapter 3) 
Mrp2 is the primary efflux pump responsible for the biliary excretion of 
fexofenadine in mice (3). Infusion of fexofenadine to Abcc2(-/-) mouse livers 
resulted in an ~85% decrease in biliary excretion, but interestingly, 
concentrations of fexofenadine in outflow perfusate were significantly higher, and 
total and unbound concentrations in the liver were reduced compared to wild-
type (WT) livers, emphasizing the importance of basolateral efflux.  Because 
many Mrp2 substrates also undergo basolateral export into the blood by Mrp3, 
the roles of Mrp2, Mrp3, and Mrp4 in the hepatobiliary disposition of fexofenadine 
were examined in perfused livers from relevant transporter-gene knockout mice.  
The study design involved an infusion to steady state to preload the liver followed 
by a washout phase to determine the degree of basolateral and canalicular 
efflux.  Decreased fexofenadine perfusate concentrations were observed at the 
initiation of the washout phase of perfusion in Abcc3(-/-) mice.  In order to 
quantify the impact of Mrp3 and Mrp4 on the basolateral efflux of fexofenadine 
from the liver, recovery of fexofenadine in perfusate during the washout phase 
was expressed as the percentage of liver drug content at the end of the infusion.  
The fraction of fexofenadine excreted into outflow perfusate was significantly 
decreased ~50% in livers from Abcc3(-/-) mice.  In contrast, hepatic basolateral 
excretion of fexofenadine in livers from Abcc4(-/-) mice was unchanged.  The 
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 fraction of fexofenadine excreted into perfusate was significantly increased ~60% 
in Abcc2(-/-) relative to WT mouse livers.  Interestingly, hepatic basolateral 
excretion of fexofenadine in livers from Abcc2(-/-)/Abcc3(-/-) mice was not 
decreased, and was even ~10% higher than in WT control livers. 
Fexofenadine recovery in bile was significantly decreased in Abcc2(-/-) 
and Abcc2(-/-)/Abcc3(-/-) mice and unchanged in Abcc3(-/-) and Abcc4(-/-) 
mouse livers relative to WT controls.  Total recovery of fexofenadine in bile 
during the washout phase (normalized to drug liver content at the end of the 
infusion) was significantly lower in Abcc2(-/-) and Abcc2(-/-)/Abcc3(-/-) relative to 
WT mice, ~61% and ~53%, respectively.  In summary, fexofenadine, in the 
hepatocyte undergoes bidirectional excretion via Mrp2, Mrp3, and residual 
unknown transport mechanisms.  Mrp4 did not appear to contribute to hepatic 
basolateral excretion of fexofenadine in the intact mouse liver.  This further 
supports fexofenadine as a substrate of multiple transport proteins in the liver, 
making it a poor candidate probe substrate for specific hepatic transport proteins 
such as P-gp. 
 
Evaluation of 99mTc-MEB and 99mTc-MIBI as Specific Probes for Hepatic 
Transport Protein Function in Rats and Humans (Chapter 4) 
99mTc-MIBI and analogs of 99mTc-MEB have been used as probe 
substrates to assess interindividual variation in hepatic drug handling and 
function (9-11).  99mTc-MIBI has been used to phenotype P-gp function with the 
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 P-gp inhibitors PSC833 and LY335979 resulting in prolonged hepatic exposure 
(12-14).  Alterations in 99mTc-MIBI pharmacokinetics were assessed in a cohort of 
cancer patients with common single nucleotide polymorphisms (SNPs) in ABCB1 
exons 12 (C1236T) and 26 (C3435T) resulting in a significantly decreased 
elimination rate constant (11).  However, the mechanisms of hepatic transport 
have not been fully investigated, including potential compensatory proteins 
involved in hepatobiliary disposition.   
Uptake in human and rat hepatocytes was assessed with the use of 
specific inhibitors for each subfamily of hepatic transport proteins [i.e. 
OATPs/Oatps, organic anion transporters (OATs/Oats) and organic cation 
transporters (OCTs/Octs)] validated with the use of probes (i.e. estradiol-17-β-D-
glucuronide, para-aminohippuric acid and tetraethylammonium) to confirm their 
specificity.  To assess sodium-dependent transport by the sodium taurocholate 
co-transporting polypeptide (Ntcp), choline-based buffer was substituted for 
sodium-based buffer in suspended hepatocytes.  99mTc-MIBI initial uptake was 
within 10% of control, and not influenced by inhibitors or the absence of sodium 
suggesting that an active transport process is not involved in 99mTc-MIBI hepatic 
uptake at these low concentrations.  This is consistent with previous reports that 
uptake is a function of free diffusion based on electrical potentials across the 
plasma and mitochondrial membranes, with localization in the mitochondria by 
electrostatic forces (15, 16).  Similar findings were expected in human 
hepatocytes and therefore, experiments were not continued in human 
hepatocytes to conserve this limited resource.  As expected, 99mTc-MEB initial 
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 uptake was sodium-independent, and was only affected by the OATP/Oatp 
inhibitors rifamycin SV and glycyrrhizic acid.  These data support the hypothesis 
that 99mTc-MEB uptake is predominantly mediated by OATPs/Oatps in human 
and rat and is in agreement with data demonstrating 99mTc-MEB is a substrate of 
OATP1B1 and OATP1B3 (17).   
Further studies were undertaken to examine the efflux processes involved 
in 99mTc-MEB hepatic disposition.  99mTc-MEB canalicular efflux was completely 
abated in TR- rat sandwich-cultured hepatocytes and decreased in WT rat and 
human sandwich-cultured hepatocytes 665% and only 30% in the presence of 
the Mrp2 inhibitor MK571.  99mTc-MEB basolateral efflux was increased in TR- 
sandwich-cultured rat hepatocytes compared to WT, and in the presence of 
MK571, while intracellular accumulation of 99mTc-MEB was unchanged.  These 
important findings suggest that this probe can be redirected from biliary excretion 
to basolateral efflux.  This increase in basolateral efflux also could be due, in 
part, to inhibition of 99mTc-MEB hepatic re-uptake, because MK571 has been 
shown to inhibit OATP1B3 with a reported Ki of 0.6 µM (18).    
Further studies were conducted to investigate the efflux processes 
involved in 99mTc-MIBI hepatic disposition.  The absence of Mrp2 based on efflux 
studies in TR- rat SCH did not alter basolateral or canalicular efflux, suggesting 
that either Mrp2 is not involved, or other proteins (e.g. P-gp) are able to fully 
compensate.   99mTc-MIBI basolateral efflux was GW918 sensitive, suggesting an 
active transport process.  Recently, GW918 was demonstrated to inhibit MRP4 in 
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 inside-out membrane vesicles prepared from transiently transfected HEK293 
cells (19).  99mTc-MIBI canalicular efflux also was GW918 sensitive, consistent 
with a role for P-gp and/or Bcrp in biliary excretion of this probe.  Hepatocellular 
accumulation of 99mTc-MIBI increased in the presence GW918 due to the 
decreased basolateral and canalicular efflux of 99mTc-MIBI.  
In order to investigate further the transport processes involved in 99mTc-
MIBI biliary excretion, accumulation studies were conducted in rat SCH.  The 
involvement of Bcrp in the biliary excretion of 99mTc-MIBI was assessed with the 
use of RNAi knockdown of Bcrp, which did not affect 99mTc-MIBI cellular 
accumulation or biliary excretion.  99mTc-MIBI biliary excretion was completely 
inhibited by 2 µM GF120918, used previously to inhibit P-gp in rat SCH (20).  
Cellular accumulation also increased in the presence of GF120918, suggesting 
that Pgp is the primary protein responsible for the biliary excretion of 99mTc-MIBI 
in rat SCH.   
In summary, the hepatic uptake of 99mTc-MIBI appears to occur by passive 
diffusion; 99mTc-MIBI biliary excretion is mediated by P-gp.  99mTc-MEB hepatic 
uptake is predominantly Oatp/OATP-mediated with biliary excretion by 
MRP2/Mrp2.  Remarkable species differences exist between rat and human in 
the total efflux and route of efflux for 99mTc-MEB.  Preloading SCH and 
measurement of efflux over 20 min in SCH is a useful approach to investigate the 
route of hepatic excretion (basolateral vs. canalicular), species differences in 
basolateral and canalicular efflux, and compensatory changes in canalicular and 
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 basolateral efflux due to impaired transport function associated with drug 
interactions, disease state alterations or genetic variation. 
 
Hepatobiliary Disposition of Sorafenib in Human Hepatocytes (Chapter 5) 
 The objective of this aim was to validate the use of 99mTc-MEB and/or 
99mTc-MIBI as probe substrates to predict the hepatic clearance of the anticancer 
agent, sorafenib, by confirming similar mechanisms of hepatic transport.  
Sorafenib, a recently developed oral multikinase inhibitor, relies heavily on the 
liver for elimination in humans.  The liver is also the target site for individuals with 
unresectable hepatocellular carcinoma (HCC). Furthermore, sorafenib 
administration in patients with hepatic dysfunction, defined by increased serum 
concentrations of total bilirubin, aspartate transaminase and albumin, resulted in 
dose-limiting elevations in total bilirubin concentrations (21).  Possible 
explanations for the sorafenib-mediated increases in serum bilirubin include 
inhibition of the transport proteins responsible for the hepatobiliary disposition of 
bilirubin or its conjugates, or UGT1A1 inhibition of bilirubin glucuronidation, as 
demonstrated in vitro (22).  Therefore, elucidating the mechanisms of hepatic 
uptake and the extent of biliary excretion of sorafenib in humans is of utmost 
importance.   
Sorafenib uptake in suspended human hepatocytes, CHO cells and 
sandwich-cultured human hepatocytes was extensive.  Uptake into human 
hepatocytes and CHO cells was temperature dependent and decreased ~50% at 
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 4°C, suggesting a high degree of passive diffusion.  The hepatic uptake in freshly 
isolated suspended human hepatocytes was sensitive to rifamycin SV and 
decynium 22, suggesting OATP- and OCT-mediated uptake.  OCT1-mediated 
uptake of sorafenib was confirmed in OCT1 overexpressing CHO cells.  Biliary 
excretion of sorafenib in human SCH was low.   
Thus, of the model probes selected, both undergo similar routes of hepatic 
uptake as sorafenib.  99mTc-MIBI would be predictive of the predominant process 
of uptake which occurs by passive diffusion.  Sorafenib’s rifamycin SV-sensitive 
uptake mechanism (presumably OATP-mediated) is the predominant uptake 
route for 99mTc-MEB.  The biliary excretion of sorafenib is low, suggesting this is 
not an important elimination pathway.  However, sorafenib is a substrate and 
inhibitor of P-gp (Mark Gnoth, personal communication), which also primarily 
excretes 99mTc-MIBI.  Secondly, sorafenib undergoes phase II glucuronidation 
catalyzed by uridine disphosphate-glucuronsyl-transferase (UGT1A9) (23).  It is 
well understood that glucuronide conjugates are substrates of MRP2 and MRP3 
(24-26), which are responsible for biliary excretion and basolateral efflux into 
sinusoidal blood, respectively.  These are the predominant transport proteins 
governing the hepatobiliary disposition of the probe substrate 99mTc-MEB.  
Therefore, it appears both probes are necessary to phenotype function of the 
transport proteins responsible for sorafenib hepatic disposition. 
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 Pharmacokinetics and Hepatic Exposure of 99mTc-MEB and 99mTc-MIBI 
Compared Between a Patient with Hepatocellular Carcinoma and Child's 
Pugh B Cirrhosis versus Healthy Volunteers: An Exploratory Analysis 
(Chapter 6) 
Many patients with HCC and cirrhosis have impaired hepatic function, 
which results in highly variable clearance of drugs.  In fact, the apparent oral 
clearance of sorafenib has been reported to be highly variable [median 5.32 
(range, 0.17 – 26.4) L/hr], and does not appear to be related to age, body weight, 
sex or hepatic dysfunction (oral clearance was not different among mild, 
moderate, severe and very severe hepatic dysfunction cohorts).  Among the four 
hepatic dysfunction cohorts, only the cohort with mild liver dysfunction was able 
to tolerate the recommended dose of 400 mg BID; other cohorts experienced 
dose-limiting toxicities resulting in decreased maximal tolerated doses (27).  The 
variability in sorafenib pharmacokinetics could be attributed, in part, to 
differences in hepatic transport protein levels and function.  It is well recognized 
that patients with liver disease develop adaptive changes in transport protein 
expression, which protect the hepatocyte from the intracellular accumulation of 
toxic compounds such as bile acids (28-30).  For example, patients with primary 
biliary cirrhosis exhibit down-regulation of basolateral uptake transport proteins 
often coupled with up-regulation of canalicular and basolateral efflux proteins 
(31-33).  These changes in protein levels result in functional changes which can 
be assessed in vivo with the use of probes that have been shown to be sensitive 
to specific clearance mechanisms, such as metabolizing enzymes or transport 
267 
 
 proteins (9, 10, 34, 35).  Furthermore, because systemic concentrations may not 
represent intracellular concentrations, the use of radiolabeled probes provides a 
noninvasive method to quantify tissue exposure in vivo in order to elucidate 
functional changes in vectorial transport  (11-13, 36).   
Thus, the long-term objective of these studies was to compare sorafenib 
pharmacokinetics with the pharmacokinetics and hepatic exposure of the non-
invasive imaging agents, 99mTc-MEB and 99mTc-MIBI, in patients with locally 
advanced or metastatic HCC and Child's B cirrhosis.  However, due to slow 
patient accrual, an interim analysis was not possible in a reasonable timeframe.  
Therefore, the studies detailed in this dissertation were designed to test the 
hypothesis that adaptive changes in transport protein expression due to cirrhosis 
and HCC result in functional changes that impact the disposition of substrates, 
and that the two probes, 99mTc-MEB and 99mTc-MIBI, can serve as tools to predict 
the locus and extent of modulation in hepatic transport.  Pharmacokinetic models 
were developed to describe the distribution and elimination of 99mTc-MEB and 
99mTc-MIBI utilizing quantitative hepatic scintigraphy, blood concentrations, and 
cumulative mass in bile (only in healthy volunteers) and urine from patients with 
Child’s Pugh B cirrhosis and HCC, and from healthy human volunteers.  
Parameters generated from the pharmacokinetic models representing the hepatic 
uptake and efflux mechanisms, and hepatic exposure generated form 
quantitative hepatic scintigraphy, were compared between healthy and diseased 
subjects.   
268 
 
 Overall, the rate constants representing the disposition of 99mTc-MIBI in 
the liver were modulated to decrease hepatic exposure.  99mTc-MIBI hepatic 
exposure over the 180-min imaging time was decreased ~76% in the patient with 
HCC and Child’s Pugh B cirrhosis compared to the mean simulated hepatic 
exposure in healthy individuals.  The parameter representing hepatic uptake was 
reduced and the basolateral efflux parameter was increased in the subject with 
HCC and cirrhosis compared to healthy subjects, consistent with the known 
decreased hepatic uptake, decreased hepatic blood flow, altered liver perfusion 
and up-regulated basolateral efflux proteins in this disease state (31, 32, 37, 38).  
As shown in Chapter 4, 99mTc-MIBI biliary excretion is mediated by P-gp (11-13); 
the rate constant governing biliary excretion was increased ~4-fold in the patient 
with HCC and cirrhosis, consistent with previous reports of increased mRNA and 
protein in patients with primary biliary cirrhosis  (32, 37).        
99mTc-MEB has a high hepatic extraction; therefore, a semi-physiologic 
pharmacokinetic model incorporating hepatic blood flow was used to describe the 
data.  In In healthy subjects, hepatic blood flow was the rate-limiting step; the 
estimates for Cli,uptake were ~4-fold or greater than liver blood flow.  The model 
structure that best described the data in healthy subjects did not require a 
process for basolateral efflux of 99mTc-MEB from the hepatocyte into sinusoidal 
blood, nor a process for renal clearance of 99mTc-MEB because no radiolabeled 
compound was detected in urine during the study period.  However, in the patient 
with HCC and cirrhosis, the model that best described the data included 
basolateral efflux and renal clearance processes; parameter estimates for 
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 basolateral clearance (0.214 L/min) were greater than biliary clearance (0.0997 
L/min).  The biliary clearance in the HCC with Child’s Pugh B cirrhosis patient 
compared to healthy subjects was decreased 3.6-fold.  Furthermore, 99mTc-MEB 
recovery in urine was increased in the patient with HCC and cirrhosis due to 
increased basolateral efflux, resulting in redirection of 99mTc-MEB from biliary to 
urinary excretion.  Surprisingly, the dose normalized hepatic exposure of MEB 
was similar between the subject with HCC and cirrhosis compared to healthy 
individuals.  This appears to be due to the decrease in uptake clearance and 
increase in basolateral efflux clearance in the diseased subject compared to 
healthy subjects, and further supports MRP3 as a compensatory mechanism that 
enables excretion of MRP2 substrates into the systemic circulation, thus avoiding 
excessive accumulation of organic anions in the hepatocyte (24, 39, 40).  
These results suggest that 99mTc-MEB and 99mTc-MIBI are potentially 
useful phenotypic probes that are sensitive to changes in hepatic function 
associated with liver disease. The hepatic exposure to 99mTc-MIBI was 
decreased in the patient with HCC and cirrhosis compared to healthy volunteers, 
whereas the hepatic exposure of 99mTc-MEB was similar.  Alterations in key rate 
constants representing hepatic uptake and efflux mechanisms secondary to 
disease may prove useful in predicting changes in drug disposition, and 
potentially drug action, for therapeutic compounds that are handled by 
mechanisms similar to those governing hepatic exposure of 99mTc-MEB and 
99mTc-MIBI. 
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 Significance 
Of the three probes investigated in this dissertation, 99mTc-MEB and 99mTc-
MIBI are most promising due to their specificity for particular transport proteins, 
as elucidated in vitro utilizing whole hepatocyte experiments with all the relevant 
hepatic transport proteins expressed.  99mTc-MEB is an organic anion that is 
taken up by the OATPs and subsequently excreted by MRP2; 99mTc-MIBI, an 
organic cation, passively diffuses into hepatocytes and is excreted by P-gp.  Both 
probes are ideal due to the gamma emitting properties of the 99mTc label, which 
allows for quantification of hepatic concentrations to assess functional changes in 
both uptake and efflux.  The in vitro studies in this dissertation validate both 
probes to assess hepatic uptake by OATP and biliary secretion by MRP2 and P-
gp.  However, more work is necessary to elucidate the proteins that are involved 
in the hepatic sinusoidal (basolateral) efflux of these probes into the bloodstream.  
For example, it remains unclear whether 99mTc-MEB is a specific substrate for 
MRP3, and what GF120918-sensitive protein is responsible for the basolateral 
efflux of  99mTc-MIBI.  These are important issues in disease states where 
transport proteins involved in hepatic uptake are down-regulated, and hepatic 
efflux proteins on both the basolateral and apical membranes are up-regulated.  
This became apparent in the clinical study when comparing 99mTc-MEB and 
99mTc-MIBI pharmacokinetics and hepatic exposure between a subject with 
hepatocellular carcinoma and cirrhosis vs. healthy volunteers.  Both probes 
exhibited a decreased hepatic uptake and increased hepatic efflux in vivo based 
on the model parameters representing these transport processes.  Most 
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 importantly, data obtained from hepatic scintigraphy demonstrated that the 
hepatic exposure of 99mTc-MEB was similar between the diseased subject and 
healthy volunteers, but the hepatic exposure of 99mTc-MIBI was decreased in the 
diseased subject compared to healthy individuals.  Interestingly, blood 
concentrations of 99mTc-MIBI in the diseased subject were higher than healthy 
volunteers, but that did not translate to higher liver exposure; this finding 
emphasizes the importance of measuring tissue concentrations.  Therefore, use 
of these probes to assess hepatic exposure of drugs that undergo similar 
mechanisms of hepatic clearance would be advantageous, especially when the 
liver is the target site (e.g. statins or anti-cancer drugs for hepatocellular 
carncinoma).   
 The importance of obtaining liver concentrations initially was highlighted 
by the work with fexofenadine in Chapter 2 through the use of compartmental 
modeling and simulation.  The simulation exercises demonstrated that a potential 
drug-drug interaction on the apical membrane of the hepatocyte would result in 
modulation of the liver concentrations without a subsequent change in the 
systemic compartment.  For this reason, fexofenadine would not be an optimal 
probe for phenotyping the function of a canalicular protein because blood 
concentrations do not reflect hepatobiliary disposition of this probe, and it is not 
practical to directly obtain liver concentrations in humans.  Furthermore, in vitro 
work in this dissertation demonstrated that fexofenadine is not a specific 
substrate for P-gp in human hepatocytes, thereby invalidating its use as a 
specific P-gp probe.  Based on studies utilizing transfected systems, 
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 fexofenadine is a substrate in vitro for multiple transport proteins; loss of function 
of one protein due to chemical inhibition or genetic knockout in preclinical models 
results in full compensation by other hepatic transport proteins. 
 In summary, transport protein probe substrates that can be imaged 
quantitatively to determine tissue concentrations have distinct advantages.  Such 
imaging agents can be used to assess alterations in the disposition of 
compounds due to modulation of uptake and efflux proteins in polarized cells and 
compartments that are not readily accessible for sampling in humans.  Of the two 
probes identified, 99mTc-MEB is limited to phenotyping hepatic transport proteins, 
but 99mTc-MIBI could be used to assess transport function at other barriers, 
including the kidney.  More work is necessary to identify probes for phentoyping 
all of the clinically relevant drug transport proteins at barrier epithelium.   
Future Directions 
 This research has prompted a number of proposed future studies 
regarding species differences in the basolateral and canalicular efflux of 
fexofenadine, 99mTc-MEB and 99mTc-MIBI, the challenge in assessing tissue 
exposure based on systemic concentration measurements, and the utility of 
quantitative hepatic scintigraphy coupled with blood concentrations to construct a 
robust pharmacokinetic model to assess changes in systemic or tissue 
concentrations and clearance pathways.  
Species Differences in Drug Transport 
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  Rodent models are used to investigate the impact of transport proteins on 
the pharmacokinetics of clinically important drugs.  For example, Mrp2-mediated 
biliary excretion of drugs and metabolites is most extensively investigated in the 
naturally occurring Mrp2-deficient (TR-) rat and Mrp2 knockout mouse (26, 41, 
42). These tools facilitate our understanding of the involvement of Mrp2 in the 
processes of drug absorption, distribution, and elimination.  Furthermore, these 
models offer the possibility of exploring how modulators (i.e., inhibitors or 
inducers) of the transport protein can modify the pharmacokinetics of a drug.  
However, data obtained in preclinical species may not necessarily correlate to 
findings in humans.  For instance, harmol sulfate biliary excretion was reduced 
significantly (~10-100-fold) in isolated perfused Bcrp-knockout mouse livers, but 
was unaffected in Mrp2- and Mdr1a/1b-knockout mouse livers (43).  However, in 
isolated perfused rat livers, GF120918 (P-gp and Bcrp inhibitor) had no effect on 
harmol sulfate biliary excretion, but the cumulative mass in bile after a 90-min 
infusion was decreased ~2.7-fold in TR- rats deficient in Mrp2 (44).  These 
findings demonstrated fundamental species differences in the hepatobiliary 
disposition of harmol sulfate, which is predominantly a substrate of Bcrp in 
mouse and Mrp2 in rat.  Zimmermann et al. demonstrated that human MRP2 and 
mouse Mrp2 have similar substrate specificities including vinblastine, docetaxel, 
saquinavir and etoposide, but have marked differences regarding transport 
efficiencies and in the modulation of transport by other compounds (45).  Their 
investigations demonstrated that sulfinpyrazone stimulated transport of 
saquinavir and estradiol-17-β-D-glucuronide by human MRP2, but strongly 
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 inhibited saquinavir transport by mouse Mrp2 (45).  These differences could be 
explained by the 78% amino acid identity between mouse Mrp2 and human 
MRP2 (46).  Many amino acid substitutions occur throughout the protein and, as 
shown by Ito et al., a single amino acid change in the last transmembrane 
segment of the protein altered MRP2 substrate specificity resulting in loss of the 
ability to transport methotrexate (47). 
 Work by Tian et al., demonstrated that in isolated perfused mouse livers 
the fexofenadine biliary excretion rate decreased 85%, and intrinsic biliary 
clearance decreased 50%, in Mrp2-knockout mice compared to wild-type control 
mice (3).  In contrast to mice, fexofenadine biliary excretion rate and intrinsic 
biliary clearance were unchanged in Mrp2-deficient TR- rats compared to wild-
type control rats. These apparently contradictory findings suggest that other 
transport proteins can completely compensate for the loss of Mrp2 function in the 
rat (3).  In this dissertation, coadministration of fexofenadine and GF120918 
(specific P-gp and Bcrp inhibitor) resulted in a 75% decrease in fexofenadine 
biliary excretion rate and a ~3.6-fold decrease in intrinsic biliary clearance 
[Chapter 2, (48)].  Fexofenadine is not a substrate of human or mouse 
BCRP/Bcrp based on previously published data generated in MDCKII cells 
transfected with human BCRP, or in Bcrp-knockout mice (2, 5).  Therefore, the 
predominant pathway for fexofenadine excretion into rat bile is likely P-gp.  
Furthermore, fexofenadine biliary excretion index and in vitro biliary clearance 
were unchanged in the presence of the P-gp inhibitor GF120918 utilizing human 
SCH.  These data suggest that GF120918-senstive protein(s) (presumably P-gp) 
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 play a minor role in fexofenadine biliary excretion in human hepatocytes.  Thus, 
the key question is, which species is more predictive of human fexofenadine 
biliary excretion, and why is Mrp2 predominantly involved in biliary excretion of 
this substrate in the mouse, wereas P-gp is primarily involved in biliary excretion 
of fexofenadine in the rat, but not in human hepatocytes?  Species differences in 
the affinity of the protein for fexofenadine, or differences in the amount of 
functional protein residing on the membrane, could help answer this question.  
Interestingly, the amount of MRP2/Mrp2 protein in the membrane fraction from 
liver samples was 10-fold higher in rats than in humans, as quantified by LC-
MS/MS (49).  Based on this information, Mrp2 should be more involved in 
fexofenadine biliary excretion in rats, than in mice or humans.  The greater 
influence of P-gp in rats may be due to a higher expression level or affinity for rat 
P-gp compared to mouse and human or perhaps just a lower affinity for Mrp2 in 
rats.  To help help explain this species difference in biliary excretion experiments 
using transfected systems that express Mrp2 and P-gp for each species 
individually to determine differences in Km and Vmax for fexofenadine.  
Remarkable species differences existed in the fraction of canalicular vs. 
basolateral efflux of 99mTc-MEB in rats (38.0% and 62.0%, respectively) and 
humans (73.3% and 26.7%, respectively), suggesting that biliary excretion would 
be the preferential route of hepatic elimination of this probe in humans.  This 
cannot be attributed to differences in the absolute amount of Mrp2/MRP2 protein 
primarily responsible for biliary excretion of 99mTc-MEB (Chapter 4). Based on 
work by Li et al., total Mrp2/MRP2 protein was not significantly different in day 4 
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 rat and day 7 human SCH (~4 fmol/µg protein) utilizing a quantitative LC-MS/MS 
analysis (50).  However, these apparent species differences could be explained 
by affinity differences, or different amounts of functional Mrp2/MRP2 protein 
residing on the canalicular membrane.  The high degree of 99mTc-MEB  biliary 
excretion is consistent with in vivo data from healthy human subjects indicating 
that ~84% of a 2.3 µCi dose of intravenously administered 99mTc-MEB was 
recovered in bile (17).  In contrast, the fraction of canalicular vs. basolateral efflux 
of 99mTc-MIBI in rats (36.8% and 63.2%, respectively) and humans (28.3% and 
71.7%, respectively), basolateral excretion of 99mTc-MIBI appears to be the 
preferential route of hepatic elimination of this probe in both rats and humans.  
This finding is consistent with biliary recovery of ~22% of a 3.1 µCi dose of 
intraveneously administered 99mTc-MIBI in healthy human subjects (17). Further 
work assessing basolateral and biliary efflux of 99mTc-MEB  and 99mTc-MIBI in 
vivo in rats is necessary to establish this efflux method in sandwich-cultured 
hepatocytes for examining the preferential route of hepatic efflux (canalicular vs. 
basolateral) and elucidating species differences in hepatic efflux. To further 
establish this methodology perhaps another compound to assess would be the 
degree of canalicular vs. basolateral efflux of acetaminophen glucuronide in rats 
vs. humans.  In the recirculating rat isolated perfused liver a 66 µmol bolus dose 
of acetaminophen resulted in a 2-fold greater recovery of acetaminophen 
glucuronide in bile (16 ± 4% of dose) compared to perfusate (8 ± 2% of dose) 
(51).  In contrast, after a 1 g dose of paracetamol in humans the bile (1.2 mg) to 
urine (433.9 mg) recovery ratio of paracetamol glucuronide was 0.31% (52, 53). 
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  The methods for determining species differences in drug transport are 
improving.  Transfected systems expressing each species-specific isoform of a 
given transport protein in the same cell line are becoming available, and some 
comparisons have been published.  This allows for investigation of differences in 
affinity or Km.  Furthermore, as mentioned above, methods to quantify absolute 
levels of transport proteins are being developed and published using LC-MS/MS 
methodology allowing for differences in Vmax to be assessed.  However, this is for 
total protein in the cell.  Utilizing methods to isolate the membrane fraction (54) 
would be more useful for determining the amount of functional protein. Lastly, 
species differences in basolateral and canalicular efflux in hepatocytes can be 
assessed in isolated perfused livers. However, in order to assess differences in 
humans, novel approaches are needed. Sandwich-cultured hepatocytes may be 
one system that can be used to address this issue.   
 This does call into question the usefulness of preclinical species to predict 
the human transport proteins involved in disposition and underlines the issue with 
extrapolating clearance across species to predict human clearance.  There are 
many available tools to study in vitro uptake and efflux of drugs with human 
materials.  However, the extrapolation to in vivo is limited due to the lack of 
corresponding in vivo kinetic parameters for determining the scaling factors to 
extrapolate the in vitro parameters to in vivo.  The use of radiolabeled probes will 
facilitate the in vitro-in vivo extrapolation by quantifying tissue concentrations, 
which are useful for obtaining tissue partition coefficients and to calculate 
clearance. 
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Organ Exposure is Not Always Represented by Systemic Concentrations 
 Drug-drug interactions may result in pharmacokinetic changes that alter 
drug efficacy and/or toxicity, especially for drugs that have a narrow therapeutic 
window.  Most of the work on drug-drug interactions is focused on changes in 
absorption, bioavailability or systemic concentrations of a drug.  However, it is 
increasingly being recognized that drug-drug interactions can affect the 
distribution of the victim drug into a particular compartment or tissue without 
significantly affecting the systemic concentration-time profile of that drug  (48, 
55).  For example, drug-drug interactions can result in CNS effects of drugs that 
normally are not targeted to the brain (56).   
The lack of significant changes in systemic exposure, despite increased 
concentrations in a particular compartment (e.g. brain, liver) may be explained by 
a relatively small amount of drug distributing into that particular compartment 
compared to the total amount of drug in the body.  Alternatively, the clearance of 
the drug from the body may be mediated by a different mechanism (e.g. transport 
protein or metabolizing enzyme) than the pathway affected by the drug-drug 
interaction in the organ where the drug distributes.  However, it is difficult to 
assess changes in the exposure of a drug in a particular compartment in vivo.  
The use of noninvasive imaging methods to measure tissue exposure is one 
approach that may address this dilemma.  For example, Sasongko et al. utilized 
the P-gp substrate 11C-verapamil to measure brain concentrations by positron 
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 emission tomography in the presence and absence of the P-gp inhibitor 
cyclosporine.  Data demonstrated an 88% increase in the AUCbrain/AUCblood ratio 
of 11C-radioactivity in the presence of cyclosporine, while the blood-to-plasma 
AUC ratio for 11C-radioacitivity during the 45-min imaging time did not differ 
significantly in the presence and absence of cyclosporine (36).  Furthermore, the 
increase in brain exposure was not confounded by changes in plasma protein 
binding, 11C-verapamil metabolism or cerebral blood flow for this rapidly diffusing 
drug. 
 In this dissertation, pharmacokinetic modeling and simulation studies were 
employed to examine the impact of hepatic transport modulation on the systemic 
and hepatic exposure of fexofenadine in humans.  Simulations revealed that 
systemic fexofenadine concentrations were most sensitive to changes in the 
fexofenadine hepatic uptake rate constant, rather than the basolateral efflux rate 
constant, or the biliary excretion rate constant [Chapter 2, (48)].  In contrast, 
results indicated that hepatic fexofenadine exposure in humans was sensitive to 
alterations in either the hepatic uptake rate constant or the biliary excretion rate 
constant.  Most importantly, the marked increase in fexofenadine hepatic 
exposure due to modulation in biliary excretion was not reflected by changes in 
the systemic concentration-time profile [Chapter 2, (48)].  This demonstrates the 
importance of assessing hepatic exposure; systemic concentrations of a 
substrate like fexofenadine may not accurately reflect hepatic exposure.  A 
similar finding has been shown using a physiologically based pharmacokinetic 
model of pravastatin in humans.  Simulations showed that changes in the hepatic 
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 uptake of pravastatin altered plasma concentrations markedly, but had a minimal 
effect on liver concentrations; in contrast, changes in canalicular efflux of 
pravastatin altered liver concentrations of pravastatin markedly, but had minor 
effects on the plasma concentration (55).  These findings are supported by an 
increase in plasma Cmax and AUC in patients with SNPs that decrease OATP1B1 
function compared to the reference allele (57-59) and decreased inhibitory effect 
on cholesterol synthesis presumably due to decreased concentrations in the 
hepatocytes (60-62).  What is more difficult to determine are changes in hepatic 
concentrations as a result of inhibition of biliary excretion.  Pravastatin is a 
substrate of BCRP, MRP2 and BSEP (63-67).  Ho et al. investigated the effects 
of polymorphisms in the efflux proteins MRP2 (ABCC2), BSEP (ABCB11) and 
BCRP (ABCG2), following a single 40 mg oral dose of pravastatin in healthy 
European-Americans and African-Americans (68).  The ABCC2, ABCB11 or 
ABCG2 genotypes were not associated with differences in pravastatin 
pharmacokinetics and support the findings from the simulations.  However what 
was not assessed were the changes in liver exposure.  This could be ascertained 
by indirectly assessing increases in hepatic concentrations of pravastatin by 
measuring decreases in cholesterol synthesis in patients with reduced BCRP, 
MRP2 and BSEP function through a combination of chemical inhibition and 
naturally occurring genetic deficiencies in these three proteins.   
 Pharmacokinetic modeling is a powerful tool to simulate concentrations in 
non-accessible sampling sites such as the brain and liver.  Physiologically-based 
pharmacokinetic (PBPK) modeling has been utilized extensively to assess tissue 
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 exposure.  However, this is considered more of an in silico approach, and is 
difficult to show experimentally in humans.   In the clinical setting, brain 
concentrations of drugs can be determined by the use of microdialysis, but under 
very special circumstances such as brain surgery.  Moreover, biopsies of a 
particular tissue can be performed, but data analysis will be limited when only a 
single data point is available.  Furthermore, obtaining this data is typically in a 
specific patient population that wouldn’t reflect healthy individuals making it 
difficult to translate the results.  A more reasonable and noninvasive method is to 
assess tissue exposure through the use of radiolabeled (gamma emitters or 
positron emitters) probes.  Imaging studies also allow continuous assessment of 
tissue concentrations of probes over multiple time points.  A radiolabeled probe is 
useful for assessing the effect of inhibitors or inducers due to drug-drug 
interactions particularly when the effect does not result in changes in systemic 
concentrations.  For example, inhibition of MRP2 in the liver may result in 
increased liver concentrations that are not represented in the blood 
compartment.  Therefore, this interaction could be elucidated with the use of 
quantitative scintigraphy when using a radiolabeled probe. 
 
Pharmacokinetic Modeling of Clinical Data Coupled with Quantitative 
Imaging 
 The advantages of quantitative imaging have been discussed above, 
including a noninvasive method for capturing concentration data in a clinical 
282 
 
 setting, the access to compartments (e.g. liver or brain) that are difficult to 
measure directly, and the continuous sampling of data over multiple time points.  
In addition, the ability to obtain tissue concentrations with a radiolabeled probe 
are not limited to a specific setting, as is the case with other methods (i.e. biopsy 
or microdialysis), in which the typical patient population undergoing this 
intervention would not be reflective of healthy individuals.  Combining the 
quantitative imaging data that can be obtained in any patient population with the 
readily accessible blood, urine and/or fecal concentrations allows for the 
construction of a robust pharmacokinetic model to describe the disposition of a 
radiolabeled probe.   
 Applying quantitative imaging data is advantageous in building a PBPK  
model.  These types of models are difficult to build to predict the disposition and 
elimination of a drug in humans due to the quality of the data sets.  Often data 
from preclinical species must be scaled up to assist model development.  With 
the use of tissue concentrations obtained from imaging, a more robust PBPK 
model can be developed.  An important parameter necessary for building a 
PBPK model and for describing the steady-state concentration of a drug in a 
tissue compared with blood is the partition coefficient for that tissue.  This 
parameter can be estimated with the use of imaging when the tissue 
concentration-time profile reaches equilibrium distribution with the blood 
concentration-time profile.   
 Further application of a complex pharmacokinetic model incorporating 
quantitative imaging can be used to assess interindividual differences in discrete 
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 drug handling pathways (e.g. metabolizing enzymes and transport proteins).  
99mTc-MIBI and an analog of 99mTc-MEB have been applied as probe substrates 
to phenotype hepatic transport protein function.  In an attempt to individualize 
dosing and reduce toxicity the time activity curves of 99mTc-MIBI and an analog of  
99mTc-MEB  were correlated with the pharmacokinetics of two anticancer drugs, 
vinorelbine and irinotecan (9, 10).  However, these studies did not quantify the 
scintigraphy data or attempt to model the data to further define interindividual 
differences in hepatic drug transport responsible for clearance of the two 
anticancer drugs.  Examining the relationship between hepatic functional imaging 
of 99mTc-MEB and 99mTc-MIBI and the pharmacokinetics of drugs used in the 
treatment of patients with inoperable HCC and Child’s B cirrhosis may assist in 
the development of individualized dosage regimens. This approach may be 
particularly valuable for drugs that exhibit a narrow range between therapeutic 
and toxic concentrations and a wide inter-subject variability in clearance and may 
be useful in optimizing efficacy.  This approach is being utilized in an ongoing 
clinical study to individualize sorafenib dosing and decrease toxicity in patients 
with hepatocellular carcinoma and Child’s Pugh B cirrhosis.  Both 99mTc-MEB and 
99mTc-MIBI are being used to assess individual variability in hepatic uptake and 
biliary excretion, and parameters generated from the functional hepatic nuclear 
imaging will be correlated with sorafenib pharmacokinetics and toxicity. 
 In conclusion, pharmacokinetic modeling of clinical data coupled with 
quantitative imaging is a powerful tool to describe the distribution and elimination 
of radiolabeled probes to elucidate changes in clearance pathways (e.g. 
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metabolizing enzymes and transport proteins) due to drug-drug interactions, 
genetic polymorphism or disease state modifications.  Furthermore, application of 
this tool to assess and explain interindividual differences in drug clearance 
mechanisms may help reduce toxicity while optimizing efficacy.  Alterations in 
critical rate constants representing key clearance mechanisms may be useful in 
predicting changes in drug disposition, and potential drug action, for therapeutic 
compounds that are handled by mechanisms similar to the radiolabeled probes. 
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Influence of Seeding Density and Extracellular Matrix on Bile Acid 
Transport and Mrp4 Expression in Sandwich-Cultured Mouse Hepatocytes 
 
 
 
 
 
 
 
 
This chapter has been accepted for publication in Molecular Pharmaceutics and 
is presented in the style of that journal. 
 Abstract 
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This study was undertaken to examine the influence of seeding density, 
extracellular matrix and days in culture on bile acid transport proteins and 
hepatobiliary disposition of the model bile acid taurocholate.  Mouse hepatocytes 
were cultured in a sandwich configuration on six-well BiocoatTM plates with an 
overlay of MatigelTM (BC/MG) or gelled-collagen (BC/GC) for 3 or 4 days at 
seeding densities of 1.0, 1.25 or 1.5 x 106 cells/well.  The lower seeding densities 
of 1.0 and 1.25 x 106 cells/well resulted in good hepatocyte morphology and bile 
canalicular network formation, as visualized by 5- (and 6)-carboxy-
2’,7’dichlorofluorescein accumulation.  In general, taurocholate cellular 
accumulation tended to increase as a function of seeding density in BC/GC; 
cellular accumulation was significantly increased in hepatocytes cultured in 
BC/MG compared to BC/GC at the same seeding density on both days 3 and 4 
of culture. In vitro intrinsic biliary clearance of taurocholate was increased 
significantly in hepatocytes seeded at 1.0 x 106 cells/well compared to 1.5 x 106 
cells/well on day 4 of culture.  Levels of bile acid transport proteins on days 3 and 
4  were not markedly influenced by seeding density or extracellular matrix except 
for multidrug resistance protein 4 (Mrp4), which was inversely related to seeding 
density.  Mrp4 levels decreased ~2- to 3-fold between seeding densities of 1.0 x 
106 and 1.25 x 106 cells/well regardless of extracellular matrix; an additional ~3- 
to 5-fold decrease in Mrp4 protein was noted in BC/GC between seeding 
densities of 1.25 x 106  and 1.5 x 106 cells/well.  Results suggest that seeding 
density, extracellular matrix and days in culture profoundly influence Mrp4 
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expression in sandwich-cultured mouse hepatocytes.  Primary mouse 
hepatocytes seeded in a BC/MG configuration at densities of 1.25 x 106 cells/well 
and 1.0 x 106, and cultured for 3 days, yielded optimal transport based on the 
probes studied. This work demonstrates the applicability of the sandwich-cultured 
model to mouse hepatocytes.   
 Introduction 
Primary hepatocytes are a widely accepted in vitro tool to evaluate hepatic 
drug uptake, metabolism and cytochrome P450 induction.  Maintaining 
hepatocytes between two layers of gelled collagen (sandwich-culture 
configuration) facilitates the development of intact canalicular networks, 
reestablishment of polarized excretory function and maintenance of hepatic 
transport protein expression and function 1-5.  Dunn et al. first demonstrated that 
the sandwich configuration enhanced the morphology and viability of 
hepatocytes, and helped maintain normal secretion of many liver-specific 
proteins and organic compounds 6-8.  Subsequent studies have demonstrated 
that the sandwich configuration facilitates the formation of gap junctions and 
functional bile canalicular networks during culture 2, 3.  Several studies also have 
shown that sandwich-cultured hepatocytes are capable of performing a wide 
variety of cellular functions normally attributed to hepatocytes in vivo including 
albumin secretion, bile acid synthesis and excretion, and P450 enzyme induction, 
especially when compared to hepatocytes cultured under conventional conditions 
2, 3, 8-11. 
Sandwich-cultured hepatocytes have been used to investigate hepatic 
accumulation and excretion of a wide variety of substrates 12-14.  In fact, the in 
vitro intrinsic biliary clearance generated from the sandwich-cultured hepatocyte 
model has been shown to correlate with in vivo biliary clearance data in rats 15, 16 
and humans 17, 18.  Thus, the sandwich-cultured hepatocyte model is very 
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 promising for characterizing biliary excretion and the hepatic disposition of drug 
candidates.  With all relevant hepatic transport proteins and xenobiotic 
metabolizing enzymes expressed, substrate uptake, metabolism, and 
parent/metabolite efflux can be assessed.  Recent work has demonstrated that 
sandwich-cultured primary mouse hepatocytes maintain metabolic competence 
longer than rat hepatocytes based on gene expression profiles and cytochrome 
P450 activity 19.  Furthermore, the application of this method to hepatocytes from 
gene-disrupted mice in which specific transport proteins have been knocked out 
may provide new insight into the many roles of hepatic transport proteins.  
Numerous investigators have examined the influence of culture conditions on 
hepatic transport protein expression and function in sandwich-cultured rat and 
human hepatocytes 9, 20-23.  However, culture conditions have not been optimized 
for transport protein expression and function in sandwich-cultured mouse 
hepatoctyes.  As interest grows in utilizing the phenotypic diversity of various 
mouse strains (e.g., the Collaborative Cross 24) to predict drug-induced 
hepatotoxicity, higher throughput screening systems, such as sandwich-cultured 
mouse hepatocytes, may prove to be particularly useful.  
Hepatic transport proteins play an important role in the vectorial transport 
of bile acids from sinusoidal blood into the bile canaliculi.  Sodium taurocholate 
cotransporting polypeptide (Ntcp) is expressed exclusively in the liver and 
mediates sodium-dependent uptake of bile acids 25, 26.  The organic anion-
transporting polypeptides (Oatps), also localized on the basolateral membrane, 
translocate bile acids in a sodium-independent manner 26.  The multidrug 
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resistance proteins 3 and 4 (Mrp3 and Mrp4) are involved in the basolateral 
excretion of bile acids from the hepatocyte across the sinusoidal membrane into 
blood 27-29.  In addition, data generated in mice deficient in the organic solute 
transporter (Ost)-α subunit have suggested that Ostα-Ostβ, a heteromeric 
organic solute and steroid transporter, also is involved in the basolateral efflux of 
bile acids 30.  The apical (canalicular) transport proteins involved in biliary 
excretion of bile acids include the bile salt export pump (Bsep) 31, the multidrug 
resistance protein 2 (Mrp2) 32, 33 and more recently, multidrug resistance P-
glycoprotein (Mdr1a/1b) 34.  Interestingly, triple knockout mice deficient in 
Mdr1a/1b and Bsep exhibited a significantly more severe phenotype than bsep-/- 
and wild-type mice, including impaired bile formation, jaundice, flaccid 
gallbladder and hepatic inflammation 34. 
The purpose of the present studies was to examine the influence of 
seeding density, extracellular matrix and days in culture on hepatic bile acid 
transport protein expression and taurocholate hepatobiliary disposition.  The 
criteria used for the selection of optimal conditions were hepatocyte morphology, 
transport protein expression, substrate accumulation, as well as the biliary 
excretion index (BEI) and biliary clearance (in vitro Clbiliary) of taurocholate. 
 
 
 
 Experimental Details 
Materials. Dulbecco’s modified Eagle’s medium (DMEM), MEM non-essential 
amino acids solution (100x), L-glutamine, insulin, penicillin G-streptomycin 
solution, and 5- (and 6)-carboxy-2’,7’dichlorofluorescein (CDF) diacetate 
(CDFDA) were purchased from Invitrogen (Carlsbad, CA).  Collagenase (type 4), 
fetal bovine serum (FBS), sodium taurocholate, Triton X-100, dexamethasone, 
and Hanks’ balanced salt solution (HBSS) modified with (H-1387) or without (H-
4891) calcium chloride were obtained from Sigma-Aldrich (St. Louis, MO). 
BioCoat™ collagen I plates, Matrigel™ basement membrane matrix, rat tail 
collagen (type I), and ITS+™ (insulin/transferrin/selenium) culture supplement 
were purchased from BD Biosciences Discovery Labware (Bedford, MA).  
[3H]Taurocholate (5 Ci/mmol, >97% purity) was obtained from PerkinElmer Life 
and Analytical Sciences (Boston, MA). Bio-Safe II™ liquid scintillation cocktail 
was obtained from Research Products International (Mt. Prospect, IL). 
Bicinchoninic acid (BCA) protein assay reagents and BSA for the protein assay 
standard were purchased from Pierce Chemical Co. (Rockford, IL). All other 
chemicals and reagents were of analytical grade and available from commercial 
sources. 
Isolation and In Vitro Culture of Primary Mouse Hepatocytes 
Male C57BL/6 mice (27.7-30.3 g) were purchased from Charles River 
Laboratories, Inc. (Raleigh, NC).  Mice had free access to water and food prior to 
surgery.  All animal procedures complied with the guidelines of the Institutional 
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 Animal Care and Use Committee (University of North Carolina, Chapel Hill, NC).  
Hepatocytes were isolated by a two-step collagenase perfusion, as described 
previously 35, with modifications.  The inferior vena cava was cannulated and 
buffers were perfused retrograde to blood flow.  Cell viability, determined by 
trypan blue exclusion, was 89–93%.  In pilot studies, hepatocytes were seeded 
on six-well plates with gelled collagen solution, as described previously 21, or six-
well BiocoatTM plates.  In subsequent studies, hepatocytes were seeded at 1.0, 
1.25 or 1.5 x 106 cells/well in 6-well BioCoat™ plates in DMEM without phenol red 
supplemented with 2 mM L-glutamine, 1% (v/v) MEM non-essential amino acids, 
100 units penicillin G sodium, 100 µg streptomycin sulfate, 1 µM 
dexamethasone,  5% (v/v) FBS, and 10 µM insulin (day 0 of culture), and allowed 
to attach for 2-6 h in a humidified incubator (95% O2, 5% CO2) at 37oC. After cell 
attachment, culture plates were swirled gently and the culture medium was 
replaced with the same medium.  Cells were overlaid 16-24 h (day 1 of culture) 
after seeding with ice-cold Matrigel™ basement membrane matrix (BC/MG) or 
gelled collagen (BC/GC).  Matrigel was overlaid at a concentration of 0.25 mg/mL 
in 2 mL/well cold serum-free DMEM containing 2 mM  L-glutamine, 1% (v/v) 
MEM non-essential amino acids, 100 units penicillin G sodium, 100 µg 
streptomycin sulfate, 0.1 µM dexamethasone, and 1% (v/v) ITS+™.  Gelled 
collagen solution (~1.5 mg/mL) was prepared by adding 4 mL of rat tail type I 
collagen, 4 mL sterile deionized water, and 1 mL of 10X DMEM, and the pH was 
adjusted to 7.4 with 2N NaOH.  Hepatocyte cultures were aspirated and the 
monolayer was overlaid with 0.1 mL/well of ice-cold neutralized type I gelled 
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 collagen and placed at 37°C in a humidified incubator for ~1 hour to allow the 
matrix to gel, followed by the addition of 1.5 mL/well of warm DMEM with the 
same supplements as the cells overlaid with matrigel.  The culture medium was 
changed every 24 h until experiments were performed on day 3-4 of culture. 
Accumulation Experiments 
The method to determine substrate accumulation in sandwich-cultured 
hepatocytes has been described previously 16. Briefly, hepatocytes were rinsed 
twice with 2 mL warm HBSS containing Ca2+ (standard buffer) or Ca2+-free 
HBSS, and incubated with 2 mL of the same buffer for 10 min at 37oC to maintain 
tight junction integrity and bile canalicular networks (cells+bile), or disrupt tight 
junctions and open bile canalicular networks (cells), respectively. The buffer was 
removed, and the cells were incubated for 10 min at 37oC with 1.5 mL of 
[3H]taurocholate (1 µM) or CDFDA (2 µM) in standard buffer. Hepatocytes were 
rinsed vigorously three times with 2 mL ice-cold standard buffer following the 
incubation. CDFDA-treated hepatocytes were viewed immediately and digital 
images captured with a Zeiss Axiovert 200TV inverted phase contrast 
microscope.  Taurocholate-treated hepatocytes were lysed with 1 mL 0.5% (v/v) 
Triton X-100 in phosphate-buffered saline by placing plates on an orbital shaker 
for a minimum of 20 min at room temperature. Taurocholate uptake was 
corrected for nonspecific binding by subtracting uptake on blank six-well 
BiocoatTM plates overlaid with MatrigelTM or gelled collagen.  Data were 
normalized to protein concentration in each well, determined in duplicate aliquots 
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 using BCA protein assay reagent kit (Pierce) as instructed by the manufacturer.  
BSA, as supplied by the manufacturer, was used as a standard (0.2–2 mg/mL).  
The [3H]taurocholate samples were analyzed by liquid scintillation spectroscopy 
in a Packard Tri-Carb scintillation counter (PerkinElmer Life and Analytical 
Sciences).  
Cytotoxicity Assay. 
The activity of lactate dehydrogenase (LDH), a stable cytosolic enzyme that is 
released upon cell lysis, was measured in the medium of sandwich-cultured 
hepatocytes using a cytotoxicity kit according to the manufacturer’s instructions 
(Roche, Indianapolis, IN).  The degree of LDH release was expressed as a 
percentage of the maximum cellular LDH release, measured by adding 0.5% 
Triton X-100 to sandwich-cultured mouse hepatocytes at each seeding density. 
Immunoblots. 
Cells were washed once with HBSS, and resuspended in lysis buffer consisting 
of 1% SDS, 1 mM EDTA and Complete protease inhibitor cocktail tablets (Roche 
Diagnostics, Mannheim, Germany).  Protein concentrations were determined by 
the BCA assay.  Whole-cell lysates (30-40 µg) were resolved on NuPAGE 4 to 
20% Bis-Tris gel (Invitrogen Corp, Carlsbad, CA) and the proteins were 
transferred to polyvinylidene difluoride (PVDF) membranes.  After blocking in 5% 
milk-Tris-buffered saline with Tween 20 (TBST) for 30 min, blots were incubated 
overnight at 4°C with the following antibodies: Mrp2 (Abcc2; M2III-6), Mrp3 
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 (Abcc3; M3II-21), Mrp4 (Abcc4; M4I-10), Mdr1a/1b (Abcb1; C-219), Breast 
cancer resistance protein [Bcrp (Abcg2); BXP-53], which were supplied by Alexis 
Biochemicals, San Diego, CA; Bsep (Abcb11; K44) and Ntcp (Slc10a1; K4), 
which were a kind gift from Drs. Bruno Stieger and Peter Meier; and β-actin (C4, 
Chemicon, San Francisco, CA).  After incubation with HRP-conjugated 
secondary antibody, signals were detected by chemiluminescent substrate 
Supersignal West Dura (Pierce, Rockford, IL) with a Bio-Rad VersaDoc imaging 
system; densitometry analysis was performed using Quantity One v4.1 software 
(Bio-Rad Laboratories, Hercules, CA). 
Data Analysis 
For accumulation studies, the biliary excretion index (BEI, %) and in vitro intrinsic 
biliary clearance (Clbiliary, mL/min/kg) were calculated using B-CLEAR® 
technology (Qualyst, Inc., Raleigh, NC;16):  
 
100
onAccumulati
onAccumulationAccumulati
BEI
BileCells
CellsBileCells ×−=
+
+                                (1) 
 
where substrate accumulation in the cells+bile compartments was determined in 
hepatocytes preincubated in standard buffer; cellular accumulation of substrate 
was determined in hepatocytes preincubated with Ca2+-free HBSS.  
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where AUC0-T represents the product of the incubation time (T) and the initial 
taurocholate concentration in the medium.  In vitro Clbiliary values were scaled per 
kilogram body weight using 0.63, 0.72 and 0.78 mg protein per 1.0, 1.25, and 1.5 
x 106 cells, respectively (the average value obtained in all preparations), 135 x 
106 hepatocytes/g of mouse liver tissue 36,  and 87.5 g of liver tissue per kg of 
body weight (1.75 g/ 0.02 kg mouse) 37.   
 Statistical analysis of the [3H]taurocholate cellular accumulation and in 
vitro intrinsic biliary clearance data was performed using a three-way analysis of 
variance for the factors of day in culture, seeding density and extracellular matrix, 
with Bonferroni’s post hoc test (SAS version 9.1, Cary, NC). 
 Results 
Sandwich-Cultured Mouse Hepatocyte Viability and Bile Canalicular 
Network Formation 
Initial experiments plating mouse hepatocytes on gelled collagen plates resulted 
in decreased attachment and adherence after overlay compared to BiocoatTM 
plates.  Therefore, subsequent experiments utilized BiocoatTM plates only, on 
which hepatocytes flattened to form confluent monolayers.  Hepatocyte 
morphology was evaluated by light microscopy, and canalicular network 
formation was determined by CDF imaging.  Mouse hepatocytes cultured in 
sandwich-configuration and maintained in DMEM for up to 4 days were cuboidal 
in shape and formed extensive canalicular networks (Fig. A.1.1 and A.1.2).  The 
intensity of CDF accumulation in the bile canaliculi appeared to be more 
extensive in mouse hepatocytes cultured in the BC/GC configuration compared 
to the BC/MG configuration based on visual inspection; the BC/MG matrix 
appeared to have greater intracellular accumulation of CDF compared to BC/GC.  
Based on the light microscopy images, the higher seeding density of 1.5 x 106 
cells/well resulted in greater accumulation of dead cells and debris compared to 
the lower seeding densities (Fig. A.1.1 and A.1.2).  Based on LDH leakage, cell 
death primarily occurred in the first 24 hr before overlay; medium LDH levels 
during the first 24 hr after plating reached ~25% of Triton X-100 control.  
Cumulative LDH leakage after overlay through day 4 in culture was negligible (< 
306 
 
 12% of Triton X-100 control), regardless of seeding density or extracellular matrix 
(data not shown).    
 
Transport Protein Expression 
Representative immunoblots of Ntcp, Mrp4, Mrp3, Mrp2, Bsep, Bcrp, and 
Mdr1a/1b in sandwich-cultured mouse hepatocytes seeded at different densities 
on BC/MG and BC/GC are shown in Figure A.1.3.  Relevant bile acid transport 
proteins were expressed in sandwich-cultured mouse hepatocytes by day 3; 
culture configuration and seeding density had modest effects on Mrp3, Mrp2, 
Bcrp, Ntcp Mdr1a/1b or Bsep protein. Interestingly, Mrp4 protein increased (~2-
fold or greater) as seeding density decreased, regardless of extracellular matrix 
on both day 3 and 4 (Fig. A.1.3 and A.1.4).   
Hepatobiliary Disposition of the Model Bile Acid Taurocholate 
 The influence of seeding density, overlay matrix composition and days in culture 
on the accumulation and biliary excretion of [3H]taurocholate was assessed in 
sandwich-cultured mouse hepatocytes.  Cellular accumulation of [3H]taurocholate  
was significantly lower on day 4 compared to day 3 (Fig. A.1.5).  
[3H]Taurocholate cellular accumulation tended to increase as a function of 
seeding density for BC/GC; [3H]taurocholate cellular accumulation was 
significantly greater in mouse hepatocytes cultured in the BC/MG  configuration 
compared to the BC/GC configuration at each seeding density on both days 3 
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and 4 of culture (Fig. A.1.5).  In vitro intrinsic biliary clearance of taurocholate 
significantly increased comparing 1.0 x 106 cells/well to 1.5 x 106 cells/well, 
taurocholate BEI values were not significantly different across seeding density 
(Table A.1.1).    
 Discussion 
 Sandwich-cultured primary hepatocytes have been used extensively to 
study hepatic uptake, metabolism and efflux.  To date, limited data have been 
published utilizing sandwich-cultured mouse hepatocytes to study hepatic 
transport mechanisms and biliary excretion.  Previous reports have demonstrated 
the influence of culture conditions including the type of culture media, media 
supplements, extracellular matrix and confluency on cell morphology, bile 
canalicular network formation, substrate accumulation and BEI in both rat and 
cryopreserved human hepatoctyes 20-22.  In the present study, the influence of 
seeding density, extracellular matrix and days in culture on protein levels of bile 
acid transporters, and the hepatobiliary disposition of taurocholate in sandwich-
cultured mouse hepatocytes were assessed.   
 Both extracellular matrix overlay and seeding density had profound effects 
on the health, morphology, and bile canalicular network formation of sandwich-
cultured mouse hepatocytes.  The cell morphology of mouse hepatocytes 
cultured on BiocoatTM plates was similar to prior observations with rat 
hepatocytes; cells spread out to form a confluent monolayer resulting in a 
flattened appearance on this rigid collagen when compared to hepatocytes 
cultured on gelled collagen 2, 22.  Mouse hepatocytes overlaid with MatrigelTM 
(BC/MG) exhibited a similar attachment efficiency and cell morphology compared 
to those overlaid with gelled collagen (BC/GC).  However, MatrigelTM provides a 
more uniform, reproducible overlay.  CDFDA, which is hydrolyzed to fluorescent 
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 CDF inside hepatocytes, is a good Mrp2 probe substrate 38 that has been used 
extensively to visualize the bile canaliculi 2, 20, 21.  CDF was excreted into bile 
canaliculi in all culture conditions.  However, more CDF accumulation in bile 
canalicular networks was observed by fluorescense microscopy in BC/GC 
compared to BC/MG at lower seeding densities, which may be attributed to more 
extensive formation of bile canalicular networks (Fig. A.1.1 and A.1.2).  Although 
levels of Mrp2 protein were similar across extracellular matrix and days in culture 
(Fig. A.1.3), differences in the amount of functional Mrp2 protein on the apical 
membrane also may contribute to the increased accumulation of CDF in bile 
canalicular networks observed at the lower seeding densities.  Furthermore, CDF 
intracellular accumulation was greater in mouse hepatocytes cultured on BC/MG 
compared to BC/GC based on visual inspection of the  fluorescent images (Fig. 
A.1.1 and A.1.2); similar findings were noted for taurocholate cellular 
accumulation (Fig. A.1.5).   
Mouse hepatocytes seeded at 1.5 x 106 cells/well resulted in greater 
accumulation of dead cells and decreased network formation, as visualized by 
CDF.  Cell death occurred primarily during the first day of culture, shortly after 
hepatocytes were seeded, based on LDH measurements.  Most of the 
unattached and dead cells were washed away when the medium was changed at 
24 hr, prior to overlay, but some cell debris presumably was stuck to the 
collagen, as visualized in Fig. A.1.1 and A.1.2.   The cell death observed in this 
study may be attributed primarily to  collagenase digestion used during 
hepatocyte isolation, which has been shown by many investigators to influence 
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 cell viability 39-42, and cannot be explained by complete consumption of nutrients 
or growth factors in the cell medium.  Greater cell death at higher seeding 
densities was similar to findings observed in mouse hepatocytes cultured at an 
overconfluent stage, which resulted in cell death by apoptosis 43.  The 
observation that mouse hepatocytes perform better at a lower seeding density 
compared to other species (rat and human hepatocytes typically are seeded at 
~1.75 x 106 cells/well on 6-well plates 44, 45) may be attributed to the increased 
oxygen demand in vivo in mice (liver blood flow in mice is ~90 ml/min/kg 
compared to ~55.2 and ~20.7 ml/min/kg in rats and humans, respectively 37. 
 Overlay matrix composition (BC/MG or BC/GC) and days in culture (day 3 
or 4) appeared to have little effect on protein levels of Bsep, Bcrp, Ntcp, Mrp3, 
Mrp2 and Mdr1a/1b in sandwich-cultured mouse hepatocytes.  Surprisingly, 
protein levels of Ntcp were well-maintained compared to sandwich-cultured rat 
hepatocytes, where significant down-regulation of Ntcp protein 3 (~80% decrease 
46) and a ~75-80% decrease in mRNA 47 have been reported over days in 
culture.     
Another profound observation noted in the present studies was that Mrp4 
protein levels were higher at lower seeding densities (Fig. A.1.3 and A.1.4).  
Mrp4 is localized on the basolateral membrane of hepatocytes and has been 
shown to efflux bile acids in a glutathione-dependent manner 28.  Mrp4 plays an 
important role in detoxifying the liver; bile-duct ligated Mrp4-/- mice exhibited 
increased liver toxicity based on histological analysis, with a 4-fold decrease in 
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 serum bile acid concentrations and increased serum liver enzymes, compared to 
bile duct-ligated wild-type mice 48.  Although, levels of the basolateral efflux 
transport protein Mrp3 were increased modestly in common bile duct-ligated 
mice compared to sham-operated controls 49,  in bile duct-ligated mice lacking 
Mrp3, serum and liver bile acid concentrations were similar compared to sham-
operated wild-type controls 50, 51.  Furthermore, Mrp4 protein was increased more 
than 2-fold in bile duct-ligated wild-type mice while Mrp3 protein was unchanged 
compared to sham-operated wild-type controls 48.  As an adaptive response to 
cholestasis, Mrp3 and Mrp4 are upregulated to efflux bile acids across the 
basolateral membrane, thereby reducing intracellular accumulation of bile acids 
in hepatocytes and subsequent toxicity due to the detergent effects on the cell 
membrane and resulting mitochondrial dysfunction 52, 53.  When mouse 
hepatocytes were seeded at 1 x 106 cells/well, less bile canalicular networks 
formed compared to those seeded at 1.25 x 106 cells/well (Fig. A.1.1 and A.1.2), 
potentially leading to increased hepatocellular accumulation of endogenous bile 
acids and upregulation of Mrp4 as a compensatory mechanism; no change in 
Mrp3 protein was observed in sandwich-cultured mouse hepatocytes across 
extracellular matrix and days in culture (Fig. A.1.3). 
 Taurocholate accumulation in mouse hepatocytes cultured on both 
BC/MG and BC/GC supported the observation that Mrp4 protein decreased as a 
function of increased seeding density (Fig. A.1.4 and A.1.5).  Clearly, on day 4 of 
culture, cellular accumulation (white bars) of [3H]taurocholate increased from 
93.6 to 121 pmol/mg protein in BC/MG, and from 49.2 to 83.0 pmol/mg protein in 
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 BC/GC in mouse hepatocytes seeded at 1.0 x 106  and 1.5 x 106 cells/well, 
respectively (Fig. A.1.5).  This could not be attributed to differences in the 
primary bile acid transport proteins because total protein levels of Ntcp, Mdr1a/1b 
and Bsep were similar across seeding density and collagen matrix (Fig. A.1.4).  
However, Mrp4 was decreased ~3-fold when mouse hepatocytes were seeded at 
a density of 1.0 x 106 cells/well compared to 1.25 x 106 cells/well on BC/MG, and 
decreased ~8-fold when mouse hepatocytes were seeded at a density of 1.0 x 
106 cells/well compared to 1.5 x 106 cells/well on BC/GC (Fig. A.1.4).  Perhaps 
the increased Mrp4 expression at lower seeding densities resulted in redirection 
of some taurocholate excretion across the basolateral rather than the canalicular 
membrane, thus reducing the cellular accumulation of taurocholate compared to 
the higher seeding density in which Mrp4 expression was ~3- to 8-fold lower and 
cellular accumulation was higher (Table A.1.1, Fig. A.1.4).  Furthermore, the 
cellular accumulation of [3H]taurocholate in BC/MG was higher than BC/GC for all 
seeding densities, whereas Mrp4 protein was lower in BC/MG compared to 
BC/GC for all seeding densities.   
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  The hepatocyte accumulation of [3H]taurocholate in sandwich-cultured 
mouse hepatocytes was increased when compared to sandwich-cultured rat and 
human hepatocytes.  The cellular accumulation of taurocholate on day 3 
following a 10-min incubation with 1 µM [3H]taurocholate in sandwich-cultured 
mouse hepatocytes seeded at 1.5 x 106 cells/well was 187 ± 16  and 116 ± 3 
pmol/mg protein on BC/MG and BC/GC, respectively (Fig. A.1.5).  This was 
much greater than the reported cellular accumulation of taurocholate on day 4 
 
 following a 10-min incubation with 1 µM [3H]taurocholate in sandwich-cultured rat 
hepatocytes on BC/MG and BC/GC (<1044, 54 and ~5016  pmol/mg protein, 
respectively), or day 7 sandwich-cultured human hepatocytes (67.0 ± 25.018 and 
65.8 ± 11.355 pmol/mg protein, both cultured on BC/MG).  The in vitro intrinsic 
biliary clearance also was greater in mouse sandwich-cultured hepatocytes 
relative to rat and human sandwich-cultured hepatocytes.  On day 3, the in vitro 
Clbiliary in mouse sandwich-cultured hepatocytes seeded at 1.5 x 106 cells/well on 
BC/MG and BC/GC, was 73.7 ± 24.6 and 96 ± 21.1 mL/min/kg, respectively, 
compared to 34.9 ± 12.044 and ~5516 mL/min/kg, respectively, in day 4 rat 
sandwich-cultured hepatocytes, and 15.8 ± 4.518 and 15.2 ± 5.055 mL/min/kg 
(both cultured on BC/MG only) in day 7 human sandwich-cultured hepatocytes.  
The differences in taurocholate accumulation and in vitro intrinsic biliary 
clearance are controlled by the transport proteins responsible for uptake, biliary 
excretion and basolateral efflux of bile acids.  The observed differences are not 
due to the affinity of these hepatic transport proteins for taurocholate in mouse 
compared to rat and human hepatocytes because the Km values for NTCP/Ntcp, 
OATPs/Oatps and BSEP/Bsep are similar between species 48, 56-60.  Km values 
have been reported for human MRP4 (25.8 µM) 27.  Therefore, the reason for 
greater taurocholate accumulation and in vitro intrinsic biliary clearance in 
sandwich-cultured mouse hepatocytes relative to sandwich-cultured rat and 
human hepatocytes may be attributed, in part, to maintenance of Ntcp and 
decreased Mrp4 (Fig. A.1.4) protein when seeded at 1.5 x 106 cells/well.  
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 Alternatively, species-dependent differences in the taurocholate Km for Mrp4 may 
exist. 
Conclusion 
In summary, extracellular matrix, seeding density and days in culture impact 
Mrp4 protein expression, bile canalicular network formation and taurocholate 
hepatobiliary disposition in sandwich-cultured primary mouse hepatocytes.  
Mouse hepatocytes seeded at densities of 1.25 x 106 cells/well, or below, 
resulted in improved attachment, more extensive bile canalicular network 
formation and overall healthier hepatocytes.  Total protein levels of Mrp3, Mrp2, 
Ntcp, Bcrp, Mdr1a/1b and Bsep were similar across seeding density and collagen 
matrix.  Taurocholate accumulation was greater in BC/MG compared to BC/GC, 
and tended to increase as a function of seeding density for BC/GC.  In vitro 
intrinsic biliary clearance was significantly increased comparing 1.0 x 106 
cells/well to 1.5 x 106 cells/well while taurocholate BEI trended to increase 
without reaching significance.  Hepatocellular accumulation and in vitro intrinsic 
biliary clearance of taurocholate were greater on day 3 compared to day 4.  CDF 
biliary excretion also was more extensive on day 3 compared to day 4 suggesting 
more extensive formation of bile canalicular networks.  Primary mouse 
hepatocytes seeded in a BC/MG configuration at densities of 1.25 x 106 and 1.0 
x 106 cells/well, and cultured for 3 days, yielded optimal transport based on the 
probes utilized in this study. This higher-throughput in vitro system could 
maximize the use of gene-disrupted mice from various strains to study hepatic 
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 function and to investigate the influence of gene disruption on hepatobiliary 
drug/metabolite disposition and hepatotoxicity. 
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20, TBST. 
Sodium taurocholate cotransporting polypeptide, Ntcp; multidrug resistance 
protein 4, Mrp4 multidrug resistance protein 3, Mrp3; organic solute transporter, 
Ost; bile salt export pump, Bsep; multidrug resistance protein 2, Mrp2; breast 
cancer resistance protein, Bcrp; multidrug resistance P-glycoprotein, Mdr1a/1b; 
Biliary excretion index, BEI; biliary clearance, in vitro Clbiliary;  Dulbecco’s 
modified Eagle’s medium, DMEM; 5- (and 6)-carboxy-2’,7’dichlorofluorescein 
diacetate, CDFDA; fetal bovine serum, FBS; Hanks’ balanced salt solutio
HBSS; Bicinchoninic acid, BCA, MatrigelTM basement membrane matrix, MG; 
gelled rat tail collagen type I, GC; polyvinylidene difluoride, PVDF;  Tris-buffered 
saline with Tween 
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 Legends 
Figure A.1.1.  Effect of seeding density and extracellular matrix on cell 
morphology and bile canalicular network formation in day 3 sandwich-cultured 
mouse hepatocytes.  Representative (n =3) CDF fluorescence (A – F) and light 
microscopy (G – L) images of mouse hepatocytes cultured in a 
BiocoatTM/MatrigelTM (BC/MG; A-C & G-I) or BiocoatTM/gelled-collagen (BC/GC; 
D-F & J-L) sandwich configuration in six-well plates (maintained with DMEM for 3 
days); seeding densities (1.0, 1.25 or 1.5 x 106 cells/well) are noted at the top of 
each column.  Sandwich-cultured mouse hepatocytes were incubated with 2 µM 
CDFDA for 10 min. 
Figure A.1.2.  Effect of seeding density and extracellular matrix on cell 
morphology and bile canalicular network formation in day 4 sandwich-cultured 
mouse hepatocytes.  Representative (n = 3) CDF fluorescence (A – F) and light 
microscopy (G – L) images of mouse hepatocytes cultured in a 
BiocoatTM/MatrigelTM (BC/MG; A-C & G-I) or BiocoatTM/gelled-collagen (BC/GC; 
D-F & J-L) sandwich configuration in six-well plates (maintained with DMEM for 4 
days); seeding densities (1.0, 1.25 or 1.5 x 106 cells/well) are noted at the top of 
each column.  Sandwich-cultured mouse hepatocytes were incubated with 2 µM 
CDFDA for 10 min. 
Figure A.1.3.  Influence of seeding density, extracellular matrix and day in 
culture on transport protein levels in sandwich-cultured mouse hepatocytes.  
Representative immunoblots of Bcrp, Ntcp, Mrp4, Mrp3, Mrp2, Bsep, and 
Mdr1a/1b in mouse hepatocytes cultured in BiocoatTM/MatrigelTM (BC/MG) or 
BiocoatTM/gelled-collagen (BC/GC) sandwich configuration in six-well plates and 
maintained with DMEM for 3 or 4 days (n = 2).  Β-actin was used as a loading 
control. 
Figure A.1.4.  Relative expression of Mrp4 protein compared with β-actin in 
sandwich-cultured mouse hepatocytes cultured in BiocoatTM/MatrigelTM (BC/MG) 
or BiocoatTM/gelled-collagen (BC/GC) sandwich configuration in six-well plates 
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and maintained with DMEM for 3-4 days.  Densitometry was performed with 
Quantity One software (version 4.1; Bio-Rad, Hercules, CA). 
Figure A.1.5.  Accumulation in cells+bile (black bars) and cells (white bars) after 
a 10-min incubation with 1 µM [3H]taurocholate  in mouse hepatocytes cultured in 
BiocoatTM/MatrigelTM (BC/MG) or BiocoatTM/gelled-collagen (BC/GC) sandwich 
configuration in six-well plates and maintained with DMEM for 3 or 4 days (Mean 
± S.E.M.; n=3). Cellular accumulation (white bars) of [3H]taurocholate  was 
significantly increased on day 3 compared to day 4, and significantly greater 
when cultured in BC/MG configuration compared to the BC/GC configuration on 
both days 3 and 4 of culture. * p < 0.05 
 
 
Tables 
Table A.1.1. Mean biliary excretion index (BEI) and in vitro biliary clearance (in vitro Clbiliary) of 
[3H]taurocholate after a 10-min incubation with 1 µM [3H]taurocholate in sandwich-cultured mouse 
hepatocytes.  (Mean ± SEM; n = 3 per group).  Primary mouse hepatocytes were seeded at designated 
densities and cultured in BiocoatTM/MatrigelTM (BC/MG) or BiocoatTM/gelled-collagen (BC/GC) sandwich 
configuration in six-well plates and maintained with DMEM for 3 or 4 days.  In vitro intrinsic biliary 
clearance of [3H]taurocholate  was significantly increased as a function of seeding density within culture 
day. (†, * 1.0 x 106 is different than 1.25 x 106 and 1.5 x 106 , ** p < 0.05) 
Day in Culture  BC/MG BC/GC 
  1.0 x 10
6 
cells/well 
1.25 x 106 
cells/well 
1.5 x 106 
cells/well 
1.0 x 106 
cells/well 
1.25 x 106 
cells/well 
1.5 x 106 
cells/well 
3 BEI (%) 26.3 ± 10.8 27.6 ± 5.5 29.6 ± 8.2 35.4 ± 3.9 49.9 ± 6.3 46.9 ± 6.4 
In Vitro Clbiliary 
(mL/min/kg)  48.7 ± 20.5 60.4 ± 15.8 73.7 ± 24.6  33.6 ± 7.6 † 84.0 ± 15.6† 96.0 ± 21.1† 
4 
BEI (%) 36.2 ± 9.0 32.5 ± 10.3 34.2 ± 5.0 32.4 ± 7.7 39.9 ± 3.5 43.5 ± 6.4 
In Vitro Clbiliary 
(mL/min/kg)  38.3 ± 5.0** 45.4 ± 10.6 57.8 ± 14.7** 18.0 ± 6.4* 40.4 ± 5.7* 60.3 ± 19.3* 
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 Figure A.1.2. 
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 Figure A.1.5. 
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Chapter 2: Fexofenadine in Single-Pass Perfused TR- Rat livers 
Bile Flow  
8-16-07 Fex only 
Mid Time (min) Tube Weight Total Weight Bile Vol (µl) Bile Flow Rate (µl/min) Normalized to Liver WT 
5 0.4193 0.4569 37.600 3.760 0.3579 
15 0.4247 0.4642 39.500 3.950 0.3760 
25 0.4191 0.4773 58.200 5.820 0.5541 
35 0.4247 0.484 59.300 5.930 0.5645 
45 0.4272 0.4826 55.400 5.540 0.5274 
55 0.4188 0.4709 52.100 5.210 0.4960 
Liver Weight(g) 10.5044 
10-16-07 Fex only 
Mid Time (min) Tube Weight Total Weight Bile Vol (µl) Bile Flow Rate (µl/min) Normalized to Liver WT 
5 0.4247 0.4867 62.000 6.200 0.6046 
15 0.4225 0.4811 58.600 5.860 0.5715 
25 0.4192 0.4837 64.500 6.450 0.6290 
35 0.4216 0.4806 59.000 5.900 0.5754 
45 0.4189 0.4732 54.300 5.430 0.5295 
55 0.4189 0.4821 63.200 6.320 0.6163 
Liver Weight(g) 10.2546 
10-22-07 Fex only 
Mid Time (min) Tube Weight Total Weight Bile Vol (µl) Bile Flow Rate (µl/min) Normalized to Liver WT 
5 0.4183 0.4726 54.300 5.430 0.4199 
15 0.4168 0.4753 58.500 5.850 0.4524 
25 0.4185 0.4747 56.200 5.620 0.4346 
35 0.4213 0.4785 57.200 5.720 0.4423 
45 0.4275 0.4873 59.800 5.980 0.4624 
55 0.4194 0.4919 72.500 7.250 0.5606 
Liver Weight(g) 12.932 
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 10-23-07 Fex only 
Mid Time (min) Tube Weight Total Weight Bile Vol (µl) Bile Flow Rate (µl/min) Normalized to Liver WT 
5 0.4214 0.4698 48.400 4.840 0.4839 
15 0.4189 0.4688 49.900 4.990 0.4989 
25 0.4218 0.472 50.200 5.020 0.5019 
35 0.4169 0.4657 48.800 4.880 0.4879 
45 0.4172 0.465 47.800 4.780 0.4779 
55 0.4216 0.4751 53.500 5.350 0.5349 
Liver Weight(g) 10.0027 
10-24-07 Fex only 
Mid Time (min) Tube Weight Total Weight Bile Vol (µl) Bile Flow Rate (µl/min) Normalized to Liver WT 
5 0.4189 0.4689 50.000 5.000 0.4390 
15 0.4188 0.4747 55.900 5.590 0.4908 
25 0.4253 0.4817 56.400 5.640 0.4952 
35 0.4276 0.4875 59.900 5.990 0.5260 
45 0.4213 0.4828 61.500 6.150 0.5400 
55 0.4277 0.4906 62.900 6.290 0.5523 
Liver Weight(g) 11.3885 
10-17-07 Fex no TC 
Mid Time (min) Tube Weight Total Weight Bile Vol (µl) Bile Flow Rate (µl/min) Normalized to Liver WT 
5 0.4188 0.463 44.200 4.420 0.3578 
15 0.4173 0.4596 42.300 4.230 0.3424 
25 0.4248 0.4651 40.300 4.030 0.3262 
35 0.4188 0.4604 41.600 4.160 0.3367 
45 0.4276 0.4684 40.800 4.080 0.3302 
54 0.4189 0.4594 40.500 4.050 0.3278 
Liver Weight(g) 12.3545 
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 10-29-07 Fex no TC 
Mid Time (min) Tube Weight Total Weight Bile Vol (µl) Bile Flow Rate (µl/min) Normalized to Liver WT 
5 0.4268 0.4735 46.700 4.670 0.4199 
15 0.4214 0.4611 39.700 3.970 0.3570 
25 0.4271 0.4641 37.000 3.700 0.3327 
35 0.4214 0.4631 41.700 4.170 0.3749 
45 0.4211 0.4562 35.100 3.510 0.3156 
54 0.4249 0.4572 32.300 3.230 0.2904 
Liver Weight(g) 11.1219 
11-1-07 Fex no TC 
Mid Time (min) Tube Weight Total Weight Bile Vol (µl) Bile Flow Rate (µl/min) Normalized to Liver WT 
5 0.423 0.4597 36.700 3.670 0.2850 
15 0.4172 0.4544 37.200 3.720 0.2889 
25 0.4178 0.4637 45.900 4.590 0.3565 
35 0.4167 0.4501 33.400 3.340 0.2594 
45 0.4276 0.4599 32.300 3.230 0.2508 
54 0.4293 0.4603 31.000 3.100 0.2407 
Liver Weight(g) 12.8765 
11-8-07 Fex no TC 
Mid Time (min) Tube Weight Total Weight Bile Vol (µl) Bile Flow Rate (µl/min) Normalized to Liver WT 
5 0.4188 0.4478 29.000 2.900 0.2340 
15 0.4217 0.4488 27.100 2.710 0.2187 
25 0.4194 0.4423 22.900 2.290 0.1848 
35 0.4188 0.4391 20.300 2.030 0.1638 
45 0.4224 0.4422 19.800 1.980 0.1598 
54 0.4212 0.4409 19.700 1.970 0.1590 
Liver Weight(g) 12.3932 
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9-7-07 2µM GF120918 
Mid Time (min) Tube Weight Total Weight Bile Vol (µl) Bile Flow Rate (µl/min) Normalized to Liver WT 
5 0.4227 0.4723 49.600 4.960 0.4235 
15 0.4223 0.4772 54.900 5.490 0.4688 
25 0.4193 0.4745 55.200 5.520 0.4713 
35 0.4248 0.478 53.200 5.320 0.4542 
45 0.4194 0.4691 49.700 4.970 0.4244 
55 0.4223 0.476 53.700 5.370 0.4585 
Liver Weight(g) 11.7118 
11-1-07 2µM GF120918 
Mid Time (min) Tube Weight Total Weight Bile Vol (µl) Bile Flow Rate (µl/min) Normalized to Liver WT 
5 0.4277 0.4869 59.200 5.920 0.5527 
15 0.4211 0.48 58.900 5.890 0.5499 
25 0.4244 0.4858 61.400 6.140 0.5732 
35 0.4247 0.4844 59.700 5.970 0.5574 
45 0.4217 0.4804 58.700 5.870 0.5480 
55 0.4215 0.4803 58.800 5.880 0.5490 
Liver Weight(g) 10.7113 
11-26-07 2µM GF120918 
Mid Time (min) Tube Weight Total Weight Bile Vol (µl) Bile Flow Rate (µl/min) Normalized to Liver WT 
5 0.4191 0.4632 44.100 4.410 0.4115 
15 0.422 0.4803 58.300 5.830 0.5441 
25 0.4216 0.4797 58.100 5.810 0.5422 
35 0.4174 0.4738 56.400 5.640 0.5263 
45 0.4278 0.4843 56.500 5.650 0.5273 
55 0.4218 0.4761 54.300 5.430 0.5067 
Liver Weight(g) 10.7159 
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10-16-07 5µM Bosentan 
Mid Time (min) Tube Weight Total Weight Bile Vol (µl) Bile Flow Rate (µl/min) Normalized to Liver WT 
5 0.4186 0.453 34.400 3.440 0.3082 
15 0.4276 0.4715 43.900 4.390 0.3933 
25 0.4223 0.4702 47.900 4.790 0.4292 
35 0.4229 0.4781 55.200 5.520 0.4946 
45 0.4193 0.4788 59.500 5.950 0.5331 
55 0.427 0.4838 56.800 5.680 0.5089 
Liver Weight(g) 11.1608 
10-26-07 5µM Bosentan 
Mid Time (min) Tube Weight Total Weight Bile Vol (µl) Bile Flow Rate (µl/min) Normalized to Liver WT 
5 0.429 0.4955 66.500 6.650 0.6783 
15 0.4188 0.4866 67.800 6.780 0.6916 
25 0.4218 0.4958 74.000 7.400 0.7548 
35 0.4222 0.5002 78.000 7.800 0.7956 
45 0.4246 0.4983 73.700 7.370 0.7518 
55 0.423 0.4942 71.200 7.120 0.7263 
Liver Weight(g) 9.8036 
10-29-07 5µM Bosentan 
Mid Time (min) Tube Weight Total Weight Bile Vol (µl) Bile Flow Rate (µl/min) Normalized to Liver WT 
5 0.4173 0.477 59.700 5.970 0.4750 
15 0.4216 0.4863 64.700 6.470 0.5147 
25 0.4247 0.491 66.300 6.630 0.5275 
35 0.4216 0.4916 70.000 7.000 0.5569 
45 0.4246 0.5019 77.300 7.730 0.6150 
55 0.4248 0.5011 76.300 7.630 0.6070 
Liver Weight(g) 12.5695 
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 10-31-07 5µM Bosentan 
Mid Time (min) Tube Weight Total Weight Bile Vol (µl) Bile Flow Rate (µl/min) Normalized to Liver WT 
5 0.4192 0.4957 76.500 7.650 0.6354 
15 0.4225 0.4901 67.600 6.760 0.5615 
25 0.4248 0.4984 73.600 7.360 0.6113 
35 0.4183 0.4966 78.300 7.830 0.6503 
45 0.4217 0.4996 77.900 7.790 0.6470 
55 0.4167 0.4948 78.100 7.810 0.6487 
Liver Weight(g) 12.04 
 
Perfusate Concentrations  
8-16-07 Fex only 10-16-07 Fex only 
Time Calculated Conc Amount Calculated Conc Amount 
min ng/ml ng pmole/ml ng/ml ng pmole/ml 
10 65.6 20336 130.76 44.1 12480.3 87.90 
20 68.5 20892.5 136.54 36.7 10459.5 73.15 
30 72 22320 143.51 33 9405 65.78 
40 64.9 19794.5 129.36 33.1 9268 65.98 
50 66.1 20160.5 131.75 42.2 11605 84.11 
60 71 21655 141.52 37.9 10422.5 75.54 
10-22-07 Fex only 10-23-07 Fex only 10-24-07 Fex only 
Time Calculated Conc Amount Calculated Conc Amount Calculated Conc Amount 
min ng/ml ng pmole/ml ng/ml ng pmole/ml ng/ml ng pmole/ml
10 43 12341 85.71 47.8 13384 95.28 35.5 9762.5 70.76 
20 44.9 12796.5 89.50 37.1 10573.5 73.95 38.8 10864 77.34 
30 50.3 14335.5 100.26 48.2 13737 96.07 36.3 10164 72.35 
40 52.1 14848.5 103.85 54.2 15447 108.03 151 42280 
50 44.1 12568.5 87.90 55.7 15596 111.02 41.9 11732 83.52 
60 34.2 9747 68.17 48.3 13524 96.27 40.1 11228 79.93 
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10-17-07 Fex no TC 10-29-07 Fex no TC 
Time Calculated Conc Amount Calculated Conc Amount 
min ng/ml ng pmole/ml ng/ml ng pmole/ml 
10 66.9 18732 133.35 49.9 15469 99.46 
20 64.3 18132.6 128.16 42.1 13051 83.91 
30 62.6 17841 124.78 40.4 12524 80.53 
40 62.3 17755.5 124.18 39.8 12935 79.33 
50 64.1 17948 127.77 42.7 12596.5 85.11 
60 66.7 19009.5 132.95 58.6 19045 116.80 
11-1-07 Fex no TC 11-8-07 Fex no TC 
Time Calculated Conc Amount Calculated Conc Amount 
min ng/ml ng pmole/ml ng/ml ng pmole/ml 
10 52.2 16182 104.05 50.6 14421 100.86 
20 96.8 30492 192.94 52.8 15312 105.24 
30 48.7 15097 97.07 55 15675 109.63 
40 56.2 17422 112.02 62.6 17841 124.78 
50 60.7 19120.5 120.99 70.9 19852 141.32 
60 62.9 19499 125.37 83.2 23296 165.84 
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9-7-07 2µM GF120918 11-1-07 2µM GF120918 11-26-07 2µM GF120918 
Time Calculated Conc Amount Calculated Conc Amount Calculated Conc Amount 
min ng/ml ng pmole/ml ng/ml ng pmole/ml ng/ml ng pmole/ml
10 41.3 11977 82.32 35.6 11036 70.96 38.1 11049 75.94 
20 50.5 14645 100.66 47.8 14818 95.28 44.2 13039 88.10 
30 55.1 15979 109.83 56.2 17422 112.02 49.5 14602.5 98.66 
40 63.6 18444 126.77 59.6 18595.2 118.80 56.8 16756 113.22 
50 111 31635 221.25 65.3 20243 130.16 70.1 20679.5 139.72 
60 120 34800 239.19 67.2 20832 133.94 70.9 21270 141.32 
 
 
 
 
  
10-16-07 5µM Bosentan 10-26-07 5µM Bosentan 
Time Calculated Conc Amount Calculated Conc Amount 
min ng/ml ng pmole/ml ng/ml ng pmole/ml 
10 69.8 17101 139.13 69.4 21514 138.33 
20 98.3 26541 195.93 90.7 28117 180.79 
30 105 28350 209.29 85.2 26412 169.82 
40 109 29430 217.26 83.8 25978 167.03 
50 85.4 23058 170.22 87 26970 173.41 
60 94.5 25515 188.36 104 32240 207.30 
10-29-07 5µM Bosentan 10-31-07 5µM Bosentan 
Time Calculated Conc Amount Calculated Conc Amount 
min ng/ml ng pmole/ml ng/ml ng pmole/ml 
10 67.8 21018 135.14 60.8 18848 121.19 
20 80.7 25017 160.85 81.9 25389 163.24 
30 88.3 27373 176.00 89 27590 177.40 
40 105 32550 209.29 98.4 30996 196.13 
50 102 31620 203.31 113 35030 225.23 
60 103 31930 205.30 118 36580 235.20 
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 Bilary Excretion Rate  
8-16-07 Fex only 
Time 
Mid 
Time Calculated Conc Dilution Factor  
Bile 
Vol Amount Amount BER BER BER 
min min ng/ml ng/ml (*100) µl ng nmole pmol/min 
pmol/min/g 
liver 
pmol/hr/g 
liver 
10 5 181 18100 37.600 680.56 1.36 135.651 12.914 774.8226685
20 15 1140 114000 39.500 4503 8.98 897.548 85.445 5126.699301
30 25 1670 167000 58.200 9719.4 19.37 1937.293 184.427 11065.60986
40 35 1840 184000 59.300 10911.2 21.75 2174.846 207.041 12422.4831
50 45 2180 218000 55.400 12077.2 24.07 2407.255 229.166 13749.98286
60 55 2080 208000 52.100 10836.8 21.60 2160.016 205.630 12337.77815
Liver 
WT 10.5044 
10-16-07 Fex only 
Time 
Mid 
Time Calculated Conc Dilution Factor  
Bile 
Vol Amount Amount BER BER BER 
min min ng/ml ng/ml (*100) µl ng nmole pmol/min 
pmol/min/g 
liver 
pmol/hr/g 
liver 
10 5 236 23600 62.0 1463 2.92 291.648 28.441 1706.444301
20 15 1410 141000 58.6 8263 16.47 1646.920 160.603 9636.185539
30 25 1980 198000 64.5 12771 25.46 2545.545 248.234 14894.06791
40 35 2180 218000 59.0 12862 25.64 2563.683 250.003 15000.19587
50 45 2750 275000 54.3 14933 29.76 2976.380 290.248 17414.89853
60 55 2670 267000 63.2 16874 33.63 3363.444 327.994 19679.62255
Liver 
WT 10.2546 
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 10-22-07 Fex only 
Time 
Mid 
Time Calculated Conc Dilution Factor  
Bile 
Vol Amount Amount BER BER BER 
min min ng/ml ng/ml (*100) µl ng nmole pmol/min 
pmol/min/g 
liver 
pmol/hr/g 
liver 
10 5 213 21300 54.300 1156.59 2.31 230.534 17.827 1069.598749
20 15 1020 102000 58.500 5967 11.89 1189.356 91.970 5518.200691
30 25 1550 155000 56.200 8711 17.36 1736.297 134.264 8055.814684
40 35 1800 180000 57.200 10296 20.52 2052.222 158.693 9521.601193
50 45 1790 179000 59.800 10704.2 21.34 2133.586 164.985 9899.099018
60 55 1730 173000 72.500 12542.5 25.00 2500.000 193.319 11599.13393
Liver 
WT 12.932 
10-23-07 Fex only 
Time 
Mid 
Time Calculated Conc Dilution Factor  
Bile 
Vol Amount Amount BER BER BER 
min min ng/ml ng/ml (*100) µl ng nmole pmol/min 
pmol/min/g 
liver 
pmol/hr/g 
liver 
10 5 278 27800 48.4 1345.52 2.68 268.192 20.739 1244.318652
20 15 909 90900 49.9 4535.91 9.04 904.108 69.912 4194.748064
30 25 1550 155000 50.2 7781 15.51 1550.927 119.929 7195.763294
40 35 1930 193000 48.8 9418.4 18.77 1877.297 145.167 8710.008612
50 45 1830 183000 47.8 8747.4 17.44 1743.552 134.825 8089.476911
60 55 1820 182000 53.5 9737 19.41 1940.801 150.077 9004.645572
Liver 
WT 10.0027 
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10-24-07 Fex only 
Time 
Mid 
Time Calculated Conc Dilution Factor  
Bile 
Vol Amount Amount BER BER BER 
min min ng/ml ng/ml (*100) µl ng nmole pmol/min 
pmol/min/g 
liver 
pmol/hr/g 
liver 
10 5 258 25800 50.0 1290 2.57 257.126 19.883 1192.974508
20 15 1210 121000 55.9 6763.9 13.48 1348.196 104.253 6255.163006
30 25 1830 183000 56.4 10321.2 20.57 2057.245 159.082 9544.905811
40 35 1910 191000 59.9 11440.9 22.80 2280.427 176.340 10580.38919
50 45 2100 210000 61.5 12915 25.74 2574.248 199.060 11943.61688
60 55 2210 221000 62.9 13900.9 27.71 2770.759 214.256 12855.36383
Liver 
WT 11.3885 
10-17-07 Fex no TC 
Time 
Mid 
Time Calculated Conc Dilution Factor  
Bile 
Vol Amount Amount BER BER BER 
min min ng/ml ng/ml (*100) µl ng nmole pmol/min 
pmol/min/g 
liver 
pmol/hr/g 
liver 
10 5 119 11900 44.2 525.98 1.05 104.840 8.107 486.419172
20 15 502 50200 42.3 2123.46 4.23 423.253 32.729 1963.747015
30 25 1050 105000 40.3 4231.5 8.43 843.432 65.221 3913.233823
40 35 1370 137000 41.6 5699.2 11.36 1135.978 87.842 5270.542882
50 45 1720 172000 40.8 7017.6 13.99 1398.764 108.163 6489.781326
60 55 1810 181000 40.5 7330.5 14.61 1461.132 112.986 6779.147003
Liver 
WT 12.3545 
344 
 
 
 
 
10-29-07 Fex no TC 
Time 
Mid 
Time Calculated Conc Dilution Factor  
Bile 
Vol Amount Amount BER BER BER 
min min ng/ml ng/ml (*100) µl ng nmole pmol/min 
pmol/min/g 
liver 
pmol/hr/g 
liver 
10 5 295 29500 46.700 1377.65 2.75 274.596 26.141 1568.464866
20 15 1300 130000 39.700 5161 10.29 1028.702 97.931 5875.83724
30 25 1970 197000 37.000 7289 14.53 1452.860 138.310 8298.581214
40 35 2050 205000 41.700 8548.5 17.04 1703.907 162.209 9732.531418
50 45 2410 241000 35.100 8459.1 16.86 1686.087 160.512 9630.748847
60 55 2760 276000 32.300 8914.8 17.77 1776.918 169.159 10149.56672
Liver 
WT 11.1219 
11-1-07 Fex no TC 
Time Mid 
Time Calculated Conc Dilution Factor  
Bile 
Vol Amount Amount BER BER BER 
min min ng/ml ng/ml (*100) µl ng nmole pmol/min 
pmol/min/g 
liver 
pmol/hr/g 
liver 
10 5 190 19000 36.700 697.3 1.39 138.987 13.231 793.8812842
20 15 1300 130000 37.200 4836 9.64 963.923 91.764 5505.822301
30 25 1810 181000 45.900 8307.9 16.56 1655.950 157.643 9458.606512
40 35 2300 230000 33.400 7682 15.31 1531.194 145.767 8746.014664
50 45 2570 257000 32.300 8301.1 16.55 1654.594 157.514 9450.864661
60 55 2760 276000 31.000 8556 17.05 1705.402 162.351 9741.070225
Liver 
WT 12.8765 
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11-8-07 Fex no TC 
Time 
Mid 
Time Calculated Conc Dilution Factor  
Bile 
Vol Amount Amount BER BER BER 
min min ng/ml ng/ml (*100) µl ng nmole pmol/min 
pmol/min/g 
liver 
pmol/hr/g 
liver 
10 5 138 13800 29.000 400.2 0.80 79.769 7.594 455.6307041
20 15 1110 111000 27.100 3008.1 6.00 599.581 57.079 3424.74443
30 25 1970 197000 22.900 4511.3 8.99 899.203 85.602 5136.148914
40 35 2500 250000 20.300 5075 10.12 1011.561 96.299 5777.925595
50 45 2770 277000 19.800 5484.6 10.93 1093.203 104.071 6244.258269
60 55 2700 270000 19.700 5319 10.60 1060.195 100.929 6055.721426
Liver 
WT 12.3932 
9-7-07 2µM GF120918 
Time Mid 
Time Calculated Conc Dilution Factor  
Bile 
Vol Amount Amount BER BER BER 
min min ng/ml ng/ml (*100) µl ng nmole pmol/min 
pmol/min/g 
liver 
pmol/hr/g 
liver 
10 5 84.3 8430 49.600 418.128 0.83 83.342 7.934 476.0418666
20 15 521 52100 54.900 2860.29 5.70 570.120 54.274 3256.461635
30 25 608 60800 55.200 3356.16 6.69 668.958 63.684 3821.013353
40 35 653 65300 53.200 3473.96 6.92 692.438 65.919 3955.129537
50 45 711 71100 49.700 3533.67 7.04 704.339 67.052 4023.10982
60 55 577 57700 53.700 3098.49 6.18 617.598 58.794 3527.654123
Liver 
WT 11.7118 
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11-1-07 2µM GF120918 
Time 
Mid 
Time Calculated Conc Dilution Factor  
Bile 
Vol Amount Amount BER BER BER 
min min ng/ml ng/ml (*100) µl ng nmole pmol/min 
pmol/min/g 
liver 
pmol/hr/g 
liver 
10 5 140 14000 59.200 828.8 1.65 165.198 15.727 943.5950213
20 15 591 59100 58.900 3480.99 6.94 693.839 66.052 3963.133245
30 25 741 74100 61.400 4549.74 9.07 906.865 86.332 5179.913142
40 35 699 69900 59.700 4173.03 8.32 831.778 79.184 4751.025979
50 45 598 59800 58.700 3510.26 7.00 699.673 66.608 3996.457359
60 55 552 55200 58.800 3245.76 6.47 646.952 61.589 3695.322124
Liver 
WT 10.7113 
11-26-07 2µM GF120918 
Time 
Mid 
Time Calculated Conc Dilution Factor  
Bile 
Vol Amount Amount BER BER BER 
min min ng/ml ng/ml (*100) µl ng nmole pmol/min 
pmol/min/g 
liver 
pmol/hr/g 
liver 
10 5 157 15700 44.100 692.37 1.38 138.005 13.138 788.2684422
20 15 474 47400 58.300 2763.42 5.51 550.811 52.436 3146.174413
30 25 575 57500 58.100 3340.75 6.66 665.886 63.391 3803.468952
40 35 568 56800 56.400 3203.52 6.39 638.533 60.787 3647.231567
50 45 466 46600 56.500 2632.9 5.25 524.796 49.960 2997.576414
60 55 480 48000 54.300 2606.4 5.20 519.514 49.457 2967.405965
Liver 
WT 10.7159 
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10-16-07 5µM Bosentan 
Time 
Mid 
Time Calculated Conc Dilution Factor  
Bile 
Vol Amount Amount BER BER BER 
min min ng/ml ng/ml (*100) µl ng nmole pmol/min 
pmol/min/g 
liver 
pmol/hr/g 
liver 
10 5 59.7 5970 34.400 205.368 0.41 40.934 3.897 233.8130096
20 15 501 50100 43.900 2199.39 4.38 438.387 41.734 2504.022024
30 25 636 63600 47.900 3046.44 6.07 607.223 57.807 3468.394808
40 35 757 75700 55.200 4178.64 8.33 832.896 79.290 4757.413006
50 45 614 61400 59.500 3653.3 7.28 728.184 69.322 4159.309473
60 55 926 92600 56.800 5259.68 10.48 1048.372 99.803 5988.185161
Liver 
WT 11.1608 
10-26-07 5µM Bosentan 
Time 
Mid 
Time Calculated Conc Dilution Factor  
Bile 
Vol Amount Amount BER BER BER 
min min ng/ml ng/ml (*100) µl ng nmole pmol/min 
pmol/min/g 
liver 
pmol/hr/g 
liver 
10 5 237 23700 66.500 1576.05 3.14 314.142 29.906 1794.344755
20 15 877 87700 67.800 5946.06 11.85 1185.182 112.827 6769.633943
30 25 959 95900 74.000 7096.6 14.15 1414.511 134.659 8079.53237
40 35 1170 117000 78.000 9126 18.19 1819.015 173.167 10390.0195
50 45 1250 125000 73.700 9212.5 18.36 1836.257 174.808 10488.5004
60 55 1200 120000 71.200 8544 17.03 1703.010 162.123 9727.408134
Liver 
WT 9.8036 
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10-29-07 5µM Bosentan 
Time 
Mid 
Time Calculated Conc Dilution Factor  
Bile 
Vol Amount Amount BER BER BER 
min min ng/ml ng/ml (*100) µl ng nmole pmol/min 
pmol/min/g 
liver 
pmol/hr/g 
liver 
10 5 185 18500 59.700 1104.45 2.20 220.142 20.957 1257.424615
20 15 853 85300 64.700 5518.91 11.00 1100.042 104.722 6283.320462
30 25 1160 116000 66.300 7690.8 15.33 1532.948 145.934 8756.03353
40 35 1050 105000 70.000 7350 14.65 1465.019 139.467 8368.030172
50 45 1180 118000 77.300 9121.4 18.18 1818.098 173.080 10384.78237
60 55 1090 109000 76.300 8316.7 16.58 1657.704 157.810 9468.625378
Liver 
WT 12.5695 
10-31-07 5µM Bosentan 
Time 
Mid 
Time Calculated Conc Dilution Factor  
Bile 
Vol Amount Amount BER BER BER 
min min ng/ml ng/ml (*100) µl ng nmole pmol/min 
pmol/min/g 
liver 
pmol/hr/g 
liver 
10 5 240 24000 76.500 1836 3.66 365.956 34.838 2090.299782
20 15 868 86800 67.600 5867.68 11.70 1169.559 111.340 6680.397725
30 25 1100 110000 73.600 8096 16.14 1613.713 153.623 9217.356772
40 35 1240 124000 78.300 9709.2 19.35 1935.260 184.233 11053.99708
50 45 1040 104000 77.900 8101.6 16.15 1614.830 153.729 9223.732414
60 55 1000 100000 78.100 7810 15.57 1556.707 148.196 8891.743625
Liver 
WT 12.04 
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Liver Concentrations 
 
 
 
 
 
Calculated 
Conc Dilution Factor 
Liver 
Weight 
Total 
Mass Conc Mass Concentration 
ng/ml *10  g ng 
nM = 
pmol/ml Mean SD Mean SD 
Homogenate Fex only 8-16-07 412 4120 10.5044 129834.38 8212.08 
121142 20407 7295 786 
Homogenate Fex only 10-16-07 366 3660 10.2546 112595.51 7295.20 
Homogenate Fex only 10-22-07 394 3940 12.932 152856.24 7853.30 
Homogenate Fex only 10-23-07 346 3460 10.0027 103828.03 6896.55 
Homogenate Fex only 10-24-07 312 3120 11.3885 106596.36 6218.86 
Homogenate Fex no TC 10-17-07 258 2580 12.3545 95623.83 5142.52 
130661 25323 7156 1529 
Homogenate Fex no TC 10-29-07 437 4370 11.1219 145808.11 8710.38 
Homogenate Fex no TC 11-1-07 394 3940 12.8765 152200.23 7853.30 
Homogenate Fex no TC 11-8-07 347 3470 12.3932 129013.21 6916.48 
Homogenate Fex + 918 9-7-07 370 3700 11.7118 130000.98 7374.93 
135256 5946 8159 720 
Homogenate Fex + 918 11-1-07 441 4410 10.7113 141710.50 8790.11 
Homogenate Fex + 918 11-26-07 417 4170 10.7159 134055.91 8311.74 
Homogenate Fex + Bos 10-16-07 282 2820 11.1608 94420.37 5620.89 
95513 20227 5561 873 
Homogenate Fex + Bos 10-26-07 281 2810 9.8036 82644.35 5600.96 
Homogenate Fex + Bos 10-29-07 330 3300 12.5695 124438.05 6577.64 
Homogenate Fex + Bos 10-31-07 223 2230 12.04 80547.60 4444.89 
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Chapter 3: Fexofenadine in Single Pass Perfused Mouse Livers Perfusate Concentrations  
Time(min) WT-2 WT-3 WT-4 WT-5 AVG (ng/mL) SD 
Amount 
(ng) 
Cumulative 
Amount 
(ng) 
Avg PS 
Rate 
(ng/min) 
1 74.5 302 239 311 115.8125 54.8 579.0625 579.0625 579.0625
2 237 525 406 481 206.125 63.4 2061.25 2640.313 1030.625
4 356 699 428 534 252.125 74.5 2521.25 5161.563 1260.625
6 340 644 410 585 247.375 71.6 2473.75 7635.313 1236.875
10 460 691 457 651 282.375 61.9 5647.5 13282.81 1411.875
15 574 770 505 682 316.375 58.5 7909.375 21192.19 1581.875
20 571 824 545 689 328.625 63.8 8215.625 29407.81 1643.125
25 544 758 596 695 324.125 48.2 8103.125 37510.94 1620.625
30 656 745 676 705 347.75 19.3 8693.75 46204.69 1738.75
30.25 531 639 545 568 285.375 24.0 356.7188 46561.41 1426.875
30.75 494 719 504 599 289.5 52.3 723.75 47285.16 1447.5
32 412 465 378 516 221.375 30.3 1383.594 48668.75 1106.875
36 279 157 199 283 114.75 31.0 2295 50963.75 573.75
40 198 90.1 138 184 76.2625 24.4 1525.25 52489 381.3125
45 182 64.4 108 153 63.425 25.8 1585.625 54074.63 317.125
50 169 47 101 136 56.625 26.1 1415.625 55490.25 283.125
55 147 42.8 90.3 131 51.3875 23.3 1284.688 56774.94 256.9375
60 143 41.2 87.4 106 47.2 21.2 1180 57954.94 236
65 142 32.6 75 92.8 42.8 22.6 1070 59024.94 214
70 136 30.1 68.9 97.1 41.5125 22.4 1037.813 60062.75 207.5625
75 131 32.2 64.7 87.5 39.425 20.8 985.625 61048.38 197.125
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Time(min) Mrp3KO-1 Mrp3KO-2 Mrp3KO-4 
AVG 
(ng/mL) SD 
Amount 
(ng) 
Cumulative 
Amount (ng) 
Avg PS 
Rate 
(ng/min) 
1 243 153 246 107 26.42442 535 535 535
2 518 323 534 229.1667 58.73741 2291.667 2826.667 1145.833
4 807 510 651 328 74.28156 3280 6106.667 1640
6 828 665 744 372.8333 40.75639 3728.333 9835 1864.167
10 1000 630 752 397 94.27089 7940 17775 1985
15 1000 624 807 405.1667 94.01108 10129.17 27904.17 2025.833
20 957 680 671 384.6667 81.29319 9616.667 37520.83 1923.333
25 1030 656 772 409.6667 95.72008 10241.67 47762.5 2048.333
30 1020 709 815 424 79.0522 10600 58362.5 2120
30.25 837 490 571 316.3333 90.76664 395.4167 58757.92 1581.667
30.75 789 505 577 311.8333 73.8196 779.5833 59537.5 1559.167
32 531 401 415 224.5 35.67913 1403.125 60940.63 1122.5
36 187 177 177 90.16667 2.886751 1803.333 62743.96 450.8333
40 80.5 93.1 97.6 45.2 4.431986 904 63647.96 226
45 66.4 77.4 77.9 36.95 3.25 923.75 64571.71 184.75
50 52.7 65.7 70.8 31.53333 4.666458 788.3333 65360.04 157.6667
55 48 59.1 67.8 29.15 4.962106 728.75 66088.79 145.75
60 46.2 61 61.5 28.11667 4.346359 702.9167 66791.71 140.5833
65 35 54.2 73.2 27.06667 9.550044 676.6667 67468.38 135.3333
70 40.2 50.1 65.7 26 6.427869 650 68118.38 130
75 33.8 52.8 57.1 23.95 6.199395 598.75 68717.13 119.75
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 Time(min) Mrp4KO-1 Mrp4KO-2 
Mrp4KO-
3 Mrp4KO-4 
AVG 
(ng/mL) SD 
Amount 
(ng) 
Cumulative 
Amount 
(ng) 
Avg PS Rate 
(ng/min) 
1 146 173 334 186 104.875 42.24606 524.375 524.375 524.375 
2 342 449 584 341 214.5 57.54563 2145 2669.375 1072.5 
4 490 519 758 435 275.25 71.32613 2752.5 5421.875 1376.25 
6 513 690 840 480 315.375 83.60958 3153.75 8575.625 1576.875 
10 518 585 934 488 315.625 102.9331 6312.5 14888.13 1578.125 
15 563 564 1000 521 331 113.1113 8275 23163.13 1655 
20 646 699 871 568 348 64.23784 8700 31863.13 1740 
25 700 743 892 609 368 59.02683 9200 41063.13 1840 
30 740 812 890 647 386.125 51.77898 9653.125 50716.25 1930.625 
30.25 682 521 718 504 303.125 54.73325 378.9063 51095.16 1515.625 
30.75 643 501 655 553 294 36.86462 735 51830.16 1470 
32 620 617 485 474 274.5 40.19328 1715.625 53545.78 1372.5 
36 408 199 199 298 138 49.80462 2760 56305.78 690 
40 346 131 95.9 230 100.3625 56.13355 2007.25 58313.03 501.8125 
45 309 83.1 61.6 224 84.7125 58.83441 2117.813 60430.84 423.5625 
50 291 85 56.7 171 75.4625 52.63749 1886.563 62317.41 377.3125 
55 251 103 49.6 188 73.95 44.64351 1848.75 64166.16 369.75 
60 223 76 54.3 179 66.5375 40.47496 1663.438 65829.59 332.6875 
65 198 64.6 35.3 156 56.7375 38.13676 1418.438 67248.03 283.6875 
70 167 74.5 35 139 51.9375 30.03496 1298.438 68546.47 259.6875 
75 150 64.6 35.1 138 48.4625 27.9454 1211.563 69758.03 242.3125 
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 Time(min) Mrp2/3KO-2 Mrp2/3KO-3 Mrp2/3KO-4 AVG (ng/mL) SD 
Amount 
(ng) 
Cumulative 
Amount 
(ng) 
Avg PS 
Rate 
(ng/min)
1 183 129 113 70.83333 18.33939 354.1667 354.1667 354.1667
2 449 300 325 179 39.89674 1790 2144.167 895
4 694 483 436 268.8333 68.7065 2688.333 4832.5 1344.167
6 836 553 548 322.8333 82.42623 3228.333 8060.833 1614.167
10 953 596 555 350.6667 109.4559 7013.333 15074.17 1753.333
15 957 548 509 335.6667 124.081 8391.667 23465.83 1678.333
20 1080 667 580 387.8333 133.563 9695.833 33161.67 1939.167
25 1090 578 539 367.8333 153.7403 9195.833 42357.5 1839.167
30 1080 647 648 395.8333 124.8522 9895.833 52253.33 1979.167
30.25 723 557 579 309.8333 45.08141 387.2917 52640.63 1549.167
30.75 819 536 528 313.8333 82.8739 784.5833 53425.21 1569.167
32 690 399 473 260.3333 75.62132 1627.083 55052.29 1301.667
36 398 214 273 147.5 46.97606 2950 58002.29 737.5
40 244 120 205 94.83333 31.70305 1896.667 59898.96 474.1667
45 175 97.2 229 83.53333 33.12859 2088.333 61987.29 417.6667
50 157 83 260 83.33333 44.44753 2083.333 64070.63 416.6667
55 137 92.1 290 86.51667 51.87703 2162.917 66233.54 432.5833
60 117 80.2 241 73.03333 42.12426 1825.833 68059.38 365.1667
65 95.7 83.1 215 65.63333 36.39417 1640.833 69700.21 328.1667
70 75.2 77.9 186 56.51667 31.6027 1412.917 71113.13 282.5833
75 73.1 84 183 56.68333 30.275 1417.083 72530.21 283.4167
354 
 
 
 Time(min) Mrp2KO-1 Mrp2KO-2 
Mrp2KO-
3 
AVG 
(ng/mL) SD 
Amount 
(ng) 
Cumulative 
Amount 
(ng) 
Avg PS 
Rate 
(ng/min)
1 289 288 191 128 28.15 640 640 640
2 517 529 452 249.6667 20.71 2496.667 3136.667 1248.333
4 845 689 554 348 72.81 3480 6616.667 1740
6 938 800 642 396.6667 74.06 3966.667 10583.33 1983.333
10 1000 919 716 439.1667 73.15 8783.333 19366.67 2195.833
15 1000 918 781 449.8333 55.32 11245.83 30612.5 2249.167
20 1140 950 820 485 80.47 12125 42737.5 2425
25 1210 996 886 515.3333 82.38 12883.33 55620.83 2576.667
30 1180 1070 976 537.6667 51.05 13441.67 69062.5 2688.333
30.25 926 854 786 427.6667 35.00 534.5833 69597.08 2138.333
30.75 903 766 781 408.3333 37.57 1020.833 70617.92 2041.667
32 761 589 555 317.5 55.22 1984.375 72602.29 1587.5
36 450 365 434 208.1667 22.59 4163.333 76765.63 1040.833
40 308 254 345 151.1667 22.88 3023.333 79788.96 755.8333
45 255 198 339 132 35.46 3300 83088.96 660
50 215 166 262 107.1667 24.00 2679.167 85768.13 535.8333
55 166 150 235 91.83333 22.59 2295.833 88063.96 459.1667
60 146 132 218 82.66667 23.07 2066.667 90130.63 413.3333
65 117 118 204 73.16667 24.97 1829.167 91959.79 365.8333
70 93.9 107 173 62.31667 21.20 1557.917 93517.71 311.5833
75 90.4 90.9 157 56.38333 19.15 1409.583 94927.29 281.9167
355 
 
 
Biliary Excretion Rate  
WT-2 
Time 
(min) MidTim(min) 
Tube 
Weight  
Total 
Weight 
Bile Vol. 
(uL) 
Bile Rate 
(uL/min) Amount(ng) 
Cumulative 
Amunt(ng) 
Biliary Excretion 
Rate (ng/min) 
7 3.5 3318 3426 10.8 1.542857 1.836 1.836 0.262285714
14 10.5 3282 3411 12.9 1.842857 291.54 293.376 41.64857143
21 17.5 3286 3404 11.8 1.685714 1178.82 1472.196 168.4028571
28 24.5 3339 3451 11.2 1.6 1881.6 3353.796 268.8
35 31.5 3358 3460 10.2 1.457143 1999.2 5352.996 285.6
42 38.5 3396 3490 9.4 1.342857 2180.8 7533.796 311.5428571
49 45.5 3298 3377 7.9 1.128571 1603.7 9137.496 229.1
56 52.5 3354 3442 8.8 1.257143 1346.4 10483.896 192.3428571
63 59.5 3313 3377 6.4 0.914286 736 11219.896 105.1428571
70 66.5 3318 3412 9.4 1.342857 826.26 12046.156 118.0371429
77 73.5 3365 3433 6.8 0.971429 409.36 12455.516 58.48
Liver Wt 1.4 1.371429 12455.516 
Body Wt 28.4 
356 
 
 
WT-3 
Time 
(min) 
MidTime 
(min) 
Tube 
Weight  
Total 
Weight 
Bile 
Vol. 
Bile Rate 
(uL/min) Amount(ng) 
Cumulative 
Amunt(ng) 
Biliary Excretion 
Rate (ng/min) 
7 3.5 3370 3464 9.4 1.342857 1.2972 1.2972 0.185314286
14 10.5 3358 3450 9.2 1.314286 135.24 136.5372 19.32
21 17.5 3359 3450 9.1 1.3 518.7 655.2372 74.1
28 24.5 3316 3412 9.6 1.371429 1056 1711.2372 150.8571429
35 31.5 3355 3446 9.1 1.3 1283.1 2994.3372 183.3
42 38.5 3344 3435 9.1 1.3 1610.7 4605.0372 230.1
49 45.5 3369 3457 8.8 1.257143 1654.4 6259.4372 236.3428571
56 52.5 3357 3456 9.9 1.414286 1514.7 7774.1372 216.3857143
63 59.5 3353 3444 9.1 1.3 1046.5 8820.6372 149.5
70 66.5 3361 3451 9 1.285714 972 9792.6372 138.8571429
77 73.5 3324 3406 8.2 1.171429 807.7 10600.3372 115.3857143
Liver Wt 1.18 1.305195 10600.3372 
Body Wt 28.9 
357 
 
 
WT-4 
Time 
(min) 
Mid Time 
(min) 
Tube 
Weight  
Total 
Weight 
Bile 
Vol. 
Bile Rate 
(uL/min) Amount(ng) 
Cumulative 
Amunt(ng) 
Biliary Excretion 
Rate (ng/min) 
7 3.5 3363 3482 11.9 1.7 5.831 5.831 0.833
14 10.5 3334 3481 14.7 2.1 396.9 402.731 56.7
21 17.5 3368 3491 12.3 1.757143 950.79 1353.521 135.8271429
28 24.5 3339 3470 13.1 1.871429 1755.4 3108.921 250.7714286
35 31.5 3317 3430 11.3 1.614286 1808 4916.921 258.2857143
42 38.5 3359 3455 9.6 1.371429 1881.6 6798.521 268.8
49 45.5 3359 3449 9 1.285714 1989 8787.521 284.1428571
56 52.5 3296 3402 10.6 1.514286 2162.4 10949.921 308.9142857
63 59.5 3338 3427 8.9 1.271429 1593.1 12543.021 227.5857143
70 66.5 3330 3421 9.1 1.3 1392.3 13935.321 198.9
77 73.5 3333 3449 11.6 1.657143 1589.2 15524.521 227.0285714
Liver Wt 1 1.585714 15524.521 
Body Wt 26.4 
358 
 
 
WT-5 
Time 
(min) 
MidTime 
(min) 
Tube 
Weight  
Total 
Weight Bile Vol. 
Bile Rate 
(uL/min) Amount(ng) 
Cumulative 
Amunt(ng) 
Biliary  Excretion 
Rate (ng/min) 
7 3.5 3360 3503 14.3 2.042857 46.046 46.046 6.578
14 10.5 3326 3416 9 1.285714 399.6 445.646 57.08571429
21 17.5 3362 3466 10.4 1.485714 1175.2 1620.846 167.8857143
28 24.5 3395 3492 9.7 1.385714 1416.2 3037.046 202.3142857
35 31.5 3339 3470 13.1 1.871429 2397.3 5434.346 342.4714286
42 38.5 3362 3454 9.2 1.314286 2088.4 7522.746 298.3428571
49 45.5 3320 3415 9.5 1.357143 2289.5 9812.246 327.0714286
56 52.5 3289 3394 10.5 1.5 1911 11723.246 273
63 59.5 3360 3459 9.9 1.414286 1534.5 13257.746 219.2142857
70 66.5 3368 3449 8.1 1.157143 1093.5 14351.246 156.2142857
77 73.5 3354 3452 9.8 1.4 1048.6 15399.846 149.8
Liver Wt 0.92 Mean 1.474026 15399.846
Body Wt 26.1 
359 
 
 
 
Mrp3KO-1 
Time 
(min) 
MidTime 
(min) 
Tube 
Weight  
Total 
Weight Bile Vol. 
Bile Rate 
(uL/min) Amount(ng) 
Cumulative 
Amunt(ng) 
Biliary Excretion 
Rate (ng/min) 
7 3.5 3330 3462 13.2 1.885714 3.8544 3.8544 0.550628571
14 10.5 3324 3432 10.8 1.542857 201.96 205.8144 28.85142857
21 17.5 3365 3471 10.6 1.514286 655.08 860.8944 93.58285714
28 24.5 3366 3476 11 1.571429 1287 2147.8944 183.8571429
35 31.5 3360 3463 10.3 1.471429 1565.6 3713.4944 223.6571429
42 38.5 3360 3456 9.6 1.371429 1785.6 5499.0944 255.0857143
49 45.5 3362 3458 9.6 1.371429 1660.8 7159.8944 237.2571429
56 52.5 3355 3449 9.4 1.342857 1579.2 8739.0944 225.6
63 59.5 3325 3414 8.9 1.271429 1263.8 10002.8944 180.5428571
70 66.5 3318 3400 8.2 1.171429 1016.8 11019.6944 145.2571429
77 73.5 3308 3411 10.3 1.471429 1112.4 12132.0944 158.9142857
Liver Wt 1.3 Mean 1.453247 12132.0944
Body Wt 29.7 
360 
 
 
Mrp3KO-2 
Time 
(min) MidTim(min) 
Tube 
Weight  
Total 
Weight Bile Vol. 
Bile Rate 
(uL/min) Amount(ng) 
Cumulative 
Amunt(ng) 
BiliaryExcretion
Rate(ng/min) 
7 3.5 3363 3525 16.2 2.314286 50.058 50.058 7.151142857
14 10.5 3367 3483 11.6 1.657143 658.88 708.938 94.12571429
21 17.5 3365 3491 12.6 1.8 1638 2346.938 234
28 24.5 3372 3494 12.2 1.742857 2379 4725.938 339.8571429
35 31.5 3318 3448 13 1.857143 3068 7793.938 438.2857143
42 38.5 3363 3491 12.8 1.828571 3392 11185.938 484.5714286
49 45.5 3365 3485 12 1.714286 2844 14029.938 406.2857143
56 52.5 3345 3481 13.6 1.942857 2679.2 16709.138 382.7428571
63 59.5 3398 3489 9.1 1.3 1528.8 18237.938 218.4
70 66.5 3334 3447 11.3 1.614286 1649.8 19887.738 235.6857143
77 73.5 3316 3440 12.4 1.771429 1711.2 21598.938 244.4571429
Liver Wt 1.23 Mean 1.776623 21598.938
Body Wt 29.7 
361 
 
 
Mrp3KO-4 
Time 
(min) MidTim(min) 
Tube 
Weight  
Total 
Weight Bile Vol. 
Bile Rate 
(uL/min) Amount(ng) 
Cumulative 
Amunt(ng) 
Biliary Excretion 
Rate (ng/min) 
7 3.5 3311 3413 10.2 1.457143 0.3876 0.3876 0.055371429
14 10.5 3366 3498 13.2 1.885714 186.12 186.5076 26.58857143
21 17.5 3366 3469 10.3 1.471429 580.92 767.4276 82.98857143
28 24.5 3359 3434 7.5 1.071429 810 1577.4276 115.7142857
35 31.5 3357 3462 10.5 1.5 1680 3257.4276 240
42 38.5 3355 3466 11.1 1.585714 2331 5588.4276 333
49 45.5 3363 3463 10 1.428571 2110 7698.4276 301.4285714
56 52.5 3316 3436 12 1.714286 2244 9942.4276 320.5714286
63 59.5 3358 3468 11 1.571429 1760 11702.4276 251.4285714
70 66.5 3334 3437 10.3 1.471429 1359.6 13062.0276 194.2285714
77 73.5 3370 3469 9.9 1.414286 1128.6 14190.6276 161.2285714
Liver Wt 1.04 Mean 1.506494 14190.6276
Body Wt 24.36
362 
 
 
Mrp4KO-1 
Time 
(min) 
MidTime 
(min) 
Tube 
Weight  
Total 
Weight Bile Vol. 
Bile Rate 
(uL/min) Amount(ng) 
Cumulative 
Amunt(ng) 
Biliary Excretion 
Rate (ng/min) 
7 3.5 3285 3418 13.3 1.9 11.1055 11.1055 1.5865
14 10.5 3341 3456 11.5 1.642857 388.7 399.8055 55.52857143
21 17.5 3294 3407 11.3 1.614286 1152.6 1552.4055 164.6571429
28 24.5 3351 3460 10.9 1.557143 1678.6 3231.0055 239.8
35 31.5 3334 3434 10 1.428571 2000 5231.0055 285.7142857
42 38.5 3318 3410 9.2 1.314286 1987.2 7218.2055 283.8857143
49 45.5 3326 3410 8.4 1.2 1722 8940.2055 246
56 52.5 3322 3403 8.1 1.157143 1215 10155.2055 173.5714286
63 59.5 3332 3400 6.8 0.971429 856.8 11012.0055 122.4
70 66.5 3355 3421 6.6 0.942857 693 11705.0055 99
77 73.5 3333 3411 7.8 1.114286 720.72 12425.7255 102.96
Liver Wt 1.23 Mean 1.349351 12425.7255
Body Wt 26.8
363 
 
 
Mrp4KO-2 
Time 
(min) 
MidTime 
(min) 
Tube 
Weight  
Total 
Weight Bile Vol. 
Bile Rate 
(uL/min) Amount(ng) 
Cumulative 
Amunt(ng) 
Biliary Excretion 
Rate (ng/min) 
7 3.5 3339 3362 2.3 0.328571 0 0 0
14 10.5 3313 3402 8.9 1.271429 106.8 106.8 15.25714286
21 17.5 3322 3433 11.1 1.585714 1143.3 1250.1 163.3285714
28 24.5 3367 3481 11.4 1.628571 2052 3302.1 293.1428571
35 31.5 3334 3421 8.7 1.242857 1887.9 5190 269.7
42 38.5 3345 3443 9.8 1.4 2136.4 7326.4 305.2
49 45.5 3357 3447 9 1.285714 1989 9315.4 284.1428571
56 52.5 3296 3377 8.1 1.157143 1368.9 10684.3 195.5571429
63 59.5 3286 3496 21 3 1942.5 12626.8 277.5
70 66.5 3338 3489 15.1 2.157143 1091.73 13718.53 155.9614286
77 73.5 3343 3458 11.5 1.642857 953.35 14671.88 136.1928571
Liver Wt 1.23 Mean 1.518182 14671.88
Body Wt 28.9
364 
 
 
 
Mrp4KO-3 
Time 
(min) 
MidTime 
(min) 
Tube 
Weight  
Total 
Weight Bile Vol. 
Bile Rate 
(uL/min) Amount(ng) 
Cumulative 
Amunt(ng) 
Biliary Excretion 
Rate (ng/min) 
7 3.5 3294 3363 6.9 0.985714 0 0 0
14 10.5 3366 3450 8.4 1.2 57.12 57.12 8.16
21 17.5 3318 3390 7.2 1.028571 475.2 532.32 67.88571429
28 24.5 3364 3438 7.4 1.057143 1058.2 1590.52 151.1714286
35 31.5 3357 3431 7.4 1.057143 1413.4 3003.92 201.9142857
42 38.5 3330 3403 7.3 1.042857 1708.2 4712.12 244.0285714
49 45.5 3358 3450 9.2 1.314286 1794 6506.12 256.2857143
56 52.5 3344 3397 5.3 0.757143 757.9 7264.02 108.2714286
63 59.5 3377 3450 7.3 1.042857 963.6 8227.62 137.6571429
70 66.5 3315 3396 8.1 1.157143 874.8 9102.42 124.9714286
77 73.5 3364 3466 10.2 1.457143 984.3 10086.72 140.6142857
Liver Wt 1.06 Mean 1.1 10086.72
Body Wt 25.3
365 
 
 
Mrp4KO-4 
Time 
(min) 
MidTime 
(min) 
Tube 
Weight  
Total 
Weight Bile Vol. 
Bile Rate 
(uL/min) Amount(ng) 
Cumulative 
Amunt(ng) 
Biliary Excretion 
Rate (ng/min) 
7 3.5 3342 3473 13.1 1.871429 29.344 29.344 4.192
14 10.5 3365 3479 11.4 1.628571 599.64 628.984 85.66285714
21 17.5 3368 3489 12.1 1.728571 1645.6 2274.584 235.0857143
28 24.5 3333 3442 10.9 1.557143 2299.9 4574.484 328.5571429
35 31.5 3364 3457 9.3 1.328571 2427.3 7001.784 346.7571429
42 38.5 3366 3447 8.1 1.157143 2235.6 9237.384 319.3714286
49 45.5 3314 3400 8.6 1.228571 2098.4 11335.784 299.7714286
56 52.5 3310 3490 18 2.571429 3582 14917.784 511.7142857
63 59.5 3316 3459 14.3 2.042857 2288 17205.784 326.8571429
70 66.5 3357 3416 5.9 0.842857 767 17972.784 109.5714286
77 73.5 3360 3436 7.6 1.085714 904.4 18877.184 129.2
Liver Wt 0.82 Mean 1.549351 18877.184
Body Wt 23.33
366 
 
 
 
Mrp2/3KO-2 
Time 
(min) 
MidTime 
(min) 
Tube 
Weight  
Total 
Weight Bile Vol. 
Bile Rate 
(uL/min) Amount(ng) 
Cumulative 
Amunt(ng) 
Biliary Excretion 
Rate (ng/min) 
7 3.5 3362 3436 7.4 1.057143 0.69782 0.69782 0.099688571
14 10.5 3370 3440 7 1 30.94 31.63782 4.42
21 17.5 3364 3447 8.3 1.185714 251.49 283.12782 35.92714286
28 24.5 3354 3442 8.8 1.257143 497.2 780.32782 71.02857143
35 31.5 3322 3406 8.4 1.2 677.88 1458.20782 96.84
42 38.5 3359 3439 8 1.142857 744 2202.20782 106.2857143
49 45.5 3326 3400 7.4 1.057143 677.84 2880.04782 96.83428571
56 52.5 3333 3407 7.4 1.057143 502.46 3382.50782 71.78
63 59.5 3335 3440 10.5 1.5 569.1 3951.60782 81.3
70 66.5 3358 3428 7 1 313.6 4265.20782 44.8
77 73.5 3318 3404 8.6 1.228571 304.44 4569.64782 43.49142857
Liver Wt 1.47 Mean 1.153247 4569.64782
Body Wt 25.7
367 
 
 
 
Mrp2/3KO-3 
Time 
(min) 
MidTime 
(min) 
Tube 
Weight  
Total 
Weight Bile Vol. 
Bile Rate 
(uL/min) Amount(ng) 
Cumulative 
Amunt(ng) 
Biliary Excretion 
Rate (ng/min) 
7 3.5 3289 3489 20 2.857143 0.362 0.362 0.051714286
14 10.5 3339 3442 10.3 1.471429 41.921 42.283 5.988714286
21 17.5 3360 3416 5.6 0.8 127.68 169.963 18.24
28 24.5 3360 3490 13 1.857143 700.7 870.663 100.1
35 31.5 3321 3372 5.1 0.728571 302.94 1173.603 43.27714286
42 38.5 3367 3496 12.9 1.842857 1071.99 2245.593 153.1414286
49 45.5 3321 3452 13.1 1.871429 379.9 2625.493 54.27142857
56 52.5 3355 3511 15.6 2.228571 427.44 3052.933 61.06285714
63 59.5 3335 3450 11.5 1.642857 511.75 3564.683 73.10714286
70 66.5 3330 3520 19 2.714286 695.4 4260.083 99.34285714
77 73.5 3341 3568 22.7 3.242857 537.99 4798.073 76.85571429
Liver Wt 1.8 Mean 1.932468 4798.073
Body Wt 28.8
368 
 
 
 
Mrp2/3KO-4 
Time 
(min) 
MidTime 
(min) 
Tube 
Weight  
Total 
Weight Bile Vol. 
Bile Rate 
(uL/min) Amount(ng) 
Cumulative 
Amunt(ng) 
Biliary Excretion 
Rate (ng/min) 
7 3.5 3356 3484 12.8 1.828571 6.6816 6.6816 0.954514286
14 10.5 3298 3414 11.6 1.657143 226.2 232.8816 32.31428571
21 17.5 3343 3468 12.5 1.785714 751.25 984.1316 107.3214286
28 24.5 3332 3447 11.5 1.642857 1288 2272.1316 184
35 31.5 3349 3435 8.6 1.228571 1178.2 3450.3316 168.3142857
42 38.5 3360 3451 9.1 1.3 1419.6 4869.9316 202.8
49 45.5 3359 3440 8.1 1.157143 1312.2 6182.1316 187.4571429
56 52.5 3335 3404 6.9 0.985714 966 7148.1316 138
63 59.5 3363 3430 6.7 0.957143 783.9 7932.0316 111.9857143
70 66.5 3343 3416 7.3 1.042857 788.4 8720.4316 112.6285714
77 73.5 3361 3458 9.7 1.385714 979.7 9700.1316 139.9571429
Liver Wt 1.77 Mean 1.361039 9700.1316
Body Wt 28.9
369 
 
 
 
Mrp2/3KO-5 
Time 
(min) 
MidTime 
(min) 
Tube 
Weight  
Total 
Weight Bile Vol. 
Bile Rate 
(uL/min) Amount(ng) 
Cumulative 
Amunt(ng) 
Biliary Excretion 
Rate (ng/min) 
7 3.5 3363 3473 11 1.571429 1.76 1.76 0.251428571
14 10.5 3361 3466 10.5 1.5 67.725 69.485 9.675
21 17.5 3371 3461 9 1.285714 353.7 423.185 50.52857143
28 24.5 3316 3398 8.2 1.171429 664.2 1087.385 94.88571429
35 31.5 3361 3439 7.8 1.114286 803.4 1890.785 114.7714286
42 38.5 3325 3414 8.9 1.271429 1157 3047.785 165.2857143
49 45.5 3361 3455 9.4 1.342857 1240.8 4288.585 177.2571429
56 52.5 3315 3395 8 1.142857 1016 5304.585 145.1428571
63 59.5 3296 3363 6.7 0.957143 757.1 6061.685 108.1571429
70 66.5 3324 3392 6.8 0.971429 700.4 6762.085 100.0571429
77 73.5 3295 3401 10.6 1.514286 1019.72 7781.805 145.6742857
Liver Wt 1.62 Mean 1.258442 7781.805
Body Wt 27.3
370 
 
 
 
Mrp2KO-1 
Time 
(min) 
MidTime 
(min) 
Tube 
Weight  
Total 
Weight Bile Vol. 
Bile Rate 
(uL/min) Amount(ng) 
Cumulative 
Amunt(ng) 
Biliary Excretion 
Rate (ng/min) 
7 3.5 3318 3431 11.3 1.614286 0 0 0
14 10.5 3332 3427 9.5 1.357143 67.26 67.26 9.608571429
21 17.5 3366 3467 10.1 1.442857 307.04 374.3 43.86285714
28 24.5 3320 3426 10.6 1.514286 520.46 894.76 74.35142857
35 31.5 3292 3395 10.3 1.471429 622.12 1516.88 88.87428571
42 38.5 3295 3401 10.6 1.514286 695.36 2212.24 99.33714286
49 45.5 3317 3420 10.3 1.471429 622.12 2834.36 88.87428571
56 52.5 3363 3456 9.3 1.328571 398.04 3232.4 56.86285714
63 59.5 3356 3450 9.4 1.342857 326.18 3558.58 46.59714286
70 66.5 3297 3387 9 1.285714 256.5 3815.08 36.64285714
77 73.5 3370 3474 10.4 1.485714 221.52 4036.6 31.64571429
Liver Wt 1.68 Mean 1.438961 4036.6
Body Wt 30.9
371 
 
 
 
Mrp2KO-2 
Time 
(min) 
MidTime 
(min) 
Tube 
Weight  
Total 
Weight Bile Vol. 
Bile Rate 
(uL/min) Amount(ng) 
Cumulative 
Amunt(ng) 
Biliary Excretion 
Rate (ng/min) 
7 3.5 3362 3449 8.7 1.242857 0 0 0
14 10.5 3336 3433 9.7 1.385714 59.849 59.849 8.549857143
21 17.5 3338 3437 9.9 1.414286 393.03 452.879 56.14714286
28 24.5 3341 3448 10.7 1.528571 735.09 1187.969 105.0128571
35 31.5 3313 3419 10.6 1.514286 981.56 2169.529 140.2228571
42 38.5 3368 3445 7.7 1.1 831.6 3001.129 118.8
49 45.5 3331 3464 13.3 1.9 1327.34 4328.469 189.62
56 52.5 3339 3413 7.4 1.057143 613.46 4941.929 87.63714286
63 59.5 3358 3450 9.2 1.314286 681.72 5623.649 97.38857143
70 66.5 3353 3453 10 1.428571 617 6240.649 88.14285714
77 73.5 3349 3434 8.5 1.214286 438.6 6679.249 62.65714286
Liver Wt 1.55 Mean 1.372727 6679.249
Body Wt 30
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Mrp2KO-3 
Time 
(min) 
MidTime 
(min) 
Tube 
Weight  
Total 
Weight Bile Vol. 
Bile Rate 
(uL/min) Amount(ng) 
Cumulative 
Amunt(ng) 
Biliary Excretion 
Rate (ng/min) 
7 3.5 3344 3425 8.1 1.157143 0 0 0
14 10.5 3342 3449 10.7 1.528571 119.84 119.84 17.12
21 17.5 3359 3469 11 1.571429 528 647.84 75.42857143
28 24.5 3286 3390 10.4 1.485714 859.04 1506.88 122.72
35 31.5 3289 3382 9.3 1.328571 976.5 2483.38 139.5
42 38.5 3289 3381 9.2 1.314286 966 3449.38 138
49 45.5 3361 3439 7.8 1.114286 881.4 4330.78 125.9142857
56 52.5 3343 3427 8.4 1.2 661.92 4992.7 94.56
63 59.5 3336 3403 6.7 0.957143 510.54 5503.24 72.93428571
70 66.5 3338 3409 7.1 1.014286 438.07 5941.31 62.58142857
77 73.5 3314 3403 8.9 1.271429 429.87 6371.18 61.41
Liver Wt 1.47 Mean 1.267532 6371.18
Body Wt 27.3
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Mass Balance at the end of the 75 perfusion 
  Amount in  Amount in Amount in 
  Total Dose (ng) 
Perfusate 
(ng) Bile (ng) Liver (ng) 
% in 
Perfusate % in Bile % in Liver Total 
WT 
  
  
  
111750 58303 12456 5670 52.2 11.1 5.1 68.4
100875 63256 10600 4035.6 62.7 10.5 4.0 77.2
99750 52361 15525 5370 52.5 15.6 5.4 73.4
117000 66151 15400 4968 56.5 13.2 4.2 73.9
Mrp3KO 
  
  
121500 80038 12132 3350.1 65.9 10.0 2.8 78.6
123375 56873 21599 6383.7 46.1 17.5 5.2 68.8
125250 65804 14191 6364.8 52.5 11.3 5.1 68.9
Mrp4KO 
  
  
  
139875 75098 12426 4723.2 53.7 8.9 3.4 65.9
127875 61740 14672 6051.6 48.3 11.5 4.7 64.5
116625 75115 10087 2385.0 64.4 8.6 2.0 75.1
124500 62790 18877 3985.2 50.4 15.2 3.2 68.8
Mrp2/3KO 
  
  
117000 91774 4570 4895.1 78.4 3.9 4.2 86.5
124125 55786 4798 8964.0 44.9 3.9 7.2 56.0
132375 67345 9700 10195.2 50.9 7.3 7.7 65.9
Mrp2KO 
  
  
148500 102762 4037 2182.32 69.2 2.7 1.5 73.4
123750 89398 6679 4082.7 72.2 5.4 3.3 80.9
129750 88877 6371 5424.3 68.5 4.9 4.2 77.6
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 Chapter 4: 
99mTc-MIBI uptake in suspended Rat Hepatocytes 
   Time (min)   Mean  SD  Time (min)   Mean  SD  Mean  SD 
Ctrl 
1  0.025  0.003  0.5 0.020  0.001  0.020  0.001 
2.5  0.045  0.002  1 0.034  0.006  0.030  0.001 
5  0.078  0.013  2.5 0.060  0.003  0.061  0.003 
Rifamycin SV 
1  0.024  0.002  0.5 0.016  0.001  0.020  0.002 
2.5  0.044  0.004  1 0.037  0.015  0.035  0.002 
5  0.078  0.004  2.5 0.055  0.003  0.063  0.007 
Glycyrrhizic Acid 
1  0.024  0.001  0.5 0.017  0.002  0.019  0.000 
2.5  0.043  0.001  1 0.027  0.001  0.031  0.003 
5  0.072  0.002  2.5 0.056  0.003  0.063  0.001 
Clonidine 
1  0.022  0.001  0.5 0.017  0.003  0.019  0.001 
2.5  0.039  0.001  1 0.026  0.004  0.029  0.002 
5  0.065  0.004  2.5 0.054  0.006  0.059  0.006 
Desipramine 
1  0.021  0.002  0.5 0.015  0.001  0.020  0.000 
2.5  0.041  0.003  1 0.025  0.001  0.030  0.001 
5  0.064  0.002  2.5 0.053  0.002  0.058  0.002 
Ketoprofen 
1  0.023  0.002  0.5 0.015  0.001  0.020  0.001 
2.5  0.045  0.003  1 0.028  0.003  0.034  0.001 
5  0.067  0.005  2.5 0.050  0.001  0.062  0.006 
Choline Buffer 
1  0.019  0.000  0.5 0.015  0.001  0.021  0.001 
2.5  0.035  0.001  1 0.023  0.001  0.037  0.004 
5  0.056  0.001  2.5 0.045  0.003  0.063  0.002 
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 99mTc-MEB uptake in suspended Rat Hepatocytes 
   Time (min)  Mean  SD  Mean  SD  Mean  SD 
Ctrl 
0.5  0.092  0.006  0.115  0.003  0.087  0.004 
1  0.117  0.007  0.156  0.001  0.116  0.005 
1.5  0.123  0.008  0.175  0.001  0.145  0.006 
Rifamycin SV 
0.5  0.015  0.002  0.025  0.001  0.027  0.003 
1  0.018  0.002  0.024  0.005  0.031  0.004 
1.5  0.021  0.002  0.033  0.008  0.038  0.000 
Glycyrrhizic Acid 
0.5        0.034  0.003  0.033  0.003 
1        0.053  0.005  0.038  0.007 
1.5        0.068  0.001  0.058  0.001 
Clonidine 
0.5  0.079  0.005  0.094  0.011  0.076  0.003 
1  0.095  0.006  0.131  0.019  0.110  0.008 
1.5  0.104  0.004  0.151  0.023  0.130  0.006 
Desipramine 
0.5  0.078  0.002  0.096  0.003  0.073  0.005 
1  0.102  0.004  0.134  0.002  0.112  0.016 
1.5  0.107  0.002  0.152  0.006  0.126  0.008 
Ketoprofen 
0.5  0.065  0.005  0.086  0.007  0.056  0.019 
1  0.084  0.004  0.114  0.010  0.082  0.021 
1.5  0.093  0.001  0.132  0.012  0.105  0.019 
Choline Buffer 
0.5  0.055  0.004  0.086  0.004  0.071  0.005 
1  0.083  0.006  0.117     0.093    
1.5  0.090  0.002  0.147  0.015  0.122  0.008 
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 [3H]E217βG uptake in Rat Hepatoctyes 
Mean  SD  Mean  SD 
Ctrl 
0.5  12.38524  2.170438 Ctrl  0.5 9.870482  0.142666
1  15.09243  2.062472 1 14.65886  1.051743
2.5  18.85566  2.330778 Rifamycin SV  0.5 2.193125  0.784988
5  25.16313  0.666116 1 2.091985  0.210735
Rifamycin SV 
0.5  2.738443  0.306133
Glycyrrhizic 
Acid  0.5 2.048354  0.989725
1  2.517903  0.020512 1 1.833771  0.575905
2.5  2.974957  0.413613 Clonidine  0.5 9.474591  0.401928
5  3.069813  0.049867 1 15.25649  0.246573
Glycyrrhizic 
Acid 
0.5  3.030449  0.106825 Desipramine  0.5 11.57111  1.02265
1  3.925705  1.97042 1 15.84401  0.574169
2.5  5.413246  3.861875 Ketoprofen  0.5 8.023864  1.358714
5  5.856332  3.890866 1 13.02364  2.307888
Clonidine 
0.5  9.970687  4.220903
1  13.37733  7.334079
2.5  19.26212  4.667984
5  25.21137  1.654966
Desipramine 
0.5  13.77704  1.291401
1  17.35233  0.133057
2.5  23.89008  5.098736
5  23.95633  3.23873
Ketoprofen 
0.5  11.56112  1.417318
1  14.39834  2.223683
2.5  17.15951  0.504023
5  20.50233  0.154342
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 [14C]TEA uptake in Rat Hepatocytes 
Mean  SD  Mean  SD  Mean  SD 
Ctrl 
1  19.62706  0.283542 
Ctrl 
0.5 15.67099 2.254442  12.38052 1.011012
2.5  31.50644  0.37017  1 22.10304 1.308434  13.72543 0.775908
5  36.35275  0.392576  2.5 33.46671 0.474105  30.90703 2.735914
10  36.79896  11.79346  5 41.93236 1.737362  31.85378
20  24.34477  1.191812 
Rifamycin 
SV 
0.5 14.78319 0.470174  10.67335 1.141725
Rifamycin SV 
1  40.62799  31.97156  1 18.64507 1.394285  11.58624 2.052951
2.5  28.02024  7.60156  2.5 26.53415 0.935913  21.92847 1.320568
5  27.37999  0.059177  5 34.22803 1.612172  18.77093 0.834149
10  28.86343  1.771652 
Glycyrrhizic 
Acid 
0.5 13.73598 1.010805  8.236493 4.587954
20  19.60059  3.222042  1 16.47228 1.678505  9.00971 5.696714
Glycyrrhizic 
Acid 
1  36.66742  37.57265  2.5 23.40738 3.486012  14.87233 11.29946
2.5  16.32844  8.933144  5 28.95145 5.850027  12.69465 7.759001
5  20.82923  9.205003 
Clonidine 
0.5 8.27905 1.356852  5.246362 0.948509
10  22.44201  10.85292  1 11.33615 4.136207  5.954638 0.644275
20  17.31598  0.008887  2.5 7.966801 0.188376  3.835009 1.58727
Clonidine 
1  9.881845  2.028322  5 9.24062 0.790033  6.439679 1.740032
2.5  10.9993  1.370536 
Desipramine
0.5 8.628189 0.166611  6.029467 1.770394
5  10.98333  0.270778  1 73.3402 93.43815  5.538977 0.699209
10  12.63309  0.122718  2.5 9.50094 1.428023  4.698821 0.415392
20  9.3659  0.480048  5 9.346783 0.610846  7.203302 0.830726
Desipramine 
1  15.675  9.92791 
Ketoprofen 
0.5 13.66023 0.066967  10.54654 0.295093
2.5  10.45545  0.475845  1 15.64974 1.419428  12.08741 0.305804
5  12.05765  0.049089  2.5 21.5592 1.950168  20.94596 0.584993
10  12.15841  0.474319  5 26.74747 4.959626  23.02009 6.67613
20  14.0206  1.665536 
Ketoprofen 
1  22.63843  0.583946 
2.5  28.0347  7.073127 
5  42.96362  2.520017 
10  38.40968  4.693135 
20  29.59863  0.648622 
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99mTc-MEB uptake in Human Hepatocytes 
Mean  SD  Mean  SD 
Ctrl 
0.5  0.109  0.010  0.209  0.044 
1  0.145  0.015  0.292  0.043 
Rifamycin SV 
0.5  0.063  0.004  0.030  0.003 
1  0.079  0.003  0.034  0.004 
Decynium 22 
0.5  0.089  0.010  0.156  0.007 
1  0.120  0.011  0.238  0.021 
Tetracycline 
0.5  0.070  0.002  0.176  0.020 
1  0.087  0.008  0.267  0.025 
Choline Buffer 
0.5  0.101  0.005  0.170  0.004 
1  0.127  0.003  0.266  0.006 
[3H]E217βG uptake in Human Hepatoctyes 
Mean  SD  Mean  SD  Mean  SD 
Ctrl 
0.5  0.973357  0.246299 6.260282 1.451209 3.014948  0.226557
1  1.150589  0.071566 6.690094 0.092808 4.390121  0.992107
Rifamycin 
SV 
0.5  0.673821  0.048202 2.553705 0.043409 1.730216  0.096229
1  0.756412  0.081221 2.578198 0.084623 2.094757  0.308152
Decynium 
22 
0.5  0.808107  0.310853 4.057475 0.456242 2.390392  0.042579
1  1.057342  0.075733 5.292775 0.009627 3.783642  0.204595
Tetracycline 
0.5  0.562734  0.123431 4.756897 0.196647 2.606126  0.270383
1  0.619201  0.149388 5.806272 0.820912 3.738196  0.383336
[14C]TEA uptake in Human Hepatocytes 
Mean  SD  Mean  SD  Mean  SD 
Ctrl 
1  16.41312  1.091486 10.83375 0.121054 5.425928  0.744333
2.5  25.19218  0.546069 17.82554 0.811958 7.35569  0.158289
5  8.181197  0.647109
Rifamycin SV 
1  15.1858  1.263563 9.819604 0.789064 5.343774  0.568845
2.5  22.43821  3.457341 17.9108 1.338277 6.495763  0.279994
5  8.986862  0.156035
Decynium 22 
1  6.48014  0.44253 11.62447 0.7526 5.407475  0.005449
2.5  11.47248  0.615183 18.72718 0.382743 6.934536  0.244847
5  8.226498  0.471793
Tetracycline 
1  12.37583  1.201312 8.686384 0.773033 3.969133  0.176653
2.5  20.0061  2.596266 9.160144 0.839768 4.741283  0.110022
5  4.87555  0.064472
99mTc-MEB efflux in Sandwich-Culture Rat Hepatocytes 
5/20/2008  6/23/2008  8/4/2008  8/15/2008  Mean  SD 
Mean  SD  Mean  SD  Mean  SD  Mean  SD   
Basolateral & Apical Efflux 
47.10  1.84  38.03  6.06  34.33  4.49  41.65  2.12  40.28  5.44 
Basolateral & Apical Efflux with MK-571 
38.90  0.99  33.93  1.83  31.26  1.81  41.15  2.85  36.31  4.52 
Basolateral Efflux 
27.68  5.70  17.20  3.91  22.44  1.38  32.67  0.47  25.00  6.67 
Basolateral Efflux with MK-571 
34.03  2.30  28.77  1.75  30.22  0.40  42.99  1.67  34.00  6.39 
Apical Efflux 
19.42  20.82  11.89  8.98  15.28  5.75 
Apical Efflux with MK-571 
4.86  5.16  1.04  ‐1.84  2.31  3.34 
Total WT 
47.10  38.03  34.33  41.65  40.28  5.44 
Cells Only 48.78  1.49  61.97  6.06  65.67  4.49  58.35  2.12  58.69  7.25 
59.91  0.78  66.07  1.83  68.74  1.81  58.85  2.85  63.39  4.78 
Cells + Bile 
70.15  7.10  82.80  3.91  77.56  1.38  67.33  0.47  74.46  7.04 
64.38  2.01  71.23  1.75  69.78  0.40  57.01  1.67  65.60  6.44 
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99mTc-MEB efflux in Sandwich-Culture TR- Rat Hepatocytes 
6/30/2008  9/22/2008  9/29/2008  Mean  SD 
Mean  SD  Mean  SD  Mean  SD 
Basolateral & Apical Efflux 33.67  2.01  22.55  6.01  28.11  7.86 
Basolateral & Apical Efflux with MK-
571 45.38  5.99  26.88  1.78  36.13  13.08 
Basolateral Efflux 36.24  1.79  27.41  4.80  31.82  6.24 
Basolateral Efflux with MK-571 46.74  1.34  34.85  3.71  40.80  8.41 
Apical Efflux ‐2.57  ‐   ‐4.86 3.71  1.62 
Apical Efflux with MK-571 ‐1.36  ‐   ‐7.96 4.66  4.67 
Total Efflux 
Cells Only 66.33  2.01  77.45  6.01  92.64  0.88  78.81  13.21 
54.62  5.99  73.12  1.78  92.23  0.66  73.32  18.81 
Cells + Bile 
63.76  1.79  72.59  4.80  94.11  0.92  76.82  15.61 
53.26  1.34  65.15  3.71  94.34  0.86  70.92  21.14 
99mTc-MEB efflux in Sandwich-Culture Human Hepatocytes 
8/28/2009  8/31/2009 
Mean  SD  Mean  SD  Mean  Range 
Basolateral & Apical Efflux 68.08  0.88  56.76  0.98  62.42  8.00 
Basolateral & Apical Efflux with MK-
571 72.60  1.34  72.03  2.74  72.32  0.40 
Basolateral Efflux 16.23  3.50  17.09  4.07  16.66  0.61 
Basolateral Efflux with MK-571 39.71  4.59  40.32  1.05  40.02  0.43 
Apical Efflux 51.84  39.67  45.76  8.61 
Apical Efflux with MK-571 32.89  31.71  32.30  0.83 
Total Efflux 68.08  56.76  62.42  8.00 
Cells Only 
31.92  0.88  43.24  0.98  37.58  8.00 
27.40  1.34  27.97  2.74  27.68  0.40 
Cells + Bile 
83.77  3.50  82.91  4.07  83.34  0.61 
60.29  4.59  59.68  1.05  59.98  0.43 
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99mTc-MIBI efflux in Sandwich-Culture Rat Hepatocytes 
5/20/2008  6/23/2008  8/4/2008  8/15/2008  Mean SD 
Mean SD  Mean SD  Mean  SD  Mean SD 
Basolateral & Apical Efflux 51.84  1.92 69.03  2.41 66.77  1.55  68.45  0.87 64.02  8.18
Basolateral & Apical Efflux with 20µM 
GF918 25.23  1.38 30.62  0.64 44.98  2.84  34.18  1.50 33.75  8.34
Basolateral Efflux 30.76  0.82 47.22  3.35 38.14  2.18  45.70  1.33 40.46  7.59
Basolateral Efflux with 20µM GF918 12.44  0.28 16.79  0.81 21.38  0.22  21.01  2.48 17.91  4.20
Apical Efflux 21.08  21.81  28.63  22.74  23.57  3.45
Apical Efflux with 20µM GF918 12.80  13.83  23.61  13.17  15.85  5.19
Total Efflux 51.84  69.03  66.77  68.45  64.02  8.18
Cells Only 
40.36  4.53 30.97  2.41 33.23  1.55  31.55  0.87 34.03  4.33
68.24  0.40 69.38  0.64 55.02  2.84  65.82  1.50 64.61  6.57
Cells + Bile 64.48  1.58 52.78  3.35 61.86  2.18  54.30  1.33 58.35  5.69
85.17  0.41 83.21  0.81 78.62  0.22  78.99  2.48 81.50  3.22
99mTc-MIBI efflux in Sandwich-Culture TR- Rat Hepatocytes 
6/30/2008  9/22/2008  9/29/2008  Mean  SD 
Mean SD  Mean SD  Mean SD 
Basolateral & Apical Efflux 76.59  1.80 67.64  1.76 66.78  0.56  70.34  5.43 
Basolateral & Apical Efflux with 20µM 
GF918 39.61  2.44 43.93  1.88 39.70  0.68  41.08  2.47 
Basolateral Efflux 47.27  1.61 37.45  1.49 33.45  4.70  39.39  7.11 
Basolateral Efflux with 20µM GF918 25.54  0.25 23.50  0.90 20.07  3.51  23.03  2.76 
Apical Efflux 29.32  30.19  33.33  30.95  2.11 
Apical Efflux with 20µM GF918 14.08  20.43  19.63  18.05  3.46 
Total Efflux 
Cells Only 
23.41  1.80 32.36  1.76 33.22  0.56  29.66  5.43 
60.39  2.44 56.07  1.88 60.30  0.68  58.92  2.47 
Cells + Bile 
52.73  1.61 62.55  1.49 66.55  4.70  60.61  7.11 
74.46  0.25 76.50  0.90 79.93  3.51  76.97  2.76 
382 
 
 
99mTc-MIBI efflux in Sandwich-Culture Human Hepatocytes 
8/28/2008  8/31/2008 
Mean SD  Mean SD  Mean Range 
Basolateral & Apical Efflux 88.07  1.18 90.64  1.06 89.35  1.82 
Basolateral & Apical Efflux with 20µM 
GF918 42.32  2.78 26.67  0.96 34.49  11.06 
Basolateral Efflux 66.99  3.12 61.02  5.75 64.00  4.23 
Basolateral Efflux with 20µM GF918 24.64  4.85 19.88  6.75 22.26  3.36 
Apical Efflux 21.08  29.63  25.35  6.05 
Apical Efflux with 20µM GF918 17.68  6.79  12.24  7.70 
Total Efflux 88.07  90.64  89.35  1.82 
Cells Only 
11.93  1.18 9.36  1.06 10.65  1.82 
57.68  2.78 73.33  0.96 65.51  11.06 
Cells + Bile 33.01  3.12 38.98  5.75 36.00  4.23 
75.36  4.85 80.12  6.75 77.74  3.36 
383 
99mTc-MIBI accumulation in Sandwich-Culture Rat Hepatocytes using RNAi 
WT 12‐11‐08 
0.5µCi/mL 
0.5µCi/mL + 
siNT 
0.5µCi/mL + siNT+ 
2 µM GF918  0.5µCi/mL + siBcrp 
0.5µCi/mL + siBcrp+ 
2 µM GF918 
Accumulation Cells + Bile  2.82  3.55  6.29  3.41  4.78 
SD  0.04  0.44  0.57  0.25  0.38 
Accumulation Cells  1.94  2.31  6.40  2.47  5.13 
SD  0.12  0.11  0.32  0.19  0.86 
BEI  31.29  35.03  ‐   ‐1.89  27.59 7.41 
 
 
 
 
 WT 06‐08‐09 
0.5µCi/mL  0.5µCi/mL + siNT 
0.5µCi/mL + siNT 
+ 2 µM GF918  0.5µCi/mL + siBcrp 
0.5µCi/mL + siBcrp +  
2 µM GF918 
Accumulation Cells + Bile  1.99  1.90  2.69  1.93  2.64 
SD  0.04  0.06  0.37  0.15  0.16 
Accumulation Cells  1.56  1.5  3.2  1.39  3.1 
SD  0.14  0.1  0.1  0.09  0.2 
BEI  22.02  20.88    ‐‐18.82  27.90 17.74 
 
WT 07‐09‐09 
0.5µCi/mL  0.5µCi/mL + siNT 
0.5µCi/mL + siNT 
+ 2 µM GF918  0.5µCi/mL + siBcrp 
0.5µCi/mL + siBcrp + 
 2 µM GF918 
Accumulation Cells + Bile  2.84  2.74  3.75  2.70  3.83 
SD  0.05  0.22  0.23  0.09  0.52 
Accumulation Cells  2.21  1.97  4.4  2.1  4.6 
SD  0.20  0.13  0.2  0.1  0.1 
BEI  22.02  27.90
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    ‐‐17.74  20.88 18.82 
 
 
 
 
 
 
 
 
 Chapter 5: 
[14C]Sorafenib uptake in Human Hepatocytes 
5/27/2009  7/15/2009 
pmol taken up  pmol/mg  pmol taken up  pmol/mg 
Mean  SD  Mean  SD  Mean  SD  Mean  SD 
Ctrl 
0.5  6.185  1.902  52.142  14.706  5.134  0.996  36.784  5.542 
1.5  9.056  2.251  76.983  19.852  9.375  1.411  67.725  11.456 
2.5  10.405  1.477  88.303  13.125  11.193  0.679  80.576  2.120 
Rifamycin SV  0.5  5.876  1.450  48.901  12.059  4.309  3.833  30.962  28.577 
1.5  5.144  1.834  42.076  14.164  6.561  0.030  44.036  0.357 
2.5  6.540  3.360  53.936  26.264  6.420  1.046  44.322  7.327 
Ketoprofen 
0.5  4.267  3.920  33.133  29.430  4.856  1.006  33.721  5.948 
1.5  9.690  0.379  74.781  6.725  9.205  0.984  64.090  5.035 
2.5  6.929  2.586  52.801  17.345  11.407  0.719  79.509  3.371 
Decynium 22 
0.5  6.478  0.202  56.443  12.575  4.294  1.145  27.892  5.979 
1.5  5.784  0.447  52.427  18.503  7.550  1.421  49.887  12.004 
2.5  7.299  1.167  64.645  22.330  9.250  1.175  60.194  12.355 
Choline Buffer 
0.5  5.875  2.736  63.597  26.126  4.799  0.696  46.202  8.791 
1.5  9.358  2.615  101.068  18.067  7.519  1.326  71.599  8.506 
2.5  10.031  1.036  109.700  2.239  8.805  2.179  83.663  16.094 
4°C 
0.5  3.177  0.395  23.169  1.659  2.558  2.212  18.163  16.184 
1.5  4.124  0.039  30.257  2.566  3.579  0.940  25.324  7.469 
2.5  8.049  4.009  56.341  16.749  3.401  0.121  24.519  15.278 
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[14C]Sorafenib uptake in CHO cells on 7-31-09 (data not graphed in dissertation) 
MOCK  MOCK (4C)  hOCT1  5mM MPP  5uM Decynium 22 
0.5  21.90  2.91  9.30 2.34 49.22 4.43 48.31  3.13 30.28 3.13
1  31.53  1.73  20.03 2.92 70.49 7.83 78.62  5.49 54.35 8.86
2  57.47  3.59  38.81 10.90 117.23 9.22 136.51  16.73 60.21 52.26
5  120.68  27.57  63.17 6.84 209.60 22.60 262.21  21.80 172.27 12.73
10  149.85  14.18  87.34 10.89 331.63 18.39 349.20  32.59 227.16 7.55
20  163.19  29.31  133.69 9.75 404.45 58.63 426.67  20.09 309.38 11.93
30  241.80  35.06  210.44 40.64 424.68 16.40 438.61  29.24 364.79 45.57
386  
[14C]Sorafenib uptake in CHO cells on 8-04-09  
Time  Mock  Mock + D22  OCT   OCT + D22 
0.5  42.50062  7.226721  48.45512 3.086695 58.60809 4.697704 44.97996  4.589214
1  56.86105  3.977197  61.22597 0.222685 84.5143 10.43798 62.09995  3.583897
2  117.3075  9.950514  118.7676 4.392815 150.0874 31.3572 99.31056  5.502464
5  144.6614  13.60159  162.9711 5.404094 292.415 33.28804 197.7324  10.87009
10  229.0946  21.12277  247.0291 25.79778 385.2181 22.47608 287.7248  20.62574
20  271.3955  16.00803  273.2648 38.92738 488.141 37.779 345.8728  12.58161
30  319.4655  26.42162  343.8191 52.70886 529.1106 40.20235 398.7762  23.78705
 
 
 
 
 
Chapter 6:   
99mTc-MEB in HCC+CPB Subject #01 
Dose (µCi)  4818 
Time (min)  Blood (nCi/mL) 
2.5  486.80 
5  no sample 
7.5  548.61 
10  405.09 
20  311.83 
40  182.43 
60  170.59 
80  122.31 
100  104.84 
120  105.70 
140  90.13 
165  76.66 
180  74.87 
Time (min)  Urine (µCi) 
180  196.25 
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Time 
(min) 
Activity 
(uCi) 
Time 
(min) 
Activity 
(uCi)
Time 
(min)
Activity 
(uCi)
Time 
(min)
Activity 
(uCi)
Time 
(min) 
Activity 
(uCi)
Time 
(min)
Activity 
(uCi)
Time 
(min)
Activity 
(uCi)
2.0  548.2  30.0  1314.5 58.0 1114.6 86.0 1028.5 114.0  907.4 142.0 772.9 170.0 645.6
3.0  616.7  31.0  1342.3 59.0 1104.2 87.0 1003.3 115.0  841.1 143.0 759.3 171.0 642.0
4.0  686.8  32.0  1348.3 60.0 1090.5 88.0 992.6 116.0  837.7 144.0 762.0 172.0 620.5
5.0  756.1  33.0  1347.2 61.0 1073.5 89.0 989.3 117.0  817.2 145.0 769.1 173.0 612.2
6.0  812.1  34.0  1330.8 62.0 1077.7 90.0 986.8 118.0  841.5 146.0 698.8 174.0 589.4
7.0  873.0  35.0  1337.2 63.0 1078.1 91.0 966.0 119.0  843.2 147.0 715.5 175.0 629.3
8.0  932.3  36.0  1303.5 64.0 1059.7 92.0 939.1 120.0  852.5 148.0 709.0 176.0 613.4
9.0  977.4  37.0  1321.0 65.0 1087.0 93.0 928.9 121.0  824.9 149.0 722.1 177.0 614.0
10.0  1034.4  38.0  1293.1 66.0 1057.2 94.0 966.4 122.0  831.1 150.0 723.1 178.0 653.6
11.0  1080.0  39.0  1290.9 67.0 1063.9 95.0 939.3 123.0  803.2 151.0 730.8 179.0 626.4
12.0  1114.0  40.0  1270.5 68.0 1043.6 96.0 960.7 124.0  816.4 152.0 710.3 180.0 615.6
13.0  1153.1  41.0  1276.6 69.0 1076.5 97.0 943.6 125.0  820.5 153.0 717.6
14.0  1185.8  42.0  1242.6 70.0 1108.2 98.0 942.4 126.0  845.3 154.0 698.6
15.0  1228.3  43.0  1242.7 71.0 1108.1 99.0 934.7 127.0  812.3 155.0 708.5
16.0  1265.8  44.0  1230.3 72.0 1111.6 100.0 951.3 128.0  787.7 156.0 634.8
17.0  1289.4  45.0  1225.1 73.0 1119.2 101.0 924.6 129.0  786.7 157.0 654.1
18.0  1307.3  46.0  1224.5 74.0 1099.4 102.0 886.8 130.0  785.8 158.0 624.0
19.0  1325.5  47.0  1200.7 75.0 1093.4 103.0 869.3 131.0  789.0 159.0 641.9
20.0  1355.9  48.0  1191.5 76.0 1087.9 104.0 915.4 132.0  833.0 160.0 683.3
21.0  1366.5  49.0  1194.1 77.0 1132.3 105.0 918.4 133.0  819.2 161.0 695.2
22.0  1372.8  50.0  1190.3 78.0 1143.5 106.0 930.3 134.0  811.2 162.0 697.6
23.0  1376.2  51.0  1203.0 79.0 1123.4 107.0 917.9 135.0  803.8 163.0 705.7
24.0  1356.8  52.0  1173.0 80.0 1102.9 108.0 916.3 136.0  832.0 164.0 704.3
25.0  1362.6  53.0  1171.2 81.0 1055.8 109.0 922.3 137.0  827.2 165.0 693.3
26.0  1340.1  54.0  1158.3 82.0 1020.8 110.0 915.9 138.0  774.5 166.0 684.2
27.0  1342.6  55.0  1154.1 83.0 1052.3 111.0 883.7 139.0  777.6 167.0 689.1
28.0  1323.4  56.0  1153.1 84.0 1022.7 112.0 939.9 140.0  787.9 168.0 698.2
29.0  1317.2  57.0  1134.3 85.0 1021.0 113.0 928.9 141.0  783.7 169.0 677.2
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99mTc-MIBI in HCC+CPB Subject #01 
Dose (µCi)  3860 
Time (min)  Blood (nCi/mL) 
1  0.94 
2.5  2.36 
5  4.72 
7.5  7.08 
10  9.43 
20  18.87 
40  37.74 
80  75.47 
100  no sample 
120  113.21 
140  no sample 
165  no sample 
180  169.81 
Time (min)  Urine (µCi) 
180  241.5 
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Time 
(min) 
Activity 
(uCi) 
Time 
(min) 
Activity 
(uCi) 
Time 
(min)
Activity 
(uCi) 
Time 
(min)
Activity 
(uCi) 
Time 
(min) 
Activity 
(uCi) 
Time 
(min)
Activity 
(uCi) 
Time 
(min) 
Activity 
(uCi) 
2  652  30  715 58 587 86 525 114  472 142 526 170 443
3  712  31  720 59 567 87 537 115  516 143 527 171 431
4  760  32  680 60 572 88 538 116  465 144 489 172 428
5  760  33  680 61 572 89 514 117  505 145 512 173 488
6  793  34  674 62 551 90 534 118  491 146 529 174 456
7  805  35  658 63 568 91 526 119  464 147 535 175 483
8  792  36  661 64 622 92 518 120  512 148 476 176 455
9  798  37  676 65 533 93 547 121  544 149 535 177 412
10  826  38  651 66 539 94 543 122  478 150 495 178 483
11  795  39  674 67 571 95 518 123  505 151 456 179 429
12  828  40  655 68 543 96 536 124  517 152 505 180 492
13  806  41  630 69 591 97 538 125  500 153 505
14  796  42  654 70 560 98 521 126  514 154 478
15  829  43  646 71 556 99 530 127  524 155 528
16  812  44  621 72 594 100 529 128  509 156 459
17  771  45  622 73 549 101 524 129  500 157 481
18  795  46  630 74 552 102 534 130  517 158 380
19  791  47  598 75 566 103 537 131  506 159 454
20  750  48  617 76 550 104 515 132  484 160 463
21  772  49  609 77 545 105 532 133  497 161 437
22  759  50  580 78 553 106 531 134  493 162 465
23  747  51  615 79 555 107 516 135  488 163 432
24  750  52  622 80 533 108 532 136  499 164 359
25  754  53  591 81 554 109 433 137  457 165 339
26  711  54  604 82 556 110 448 138  508 166 422
27  725  55  597 83 539 111 499 139  487 167 351
28  728  56  600 84 543 112 527 140  487 168 404
29  694  57  596 85 539 113 512 141  475 169 393
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